


**CUMULATIVE  
SUPPLEMENT 5  
May 2026**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**46th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**46<sup>th</sup> EDITION**

**Cumulative Supplement 5  
May 2026**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT .....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT .....	vi
1.3	LEVOTHYROXINE SODIUM .....	vii
1.4	AVAILABILITY OF THE EDITION.....	viii
1.5	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	ix
1.6	CUMULATIVE SUPPLEMENT LEGEND.....	x
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Products Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**46<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 5  
May 2026**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPR) of any changes or corrections. The DOBPR can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

#### 1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2025</u>	<u>MAR</u> <u>2026</u>	<u>JUN</u> <u>2026</u>	<u>SEP</u> <u>2026</u>	<u>DEC</u> <u>2026</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	24120	24441			
	2765	2813			
	(11.5%)	(11.5%)			
MULTISOURCE	21355	21628			
	(88.5%)	(88.5%)			
THERAPEUTICALLY EQUIVALENT	21260	21534			
	(87.1%)	(88.1%)			
NOT THERAPEUTICALLY EQUIVALENT	95	94			
	(0.4%)	(0.4%)			

EXCEPTIONS <sup>4</sup>	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	19	41
NUMBER OF APPLICANTS	1198	1198

## 1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CPOT Change. Potency amount/unit.  
CRLD Change. Reference Listed Drug  
CHRS Change. Reference Standard  
CTEC Change. Therapeutic Equivalence Code.  
CTNA Change. Trade Name.  
DISC Discontinued. The Rx or OTC listed product is not  
being marketed and will appear in the discontinued  
section in the next edition.

ABAMETAPIR

LOTION; TOPICAL  
 XEGLYZE

@ + LNHC 0.74% N206966 001 Jul 24, 2020 Apr CAHN

ABARELIX

POWDER; INTRAMUSCULAR  
 PLENAXIS

@ SPECIALITY EUROPEAN 100MG/VIAL N021320 001 Nov 25, 2003 Jan CDFR

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL  
 ACAMPROSATE CALCIUM

AB APPCO 333MG A218984 001 Mar 16, 2026 Mar NEWA

ACARBOSE

TABLET; ORAL  
 ACARBOSE

@ NATCO PHARMA USA 25MG A091053 001 Jan 06, 2011 Mar CAHN  
 @ 50MG A091053 002 Jan 06, 2011 Mar CAHN  
 @ 100MG A091053 003 Jan 06, 2011 Mar CAHN

ACETAMINOPHEN

SOLUTION; INTRAVENOUS  
 ACETAMINOPHEN

>A> AP1 APOTEX 1GM/100ML (10MG/ML) A205746 001 Apr 18, 2023 May CAHN  
 >D> AP1 WOCKHARDT BIO AG 1GM/100ML (10MG/ML) A205746 001 Apr 18, 2023 May CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL  
 BUTAPAP

AA ! MIKART 325MG; 50MG A089987 001 Oct 26, 1992 Mar CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA INGENUS PHARMS LLC 300MG; 50MG; 40MG A215047 001 Nov 17, 2021 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL  
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

@ QUAGEN 325MG; 50MG; 40MG; 30MG A204649 001 Jul 08, 2020 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA LANNETT CO INC 300MG; 5MG A207171 001 Jun 20, 2017 Mar CMFD  
 AA 300MG; 7.5MG A207171 002 Jun 20, 2017 Mar CMFD  
 AA 300MG; 10MG A207171 003 Jun 20, 2017 Mar CMFD  
 AA 325MG; 5MG A207172 001 Jun 22, 2017 Mar CMFD  
 AA 325MG; 7.5MG A207172 002 Jun 22, 2017 Mar CMFD  
 AA 325MG; 10MG A207172 003 Jun 22, 2017 Mar CMFD  
 @ STRIDES PHARMA INTL 325MG; 5MG A040655 001 Jan 19, 2006 Jan DISC  
 @ 325MG; 7.5MG A040656 001 Jan 19, 2006 Jan DISC  
 @ 325MG; 10MG A040355 001 May 31, 2000 Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL  
 OXYCODONE AND ACETAMINOPHEN

AA LANNETT CO INC 325MG; 5MG A207333 001 Sep 25, 2017 Feb CMFD  
 AA 325MG; 10MG A207333 002 Sep 25, 2017 Feb CMFD  
 AA ! OZANTRI 325MG; 2.5MG A040330 001 Jun 25, 1999 Apr CAHN  
 AA ! 325MG; 5MG A040330 002 Jun 25, 1999 Apr CAHN  
 @ + 325MG; 5MG A085106 002 Apr CAHN  
 AA ! 325MG; 7.5MG A040330 003 Nov 23, 2001 Apr CAHN  
 AA ! 325MG; 10MG A040330 004 Nov 23, 2001 Apr CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC  
HYDROCORTISONE AND ACETIC ACID

>D>	AT	COSETTE	2%;1%	A 040609	001	Feb 06, 2006	May	CAHN
>A>	AT	COSETTE PHARMS NC	2%;1%	A 040609	001	Feb 06, 2006	May	CAHN

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION  
TUDORZA PRESSAIR

+	!	AZURITY	0.4MG/INH	N 202450	001	Jul 23, 2012	Mar	CAHN
---	---	---------	-----------	----------	-----	--------------	-----	------

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION  
DUAKLIR PRESSAIR

+	!	AZURITY	0.4MG/INH;0.012MG/INH	N 210595	001	Mar 29, 2019	Mar	CAHN
---	---	---------	-----------------------	----------	-----	--------------	-----	------

ACYCLOVIR

OINTMENT; TOPICAL  
ACYCLOVIR

>D>	@	COSETTE	5%	A 205591	001	Nov 13, 2017	May	CAHN
>A>	@	COSETTE PHARMS NC	5%	A 205591	001	Nov 13, 2017	May	CAHN

TABLET; ORAL  
ACYCLOVIR

@		STRIDES PHARMA INTL	400MG	A 074946	001	Nov 19, 1997	Jan	DISC
@			800MG	A 074946	002	Nov 19, 1997	Jan	DISC

ADAPALENE

SOLUTION; TOPICAL  
ADAPALENE

AB		WAYLIS THERAP	0.1%	A 203981	001	Sep 23, 2016	Jan	CAHN
AB			0.1%	A 204593	001	Jan 05, 2016	Jan	CAHN

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION  
ALBUTEROL SULFATE

AB3		CIPLA	EQ 0.09MG BASE/INH	A 219409	001	Apr 22, 2026	Apr	NFTG
-----	--	-------	--------------------	----------	-----	--------------	-----	------

AB3	+	!	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N 020983	001	Apr 19, 2001	Apr	CFTG
-----	---	---	-----------------	--------------------	----------	-----	--------------	-----	------

SYRUP; ORAL  
ALBUTEROL SULFATE

>D>	@	COSETTE	EQ 2MG BASE/5ML	A 074454	001	Sep 25, 1995	May	CAHN
>A>	@	COSETTE PHARMS NC	EQ 2MG BASE/5ML	A 074454	001	Sep 25, 1995	May	CAHN

TABLET; ORAL  
ALBUTEROL SULFATE

AB		NATCO PHARMA USA	EQ 2MG BASE	A 072894	002	Jan 17, 1991	Mar	CAHN
AB		!	EQ 4MG BASE	A 072894	001	Jan 17, 1991	Mar	CAHN

ALISKIREN HEMIFUMARATE

TABLET; ORAL  
TEKTURNA

AB	+	LXO IRELAND	EQ 150MG BASE	N 021985	001	Mar 05, 2007	Jan	CAHN
AB	+	!	EQ 300MG BASE	N 021985	002	Mar 05, 2007	Jan	CAHN

ALPELISIB

GRANULE; ORAL  
VIJOICE

+	!	NOVARTIS	50MG/PACKET	N 218466	001	Apr 24, 2024	Apr	CDFR
---	---	----------	-------------	----------	-----	--------------	-----	------

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS  
INFUVITE ADULT

AP	+	SANDOZ CANADA INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N 021163	001	May 18, 2000	Apr	CFTG
----	---	-------------------	---	----------	-----	--------------	-----	------

AP	+	!	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;	N 021163	002	Jun 16, 2003	Apr	CFTG
----	---	---	--	----------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS  
INFUVITE ADULT

AP	APOTEX	30MCG/ML MULTIPLE VITAMINS INJECTION ADULT	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2 MG/ML; 660 IU/ML; 0.03MG/ML	A 210273	001	Apr 09, 2026	Apr NFTG
AP			2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2 MG/ML; 660 IU/ML; 30MCG/ML	A 210672	001	Apr 09, 2026	Apr NFTG

ALPRAZOLAM

TABLET; ORAL  
ALPRAZOLAM

@	STRIDES PHARMA INTL	0.25MG	A 090248	001	Sep 17, 2010	Jan DISC
@		0.5MG	A 090248	002	Sep 17, 2010	Jan DISC
@		1MG	A 090248	003	Sep 17, 2010	Jan DISC
@		2MG	A 090248	004	Sep 17, 2010	Jan DISC

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL  
AMANTADINE HYDROCHLORIDE

AA	POM PHARMA	50MG/5ML	A 214178	001	Aug 20, 2021	Apr CAHN
AB	POM PHARMA	100MG	A 210215	001	Mar 10, 2020	Apr CAHN

AMBRISENTAN

TABLET; ORAL  
AMBRISENTAN

>D>	AB	SUN PHARM	5MG	A 210784	001	Mar 28, 2019	May DISC
>A>	@		5MG	A 210784	001	Mar 28, 2019	May DISC

AMIFOSTINE

INJECTABLE; INJECTION  
ETHYOL

@	LEGACY PHARMA	375MG/VIAL	N 020221	002	Sep 10, 1999	Mar CAHN
+		500MG/VIAL	N 020221	001	Dec 08, 1995	Mar CMFD
@ +		500MG/VIAL	N 020221	001	Dec 08, 1995	Mar CAHN

AMINOCAPROIC ACID

INJECTABLE; INJECTION  
AMINOCAPROIC ACID

AP	ZENARA	250MG/ML	A 215374	001	Aug 28, 2025	Mar CAHN
AA	CARNEGIE	0.25GM/ML	A 214140	001	Jan 26, 2021	Feb CAHN
AB	CARNEGIE	500MG	A 213928	001	Feb 12, 2021	Feb CAHN
AB		1GM	A 213928	002	Feb 12, 2021	Feb CAHN
>A>	AB	RISING	A 213944	001	Sep 14, 2022	May CAHN
>A>	AB		A 213944	002	Sep 14, 2022	May CAHN
>D>	AB	SOMERSET THERAPS LLC	A 213944	001	Sep 14, 2022	May CAHN
>D>	AB		A 213944	002	Sep 14, 2022	May CAHN

AMINOPHYLLINE

SUPPOSITORY; RECTAL  
TRUPHYLLINE

>D>	@	COSETTE	250MG	A 085498	001	Mar 23, 1983	May CAHN
>D>	@		500MG	A 085498	002	Jan 03, 1983	May CAHN
>A>	@	COSETTE PHARMS NC	250MG	A 085498	001	Mar 23, 1983	May CAHN
>A>	@		500MG	A 085498	002	Jan 03, 1983	May CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	AUROBINDO PHARMA USA	10MG	A 086009	002		Mar	CMFD
AB		25MG	A 086009	003		Mar	CMFD
AB		50MG	A 086009	001		Mar	CMFD
AB		75MG	A 086009	004		Mar	CMFD
AB		100MG	A 086009	005		Mar	CMFD
AB		150MG	A 086009	006		Mar	CMFD
>D>	RUBICON RESEARCH	10MG	A 215376	001	May 01, 2023	May	CTEC
>A>		10MG	A 215376	001	May 01, 2023	May	CTEC
>D>		25MG	A 215376	002	May 01, 2023	May	CTEC
>A>		25MG	A 215376	002	May 01, 2023	May	CTEC
>D>		50MG	A 215376	003	May 01, 2023	May	CTEC
>A>		50MG	A 215376	003	May 01, 2023	May	CTEC
>D>		75MG	A 215376	004	May 01, 2023	May	CTEC
>A>		75MG	A 215376	004	May 01, 2023	May	CTEC
>D>		100MG	A 215376	005	May 01, 2023	May	CTEC
>A>		100MG	A 215376	005	May 01, 2023	May	CTEC
>D>		150MG	A 215376	006	May 01, 2023	May	CTEC
>A>		150MG	A 215376	006	May 01, 2023	May	CTEC

AMLODIPINE BESYLATE

FOR SOLUTION;ORAL

SDAMLO

+	BRILLIAN PHARMA	EQ 2.5MG BASE/BOT	N 219531	001	Jul 24, 2025	Jan	CMFD
+		EQ 5MG BASE/BOT	N 219531	002	Jul 24, 2025	Jan	CMFD
+		EQ 10MG BASE/BOT	N 219531	003	Jul 24, 2025	Jan	CMFD

TABLET;ORAL

AMLODIPINE BESYLATE

AB	GRAVITI PHARMS	EQ 2.5MG BASE	A 201380	003	Feb 17, 2026	Feb	NEWA
AB	TEVA PHARMS INC	EQ 2.5MG BASE	A 219686	001	Jan 22, 2026	Jan	NEWA
AB		EQ 5MG BASE	A 219686	002	Jan 22, 2026	Jan	NEWA
AB		EQ 10MG BASE	A 219686	003	Jan 22, 2026	Jan	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>D>	LUPIN PHARMS	EQ 10MG BASE;40MG	A 078466	006	Jul 05, 2011	May	CHRS
>A>	!	EQ 10MG BASE;40MG	A 078466	006	Jul 05, 2011	May	CHRS
>D>	LOTREL						
>D>	+ SANDOZ	EQ 2.5MG BASE;10MG	N 020364	002	Mar 03, 1995	May	DISC
>A>	@ +	EQ 2.5MG BASE;10MG	N 020364	002	Mar 03, 1995	May	DISC
>D>	+ SANDOZ	EQ 5MG BASE;10MG	N 020364	003	Mar 03, 1995	May	DISC
>A>	@ +	EQ 5MG BASE;10MG	N 020364	003	Mar 03, 1995	May	DISC
>D>	+ SANDOZ	EQ 5MG BASE;20MG	N 020364	004	Mar 03, 1995	May	DISC
>A>	@ +	EQ 5MG BASE;20MG	N 020364	004	Mar 03, 1995	May	DISC
>D>	+ SANDOZ	EQ 5MG BASE;40MG	N 020364	007	Apr 11, 2006	May	DISC
>A>	@ +	EQ 5MG BASE;40MG	N 020364	007	Apr 11, 2006	May	DISC
>D>	+ SANDOZ	EQ 10MG BASE;20MG	N 020364	005	Jun 20, 2002	May	DISC
>A>	@ +	EQ 10MG BASE;20MG	N 020364	005	Jun 20, 2002	May	DISC
>D>	+ SANDOZ	EQ 10MG BASE;40MG	N 020364	006	Apr 11, 2006	May	DISC
>A>	@ +	EQ 10MG BASE;40MG	N 020364	006	Apr 11, 2006	May	DISC

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET;ORAL

WIDAPLIK

>D>	+ AZURITY	EQ 1.25MG BASE;0.625MG;10MG	N 219423	001	Jun 05, 2025	May	CHRS
>A>	+	EQ 1.25MG BASE;0.625MG;10MG	N 219423	001	Jun 05, 2025	May	CHRS
	+	EQ 1.25MG BASE;0.625MG;10MG	N 219423	001	Jun 05, 2025	Mar	CMFD
	+	EQ 2.5MG BASE;1.25MG;20MG	N 219423	002	Jun 05, 2025	Mar	CMFD
	+	EQ 5MG BASE;2.5MG;40MG	N 219423	003	Jun 05, 2025	Mar	CMFD

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

@	LUPIN	EQ 5MG BASE;40MG	A 201586	001	Jan 08, 2014	Jan	DISC
@		EQ 5MG BASE;80MG	A 201586	003	Jan 08, 2014	Jan	DISC
@		EQ 10MG BASE;40MG	A 201586	002	Jan 08, 2014	Jan	DISC
@		EQ 10MG BASE;80MG	A 201586	004	Jan 08, 2014	Jan	DISC
@	MYLAN	EQ 5MG BASE;40MG	A 202516	001	Aug 26, 2014	Feb	CMFD
@		EQ 5MG BASE;40MG	A 202516	001	Aug 26, 2014	Jan	DISC

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

		EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Feb CMFD
@		EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Jan DISC
		EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Feb CMFD
@		EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Jan DISC
!		EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Feb CMFD
@		EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Jan DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

@	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Apr DISC
@		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Apr DISC
@		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Apr DISC
@		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Apr DISC

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

@	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr DISC
!	WA UNIV SCH MED	37.5mCi-800mCi/10ML (3.75-80mCi/ML)	A204506	002	Feb 13, 2026	Feb NFTG

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	PADAGIS ISRAEL	EQ 12% BASE	A075774	001	May 01, 2002	Jan CHRS
AB	! SUN PHARMA CANADA	EQ 12% BASE	A075883	001	Apr 10, 2003	Jan CHRS
AB	ZYDUS LIFESCIENCES	EQ 12% BASE	A217815	001	Feb 12, 2026	Feb NEWA

LOTION;TOPICAL

AMMONIUM LACTATE

>A>	AB	ZYDUS LIFESCIENCES	EQ 12% BASE	A217758	001	May 15, 2026	May NEWA
-----	----	--------------------	-------------	---------	-----	--------------	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	!	SANDOZ	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010	Jan CTEC
AB	+	US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Jan CMFD

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

@	INGENUS PHARMS LLC	5MG	A213763	001	Aug 24, 2020	Feb CAHN
@		10MG	A213763	002	Aug 24, 2020	Feb CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@	EUROFARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Feb CAHN
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Feb CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

>D>	@	COSETTE	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		May CAHN
>A>	@	COSETTE PHARMS NC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		May CAHN

APALUTAMIDE

TABLET;ORAL

APALUTAMIDE

>D>	AB	ZYDUS	60MG	A217113	001	Mar 17, 2025	May CAHN
>A>	AB	ZYDUS LIFESCIENCES	60MG	A217113	001	Mar 17, 2025	May CAHN

APREPITANT

EMULSION; INTRAVENOUS		APONVIE							
	+	HERON THERAPS INC	32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Mar	CTEC	
AB	+		32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Feb	CFTG	
APREPITANT									
	@	MYLAN	32MG/4.4ML (7.2MG/ML)	A218851	001	Mar 05, 2026	Mar	DISC	
AB	@		32MG/4.4ML (7.2MG/ML)	A218851	001	Mar 05, 2026	Feb	NFTG	

ARIPIPIRAZOLE

TABLET; ORAL		ARIPIPIRAZOLE							
	@	APOTEX	2MG	A078583	001	Jul 24, 2015	Apr	DISC	
	@		5MG	A078583	002	Jul 24, 2015	Apr	DISC	
	@		10MG	A078583	003	Jul 24, 2015	Apr	DISC	
	@		15MG	A078583	004	Jul 24, 2015	Apr	DISC	
	@		20MG	A078583	005	Jul 24, 2015	Apr	DISC	
	@		30MG	A078583	006	Jul 24, 2015	Apr	DISC	
TABLET, ORALLY DISINTEGRATING; ORAL		ARIPIPIRAZOLE							
AB		AUROBINDO PHARMA	10MG	A216208	001	Feb 18, 2026	Feb	NEWA	
AB			15MG	A216208	002	Feb 18, 2026	Feb	NEWA	

ARMODAFINIL

TABLET; ORAL		ARMODAFINIL							
AB		COREPHARMA	50MG	A201514	001	Mar 25, 2019	Jan	CMFD	
AB			150MG	A201514	002	Mar 25, 2019	Jan	CMFD	
AB			250MG	A201514	003	Mar 25, 2019	Jan	CMFD	

ARSENIC TRIOXIDE

INJECTABLE; INJECTION		ARSENIC TRIOXIDE							
AP		INGENUS PHARMS LLC	1MG/ML	A209315	001	Nov 15, 2018	Feb	CAHN	
	@		2MG/ML	A209315	002	Jan 14, 2021	Feb	CAHN	

ARTICAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC		CYKLX							
	@ +	AM GENOMICS	EQ 8% BASE	N218643	001	Aug 15, 2025	Feb	DISC	
	@ +	THEA PHARMA	EQ 8% BASE	N218643	001	Aug 15, 2025	Apr	CAHN	

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS		INFUVITE PEDIATRIC							
AP	+	SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	001	Feb 21, 2001	Apr	CFTG	
AP	+	SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	002	Jan 29, 2004	Apr	CFTG	
AP		APOTEX	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	A210671	001	Apr 21, 2026	Apr	NFTG	
AP		APOTEX	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	A210456	001	Apr 21, 2026	Apr	NFTG	

ASENAPINE MALEATE

		TABLET; SUBLINGUAL							
		SAPHRIS							
AB	+	ABBVIE	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Mar	CAHN	
AB	+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Mar	CAHN	
AB	+	!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Mar	CAHN	

ASPIRIN; CARISOPRODOL

		TABLET; ORAL							
		CARISOPRODOL AND ASPIRIN							
>A>	@	INGENUS PHARMS LLC	325MG;200MG	A040832	001	Jan 07, 2010	May	CAHN	
>D>	@	NOVAST LABS	325MG;200MG	A040832	001	Jan 07, 2010	May	CAHN	

ASPIRIN; OXYCODONE HYDROCHLORIDE

		TABLET; ORAL							
		OXYCODONE AND ASPIRIN							
	@	EPIC PHARMA LLC	325MG;4.8355MG	A040910	001	Jul 16, 2020	Apr	DISC	
	@ +	ENDO OPERATIONS	325MG;4.8355MG	N007337	007	Aug 05, 2005	Apr	DISC	

ATENOLOL

		TABLET; ORAL							
		ATENOLOL							
AB		IPCA LABS LTD	25MG	A077877	001	Dec 27, 2006	Jan	CMFD	
AB			50MG	A077877	002	Dec 27, 2006	Jan	CMFD	
AB			100MG	A077877	003	Dec 27, 2006	Jan	CMFD	

ATENOLOL; CHLORTHALIDONE

		TABLET; ORAL							
		ATENOLOL AND CHLORTHALIDONE							
AB	!	UNICHEM	100MG;25MG	A213302	002	Nov 25, 2020	Apr	CHRS	
	@ +	TWI PHARMS	100MG;25MG	N018760	001	Jun 08, 1984	Apr	DISC	
	@ +	TWI PHARMS	50MG;25MG	N018760	002	Jun 08, 1984	Apr	DISC	

ATOMOXETINE HYDROCHLORIDE

		SOLUTION; ORAL							
		ATONCY							
	+	MAP77	EQ 4MG BASE/ML	N220320	001	Mar 20, 2026	Mar	NEWA	

ATROPINE SULFATE

		SOLUTION/DROPS; OPHTHALMIC							
		ATROPINE SULFATE							
AT1		EDENBRIDGE PHARMS	1%	A219013	001	Apr 15, 2026	Apr	NEWA	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

		TABLET; ORAL							
		DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE							
	@	QUAGEN	0.025MG;2.5MG	A085762	001		Apr	CAHN	
	@		0.025MG;2.5MG	A210571	001	Aug 31, 2018	Feb	CAHN	

AXITINIB

		TABLET; ORAL							
		AXITINIB							
	@	APOTEX	1MG	A211650	001	Oct 30, 2025	Apr	DISC	
	@		5MG	A211650	002	Oct 30, 2025	Apr	DISC	
	+	PF PRISM CV	1MG	N202324	001	Jan 27, 2012	Apr	CTEC	
	+	!	5MG	N202324	002	Jan 27, 2012	Apr	CTEC	

AZACITIDINE

		POWDER; INTRAVENOUS, SUBCUTANEOUS							
		AZACITIDINE							
	@	AMNEAL	100MG/VIAL	A211549	001	Feb 03, 2022	Apr	DISC	

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

AZILSARTAN MEDOXOMIL

AB	LUPIN	EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Apr	CMFD
AB		EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Apr	CMFD
	EDARBI						
AB	+ AZURITY	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CTEC
AB	+!	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CTEC

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

	@ CARLSBAD	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb	CAHN
AB		EQ 600MG BASE	A211068	001	May 08, 2020	Feb	CAHN

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

>D>	@ BRISTOL MYERS SQUIBB	500MG/VIAL	N050580	001	Dec 31, 1986	May	CAHN
>D> AP	+!	1GM/VIAL	N050580	002	Dec 31, 1986	May	CAHN
>D> AP	+!	2GM/VIAL	N050580	003	Dec 31, 1986	May	CAHN
>A>	@ LABS DELBERT	500MG/VIAL	N050580	001	Dec 31, 1986	May	CAHN
>A> AP	+!	1GM/VIAL	N050580	002	Dec 31, 1986	May	CAHN
>A> AP	+!	2GM/VIAL	N050580	003	Dec 31, 1986	May	CAHN

AZTREONAM

	@ HIKMA	1GM/VIAL	A207069	001	Feb 05, 2026	Feb	DISC
AP		1GM/VIAL	A207069	001	Feb 05, 2026	Jan	NEWA
	@	2GM/VIAL	A207069	002	Feb 05, 2026	Feb	DISC
AP		2GM/VIAL	A207069	002	Feb 05, 2026	Jan	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

	@ PADAGIS US	500 UNITS/GM	A061212	001		Mar	DISC
--	--------------	--------------	---------	-----	--	-----	------

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	@ PADAGIS US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Mar	DISC
--	--------------	---	---------	-----	--	-----	------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

>D>	! BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	May	CAHN
>A>	! BAUSCH AND LOMB INC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	May	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

>D> AT	! BAUSCH AND LOMB	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064064	001	Oct 30, 1995	May	CAHN
>A> AT	! BAUSCH AND LOMB INC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064064	001	Oct 30, 1995	May	CAHN
	@ PADAGIS US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Mar	DISC

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

>D>	! BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	A064046	001	Jan 26, 1995	May	CAHN
	!	500 UNITS/GM;10,000 UNITS/GM	A064046	001	Jan 26, 1995	Mar	CTEC
>A>	! BAUSCH AND LOMB INC	500 UNITS/GM;10,000 UNITS/GM	A064046	001	Jan 26, 1995	May	CAHN
	@ PADAGIS US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Mar	DISC

BACLOFEN

GRANULE;ORAL							
LYVISPAAH							
@ +	STRIDES PHARMA INTL	5MG/PACKET	N215422	001	Nov 22, 2021	Apr	CDFR
@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Apr	CDFR
@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Apr	CDFR
GRANULES;ORAL							
LYVISPAAH							
@ +	STRIDES PHARMA INTL	5MG/PACKET	N215422	001	Nov 22, 2021	Jan	CAHN
@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Jan	CAHN
@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Jan	CAHN
TABLET;ORAL							
BACLOFEN							
>D>	BX HIBROW HLTHCARE	5MG	A211555	003	Nov 30, 2021	May	CTEC
>A>	AB	5MG	A211555	003	Nov 30, 2021	May	CTEC
>D>	BX	10MG	A211555	001	Feb 01, 2019	May	CTEC
>A>	AB	10MG	A211555	001	Feb 01, 2019	May	CTEC
>D>	BX	20MG	A211555	002	Feb 01, 2019	May	CTEC
>A>	AB	20MG	A211555	002	Feb 01, 2019	May	CTEC
	AB RUBICON RESEARCH	5MG	A209102	001	Nov 28, 2017	Jan	CHRS

BALSALAZIDE DISODIUM

CAPSULE;ORAL							
BALSALAZIDE DISODIUM							
AB	CARNEGIE	750MG	A219422	001	Apr 03, 2025	Feb	CAHN
>A>	<u>BAXDROSTAT</u>						
>A>	TABLET;ORAL						
>A>	BAXFENDY						
>A>	+ ASTRAZENECA AB	1MG	N219878	001	May 15, 2026	May	NEWA
>A>	+!	2MG	N219878	002	May 15, 2026	May	NEWA

BECLOMETHASONE DIPROPIONATE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

>A>	AEROSOL, METERED; INHALATION						
>A>	TRIMBOW						
>A>	+! CHIESI	0.086MG/INH;0.0049MG/INH;0.0106MG/INH	N219622	001	May 14, 2026	May	NEWA
>A>	+!	0.172MG/INH;0.0049MG/INH;0.0106MG/INH	N219622	002	May 14, 2026	May	NEWA

BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL							
BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
@	APOTEX	5MG; 6.25MG	A078794	001	Aug 21, 2014	Mar	DISC
@		10MG; 12.5MG	A078794	002	Aug 21, 2014	Mar	DISC
@		20MG; 12.5MG	A078794	003	Aug 21, 2014	Mar	DISC
@		20MG; 25MG	A078794	004	Aug 21, 2014	Mar	DISC
AB	! SANDOZ	20MG; 25MG	A076631	004	Feb 11, 2004	Jan	CHRS
LOTENSIN HCT							
AB	+ VALIDUS PHARMS	20MG; 25MG	N020033	003	May 19, 1992	Jan	CHRS

BENDAMUSTINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS							
BENDAMUSTINE HYDROCHLORIDE							
+!	AVYXA HOLDINGS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Mar	CAHN
+!	DR REDDYS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Apr	CMFD

BENZONATATE

CAPSULE;ORAL							
BENZONATATE							
AA	ASCENT PHARMS INC	150MG	A211518	002	Feb 22, 2019	Apr	CMFD
AA	MARKSANS PHARMA	100MG	A220298	001	Mar 30, 2026	Mar	NEWA
AA		200MG	A220298	002	Mar 30, 2026	Mar	NEWA
AA	! THEPHARMANETWORK LLC	150MG	A040627	003	Sep 24, 2014	Apr	CTEC

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC							
BEPOTASTINE BESILATE							
@	APOTEX	1.5%	A206066	001	Mar 05, 2019	Apr	DISC

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	AUROBINDO PHARMA LTD	EQ 0.05% BASE	A219348	001	Jan 26, 2026	Jan	NEWA
>D>	AB	COSETTE	EQ 0.05% BASE	A210217	001	Oct 12, 2018	May CAHN
>A>	AB	COSETTE PHARMS NC	EQ 0.05% BASE	A210217	001	Oct 12, 2018	May CAHN

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

>D>	AB	COSETTE	EQ 0.05% BASE	A071467	001	Aug 10, 1987	May CAHN
>D>	@		EQ 0.05% BASE	A071882	001	Jun 06, 1988	May CAHN
>A>	AB	COSETTE PHARMS NC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	May CAHN
>A>	@		EQ 0.05% BASE	A071882	001	Jun 06, 1988	May CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

>D>	AB	COSETTE	0.064%;0.005%	A210765	001	May 11, 2020	May CAHN
>A>	AB	COSETTE PHARMS NC	0.064%;0.005%	A210765	001	May 11, 2020	May CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

@ INGENUS PHARMS LLC

0.12%

A207144 001 May 24, 2017 Feb CAHN

CREAM;TOPICAL

BETA-VAL

>D>	AB	COSETTE	EQ 0.1% BASE	N018642	001	Mar 24, 1983	May CAHN
>A>	AB	COSETTE PHARMS NC	EQ 0.1% BASE	N018642	001	Mar 24, 1983	May CAHN

LOTION;TOPICAL

BETA-VAL

>D>	@	COSETTE	EQ 0.1% BASE	A070072	001	Jun 27, 1985	May CAHN
>A>	@	COSETTE PHARMS NC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	May CAHN

OINTMENT;TOPICAL

BETA-VAL

>D>	AB	COSETTE	EQ 0.1% BASE	A070069	001	Dec 19, 1985	May CAHN
>A>	AB	COSETTE PHARMS NC	EQ 0.1% BASE	A070069	001	Dec 19, 1985	May CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	EUROFARMA	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Feb	CAHN
----	-----------	--------------	---------	-----	--------------	-----	------

BIMATOPROST

SOLUTION/DROPS;TOPICAL

BIMATOPROST

@ APOTEX

0.03%

A201894 001 Dec 01, 2014 Apr DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB	INGENUS PHARMS LLC	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Feb	CAHN
----	--------------------	-------------------	---------	-----	--------------	-----	------

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB	MICRO LABS	5MG	A218303	001	Mar 09, 2026	Feb	NEWA
AB		10MG	A218303	002	Mar 09, 2026	Feb	NEWA
	@	NATCO PHARMA USA	5MG	A075831	001	Dec 14, 2005	Mar CAHN
	@		10MG	A075831	002	Dec 14, 2005	Mar CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	2.5MG;6.25MG	A217922	001	Jan 21, 2026	Jan	NEWA
AB		5MG;6.25MG	A217922	002	Jan 21, 2026	Jan	NEWA
AB		10MG;6.25MG	A217922	003	Jan 21, 2026	Jan	NEWA
AB	UNIQUE PHARM	2.5MG;6.25MG	A219489	001	Mar 24, 2026	Mar	NEWA
AB		5MG;6.25MG	A219489	002	Mar 24, 2026	Mar	NEWA
AB		10MG;6.25MG	A219489	003	Mar 24, 2026	Mar	NEWA

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS  
BORTEZOMIB

	@	CAPLIN ONE LABS	3.5MG/VIAL	A203654	001	Jul 26, 2022	Mar	DISC
AP			3.5MG/VIAL	A203654	001	Jul 26, 2022	Jan	CAHN

BOSENTAN

TABLET, FOR SUSPENSION; ORAL  
BOSENTAN

AB		ZYDUS PHARMS	32MG	A213981	001	Feb 17, 2026	Feb	NEWA
----	--	--------------	------	---------	-----	--------------	-----	------

BRIGATINIB

TABLET; ORAL  
ALUNBRIG

	+	!	TAKEDA PHARMS USA	90MG	N208772	002	Apr 28, 2017	Jan	CHRS
	+			180MG	N208772	003	Oct 02, 2017	Jan	CHRS

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC  
BRIMONIDINE TARTRATE

>D>	AT	!	BAUSCH AND LOMB	0.2%	A076260	001	May 28, 2003	May	CAHN
>A>	AT	!	BAUSCH AND LOMB INC	0.2%	A076260	001	May 28, 2003	May	CAHN
AB			GLAND	0.1%	A219219	001	Mar 11, 2026	Feb	NEWA
AB			MANKIND PHARMA	0.1%	A220398	001	Apr 16, 2026	Apr	NEWA
AB			MICRO LABS	0.1%	A218558	001	May 07, 2026	Apr	NEWA

BRIMONIDINE TARTRATE; CARBACHOL

SOLUTION/DROPS; OPHTHALMIC  
YUVEZZI

	+	!	VISUS	0.1%; 2.75%	N220142	001	Jan 28, 2026	Jan	NEWA
--	---	---	-------	-------------	---------	-----	--------------	-----	------

BRIVARACETAM

SOLUTION; INTRAVENOUS  
BRIVARACETAM

AP			HAINAN POLY	50MG/5ML (10MG/ML)	A218249	001	Feb 23, 2026	Feb	NFTG
AP			MICRO LABS	50MG/5ML (10MG/ML)	A214880	001	Feb 23, 2026	Feb	NFTG
AP			MSN	50MG/5ML (10MG/ML)	A214924	001	Feb 23, 2026	Feb	NFTG

BRIVIACT

AP		+	!	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	Feb	CFTG
----	--	---	---	---------	--------------------	---------	-----	--------------	-----	------

SOLUTION; ORAL

BRIVARACETAM

AA			ALKEM LABS LTD	10MG/ML	A219772	001	Feb 23, 2026	Feb	NEWA
AA			INDOCO	10MG/ML	A220385	001	Feb 23, 2026	Feb	NEWA
AA			LUPIN	10MG/ML	A220164	001	Feb 23, 2026	Feb	NEWA
AA			MSN	10MG/ML	A214922	001	Feb 19, 2026	Feb	NFTG
AA			REGCON HOLDINGS	10MG/ML	A220385	001	Feb 23, 2026	Mar	CAHN
AA			ZHEJIANG POLY PHARM	10MG/ML	A218494	001	Feb 23, 2026	Feb	NEWA

BRIVIACT

AA		+	!	UCB INC	10MG/ML	N205838	001	May 12, 2016	Feb	CFTG
----	--	---	---	---------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

BRIVARACETAM

AB			APOTEX	10MG	A214875	001	Feb 23, 2026	Feb	NEWA
AB				25MG	A214875	002	Feb 23, 2026	Feb	NEWA
AB				50MG	A214875	003	Feb 23, 2026	Feb	NEWA
AB				75MG	A214875	004	Feb 23, 2026	Feb	NEWA
AB				100MG	A214875	005	Feb 23, 2026	Feb	NEWA
AB			AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023	Jan	CMFD
AB				100MG	A214848	002	Jan 06, 2023	Jan	CMFD
AB			CENTAUR PHARMS PVT	10MG	A220470	001	Feb 23, 2026	Feb	NEWA
AB				25MG	A220470	002	Feb 23, 2026	Feb	NEWA
AB				50MG	A220470	003	Feb 23, 2026	Feb	NEWA
AB				75MG	A220470	004	Feb 23, 2026	Feb	NEWA
AB				100MG	A220470	005	Feb 23, 2026	Feb	NEWA
AB			SUNSHINE	10MG	A214748	001	Jun 09, 2022	Jan	CMFD
AB				25MG	A214748	002	Jun 09, 2022	Jan	CMFD
AB				50MG	A214748	003	Jun 09, 2022	Jan	CMFD
AB				75MG	A214748	004	Jun 09, 2022	Jan	CMFD
AB				100MG	A214748	005	Jun 09, 2022	Jan	CMFD
>D>		@	ZYDUS PHARMS	10MG	A214501	001	Oct 03, 2022	May	CMFD
>A>	AB			10MG	A214501	001	Oct 03, 2022	May	CMFD
>D>		@		25MG	A214501	002	Oct 03, 2022	May	CMFD

TABLET;ORAL  
BRIVARACETAM

>A>	AB		25MG	A214501	002	Oct 03, 2022	May	CMFD
>D>	@		50MG	A214501	003	Oct 03, 2022	May	CMFD
>A>	AB		50MG	A214501	003	Oct 03, 2022	May	CMFD
>D>	@		75MG	A214501	004	Oct 03, 2022	May	CMFD
>A>	AB		75MG	A214501	004	Oct 03, 2022	May	CMFD
>D>	@		100MG	A214501	005	Oct 03, 2022	May	CMFD
>A>	AB		100MG	A214501	005	Oct 03, 2022	May	CMFD

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL  
BROMFED-DM

@	+	PHARMOBEDIENT	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jan	DISC
---	---	---------------	---------------------------	---------	-----	--------------	-----	------

BUDESONIDE

SUSPENSION;INHALATION  
PULMICORT RESPULES

AN	+	!	ASTRAZENECA	0.25MG/2ML	N020929	001	Aug 08, 2000	Jan	CHRS
AN	+	!		0.5MG/2ML	N020929	002	Aug 08, 2000	Jan	CHRS

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED;INHALATION  
SYMBICORT AEROSPHERE

+	!	ASTRAZENECA	0.08MG/INH;0.0048MG/INH	N216579	002	Apr 27, 2026	Apr	NEWA
---	---	-------------	-------------------------	---------	-----	--------------	-----	------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION  
BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

AB			TEVA PHARMS USA INC	0.08MG/INH;0.0045MG/INH	A212212	001	Apr 23, 2026	Apr	NEWA
AB				0.16MG/INH;0.0045MG/INH	A212212	002	Apr 23, 2026	Apr	NEWA

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION  
BREZTRI AEROSPHERE

+	!	ASTRAZENECA	AB	0.16MG/INH;0.0048MG/INH;0.018MG/INH	N212122	002	Apr 27, 2026	Apr	NEWA
---	---	-------------	----	-------------------------------------	---------	-----	--------------	-----	------

BUMETANIDE

INJECTABLE;INJECTION  
BUMETANIDE

AP			ANTHEA PHARMA	0.25MG/ML	A220427	001	Feb 26, 2026	Feb	NEWA
----	--	--	---------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL  
BUMETANIDE

AB			MSN	0.5MG	A215362	001	Feb 05, 2026	Jan	NEWA
AB				1MG	A215362	002	Feb 05, 2026	Jan	NEWA
AB				2MG	A215362	003	Feb 05, 2026	Jan	NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION  
BUPIVACAINE HYDROCHLORIDE

AP			ANTHEA PHARMA	0.25%	A220493	001	Apr 22, 2026	Apr	NEWA
AP				0.5%	A220493	002	Apr 22, 2026	Apr	NEWA
AP				0.75%	A220493	003	Apr 22, 2026	Apr	NEWA

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL  
BUTRANS

>A>	AB	+	KNOA PHARMA	5MCG/HR	N021306	001	Jun 30, 2010	May	CAHN
>A>	AB	+		7.5MCG/HR	N021306	005	Jun 30, 2014	May	CAHN
>A>	AB	+		10MCG/HR	N021306	002	Jun 30, 2010	May	CAHN
>A>	AB	+		15MCG/HR	N021306	004	Jul 25, 2013	May	CAHN
>A>	AB	+	!	20MCG/HR	N021306	003	Jun 30, 2010	May	CAHN
>D>	AB	+	PURDUE PHARMA LP	5MCG/HR	N021306	001	Jun 30, 2010	May	CAHN
>D>	AB	+		7.5MCG/HR	N021306	005	Jun 30, 2014	May	CAHN
>D>	AB	+		10MCG/HR	N021306	002	Jun 30, 2010	May	CAHN
>D>	AB	+		15MCG/HR	N021306	004	Jul 25, 2013	May	CAHN
>D>	AB	+	!	20MCG/HR	N021306	003	Jun 30, 2010	May	CAHN

SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS  
BRIXADI

+	!	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	Mar	CHRS
+	!		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	Mar	CHRS

SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

BRIXADI

+	!	24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	Mar	CHRS
+	!	32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	Mar	CHRS
+	!	64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	Mar	CHRS
+	!	96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	Mar	CHRS

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	EQ 2MG BASE;EQ 0.5MG BASE	A219850	001	Jan 21, 2026	Jan	NEWA
AB		EQ 4MG BASE;EQ 1MG BASE	A219850	002	Jan 21, 2026	Jan	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A219850	003	Jan 21, 2026	Jan	NEWA
AB		EQ 12MG BASE;EQ 3MG BASE	A219850	004	Jan 21, 2026	Jan	NEWA

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	SENORES PHARMS	75MG	A075584	001	Feb 07, 2000	Feb	CAHN
AB		100MG	A075584	002	Feb 07, 2000	Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	YICHANG HUMANWELL	100MG	A220529	001	May 04, 2026	Apr	NEWA
AB1		150MG	A220529	002	May 04, 2026	Apr	NEWA
AB1		200MG	A220529	003	May 04, 2026	Apr	NEWA

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

AUVELITY

+	AXSOME	105MG;30MG	N215430	002	Apr 30, 2026	Apr	NEWA
---	--------	------------	---------	-----	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL

BUCAPSOL

	EPIC PHARMA LLC	5MG	A218628	004	Apr 29, 2026	Apr	NFTG
--	-----------------	-----	---------	-----	--------------	-----	------

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

>A>	EPIC PHARMA LLC	2.5MG	A208972	006	May 13, 2026	May	NEWA
>D>	BX	5MG	A208972	001	Apr 16, 2019	May	CTEC
>A>	AB	5MG	A208972	001	Apr 16, 2019	May	CTEC
>D>	BX	7.5MG	A208972	002	Apr 16, 2019	May	CTEC
>A>	AB	7.5MG	A208972	002	Apr 16, 2019	May	CTEC
>D>	BX	10MG	A208972	003	Apr 16, 2019	May	CTEC
>A>	AB	10MG	A208972	003	Apr 16, 2019	May	CTEC
>A>		12.5MG	A208972	007	May 13, 2026	May	NEWA
>D>	BX	15MG	A208972	004	Apr 16, 2019	May	CTEC
>A>	AB	15MG	A208972	004	Apr 16, 2019	May	CTEC
>D>	BX	30MG	A208972	005	Apr 16, 2019	May	CTEC
>A>	AB	30MG	A208972	005	Apr 16, 2019	May	CTEC
	@ MYLAN	7.5MG	A076008	002	Jul 08, 2013	Feb	DISC

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

CABENUVA KIT

>D>	+	!	VIIIV HLTHCARE	400MG/2ML (200MG/ML) ; 600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021	May	CHRS
>A>	+			400MG/2ML (200MG/ML) ; 600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021	May	CHRS

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

!	MIKART	100MG;1MG	A040590	001	Sep 16, 2005	Mar	CAHN
---	--------	-----------	---------	-----	--------------	-----	------

CALCIPOTRIENE

SOLUTION;TOPICAL

CALCIPOTRIENE

>D>	AT	!	COSETTE	0.005%	A078468	001	Mar 24, 2011	May	CAHN
>A>	AT	!	COSETTE PHARMS NC	0.005%	A078468	001	Mar 24, 2011	May	CAHN

CALCITONIN SALMON

INJECTABLE; INJECTION  
CALCITONIN-SALMON

AP	ZYDUS PHARMS	200 IU/ML	A215864	001	Mar 04, 2026	Feb NEWA
----	--------------	-----------	---------	-----	--------------	----------

CALCITRIOL

CAPSULE; ORAL  
CALCITRIOL

AB	HUMANWELL PURACAP	0.25MCG	A219796	001	Feb 27, 2026	Feb NEWA
AB		0.5MCG	A219796	002	Feb 27, 2026	Feb NEWA

CALCIUM ACETATE

CAPSULE; ORAL  
CALCIUM ACETATE

	@ LUPIN	667MG	A202127	001	Jul 09, 2015	Mar DISC
--	---------	-------	---------	-----	--------------	----------

TABLET; ORAL

	@ PADAGIS US	667MG	A091561	001	Apr 13, 2011	Mar DISC
--	--------------	-------	---------	-----	--------------	----------

CALCIUM CHLORIDE

INJECTABLE; INJECTION  
CALCIUM CHLORIDE 10%

>D>	@ SQUARE PHARMS PLC	100MG/ML	A217463	001	Sep 29, 2025	May CMFD
>A> AP		100MG/ML	A217463	001	Sep 29, 2025	May CMFD
	@	100MG/ML	A217463	001	Sep 29, 2025	Mar DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION  
DEXTROSE 5% AND LACTATED RINGER'S

>D>	@ FRESENIUS KABI USA	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	A210332	001	Mar 28, 2022	May CMFD
>A> AP		20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	A210332	001	Mar 28, 2022	May CMFD

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D> AP	+ OTSUKA ICU MEDCL	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017608	001		May CHRS
>A> AP	+!	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017608	001		May CHRS

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS  
CALCIUM GLUCONATE

AP	CAPLIN	1GM/10ML (100MG/ML)	A218840	001	May 04, 2026	Apr NEWA
AP		5GM/50ML (100MG/ML)	A218840	002	May 04, 2026	Apr NEWA
AP		10GM/100ML (100MG/ML)	A218840	003	May 04, 2026	Apr NEWA
>A>	+! HQ SPCLT PHARMA	10GM/100ML (100MG/ML)	N210906	004	Nov 18, 2025	May NEWA

CANAGLIFLOZIN

TABLET; ORAL  
CANAGLIFLOZIN

AB	APOTEX	100MG	A210449	001	Apr 14, 2026	Apr NFTG
AB		300MG	A210449	002	Apr 14, 2026	Apr NFTG
	@ AUROBINDO PHARMA LTD	100MG	A210386	001	Apr 20, 2026	Apr DISC
AB		100MG	A210386	001	Apr 20, 2026	Apr NEWA
	@	300MG	A210386	002	Apr 20, 2026	Apr DISC
AB		300MG	A210386	002	Apr 20, 2026	Apr NEWA
	INVOKANA					
AB	+ JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr CFTG
AB	+!	300MG	N204042	002	Mar 29, 2013	Apr CFTG

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL  
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	SENORES PHARMS	16MG; 12.5MG	A202965	001	Jun 03, 2013	Jan CAHN
AB		32MG; 12.5MG	A202965	002	Jun 03, 2013	Jan CAHN
AB		32MG; 25MG	A202965	003	Jun 03, 2013	Jan CAHN

CANGRELOR

POWDER; INTRAVENOUS  
CANGRELOR

>A>	AP	MSN	50MG/VIAL	A213703	001	Jun 04, 2026	May	NEWA
-----	----	-----	-----------	---------	-----	--------------	-----	------

CAPECITABINE

TABLET; ORAL  
CAPECITABINE

AB	!	DR REDDYS	500MG	A204345	002	Dec 04, 2020	Jan	CHRS
		XELODA						
	@ +	CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Jan	DISC
	@ +		500MG	N020896	002	Apr 30, 1998	Jan	DISC

CAPTOPRIL

TABLET; ORAL  
CAPTOPRIL

>D>	@	COSETTE	12.5MG	A074433	001	Feb 13, 1996	May	CAHN
>D>	@		12.5MG	A074462	001	Feb 13, 1996	May	CAHN
>D>	@		12.5MG	A074483	001	Feb 13, 1996	May	CAHN
>D>	@		25MG	A074433	002	Feb 13, 1996	May	CAHN
>D>	@		25MG	A074462	002	Feb 13, 1996	May	CAHN
>D>	@		25MG	A074483	002	Feb 13, 1996	May	CAHN
>D>	@		50MG	A074433	003	Feb 13, 1996	May	CAHN
>D>	@		50MG	A074462	003	Feb 13, 1996	May	CAHN
>D>	@		50MG	A074483	003	Feb 13, 1996	May	CAHN
>D>	@		100MG	A074433	004	Feb 13, 1996	May	CAHN
>D>	@		100MG	A074462	004	Feb 13, 1996	May	CAHN
>D>	@		100MG	A074483	004	Feb 13, 1996	May	CAHN
>A>	@	COSETTE PHARMS NC	12.5MG	A074433	001	Feb 13, 1996	May	CAHN
>A>	@		12.5MG	A074462	001	Feb 13, 1996	May	CAHN
>A>	@		12.5MG	A074483	001	Feb 13, 1996	May	CAHN
>A>	@		25MG	A074433	002	Feb 13, 1996	May	CAHN
>A>	@		25MG	A074462	002	Feb 13, 1996	May	CAHN
>A>	@		25MG	A074483	002	Feb 13, 1996	May	CAHN
>A>	@		50MG	A074433	003	Feb 13, 1996	May	CAHN
>A>	@		50MG	A074462	003	Feb 13, 1996	May	CAHN
>A>	@		50MG	A074483	003	Feb 13, 1996	May	CAHN
>A>	@		100MG	A074433	004	Feb 13, 1996	May	CAHN
>A>	@		100MG	A074462	004	Feb 13, 1996	May	CAHN
>A>	@		100MG	A074483	004	Feb 13, 1996	May	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL  
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

>D>	@	COSETTE	25MG; 15MG	A074827	001	Dec 29, 1997	May	CAHN
>D>	@		25MG; 25MG	A074827	002	Dec 29, 1997	May	CAHN
>D>	@		50MG; 15MG	A074827	004	Dec 29, 1997	May	CAHN
>D>	@		50MG; 25MG	A074827	003	Dec 29, 1997	May	CAHN
>A>	@	COSETTE PHARMS NC	25MG; 15MG	A074827	001	Dec 29, 1997	May	CAHN
>A>	@		25MG; 25MG	A074827	002	Dec 29, 1997	May	CAHN
>A>	@		50MG; 15MG	A074827	004	Dec 29, 1997	May	CAHN
>A>	@		50MG; 25MG	A074827	003	Dec 29, 1997	May	CAHN

CARBAMAZEPINE

TABLET, EXTENDED RELEASE; ORAL  
CARBAMAZEPINE

AB		INGENUS PHARMS LLC	100MG	A216404	001	Dec 02, 2022	Feb	CAHN
AB			200MG	A216404	002	Dec 02, 2022	Feb	CAHN
AB			400MG	A216404	003	Dec 02, 2022	Feb	CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL  
CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		ALEMBIC	12.5MG; 200MG; 50MG	A218535	001	Feb 05, 2026	Jan	NEWA
AB			18.75MG; 200MG; 75MG	A218535	002	Feb 05, 2026	Jan	NEWA
AB			25MG; 200MG; 100MG	A218535	003	Feb 05, 2026	Jan	NEWA
AB			31.25MG; 200MG; 125MG	A218535	004	Feb 05, 2026	Jan	NEWA
AB			37.5MG; 200MG; 150MG	A218535	005	Feb 05, 2026	Jan	NEWA
AB			50MG; 200MG; 200MG	A218535	006	Feb 05, 2026	Jan	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL  
CARBIDOPA AND LEVODOPA

@	SUN PHARM INDS	25MG;100MG	A 077828	001	Aug 23, 2007	Feb	DISC
@		50MG;200MG	A 077828	002	Aug 23, 2007	Feb	DISC

CARBOPLATIN

INJECTABLE; INTRAVENOUS  
CARBOPLATIN

>A>	@	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A 208487	001	Apr 26, 2017	May	CAHN
>A>	@		150MG/15ML (10MG/ML)	A 208487	002	Apr 26, 2017	May	CAHN
>A>	@		450MG/45ML (10MG/ML)	A 208487	003	Apr 26, 2017	May	CAHN
>A>	@		600MG/60ML (10MG/ML)	A 208487	004	Apr 26, 2017	May	CAHN
>D>	@	NOVAST LABS	50MG/5ML (10MG/ML)	A 208487	001	Apr 26, 2017	May	CAHN
	@		50MG/5ML (10MG/ML)	A 208487	001	Apr 26, 2017	Feb	DISC
>D>	@		150MG/15ML (10MG/ML)	A 208487	002	Apr 26, 2017	May	CAHN
	@		150MG/15ML (10MG/ML)	A 208487	002	Apr 26, 2017	Feb	DISC
>D>	@		450MG/45ML (10MG/ML)	A 208487	003	Apr 26, 2017	May	CAHN
	@		450MG/45ML (10MG/ML)	A 208487	003	Apr 26, 2017	Feb	DISC
>D>	@		600MG/60ML (10MG/ML)	A 208487	004	Apr 26, 2017	May	CAHN
	@		600MG/60ML (10MG/ML)	A 208487	004	Apr 26, 2017	Feb	DISC
AP		QILU PHARM HAINAN	50MG/5ML (10MG/ML)	A 219999	001	Feb 04, 2026	Jan	NEWA
AP			150MG/15ML (10MG/ML)	A 219999	002	Feb 04, 2026	Jan	NEWA
AP			450MG/45ML (10MG/ML)	A 219999	003	Feb 04, 2026	Jan	NEWA
AP			600MG/60ML (10MG/ML)	A 219999	004	Feb 04, 2026	Jan	NEWA

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION  
CARBOPROST TROMETHAMINE

>A>	AP	SOMERSET THERAPS LLC	EQ 0.25MG BASE/ML	A 219529	001	May 27, 2026	May	NEWA
-----	----	----------------------	-------------------	----------	-----	--------------	-----	------

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL  
CARIPRAZINE HYDROCHLORIDE

@	AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A 213982	001	Dec 16, 2025	Jan	DISC	
@		EQ 3MG BASE	A 213982	002	Dec 16, 2025	Jan	DISC	
@		EQ 6MG BASE	A 213982	003	Dec 16, 2025	Jan	DISC	
	VRAYLAR							
	+!	ABBVIE	EQ 1.5MG BASE	N 204370	001	Sep 17, 2015	Jan	CTEC
	+		EQ 3MG BASE	N 204370	002	Sep 17, 2015	Jan	CTEC
	+		EQ 6MG BASE	N 204370	004	Sep 17, 2015	Jan	CTEC

CARISOPRODOL

TABLET; ORAL  
CARISOPRODOL

AA		INGENUS PHARMS LLC	350MG	A 040823	001	Oct 22, 2008	Feb	CAHN
----	--	--------------------	-------	----------	-----	--------------	-----	------

CARMUSTINE

INJECTABLE; INJECTION  
CARMUSTINE

>A>	@	INGENUS PHARMS LLC	100MG/VIAL	A 211011	001	Jun 21, 2022	May	CAHN
>D>	@	NOVAST LABS	100MG/VIAL	A 211011	001	Jun 21, 2022	May	CAHN

CARVEDILOL

TABLET; ORAL  
CARVEDILOL

@	LUPIN	3.125MG	A 078217	001	Sep 05, 2007	Feb	DISC
@		6.25MG	A 078217	002	Sep 05, 2007	Feb	DISC
@		12.5MG	A 078217	003	Sep 05, 2007	Feb	DISC
@		25MG	A 078217	004	Sep 05, 2007	Feb	DISC

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS  
CASPOFUNGIN ACETATE

>D>	AP	GLAND	50MG/VIAL	A 207092	001	Sep 29, 2017	May	CHRS
>A>	AP	!	50MG/VIAL	A 207092	001	Sep 29, 2017	May	CHRS
>D>	AP		70MG/VIAL	A 207092	002	Sep 29, 2017	May	CHRS
>A>	AP	!	70MG/VIAL	A 207092	002	Sep 29, 2017	May	CHRS
>D>	AP	!	HENGRUI PHARMA	A 200833	001	Jun 28, 2018	May	DISC
>A>	@		50MG/VIAL	A 200833	001	Jun 28, 2018	May	DISC
>D>	AP	!	70MG/VIAL	A 200833	002	Jun 28, 2018	May	DISC

		POWDER; INTRAVENOUS CASPOFUNGIN ACETATE							
>A>	@		70MG/VIAL	A200833	002	Jun 28, 2018	May	DISC	
		<u>CEFAZOLIN SODIUM</u>							
		POWDER; INTRAVENOUS CEFAZOLIN SODIUM							
	+!	HQ SPCLT PHARMA	EQ 3GM BASE/VIAL	N211413	002	Mar 08, 2024	Feb	NEWA	
>A>		<u>CEFEPIME HYDROCHLORIDE; ZIDEBACTAM</u>							
>A>		POWDER; INTRAVENOUS							
>A>		ZAYNICH							
>A>	+!	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;1GM/VIAL	N220787	001	May 29, 2026	May	NEWA	
		<u>CEFIXIME</u>							
		CAPSULE; ORAL CEFIXIME							
AB		AUROBINDO PHARMA LTD	400MG	A217607	001	Mar 23, 2026	Mar	NEWA	
		FOR SUSPENSION; ORAL CEFIXIME							
>A>	AB	FDC LTD	100MG/5ML	A218691	001	May 14, 2026	May	NEWA	
>A>	AB		200MG/5ML	A218691	002	May 14, 2026	May	NEWA	
		TABLET; ORAL CEFIXIME							
	!	FDC LTD	400MG	A206358	001	Dec 17, 2024	Jan	CMFD	
		<u>CEFTAROLINE FOSAMIL</u>							
		POWDER; INTRAVENOUS CEFTAROLINE FOSAMIL							
AP		APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Jan	CMFD	
AP			600MG/VIAL	A208075	002	Sep 21, 2021	Jan	CMFD	
		TEFLARO							
AP	+!	ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010	Jan	CTEC	
AP	+!		600MG/VIAL	N200327	002	Oct 29, 2010	Jan	CTEC	
		<u>CEFTRIAZONE SODIUM</u>							
		INJECTABLE; INJECTION CEFTRIAZONE							
	@	SANDOZ INC	EQ 1GM BASE/VIAL	A065204	001	May 03, 2005	Apr	DISC	
	@		EQ 2GM BASE/VIAL	A065204	002	May 03, 2005	Apr	DISC	
		<u>CEPHALEXIN</u>							
		FOR SUSPENSION; ORAL CEPHALEXIN							
>A>	AB	AUROBINDO PHARMA	EQ 125MG BASE/5ML	A213568	001	Jun 09, 2026	May	NEWA	
>A>	AB		EQ 250MG BASE/5ML	A213568	002	Jun 09, 2026	May	NEWA	
		<u>CETIRIZINE HYDROCHLORIDE</u>							
		SOLUTION; INTRAVENOUS QUZYTIR							
	+!	ESTEVE	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019	Apr	CAHN	
		SOLUTION; ORAL CETIRIZINE HYDROCHLORIDE							
AA		RUBICON RESEARCH	5MG/5ML	A220335	001	Feb 25, 2026	Feb	NEWA	
	@	TIME CAP LABS	5MG/5ML	A078757	001	Aug 28, 2009	Mar	CAHN	
		<u>CETRORELIX ACETATE</u>							
		POWDER; SUBCUTANEOUS CETRORELIX ACETATE							
>A>	AP	EPIC PHARMA LLC	EQ 0.25MG BASE/VIAL	A218740	001	Apr 29, 2026	May	CAHN	
>D>	AP	HUMANWELL	EQ 0.25MG BASE/VIAL	A218740	001	Apr 29, 2026	May	CAHN	
AP			EQ 0.25MG BASE/VIAL	A218740	001	Apr 29, 2026	Apr	NEWA	
		<u>CEVIMELINE HYDROCHLORIDE</u>							
		CAPSULE; ORAL CEVIMELINE HYDROCHLORIDE							
AB		ZYDUS LIFESCIENCES	30MG	A220267	001	Mar 11, 2026	Feb	NEWA	

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB	+	BARR	5MG	A 084768	001		Mar	CRLD
AB	+		10MG	A 083116	001		Mar	CRLD
AB	+	!	25MG	A 084769	001		Mar	CRLD
		LIBRIUM						
AB	+	BAUSCH	5MG	A 085461	001		Feb	CAHN
AB	+		10MG	A 085472	001		Feb	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIDEX

>D>	AT	+	!	3M	0.12%	N 019028	001	Aug 13, 1986	May	CAHN
>A>	AT	+	!	SOLVENTUM	0.12%	N 019028	001	Aug 13, 1986	May	CAHN

CHLOROTHIAZIDE

SUSPENSION;ORAL

DIURIL

@	+	SALIX PHARMS	250MG/5ML	N 011870	001		Jan	DISC
---	---	--------------	-----------	----------	-----	--	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@		PADAGIS US	4MG/5ML;5MG/5ML;60MG/5ML	A 204627	001	Apr 29, 2014	Mar	DISC
---	--	------------	--------------------------	----------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AA	!	GENUS	30MG/ML	A 214542	001	Jun 02, 2021	Mar	CTEC
AA	!		100MG/ML	A 214542	002	Jun 02, 2021	Mar	CTEC
>D>	AA	RUBICON	30MG/ML	A 216678	001	Oct 10, 2025	May	CAHN
AA			30MG/ML	A 216678	001	Oct 10, 2025	Mar	CTEC
>D>	AA		100MG/ML	A 216678	002	Oct 10, 2025	May	CAHN
AA			100MG/ML	A 216678	002	Oct 10, 2025	Mar	CTEC
>A>	AA	RUBICON RESEARCH	30MG/ML	A 216678	001	Oct 10, 2025	May	CAHN
>A>	AA		100MG/ML	A 216678	002	Oct 10, 2025	May	CAHN
		SONAZINE						
AA		SAPTALIS PHARMS	30MG/ML	A 080983	004		Mar	CMFD
AA			100MG/ML	A 080983	005		Mar	CMFD

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP		MSN	25MG/ML	A 216092	001	Jan 26, 2026	Jan	NEWA
----	--	-----	---------	----------	-----	--------------	-----	------

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		ZAMEER PHARMS	10MG	A 212630	001	Nov 29, 2021	Jan	CAHN
AB			25MG	A 212630	002	Nov 29, 2021	Jan	CAHN
AB			50MG	A 212630	003	Nov 29, 2021	Jan	CAHN
AB			100MG	A 212630	004	Nov 29, 2021	Jan	CAHN
AB			200MG	A 212630	005	Nov 29, 2021	Jan	CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB	!	ALKEM LABS LTD	50MG	A 213412	002	Feb 11, 2020	Mar	CHRS
>D>	@	COSETTE	50MG	A 088651	001	May 30, 1985	May	CAHN
>A>	@	COSETTE PHARMS NC	50MG	A 088651	001	May 30, 1985	May	CAHN
>A>	AB	INGENUS PHARMS LLC	25MG	A 206904	001	Mar 30, 2017	May	CAHN
>A>	AB		50MG	A 206904	002	Mar 30, 2017	May	CAHN
>D>	AB	NOVAST LABS	25MG	A 206904	001	Mar 30, 2017	May	CAHN
>D>	AB		50MG	A 206904	002	Mar 30, 2017	May	CAHN

CHLORZOAZONE

TABLET;ORAL

CHLORZOAZONE

AA		SENORES PHARMS	500MG	A 210961	001	Jan 22, 2024	Jan	CAHN
----	--	----------------	-------	----------	-----	--------------	-----	------

CHOLESTYRAMINE

		POWDER; ORAL		CHOLESTYRAMINE			
AB	MICRO LABS	EQ 4GM RESIN/PACKET	A219318	001	Mar 05, 2026	Feb	NEWA
AB	PHARMOBEDIENT	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Jan	CAHN
AB		EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Jan	CAHN
		CHOLESTYRAMINE LIGHT					
AB	ZYDUS PHARMS	EQ 4GM RESIN/PACKET	A202902	002	Apr 25, 2017	Mar	NEWA

CHROMIC CHLORIDE

		INJECTABLE; INJECTION		CHROMIC CHLORIDE			
AP	SOMERSET THERAPS LLC	EQ 0.004MG CHROMIUM/ML	A218538	001	Nov 18, 2024	Feb	CAHN

CICLESONIDE

		AEROSOL, METERED; NASAL		ZETONNA			
	@ + AZURITY	0.037MG/INH	N202129	001	Jan 20, 2012	Mar	CAHN
		SPRAY, METERED; NASAL		OMNARIS			
	+! AZURITY	0.05MG/SPRAY	N022004	001	Oct 20, 2006	Mar	CAHN

CICLOPIROX

		CREAM; TOPICAL		CICLOPIROX			
>D>	AB COSETTE	0.77%	A078463	001	Dec 20, 2010	May	CAHN
>A>	AB COSETTE PHARMS NC	0.77%	A078463	001	Dec 20, 2010	May	CAHN
		LOPROX					
AB	+! EUROFARMA	0.77%	N018748	001	Dec 30, 1982	Feb	CAHN
		SOLUTION; TOPICAL		CICLOPIROX			
>D>	@ COSETTE	8%	A078233	001	Sep 18, 2007	May	CAHN
>A>	@ COSETTE PHARMS NC	8%	A078233	001	Sep 18, 2007	May	CAHN
		SUSPENSION; TOPICAL		LOPROX			
AB	+! EUROFARMA	0.77%	N019824	001	Dec 30, 1988	Feb	CAHN

CIMETIDINE HYDROCHLORIDE

		INJECTABLE; INJECTION		CIMETIDINE HYDROCHLORIDE			
>D>	@ COSETTE	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997	May	CAHN
>A>	@ HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997	May	CAHN

CINACALCET HYDROCHLORIDE

		TABLET; ORAL		CINACALCET HYDROCHLORIDE			
	@ HETERO LABS LTD V	EQ 30MG BASE	A209403	001	Oct 07, 2020	Feb	DISC
	@	EQ 60MG BASE	A209403	002	Oct 07, 2020	Feb	DISC
	@	EQ 90MG BASE	A209403	003	Oct 07, 2020	Feb	DISC
	@ STEVENS J	EQ 30MG BASE	A204364	001	Dec 02, 2021	Feb	CPOT
	@	EQ 60MG BASE	A204364	002	Dec 02, 2021	Feb	CPOT
	@	EQ 90MG BASE	A204364	003	Dec 02, 2021	Feb	CPOT

CIPROFLOXACIN HYDROCHLORIDE

		SOLUTION/DROPS; OTIC		CIPROFLOXACIN HYDROCHLORIDE			
>A>	AB ALEMBIC THERAP	EQ 0.2% BASE	A217887	001	Nov 05, 2024	May	CAHN
>D>	AB NEW HEIGHTSRX	EQ 0.2% BASE	A217887	001	Nov 05, 2024	May	CAHN
		TABLET; ORAL		CIPROFLOXACIN HYDROCHLORIDE			
	@ AMNEAL	EQ 250MG BASE	A075939	002	Jun 09, 2004	Mar	DISC
	@	EQ 500MG BASE	A075939	003	Jun 09, 2004	Mar	DISC
	@	EQ 750MG BASE	A075939	004	Jun 09, 2004	Mar	DISC

CISATRACURIUM BESYLATE

		INJECTABLE; INJECTION		CISATRACURIUM BESYLATE			
	@ HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb	DISC
AP	PIRAMAL	EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Apr	CMFD
AP		EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Apr	CMFD

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Apr	CMFD
AP			EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Apr	CMFD
	@	HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Feb	DISC
	@		EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Feb	DISC

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

AB	+	ALMATICA	EQ 30MG BASE	N215428	001	Jan 31, 2022	Mar	CFTG
AB		AUROBINDO PHARMA LTD	EQ 30MG BASE	A219985	001	Mar 13, 2026	Mar	NFTG

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

	@	AMNEAL PHARMS NY	EQ 10MG BASE	A077289	001	Nov 30, 2006	Feb	DISC
	@		EQ 20MG BASE	A077289	002	Nov 30, 2006	Feb	DISC
	@		EQ 40MG BASE	A077289	003	Nov 30, 2006	Feb	DISC
>D>	@	COSETTE	EQ 10MG BASE	A077048	001	Nov 16, 2004	May	CAHN
>D>	@		EQ 20MG BASE	A077048	002	Nov 16, 2004	May	CAHN
>D>	@		EQ 40MG BASE	A077048	003	Nov 16, 2004	May	CAHN
>A>	@	COSETTE PHARMS NC	EQ 10MG BASE	A077048	001	Nov 16, 2004	May	CAHN
>A>	@		EQ 20MG BASE	A077048	002	Nov 16, 2004	May	CAHN
>A>	@		EQ 40MG BASE	A077048	003	Nov 16, 2004	May	CAHN

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL; VAGINAL

>A>		PHEXX						
>A>	+	EVOFEM INC	1%;1.8%;0.4%	N208352	001	May 22, 2020	May	CTNA
>D>		PHEXXI						
>D>	+	EVOFEM INC	1%;1.8%;0.4%	N208352	001	May 22, 2020	May	CTNA

CLADRIBINE

TABLET; ORAL

CLADRIBINE

AB		HOPEWELL PHARMA	10MG	A215547	001	Mar 27, 2026	Mar	NEWA
----	--	-----------------	------	---------	-----	--------------	-----	------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

	@	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Apr	DISC
>A>	AA	APPCO	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	May	CAHN
	@	PADAGIS US	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Mar	DISC
>D>	AA	SOMERSET THERAPS LLC	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	May	CAHN

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB1		AUROBINDO PHARMA LTD	EQ 1% BASE	A218942	001	Mar 18, 2026	Mar	NEWA
AB1		SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Feb	CAHN

SOLUTION; TOPICAL

CLINDA-DERM

	@	PADAGIS US	EQ 1% BASE	A063329	001	Sep 30, 1992	Mar	DISC
	@	INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Feb	CAHN
AT		RISING	EQ 1% BASE	A218300	001	Mar 23, 2026	Mar	NEWA

SWAB; TOPICAL

CLINDETS

	@	PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Mar	DISC
--	---	------------	------------	---------	-----	--------------	-----	------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

>A>	@	INGENUS PHARMS LLC	0.05%	A206805	001	Jul 31, 2017	May	CAHN
>D>	@	NOVAST LABS	0.05%	A206805	001	Jul 31, 2017	May	CAHN

GEL; TOPICAL

CLOBETASOL PROPIONATE

>A>	@	ENCUBE	0.05%	A208881	001	Mar 06, 2017	May	CAHN
>D>	@	PAI HOLDINGS PHARM	0.05%	A208881	001	Mar 06, 2017	May	CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

>D>	AB	COSETTE	0.05%	A074089	001	Feb 16, 1994	May	CAHN
-----	----	---------	-------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL  
 CLOBETASOL PROPIONATE  
 >A> AB COSETTE PHARMS NC 0.05% A 074089 001 Feb 16, 1994 May CAHN  
 SPRAY;TOPICAL  
 CLOBETASOL PROPIONATE  
 @ PADAGIS US 0.05% A 090898 001 Jun 16, 2011 Mar DISC

CLOFARABINE

SOLUTION;INTRAVENOUS  
 CLOFARABINE  
 >A> @ INGENUS PHARMS LLC 20MG/20ML (1MG/ML) A 210270 001 Sep 14, 2018 May CAHN  
 >D> @ NOVAST LABS 20MG/20ML (1MG/ML) A 210270 001 Sep 14, 2018 May CAHN  
 >D> AP PHARMOBEDIENT 20MG/20ML (1MG/ML) A 208860 001 Nov 06, 2017 May DISC  
 >A> @ 20MG/20ML (1MG/ML) A 208860 001 Nov 06, 2017 May DISC

CLOMIPHENE CITRATE

TABLET;ORAL  
 CLOMIPHENE CITRATE  
 >A> AB ASCENT PHARMS INC 50MG A 220673 001 May 15, 2026 May NEWA  
 >D> AB RUBICON 50MG A 216545 001 Nov 12, 2024 May CAHN  
 >A> AB RUBICON RESEARCH 50MG A 216545 001 Nov 12, 2024 May CAHN

CLONAZEPAM

TABLET;ORAL  
 CLONAZEPAM  
 AB CHARTWELL RX 0.5MG A 074925 001 Sep 30, 1997 Jan CMFD  
 AB 1MG A 074925 002 Sep 30, 1997 Jan CMFD  
 AB 2MG A 074925 003 Sep 30, 1997 Jan CMFD  
 @ QUAGEN 0.5MG A 074940 001 Oct 30, 1997 Apr CAHN  
 @ 1MG A 074940 002 Oct 30, 1997 Apr CAHN  
 @ 2MG A 074940 003 Oct 30, 1997 Apr CAHN  
 TABLET, ORALLY DISINTEGRATING;ORAL  
 CLONAZEPAM  
 >A> AB RUBICON RESEARCH 0.125MG A 216988 001 May 21, 2026 May NEWA  
 >A> AB 0.25MG A 216988 002 May 21, 2026 May NEWA  
 >A> AB 0.5MG A 216988 003 May 21, 2026 May NEWA  
 >A> AB 1MG A 216988 004 May 21, 2026 May NEWA  
 >A> AB 2MG A 216988 005 May 21, 2026 May NEWA

CLONIDINE

SYSTEM;TRANSDERMAL  
 CLONIDINE  
 @ DIFGEN PHARMS 0.1MG/24HR A 076157 001 Aug 18, 2009 Feb CAHN  
 @ 0.2MG/24HR A 076157 002 Aug 18, 2009 Feb CAHN  
 @ 0.3MG/24HR A 076157 003 Aug 18, 2009 Feb CAHN  
 TABLET, EXTENDED RELEASE;ORAL  
 NEXICLON XR  
 ROSEMONT EQ 0.17MG BASE N 022500 001 Dec 03, 2009 Mar CAHN  
 @ EQ 0.26MG BASE N 022500 002 Dec 03, 2009 Mar CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL  
 CLONIDINE HYDROCHLORIDE  
 ! TP ANDA HOLDINGS 0.05MG A 070923 004 Apr 06, 2026 Mar NFTG

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL  
 CLORAZEPATE DIPOTASSIUM  
 @ NATCO PHARMA USA 3.75MG A 071509 001 Oct 19, 1987 Mar CAHN  
 @ 7.5MG A 071510 001 Oct 19, 1987 Mar CAHN  
 @ 15MG A 071511 001 Oct 19, 1987 Mar CAHN

COBICISTAT

TABLET;ORAL  
 TYBOST  
 @ + GILEAD SCIENCES INC 150MG N 203094 001 Sep 24, 2014 Mar DISC

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

+! JANSSEN PRODS 150MG;EQ 675MG BASE

N205395 002 Mar 21, 2025 Mar CHRS

TABLET, FOR SUSPENSION;ORAL

PREZCOBIX PED

+! JANSSEN PRODS 90MG;EQ 600MG BASE

N220092 001 Feb 27, 2026 Feb NEWA

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

>D> AA ! GENUS LIFESCIENCES 10MG/5ML;5MG/5ML;6.25MG/5ML

A040660 001 Dec 07, 2006 May CAHN

>A> AA ! PAI HOLDINGS 10MG/5ML;5MG/5ML;6.25MG/5ML

A040660 001 Dec 07, 2006 May CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

>D> AA ! COSETTE 10MG/5ML;6.25MG/5ML

A200386 001 Jun 29, 2012 May CAHN

>A> AA ! COSETTE PHARMS NC 10MG/5ML;6.25MG/5ML

A200386 001 Jun 29, 2012 May CAHN

COLCHICINE

CAPSULE;ORAL

COLCHICINE

AB MICRO LABS 0.6MG

A212880 001 Feb 17, 2026 Feb NEWA

TABLET;ORAL

COLCHICINE

AB MACLEODS PHARMS LTD 0.6MG

A210633 001 Feb 13, 2026 Feb NEWA

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

>A> AB INGENUS PHARMS LLC 0.5MG;500MG

A040618 001 May 13, 2008 May CAHN

>D> AB NOVAST LABS 0.5MG;500MG

A040618 001 May 13, 2008 May CAHN

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL

COLESTID

>D> AB + PFIZER 5GM/SCOOPFUL

N017563 003 Sep 22, 1995 May CTEC

>A> + 5GM/SCOOPFUL

N017563 003 Sep 22, 1995 May CTEC

>D> AB +! 5GM/PACKET

N017563 004 Sep 22, 1995 May CTEC

>A> +! 5GM/PACKET

N017563 004 Sep 22, 1995 May CTEC

COLESTIPOL HYDROCHLORIDE

>D> AB IMPAX LABS 5GM/SCOOPFUL

A077277 001 May 02, 2006 May DISC

>A> @ 5GM/SCOOPFUL

A077277 001 May 02, 2006 May DISC

>D> AB 5GM/PACKET

A077277 002 May 02, 2006 May DISC

>A> @ 5GM/PACKET

A077277 002 May 02, 2006 May DISC

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

>D> AP XELLIA PHARMS APS EQ 150MG BASE/VIAL

A205356 001 May 29, 2015 May CHRS

>A> AP ! EQ 150MG BASE/VIAL

A205356 001 May 29, 2015 May CHRS

>D> COLY-MYCIN M

>D> AP +! PH HEALTH EQ 150MG BASE/VIAL

N050108 002 May DISC

>A> @ + EQ 150MG BASE/VIAL

N050108 002 May DISC

COPPER HISTIDINATE

POWDER;SUBCUTANEOUS

ZYCUBO

+! SENTYNL THERAPS INC 2.9MG/VIAL

N211241 001 Jan 12, 2026 Jan NEWA

CROTAMITON

CREAM;TOPICAL

EURAX

+! JOURNEY 10%

N006927 001 Apr CMFD

LOTION;TOPICAL

CROTAN

! LEGACY PHARMA 10%

A087204 001 Apr CHRS

10%

A087204 001 Apr CTEC

LOTION; TOPICAL  
EURAX

@ + JOURNEY 10% N009112 003 Apr DISC

CUPRIC CHLORIDE

INJECTABLE; INJECTION  
CUPRIC CHLORIDE

@ AMNEAL EQ 0.4MG COPPER/ML A217287 001 Jan 26, 2026 Mar DISC  
AP EQ 0.4MG COPPER/ML A217287 001 Jan 26, 2026 Jan NEWA  
AP STIRA EQ 0.4MG COPPER/ML A217626 001 Apr 30, 2024 Apr CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL  
CYCLOBENZAPRINE HYDROCHLORIDE

>A> AB AIPING PHARM INC 7.5MG A072854 003 May 13, 2026 May NEWA

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
PENTOLAIR

>D> AT BAUSCH AND LOMB 1% A040075 001 Apr 29, 1994 May CAHN  
>A> AT BAUSCH AND LOMB INC 1% A040075 001 Apr 29, 1994 May CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION  
CYCLOPHOSPHAMIDE

@ HAINAN POLY 500MG/VIAL A218632 001 Dec 26, 2024 Jan DISC  
@ 1GM/VIAL A218632 002 Dec 26, 2024 Jan DISC  
@ 2GM/VIAL A218632 003 Dec 26, 2024 Jan DISC

CYCLOSPORINE

EMULSION; OPHTHALMIC  
CYCLOSPORINE

>A> AB JIANGSU ANBISON 0.05% A219288 001 Jun 01, 2026 May NEWA  
AB TWI PHARMS 0.05% A209064 001 Jan 21, 2026 Jan NEWA

INJECTABLE; INJECTION  
CYCLOSPORINE

@ PADAGIS US 50MG/ML A065151 001 Oct 07, 2003 Mar DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL  
CYPROHEPTADINE HYDROCHLORIDE

AA ST JOHN PHARM 2MG/5ML A209108 001 Oct 16, 2018 Jan CAHN

TABLET; ORAL  
CYPROHEPTADINE HYDROCHLORIDE

@ ANVI 4MG A087129 001 Mar CAHN  
AA INGENUS PHARMS LLC 4MG A205087 001 Sep 23, 2015 Feb CAHN

DALBAVANCIN HYDROCHLORIDE

POWDER; INTRAVENOUS  
DALBAVANCIN HYDROCHLORIDE

>A> AP BE PHARMS EQ 500MG BASE/VIAL A219604 001 Jun 04, 2026 May NEWA  
AP LONG GROVE PHARMS EQ 500MG BASE/VIAL A218602 001 Feb 26, 2026 Feb NEWA

DAPAGLIFLOZIN

TABLET; ORAL  
DAPAGLIFLOZIN

AB AIZANT 5MG A211523 001 Apr 06, 2026 Mar NFTG  
AB 10MG A211523 002 Apr 06, 2026 Mar NFTG  
AB AJANTA PHARMA LTD 5MG A211482 001 Apr 06, 2026 Mar NFTG  
AB 10MG A211482 002 Apr 06, 2026 Mar NFTG  
AB ALEMBIC 5MG A211560 001 Apr 06, 2026 Mar NFTG  
AB 10MG A211560 002 Apr 06, 2026 Mar NFTG  
AB ALKEM LABS LTD 5MG A211545 001 Apr 06, 2026 Mar NFTG  
AB 10MG A211545 002 Apr 06, 2026 Mar NFTG  
AB AUROBINDO PHARMA 5MG A211468 001 Apr 06, 2026 Mar NFTG  
AB 10MG A211468 002 Apr 06, 2026 Mar NFTG  
AB BIOCON PHARMA 5MG A211470 001 Apr 06, 2026 Mar NFTG  
AB 10MG A211470 002 Apr 06, 2026 Mar NFTG  
AB CIPLA 5MG A211535 001 Apr 06, 2026 Mar NFTG  
AB 10MG A211535 002 Apr 06, 2026 Mar NFTG  
AB INVENTIA 5MG A211156 001 Apr 06, 2026 Mar NFTG  
AB 10MG A211156 002 Apr 06, 2026 Mar NFTG

TABLET;ORAL

DAPAGLIFLOZIN

AB	LUPIN	5MG	A211531	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211531	002	Apr 06, 2026	Mar	NFTG
AB	MACLEODS PHARMS LTD	5MG	A211506	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211506	002	Apr 06, 2026	Mar	NFTG
AB	MICRO LABS	5MG	A211467	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211467	002	Apr 06, 2026	Mar	NFTG
AB	MSN	5MG	A211478	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211478	002	Apr 06, 2026	Mar	NFTG
AB	SANDOZ	5MG	A211312	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211312	002	Apr 06, 2026	Mar	NFTG
AB	TEVA PHARMS USA	5MG	A211541	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211541	002	Apr 06, 2026	Mar	NFTG
AB	ZYDUS PHARMS	5MG	A211582	001	Apr 06, 2026	Mar	NFTG
AB		10MG	A211582	002	Apr 06, 2026	Mar	NFTG
FARXIGA							
AB	+ ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Mar	CFTG
AB	+!	10MG	N202293	002	Jan 08, 2014	Mar	CFTG

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

AB	ALKEM LABS LTD	5MG;500MG	A211563	001	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211563	002	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211563	003	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211563	004	Apr 06, 2026	Mar	NFTG
AB	AUROBINDO PHARMA	5MG;500MG	A211489	001	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211489	002	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211489	003	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211489	004	Apr 06, 2026	Mar	NFTG
AB	CIPLA	5MG;1GM	A211595	001	Apr 06, 2026	Mar	NFTG
AB	CIPLA LTD	5MG;500MG	A211536	001	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211536	002	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211536	003	Apr 06, 2026	Mar	NFTG
AB	LUPIN	5MG;500MG	A211579	001	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211579	002	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211579	003	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211579	004	Apr 06, 2026	Mar	NFTG
AB	MACLEODS PHARMS LTD	5MG;500MG	A211559	001	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211559	002	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211559	003	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211559	004	Apr 06, 2026	Mar	NFTG
AB	MICRO LABS	5MG;500MG	A211466	001	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211466	002	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211466	003	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211466	004	Apr 06, 2026	Mar	NFTG
AB	MSN	5MG;500MG	A211479	001	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211479	002	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211479	003	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211479	004	Apr 06, 2026	Mar	NFTG
AB	SUN PHARM	5MG;1GM	A211491	001	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211491	002	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211491	003	Apr 06, 2026	Mar	NFTG
AB	TEVA PHARMS USA INC	2.5MG;1GM	A211583	001	Apr 06, 2026	Mar	NFTG
AB		5MG;500MG	A211583	002	Apr 06, 2026	Mar	NFTG
AB		5MG;1GM	A211583	003	Apr 06, 2026	Mar	NFTG
AB		10MG;500MG	A211583	004	Apr 06, 2026	Mar	NFTG
AB		10MG;1GM	A211583	005	Apr 06, 2026	Mar	NFTG
XIGDUO XR							
AB	+ ASTRAZENECA AB	2.5MG;1GM	N205649	005	Jul 28, 2017	Mar	CFTG
AB	+	5MG;500MG	N205649	001	Oct 29, 2014	Mar	CFTG
AB	+	5MG;1GM	N205649	002	Oct 29, 2014	Mar	CFTG
AB	+	10MG;500MG	N205649	003	Oct 29, 2014	Mar	CFTG
AB	+	10MG;1GM	N205649	004	Oct 29, 2014	Mar	CFTG

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE

AB	! MSN	10MG;EQ 5MG BASE	A211533	001	Apr 06, 2026	Mar	NFTG
AB	TORRENT	10MG;EQ 5MG BASE	A211537	001	Apr 06, 2026	Mar	NFTG

DAPSONE

GEL; TOPICAL

DAPSONE

>A>	@	CHARTWELL RX	5%	A215087	001	Oct 31, 2023	May CAHN
>A>	@		7.5%	A212657	001	Nov 01, 2023	May CAHN
>D>	AB	COSETTE	5%	A210178	001	Mar 31, 2022	May CAHN
>A>	AB	COSETTE PHARMS NC	5%	A210178	001	Mar 31, 2022	May CAHN
>D>	@	PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	May CAHN
>D>	@		7.5%	A212657	001	Nov 01, 2023	May CAHN

TABLET; ORAL

DAPSONE

AB		ZYDUS LIFESCIENCES	25MG	A220103	001	Feb 26, 2026	Feb NEWA
AB			100MG	A220103	002	Feb 26, 2026	Feb NEWA

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

@		HENGRUI PHARMA	500MG/VIAL	A212022	001	Aug 22, 2019	Jan DISC
---	--	----------------	------------	---------	-----	--------------	----------

DASIGLUCAGON HYDROCHLORIDE

SOLUTION; SUBCUTANEOUS

ZEGALOGUE

@ +		ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Feb DISC
-----	--	----------------	---	---------	-----	--------------	----------

ZEGALOGUE (AUTOINJECTOR)

@ +		ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Feb DISC
-----	--	----------------	---	---------	-----	--------------	----------

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

@		NOVAST LABS	50MG/VIAL	A210984	001	Sep 16, 2019	Feb DISC
---	--	-------------	-----------	---------	-----	--------------	----------

DEFERIPRONE

TABLET; ORAL

FERRIPROX

@ +		CHIESI	500MG	N021825	001	Oct 14, 2011	Apr DISC
-----	--	--------	-------	---------	-----	--------------	----------

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

@		HIKMA	500MG/VIAL	A078086	001	May 30, 2007	Mar DISC
@			2GM/VIAL	A078086	002	May 30, 2007	Mar DISC

DEFLAZACORT

SUSPENSION; ORAL

DEFLAZACORT

>A>	AB	CARNEGIE	22.75MG/ML	A220709	001	May 28, 2026	May NEWA
	AB	SUN PHARM INDS INC	22.75MG/ML	A219930	001	Jan 27, 2026	Jan NEWA

DEHYDRATED ALCOHOL

SOLUTION; INTRA-ARTERIAL

ABLYSINOL

@ +		BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jan CAIN
AP	+	!	99% (5ML)	N207987	002	Jun 21, 2018	Jan CAIN

DEHYDRATED ALCOHOL

AP		ACCORD HLTHCARE	99% (5ML)	A217845	001	Jun 23, 2025	Jan CAIN
AP		BRECKENRIDGE	99% (5ML)	A219444	001	Jun 23, 2025	Jan CAIN
AP		INGENUS PHARMS LLC	99% (5ML)	A219569	001	Jul 09, 2025	Jan CAIN
AP		XGEN PHARMS	99% (5ML)	A219400	001	Jun 23, 2025	Jan CAIN

SOLUTION; INTRAVENOUS

DEHYDRATED ALCOHOL

+	!	ROYAL PHARMS	98% (5ML)	N214988	001	Oct 23, 2025	Jan CAIN
---	---	--------------	-----------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

@		HERITAGE	10MG	A207433	001	May 05, 2016	Jan DISC
@			25MG	A207433	002	May 05, 2016	Jan DISC
@			50MG	A207433	003	May 05, 2016	Jan DISC
@			75MG	A207433	004	May 05, 2016	Jan DISC

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE							
	@		100MG	A207433	005	May 05, 2016	Jan DISC
	@		150MG	A207433	006	May 05, 2016	Jan DISC
AB		INGENUS PHARMS LLC	10MG	A204963	001	Dec 26, 2017	Feb CAHN
AB			25MG	A204963	002	Dec 26, 2017	Feb CAHN
AB			50MG	A204963	003	Dec 26, 2017	Feb CAHN
AB			75MG	A204963	004	Dec 26, 2017	Feb CAHN
AB			100MG	A204963	005	Dec 26, 2017	Feb CAHN
AB			150MG	A204963	006	Dec 26, 2017	Feb CAHN

DESLORATADINE

TABLET;ORAL

DESLORATADINE							
>D>	@	NATCO PHARMA USA	5MG	A078351	001	Feb 10, 2012	May CMFD
>A>	AB		5MG	A078351	001	Feb 10, 2012	May CMFD
	@		5MG	A078351	001	Feb 10, 2012	Mar CAHN

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DESMOPRESSIN ACETATE							
AP		CAPLIN	0.004MG/ML	A219981	001	Feb 27, 2026	Feb NEWA
		SOLUTION;ORAL					
		DESMODA					
	+	ETON	0.05MG/ML	N219873	001	Feb 25, 2026	Feb NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL							
AB		ANNORA PHARMA	0.15MG;0.03MG	A219761	001	Mar 18, 2026	Mar NEWA

DESONIDE

AEROSOL, FOAM;TOPICAL  
VERDESO

	@ +	GENUS	0.05%	N021978	001	Sep 19, 2006	Apr CAHN
		CREAM;TOPICAL					
		DESONIDE					
>D>	AB	COSETTE	0.05%	A074027	001	Sep 28, 1992	May CAHN
>A>	AB	COSETTE PHARMS NC	0.05%	A074027	001	Sep 28, 1992	May CAHN
		LOTION;TOPICAL					
		DESONIDE					
>A>	@	ENCUBE	0.05%	A207855	001	Sep 28, 2017	May CAHN
>D>	@	VERTICE	0.05%	A207855	001	Sep 28, 2017	May CAHN
	@		0.05%	A207855	001	Sep 28, 2017	Apr CAHN

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE							
AB		SCIEGEN PHARMS	0.05%	A203787	001	Jan 06, 2017	Apr CMFD
AB			0.25%	A203234	001	Jun 12, 2015	Apr CMFD
		GEL;TOPICAL					
		DESOXIMETASONE					
	@	PADAGIS US	0.05%	A077552	001	Jan 09, 2006	Mar DISC
		OINTMENT;TOPICAL					
		DESOXIMETASONE					
>A>	@	ENCUBE	0.25%	A208101	001	Feb 25, 2016	May CAHN
>D>	@	PAI HOLDINGS PHARM	0.25%	A208101	001	Feb 25, 2016	May CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE							
AB		PLATINUM	EQ 50MG BASE	A204805	001	May 07, 2019	Mar CAHN
AB			EQ 100MG BASE	A204805	002	May 07, 2019	Mar CAHN
AB		YICHANG HUMANWELL	EQ 25MG BASE	A220460	001	Mar 10, 2026	Feb NEWA
AB			EQ 50MG BASE	A220460	002	Mar 10, 2026	Feb NEWA
AB			EQ 100MG BASE	A220460	003	Mar 10, 2026	Feb NEWA

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

+! HIKMA 1MG/ML A088252 001 Sep 01, 1983 Jan CRLD

TABLET; ORAL

DEXAMETHASONE

PANGEA 0.25MG A088149 001 Apr 28, 1983 Mar CMFD

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

>D> ! BAUSCH AND LOMB EQ 0.1% PHOSPHATE A040069 001 Jul 26, 1996 May CAHN  
 >A> ! BAUSCH AND LOMB INC EQ 0.1% PHOSPHATE A040069 001 Jul 26, 1996 May CAHN  
 @ CAPLIN EQ 0.1% PHOSPHATE A088771 001 Jan 16, 1985 Jan CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

>D> AT BAUSCH AND LOMB 0.1%;EQ 3.5MG BASE/GM;10,000 A064063 001 Jul 25, 1994 May CAHN  
 UNITS/GM  
 >A> AT BAUSCH AND LOMB INC 0.1%;EQ 3.5MG BASE/GM;10,000 A064063 001 Jul 25, 1994 May CAHN  
 UNITS/GM  
 @ PADAGIS US 0.1%;EQ 3.5MG BASE/GM;10,000 A062938 001 Jul 31, 1989 Mar DISC  
 UNITS/GM

SUSPENSION/DROPS; OPHTHALMIC

DEXASPORIN

>D> AT BAUSCH AND LOMB 0.1%;EQ 3.5MG BASE/ML;10,000 A064135 001 Sep 13, 1995 May CAHN  
 UNITS/ML  
 >A> AT BAUSCH AND LOMB INC 0.1%;EQ 3.5MG BASE/ML;10,000 A064135 001 Sep 13, 1995 May CAHN  
 UNITS/ML

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRAMYCIN AND DEXAMETHASONE

>D> AB BAUSCH AND LOMB 0.1%;0.3% A064134 001 Oct 27, 1999 May CAHN  
 >A> AB BAUSCH AND LOMB INC 0.1%;0.3% A064134 001 Oct 27, 1999 May CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

IGALMI

+ BIOXCEL EQ 0.18MG BASE N215390 002 Apr 05, 2022 Jan CHRS

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP BAXTER HLTHCARE CORP EQ 200MCG BASE/2ML (EQ 100MCG A208103 001 Apr 15, 2026 Apr NEWA  
 BASE/ML)  
 @ CAPLIN EQ 200MCG BASE/2ML (EQ 100MCG A091465 001 Jun 14, 2016 Apr DISC  
 BASE/ML)  
 AP EQ 200MCG BASE/2ML (EQ 100MCG A091465 001 Jun 14, 2016 Jan CAHN  
 BASE/ML)  
 AP DR REDDYS EQ 200MCG BASE/50ML (EQ 4MCG A220315 001 Feb 25, 2026 Feb NEWA  
 BASE/ML)  
 AP EQ 400MCG BASE/100ML (EQ 4MCG A220315 002 Feb 25, 2026 Feb NEWA  
 BASE/ML)  
 >D> AP KNACK EQ 200MCG BASE/2ML (EQ 100MCG A218675 001 Mar 09, 2026 May DISC  
 BASE/ML)  
 >A> @ EQ 200MCG BASE/2ML (EQ 100MCG A218675 001 Mar 09, 2026 May DISC  
 BASE/ML)  
 AP EQ 200MCG BASE/2ML (EQ 100MCG A218675 001 Mar 09, 2026 Feb NEWA  
 BASE/ML)

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 5MG A202580 002 Aug 25, 2015 Mar CMS1  
 @ 10MG A202580 003 Aug 25, 2015 Mar CMS1  
 @ 15MG A202580 004 Aug 25, 2015 Mar CMS1  
 @ 20MG A202580 005 Dec 21, 2015 Mar CMS1  
 @ 25MG A202580 006 May 04, 2021 Mar CMS1  
 @ 35MG A202580 007 May 04, 2021 Mar CMS1  
 @ 40MG A202580 008 Aug 25, 2015 Mar CMS1  
 AB PLATINUM 5MG A078992 001 Nov 23, 2021 Apr CAHN  
 AB 10MG A078992 002 Nov 23, 2021 Apr CAHN  
 AB 15MG A078992 003 Nov 18, 2013 Apr CAHN  
 AB 30MG A078992 004 Nov 18, 2013 Apr CAHN

CAPSULE, EXTENDED RELEASE;ORAL  
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		20MG	A078992	005	Nov 23, 2021	Apr	CAHN
AB		40MG	A078992	006	Nov 23, 2021	Apr	CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE;ORAL  
AZSTARYS

>A>	+	COMMAVE SUB	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021	May	CAHN
>A>	+		EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021	May	CAHN
>A>	+		EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021	May	CAHN
>D>	+	COMMAVE THERAP	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021	May	CAHN
>D>	+		EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021	May	CAHN
>D>	+		EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021	May	CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL  
DEXTROAMPHETAMINE SULFATE

@	QUAGEN	5MG	A206735	001	Jan 27, 2016	Apr	CAHN
@		10MG	A206735	002	Jan 27, 2016	Apr	CAHN
@		15MG	A206735	003	Jan 27, 2016	Apr	CAHN
@	STRIDES PHARMA INTL	5MG	A205673	001	Oct 31, 2017	Jan	DISC
@		10MG	A205673	002	Oct 31, 2017	Jan	DISC
@		15MG	A205673	003	Oct 31, 2017	Jan	DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>D>	AA	COSETTE	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	May	CAHN
>A>	AA	COSETTE PHARMS NC	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	May	CAHN
	AA	HETERO LABS LTD III	15MG/5ML;6.25MG/5ML	A218264	001	Mar 12, 2026	Mar	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

>A>	AB	SUN PHARM	20MG;10MG	A204196	001	Jun 03, 2026	May	NEWA
		NUDEXTA						
>D>	AB	+	AVANIR PHARMS	N021879	001	Oct 29, 2010	May	CAHN
>A>	AB	+	OTSUKA AMERICA PHARM	N021879	001	Oct 29, 2010	May	CAHN

DIAZEPAM

TABLET;ORAL

DIAZEPAM

@	STRIDES PHARMA INTL	2MG	A077749	001	Mar 31, 2006	Jan	DISC
@		5MG	A077749	002	Mar 31, 2006	Jan	DISC
@		10MG	A077749	003	Mar 31, 2006	Jan	DISC

DICLOFENAC POTASSIUM

CAPSULE;ORAL

ZIPSOR

AB	+	ASSERTIO SPECLTY	25MG	N022202	001	Jun 16, 2009	Feb	CAHN
----	---	------------------	------	---------	-----	--------------	-----	------

FOR SOLUTION;ORAL

CAMBIA

AB	+	ASSERTIO SPECLTY	50MG	N022165	001	Jun 17, 2009	Feb	CAHN
----	---	------------------	------	---------	-----	--------------	-----	------

TABLET;ORAL

DICLOFENAC POTASSIUM

AB		INGENUS PHARMS LLC	50MG	A215585	001	Oct 08, 2021	Feb	CAHN
----	--	--------------------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

@	AMNEAL	3%	A200936	001	Oct 28, 2013	Mar	DISC
---	--------	----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB		INGENUS PHARMS LLC	100MG	A216275	001	Sep 23, 2022	Feb	CAHN
----	--	--------------------	-------	---------	-----	--------------	-----	------

DIFAMILAST

OINTMENT; TOPICAL  
ADQUEY

+! ACROTECH BIOPHARMA 1% N219474 001 Feb 12, 2026 Feb NEWA

DIFLUPREDNATE

EMULSION; OPHTHALMIC  
DIFLUPREDNATE

AB ALEMBIC 0.05% A213774 001 Jan 26, 2026 Jan NEWA

DIGOXIN

INJECTABLE; INJECTION  
LANOXIN

AP +! AZURITY 0.25MG/ML N009330 002 Mar CAHN

LANOXIN PEDIATRIC

+! AZURITY 0.1MG/ML N009330 004 Mar CAHN

TABLET; ORAL  
DIGOXIN

>D> AB SUN PHARM INDS INC 0.125MG A076363 001 Jan 31, 2003 May DISC

>A> @ 0.125MG A076363 001 Jan 31, 2003 May DISC

>D> AB 0.25MG A076363 002 Jan 31, 2003 May DISC

>A> @ 0.25MG A076363 002 Jan 31, 2003 May DISC

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION  
DIHYDROERGOTAMINE MESYLATE

@ PADAGIS US 1MG/ML A040475 001 Apr 28, 2003 Mar DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
DILTIAZEM HYDROCHLORIDE

AB3 MACLEODS PHARMS LTD 120MG A218744 001 Feb 27, 2026 Feb NEWA

AB3 180MG A218744 002 Feb 27, 2026 Feb NEWA

AB3 240MG A218744 003 Feb 27, 2026 Feb NEWA

AB3 300MG A218744 004 Feb 27, 2026 Feb NEWA

AB3 360MG A218744 005 Feb 27, 2026 Feb NEWA

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

>D> @ ZYDUS LIFESCIENCES 30MG A219253 001 Aug 08, 2025 May CMFD

>A> AB 30MG A219253 001 Aug 08, 2025 May CMFD

@ 30MG A219253 001 Aug 08, 2025 Jan DISC

>D> @ 60MG A219253 002 Aug 08, 2025 May CMFD

>A> AB 60MG A219253 002 Aug 08, 2025 May CMFD

@ 60MG A219253 002 Aug 08, 2025 Jan DISC

>D> @ 90MG A219253 003 Aug 08, 2025 May CMFD

>A> AB 90MG A219253 003 Aug 08, 2025 May CMFD

@ 90MG A219253 003 Aug 08, 2025 Jan DISC

>D> @ 120MG A219253 004 Aug 08, 2025 May CMFD

>A> AB 120MG A219253 004 Aug 08, 2025 May CMFD

@ 120MG A219253 004 Aug 08, 2025 Jan DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL  
DIMETHYL FUMARATE

@ MYLAN 120MG A210531 001 Aug 17, 2020 Mar DISC

@ 240MG A210531 002 Aug 17, 2020 Mar DISC

DISULFIRAM

TABLET; ORAL  
DISULFIRAM

@ NATCO PHARMA USA 250MG A203916 001 Mar 04, 2015 Mar CAHN

@ 500MG A203916 002 Mar 04, 2015 Mar CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL  
DIVALPROEX SODIUM

>D> AB LUPIN EQ 125MG VALPROIC ACID A078790 001 Jul 29, 2008 May DISC

>A> @ EQ 125MG VALPROIC ACID A078790 001 Jul 29, 2008 May DISC

>D> AB EQ 250MG VALPROIC ACID A078790 002 Jul 29, 2008 May DISC

>A> @ EQ 250MG VALPROIC ACID A078790 002 Jul 29, 2008 May DISC

>D> AB EQ 500MG VALPROIC ACID A078790 003 Jul 29, 2008 May DISC

TABLET, DELAYED RELEASE;ORAL  
DIVALPROEX SODIUM

>A> @ EQ 500MG VALPROIC ACID A078790 003 Jul 29, 2008 May DISC

DOCETAXEL

INJECTABLE; INJECTION  
DOCETAXEL

@ INGENUS PHARMS LLC 20MG/2ML (10MG/ML) A207563 001 Aug 31, 2017 Feb CAHN  
 @ 80MG/8ML (10MG/ML) A207563 002 Aug 31, 2017 Feb DISC  
 AP @ 80MG/8ML (10MG/ML) A207563 002 Aug 31, 2017 Feb CAHN  
 @ 160MG/16ML (10MG/ML) A207563 003 Aug 31, 2017 Feb DISC  
 AP @ 160MG/16ML (10MG/ML) A207563 003 Aug 31, 2017 Feb CAHN

DOFETILIDE

CAPSULE;ORAL  
DOFETILIDE

@ INGENUS PHARMS LLC 0.125MG A212410 001 Dec 27, 2019 Feb CAHN  
 @ 0.25MG A212410 002 Dec 27, 2019 Feb CAHN  
 @ 0.5MG A212410 003 Dec 27, 2019 Feb CAHN  
 @ STRIDES PHARMA INTL 0.125MG A208519 001 Oct 09, 2018 Jan DISC  
 @ 0.25MG A208519 002 Oct 09, 2018 Jan DISC  
 @ 0.5MG A208519 003 Oct 09, 2018 Jan DISC

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL  
DONEPEZIL HYDROCHLORIDE

@ LUPIN 23MG A202782 001 Oct 30, 2015 Feb DISC

DORAVIRINE; ISLATRAVIR

TABLET;ORAL  
IDVNSO

+! MSD 100MG;0.25MG N216964 001 Apr 20, 2026 Apr NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>A> AT2 ALEMBIC THERAP EQ 2% BASE;EQ 0.5% BASE A216308 001 Feb 18, 2025 May CAHN  
 >D> AT2 NEW HEIGHTSRX EQ 2% BASE;EQ 0.5% BASE A216308 001 Feb 18, 2025 May CAHN

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL  
DOXEPIIN HYDROCHLORIDE

AB UNIQUE EQ 10MG BASE A217975 001 Aug 21, 2023 Mar CAHN  
 AB EQ 25MG BASE A217975 002 Aug 21, 2023 Mar CAHN  
 AB EQ 50MG BASE A217975 003 Aug 21, 2023 Mar CAHN  
 AB EQ 75MG BASE A217975 004 Aug 21, 2023 Mar CAHN  
 AB EQ 100MG BASE A217975 005 Aug 21, 2023 Mar CAHN

CREAM;TOPICAL  
DOXEPIIN HYDROCHLORIDE

AB SUN PHARMA CANADA 5% A213919 001 Apr 28, 2026 Apr NEWA

DOXERCALCIFEROL

INJECTABLE; INJECTION  
DOXERCALCIFEROL

@ CAPLIN 4MCG/2ML (2MCG/ML) A200926 001 Feb 04, 2014 Apr DISC  
 AP 4MCG/2ML (2MCG/ML) A200926 001 Feb 04, 2014 Jan CAHN  
 @ 2MCG/ML (2MCG/ML) A200926 002 Sep 04, 2014 Apr DISC  
 @ 2MCG/ML (2MCG/ML) A200926 002 Sep 04, 2014 Apr NEWA  
 @ EUGIA PHARMA 4MCG/2ML (2MCG/ML) A213717 002 Jan 24, 2022 Mar DISC  
 @ HIKMA 4MCG/2ML (2MCG/ML) A091101 001 Aug 30, 2013 Mar DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION  
DOXORUBICIN HYDROCHLORIDE

AB QILU PHARM HAINAN 20MG/10ML (2MG/ML) A219881 001 Feb 03, 2026 Jan NEWA  
 AB 50MG/25ML (2MG/ML) A219881 002 Feb 03, 2026 Jan NEWA

DOXYCYCLINE

CAPSULE; ORAL  
DOXYCYCLINE  
AB AIPING PHARM INC 40MG A219978 001 Oct 01, 2025 Jan CAHN

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION  
DOXYCYCLINE HYCLATE  
@ AVET LIFESCIENCES EQ 100MG BASE/VIAL A203276 001 Feb 19, 2026 Feb DISC  
AP EQ 100MG BASE/VIAL A203276 001 Feb 19, 2026 Feb NEWA  
TABLET; ORAL  
DOXYCYCLINE HYCLATE  
@ APOTEX EQ 75MG BASE A209243 001 Apr 15, 2019 Jan DISC  
@ EQ 150MG BASE A209243 002 Apr 15, 2019 Jan DISC  
TABLET, DELAYED RELEASE; ORAL  
DORYX  
@ + MAYNE PHARMA EQ 80MG BASE N050795 004 Apr 11, 2013 Apr DISC  
@ + EQ 200MG BASE N050795 005 Apr 11, 2013 Apr DISC

DRONABINOL

CAPSULE; ORAL  
DRONABINOL  
>A> @ RHODES 2.5MG A078292 001 Jun 27, 2008 May CAHN  
>A> @ 5MG A078292 002 Jun 27, 2008 May CAHN  
>A> @ 10MG A078292 003 Jun 27, 2008 May CAHN  
>D> @ SVC PHARMA 2.5MG A078292 001 Jun 27, 2008 May CAHN  
>D> @ 5MG A078292 002 Jun 27, 2008 May CAHN  
>D> @ 10MG A078292 003 Jun 27, 2008 May CAHN  
SOLUTION; ORAL  
SYNDROS  
@ + WELLHOUSE PHARMA 5MG/ML N205525 001 Mar 23, 2017 Jan CAHN

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL  
DRONEDARONE HYDROCHLORIDE  
@ LUPIN EQ 400MG BASE A205904 001 Jan 31, 2024 Mar DISC  
MULTAQ  
+! SANOFI AVENTIS US EQ 400MG BASE N022425 001 Jul 01, 2009 Mar CTEC

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL  
DULOXETINE HYDROCHLORIDE  
+! ALMATICA EQ 80MG BASE N219131 001 Feb 27, 2026 Feb NEWA  
+ EQ 90MG BASE N219131 002 Feb 27, 2026 Feb NEWA  
+ EQ 120MG BASE N219131 003 Feb 27, 2026 Feb NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL  
ECONAZOLE NITRATE  
AB AUROBINDO PHARMA USA 1% A210364 001 Apr 18, 2018 Mar CMFD

EDARAVONE

SOLUTION; INTRAVENOUS  
EDARAVONE  
@ DR REDDYS 60MG/100ML (0.6MG/ML) A215917 001 May 06, 2024 Apr DISC  
@ GLAND 60MG/100ML (0.6MG/ML) A216199 002 May 06, 2024 Apr DISC  
! PHARMOBEDIANT 60MG/100ML (0.6MG/ML) A217565 002 Oct 31, 2024 Apr CTEC  
RADICAVA  
@ + SHIONOGI 30MG/100ML (0.3MG/ML) N209176 001 May 05, 2017 Apr CAHN  
@ + 60MG/100ML (0.6MG/ML) N209176 002 Nov 15, 2018 Apr DISC  
AP + 60MG/100ML (0.6MG/ML) N209176 002 Nov 15, 2018 Apr CAHN  
SUSPENSION; ORAL  
RADICAVA ORS  
+! SHIONOGI 105MG/5ML N215446 001 May 12, 2022 Apr CAHN

EFINACONAZOLE

SOLUTION;TOPICAL  
EFINACONAZOLE

AB	ALEMBIC	10%	A212027	001	Feb 23, 2026	Feb	NEWA
AB	NIVAGEN PHARMS INC	10%	A211969	001	Jun 21, 2021	Mar	CAHN

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL  
ELETRIPTAN HYDROBROMIDE

@	CARLSBAD	EQ 20MG BASE	A209680	001	Jul 13, 2020	Feb	CAHN
@		EQ 40MG BASE	A209680	002	Jul 13, 2020	Feb	CAHN

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

GRANULE;ORAL  
TRIKAFTA (COPACKAGED)

+	VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG	N217660	001	Apr 26, 2023	Apr	CDFR
+	!	100MG, 75MG, 50MG;75MG	N217660	002	Apr 26, 2023	Apr	CDFR

ELIGLUSTAT TARTRATE

CAPSULE;ORAL  
ELIGLUSTAT TARTRATE

@	CIPLA	EQ 84MG BASE	A212369	001	Dec 10, 2024	Feb	DISC
---	-------	--------------	---------	-----	--------------	-----	------

ELTROMBOPAG OLAMINE

TABLET;ORAL  
ELTROMBOPAG OLAMINE

>D>	AB	AIZANT	EQ 12.5MG ACID	A220660	001	Apr 28, 2026	May	CAHN
	AB		EQ 12.5MG ACID	A220660	001	Apr 28, 2026	Apr	NEWA
>D>	AB		EQ 25MG ACID	A220660	002	Apr 28, 2026	May	CAHN
	AB		EQ 25MG ACID	A220660	002	Apr 28, 2026	Apr	NEWA
>D>	AB		EQ 50MG ACID	A220660	003	Apr 28, 2026	May	CAHN
	AB		EQ 50MG ACID	A220660	003	Apr 28, 2026	Apr	NEWA
>D>	AB		EQ 75MG ACID	A220660	004	Apr 28, 2026	May	CAHN
	AB		EQ 75MG ACID	A220660	004	Apr 28, 2026	Apr	NEWA
	AB	AMNEAL	EQ 12.5MG ACID	A212884	001	Jan 14, 2026	Jan	NEWA
	AB		EQ 25MG ACID	A212884	003	Jan 14, 2026	Jan	NEWA
	AB		EQ 50MG ACID	A212884	002	Jan 14, 2026	Jan	NEWA
	AB		EQ 75MG ACID	A212884	004	Jan 14, 2026	Jan	NEWA
>A>	AB	BIOCON PHARMA	EQ 12.5MG ACID	A220660	001	Apr 28, 2026	May	CAHN
>A>	AB		EQ 25MG ACID	A220660	002	Apr 28, 2026	May	CAHN
>A>	AB		EQ 50MG ACID	A220660	003	Apr 28, 2026	May	CAHN
>A>	AB		EQ 75MG ACID	A220660	004	Apr 28, 2026	May	CAHN
	AB	DR REDDYS	EQ 12.5MG ACID	A219121	001	Mar 16, 2026	Mar	NEWA
	AB		EQ 25MG ACID	A219121	002	Mar 16, 2026	Mar	NEWA
	AB		EQ 50MG ACID	A219121	003	Mar 16, 2026	Mar	NEWA
	AB		EQ 75MG ACID	A219121	004	Mar 16, 2026	Mar	NEWA
	AB	HIKMA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Apr	CAHN
	AB		EQ 25MG ACID	A220033	002	Apr 08, 2026	Apr	CAHN
	AB		EQ 50MG ACID	A220033	003	Apr 08, 2026	Apr	CAHN
	AB		EQ 75MG ACID	A220033	004	Apr 08, 2026	Apr	CAHN
	AB	MSN	EQ 12.5MG ACID	A220250	001	Jan 14, 2026	Jan	NEWA
	AB		EQ 25MG ACID	A220250	002	Jan 14, 2026	Jan	NEWA
	AB		EQ 50MG ACID	A220250	003	Jan 14, 2026	Jan	NEWA
	AB		EQ 75MG ACID	A220250	004	Jan 14, 2026	Jan	NEWA
	AB	SOMERSET THERAPS LLC	EQ 12.5MG ACID	A219638	001	Jan 14, 2026	Jan	NEWA
	AB		EQ 25MG ACID	A219638	002	Jan 14, 2026	Jan	NEWA
	AB		EQ 50MG ACID	A219638	003	Jan 14, 2026	Jan	NEWA
	AB		EQ 75MG ACID	A219638	004	Jan 14, 2026	Jan	NEWA
	AB	ZENARA	EQ 12.5MG ACID	A220033	001	Apr 08, 2026	Mar	NEWA
	AB		EQ 25MG ACID	A220033	002	Apr 08, 2026	Mar	NEWA
	AB		EQ 50MG ACID	A220033	003	Apr 08, 2026	Mar	NEWA
	AB		EQ 75MG ACID	A220033	004	Apr 08, 2026	Mar	NEWA
	AB	ZYDUS PHARMS	EQ 12.5MG ACID	A216281	001	Jan 14, 2026	Jan	NEWA
	AB		EQ 25MG ACID	A216281	002	Jan 14, 2026	Jan	NEWA
	AB		EQ 50MG ACID	A216281	003	Jan 14, 2026	Jan	NEWA
	AB		EQ 75MG ACID	A216281	004	Jan 14, 2026	Jan	NEWA

ELUXADOLINE

TABLET;ORAL

ELUXADOLINE

>A>	AB	AUROBINDO PHARMA	75MG	A213511	001	Jun 02, 2026	May NEWA
>A>	AB		100MG	A213511	002	Jun 02, 2026	May NEWA
		VIBERZI					
>D>	+	ABBVIE	75MG	N206940	001	May 27, 2015	May CTEC
>A>	AB		75MG	N206940	001	May 27, 2015	May CTEC
>A>	AB		75MG	N206940	001	May 27, 2015	May CTEC
>D>	+	!	100MG	N206940	002	May 27, 2015	May CTEC
>A>	AB		100MG	N206940	002	May 27, 2015	May CTEC
>A>	AB		100MG	N206940	002	May 27, 2015	May CTEC

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

AB		APOTEX	200MG;EQ 25MG BASE;EQ 25MG BASE	A214095	001	Jan 30, 2026	Jan NFTG
AB		ODEFSEY					
AB	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Jan CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		LAURUS	200MG;EQ 25MG BASE;300MG	A220232	001	Mar 04, 2026	Feb NEWA
----	--	--------	--------------------------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

AB	@	LUPIN	200MG;EQ 25MG BASE	A213926	001	Dec 13, 2024	Mar DISC
AB		MACLEODS PHARMS LTD	200MG;EQ 25MG BASE	A214216	001	Apr 07, 2026	Mar NEWA

ENSIFENTRINE

SUSPENSION;INHALATION

OHTUVAYRE

	+	MSD	3MG/2.5ML	N217389	001	Jun 26, 2024	Apr CAHN
--	---	-----	-----------	---------	-----	--------------	----------

ENSITRELVIR

TABLET;ORAL

XOCOVA

>A>							
>A>	+	SHIONOGI	125MG	N220442	001	May 29, 2026	May NEWA

ENTECAVIR

TABLET;ORAL

ENTECAVIR

	@	PHARMADAX	0.5MG	A212106	001	Aug 10, 2020	Mar CAHN
	@		1MG	A212106	002	Aug 10, 2020	Mar CAHN

ENZALUTAMIDE

TABLET;ORAL

ENZALUTAMIDE

AB		SANDOZ	40MG	A216068	001	Apr 20, 2026	Apr NFTG
AB			80MG	A216068	002	Apr 20, 2026	Apr NFTG
		XTANDI					
AB	+	ASTELLAS	40MG	N213674	001	Aug 04, 2020	Apr CFTG
AB	+	!	80MG	N213674	002	Aug 04, 2020	Apr CFTG

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

AP2		FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A219991	001	Mar 19, 2026	Mar NEWA
-----	--	--------------------	--------------------	---------	-----	--------------	----------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

	@	APOTEX	0.05%	A090919	001	Oct 31, 2011	Apr DISC
	!	SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Apr CTEC

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
EPINEPHRINE

	+	!	BAXTER HLTHCARE CORP	1MG/ML (1MG/ML)	N220626	001	Mar 30, 2026	Mar	NEWA
	+	!		30MG/30ML (1MG/ML)	N220626	002	Mar 30, 2026	Mar	NEWA
>D>	+	!	BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	May	CFTG
>A>	AP	+		1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	May	CFTG
>A>	AP		HIKMA	1MG/ML (1MG/ML)	A220562	001	May 29, 2026	May	NFTG

EPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS  
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

	+	!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N218475	002	Mar 16, 2026	Mar	NEWA
--	---	---	----------------------	--------------------------------------	---------	-----	--------------	-----	------

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

SOLUTION;INJECTION  
FLAVALTA

	+	!	DEPROCO	EQ 0.017MG BASE/1.7ML (EQ 0.01MG BASE/ML);34MG/1.7ML (20MG/ML)	N216564	001	Mar 19, 2026	Mar	NEWA
--	---	---	---------	--	---------	-----	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION  
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

	@	+	WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Apr	CRLD
--	---	---	----------------------	--------------	---------	-----	--	-----	------

EPLERENONE

TABLET;ORAL  
EPLERENONE

>D>	@		AARXION ANDA HLDING	25MG	A203896	001	Feb 02, 2017	May	CAHN
>D>	@			50MG	A203896	002	Feb 02, 2017	May	CAHN
>A>	@		INNOGENIX	25MG	A203896	001	Feb 02, 2017	May	CAHN
>A>	@			50MG	A203896	002	Feb 02, 2017	May	CAHN

EPLONTERSEN SODIUM

SOLUTION;SUBCUTANEOUS  
WAINUA

	+	!	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	002	Apr 15, 2026	Apr	NEWA
--	---	---	----------------	---	---------	-----	--------------	-----	------

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS  
ERIBULIN MESYLATE

AP			FORMOSA LABS	1MG/2ML (0.5MG/ML)	A219054	001	Mar 16, 2026	Mar	NEWA
>A>	AP		NATCO	1MG/2ML (0.5MG/ML)	A217085	001	Jun 01, 2026	May	NEWA
AP			XGEN PHARMS	1MG/2ML (0.5MG/ML)	A219054	001	Mar 16, 2026	Mar	CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL  
ERYTHROMYCIN

AB			CARNEGIE	250MG	A062746	001	Dec 22, 1986	Feb	CAHN
----	--	--	----------	-------	---------	-----	--------------	-----	------

OINTMENT;OPHTHALMIC  
ERYTHROMYCIN

>D>	AT	!	BAUSCH AND LOMB	0.5%	A064067	001	Jul 29, 1994	May	CAHN
>A>	AT	!	BAUSCH AND LOMB INC	0.5%	A064067	001	Jul 29, 1994	May	CAHN

SOLUTION;TOPICAL  
ERYTHROMYCIN

>A>		@	ENCUBE	2%	A208100	001	Nov 20, 2017	May	CAHN
>D>		@	PAI HOLDINGS PHARM	2%	A208100	001	Nov 20, 2017	May	CAHN

TABLET;ORAL  
ERYTHROMYCIN

AB			CARNEGIE	250MG	A061621	001		Feb	CAHN
AB				500MG	A061621	002		Feb	CAHN

TABLET, DELAYED RELEASE;ORAL  
ERY-TAB

AB			CARNEGIE	250MG	A062298	001		Feb	CAHN
AB				333MG	A062298	003	Mar 29, 1982	Feb	CAHN
AB		!		500MG	A062298	002		Feb	CAHN

ERYTHROMYCIN ETHYLSUCCINATE

TABLET;ORAL		E.E.S. 400					
	@	CARNEGIE	EQ 400MG BASE	A 061905	001		Feb CAHN
BX	!		EQ 400MG BASE	A 061905	002	Aug 12, 1982	Feb CAHN
ERYTHROMYCIN ETHYLSUCCINATE							
BX	!	CARNEGIE	EQ 400MG BASE	A 061904	001		Feb CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL		ESCITALOPRAM OXALATE					
		MICRO LABS	EQ 5MG BASE	A 091655	001	Apr 22, 2026	Apr NEWA
AB			EQ 10MG BASE	A 091655	002	Apr 22, 2026	Apr NEWA
AB			EQ 20MG BASE	A 091655	003	Apr 22, 2026	Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL		ESOMEPRAZOLE MAGNESIUM					
>D>	AB	CISEN	EQ 20MG BASE	A 213158	001	Sep 22, 2020	May DISC
>A>		@	EQ 20MG BASE	A 213158	001	Sep 22, 2020	May DISC
>D>	AB		EQ 40MG BASE	A 213158	002	Sep 22, 2020	May DISC
>A>		@	EQ 40MG BASE	A 213158	002	Sep 22, 2020	May DISC

ESTRADIOL

CREAM;VAGINAL		ESTRACE						
	AB	+!	ABBVIE	0.01%	A 086069	001	Jan 31, 1984	Mar CAHN
GEL;TRANSDERMAL		ESTRADIOL						
	AB		SOLARIS PHARMA CORP	0.1% (0.25GM/PACKET)	A 217863	001	Jul 12, 2024	Feb CAHN
	AB			0.1% (0.5GM/PACKET)	A 217863	002	Jul 12, 2024	Feb CAHN
	AB			0.1% (0.75GM/PACKET)	A 217863	003	Jul 12, 2024	Feb CAHN
	AB			0.1% (1GM/PACKET)	A 217863	004	Jul 12, 2024	Feb CAHN
	AB			0.1% (1.25GM/PACKET)	A 217863	005	Jul 12, 2024	Feb CAHN
	AB		XIROMED	0.1% (0.25GM/PACKET)	A 211783	001	Aug 10, 2022	Jan CAHN
	AB			0.1% (0.5GM/PACKET)	A 211783	002	Aug 10, 2022	Jan CAHN
	AB			0.1% (1GM/PACKET)	A 211783	003	Aug 10, 2022	Jan CAHN
GEL, METERED;TRANSDERMAL		ESTRADIOL						
>A>	AB		ENCUBE	0.06% (1.25GM/ACTIVATION)	A 218214	001	May 11, 2026	May NEWA
>D>	AB		LONG GROVE PHARMS	0.06% (1.25GM/ACTIVATION)	A 215096	001	Feb 02, 2026	May CAHN
	AB			0.06% (1.25GM/ACTIVATION)	A 215096	001	Feb 02, 2026	Jan NEWA
>A>	AB		PADAGIS US	0.06% (1.25GM/ACTIVATION)	A 215096	001	Feb 02, 2026	May CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL		FEMRING						
		+	MILLICENT MFG PR	EQ 0.05MG BASE/24HR	N 021367	001	Mar 20, 2003	Jan CAHN
		+!		EQ 0.1MG BASE/24HR	N 021367	002	Mar 20, 2003	Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL		COMBIPATCH						
		+!	NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N 020870	001	Aug 07, 1998	Mar CHRS

ESZOPICLONE

TABLET;ORAL		ESZOPICLONE					
	@	LUPIN LTD	1MG	A 091124	001	Sep 13, 2011	Apr DISC
	@		2MG	A 091124	002	Sep 13, 2011	Apr DISC
	@		3MG	A 091124	003	Sep 13, 2011	Apr DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28		ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL						
	AB	!	XIROMED	0.05MG;1MG	A 204704	001	Feb 09, 2016	Apr CHRS
			KELNOR 1/50					
		@	WATSON LABS	0.05MG;1MG	A 072723	001	Dec 30, 1991	Apr DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL		QUARTETTE							
AB	+!	TEVA BRANDED PHARM	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	N204061	001	Mar 28, 2013	Mar	CAHN	
TABLET; ORAL-28		MYZILRA							
	@	PH HEALTH	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A077502	001	Nov 23, 2011	Apr	DISC	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28		GILDAGIA							
	@	PH HEALTH	0.035MG; 0.4MG	A078376	001	Nov 06, 2012	Apr	DISC	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL		GILDESS 24 FE							
	@	PH HEALTH	0.02MG; 1MG	A090293	001	Dec 01, 2014	Apr	DISC	

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28		PREVIFEM							
	@	PH HEALTH	0.035MG; 0.25MG	A076334	001	Jan 09, 2004	Apr	DISC	

ETHOSUXIMIDE

CAPSULE; ORAL		ETHOSUXIMIDE							
	@	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Apr	DISC	

ETODOLAC

TABLET; ORAL		ETODOLAC							
	@	SENORES PHARMS	400MG	A074839	001	Jul 11, 1997	Jan	CAHN	

ETOPOSIDE

CAPSULE; ORAL		ETOPOSIDE							
AB	!	MYLAN	50MG	A075635	001	Sep 19, 2001	Jan	CTEC	
VEPESID									
AB	+	ONESOURCE SPECIALTY	50MG	N019557	001	Dec 30, 1986	Jan	CMFD	
INJECTABLE; INJECTION		ETOPOSIDE							
	@	NATCO PHARMA USA	20MG/ML	A203507	001	Nov 20, 2017	Mar	CAHN	
	@		20MG/ML	A204927	001	Oct 31, 2017	Mar	CAHN	
INJECTABLE; INTRAVENOUS		AVOPEF							
	+!	AVYXA HOLDINGS	100MG/5ML (20MG/ML)	N220200	001	Feb 13, 2026	Feb	NEWA	
SOLUTION; INTRAVENOUS		AVOPEF							
	+!	AVYXA HOLDINGS	100MG/5ML (20MG/ML)	N220200	001	Feb 13, 2026	Mar	CDFR	

EVEROLIMUS

TABLET; ORAL		EVEROLIMUS							
>D>	AB	ALKEM LABS LTD	1MG	A214138	004	Nov 26, 2021	May	CHRS	
>A>	AB	!	1MG	A214138	004	Nov 26, 2021	May	CHRS	
>A>	AB	APOTEX	2.5MG	A218488	001	May 12, 2026	May	NEWA	
>A>	AB		5MG	A218488	002	May 12, 2026	May	NEWA	
>A>	AB		7.5MG	A218488	003	May 12, 2026	May	NEWA	
>A>	AB		10MG	A218488	004	May 12, 2026	May	NEWA	
	AB	EUGIA PHARMA	0.25MG	A219533	001	Feb 25, 2026	Feb	NEWA	
	AB		0.5MG	A219533	002	Feb 25, 2026	Feb	NEWA	
	AB		0.75MG	A219533	003	Feb 25, 2026	Feb	NEWA	
	AB		1MG	A219533	004	Feb 25, 2026	Feb	NEWA	
	@	PH HEALTH	2.5MG	A207934	001	Dec 09, 2019	Jan	DISC	
	@		5MG	A207934	002	Dec 09, 2019	Jan	DISC	
	@		7.5MG	A207934	003	Dec 09, 2019	Jan	DISC	
	@		10MG	A207934	004	Dec 09, 2020	Jan	DISC	

	TABLET;ORAL							
	ZORTRESS							
>D>	AB	+! NOVARTIS	1MG	N021560	004	Aug 10, 2018	May	CHRS
>A>	AB	+	1MG	N021560	004	Aug 10, 2018	May	CHRS
	TABLET, FOR SUSPENSION;ORAL							
	EVEROLIMUS							
	AB	BIOCON PHARMA	2MG	A217216	001	Jan 09, 2026	Jan	NEWA
	AB		3MG	A217216	002	Jan 09, 2026	Jan	NEWA
	AB		5MG	A217216	003	Jan 09, 2026	Jan	NEWA
	<u>EZETIMIBE; SIMVASTATIN</u>							
	TABLET;ORAL							
	EZETIMIBE AND SIMVASTATIN							
	@	WATSON LABS INC	10MG;10MG	A202968	001	Apr 26, 2017	Feb	DISC
	@		10MG;20MG	A202968	002	Apr 26, 2017	Feb	DISC
	@		10MG;40MG	A202968	003	Apr 26, 2017	Feb	DISC
	@		10MG;80MG	A202968	004	Apr 26, 2017	Feb	DISC
	<u>FAMOTIDINE</u>							
	FOR SUSPENSION;ORAL							
	FAMOTIDINE							
	AB	CARNEGIE	40MG/5ML	A217137	001	Jul 07, 2023	Feb	CAHN
	AB	CONTRACT PHARMACAL	40MG/5ML	A219603	001	Mar 09, 2026	Feb	NEWA
	INJECTABLE;INJECTION							
	FAMOTIDINE							
>A>	AP	LUPIN	10MG/ML	A217432	001	May 12, 2026	May	NEWA
	TABLET;ORAL							
	FAMOTIDINE							
	AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan	CAHN
	AB		40MG	A215630	002	Jan 07, 2022	Jan	CAHN
	<u>FAMOTIDINE; IBUPROFEN</u>							
	TABLET;ORAL							
	IBUPROFEN AND FAMOTIDINE							
	AB	ZYDUS LIFESCIENCES	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb	CAHN
	<u>FENOFIBRATE</u>							
	CAPSULE;ORAL							
	FENOFIBRATE (MICRONIZED)							
>A>	@	INGENUS PHARMS LLC	67MG	A207564	001	Apr 19, 2019	May	CAHN
>A>	@		134MG	A207564	002	Apr 19, 2019	May	CAHN
>A>	@		200MG	A207564	003	Apr 19, 2019	May	CAHN
>D>	@	NOVAST LABS	67MG	A207564	001	Apr 19, 2019	May	CAHN
>D>	@		134MG	A207564	002	Apr 19, 2019	May	CAHN
>D>	@		200MG	A207564	003	Apr 19, 2019	May	CAHN
	LIPOFEN							
	@ +	CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006	Jan	CRLD
	TABLET;ORAL							
	FENOFIBRATE							
	AB	MACLEODS PHARMS LTD	54MG	A210379	001	Jan 21, 2026	Jan	NEWA
	AB		160MG	A210379	002	Jan 21, 2026	Jan	NEWA
	TRIGLIDE							
	@	JAGOTEC	50MG	N021350	001	May 07, 2005	Jan	CAHN
	@ +		160MG	N021350	002	May 07, 2005	Jan	CAHN
	<u>FENOFIBRIC ACID</u>							
	TABLET;ORAL							
	FIBRICOR							
	@ +	ROSEMONT	35MG	N022418	001	Aug 14, 2009	Mar	CAHN
	@ +		105MG	N022418	002	Aug 14, 2009	Mar	CAHN
	<u>FERRIC CITRATE</u>							
	TABLET;ORAL							
	AURYXIA							
	AB	+! KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Feb	CFTG
	FERRIC CITRATE							
	AB	TEVA PHARMS USA	EQ 210MG IRON	A212563	001	Mar 11, 2026	Feb	NFTG

FERUMOXYTOL

SOLUTION; INTRAVENOUS		FERABRIGHT							
	+!	AZURITY	EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Apr	CAHN	
	+!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025	Apr	CAHN	
FERAHEME									
AB	+!	AZURITY	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Apr	CAHN	

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

@	DR REDDYS LABS LTD	30MG	A076502	001	Apr 11, 2006	Mar	DISC	
@		60MG	A076502	002	Apr 11, 2006	Mar	DISC	
@		180MG	A076502	003	Apr 11, 2006	Mar	DISC	
@	RISING	60MG	A077081	003	Apr 11, 2008	Mar	DISC	
@		180MG	A077081	001	Apr 16, 2007	Mar	DISC	
@	TEVA	30MG	A076447	001	Sep 01, 2005	Mar	DISC	
@		60MG	A076447	002	Sep 01, 2005	Mar	DISC	
@		180MG	A076447	003	Sep 01, 2005	Mar	DISC	

FIDAXOMICIN

TABLET; ORAL

FIDAXOMICIN

AB	APOTEX	200MG	A219559	001	Feb 02, 2026	Jan	NEWA	
AB	TORRENT	200MG	A220374	001	Jan 27, 2026	Jan	NEWA	

FINAFLOXACIN

SUSPENSION/DROPS; OTIC

XTORO

+!	FONSECA BIOSCIENCES	0.3%	N206307	001	Dec 17, 2014	Apr	CMFD	
----	---------------------	------	---------	-----	--------------	-----	------	--

FINERENONE

TABLET; ORAL

KERENDIA

>D>	+!	BAYER HLTHCARE	20MG	N215341	002	Jul 09, 2021	May	CHRS	
>A>	+		20MG	N215341	002	Jul 09, 2021	May	CHRS	
>D>	+		40MG	N215341	003	Jul 11, 2025	May	CHRS	
>A>	+!		40MG	N215341	003	Jul 11, 2025	May	CHRS	

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

AB	ALEMBIC	EQ 0.5MG BASE	A207974	001	Apr 24, 2026	Apr	NEWA	
----	---------	---------------	---------	-----	--------------	-----	------	--

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB	OMSAV PHARMA	50MG	A218093	001	Apr 22, 2026	Apr	NEWA	
AB		100MG	A218093	002	Apr 22, 2026	Apr	NEWA	
AB		150MG	A218093	003	Apr 22, 2026	Apr	NEWA	

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+!	LANTHEUS	1.4-135mCi/ML	N204677	001	Mar 19, 2014	Mar	CAHN	
----	----------	---------------	---------	-----	--------------	-----	------	--

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB	UNIQUE	50MG	A076957	001	Sep 28, 2005	Mar	CAHN	
AB		100MG	A076957	002	Sep 28, 2005	Mar	CAHN	
AB		150MG	A076957	004	Feb 27, 2017	Mar	CAHN	
AB		200MG	A076957	003	Sep 28, 2005	Mar	CAHN	

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION  
 FLUDARABINE PHOSPHATE  
 @ + CAPLIN ONE LABS

50MG/2ML (25MG/ML)

N022137 001 Sep 21, 2007 Jan CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS  
 FLUDEOXYGLUCOSE F18  
 @ NUKEMED

4-500mCi/ML

A203911 001 Apr 22, 2015 Apr DISC

FLUDROCORTISONE ACETATE

TABLET; ORAL  
 FLUDROCORTISONE ACETATE

AB HIBROW HLTHCARE

0.1MG

A220308 001 Feb 10, 2026 Jan NEWA

FLUMAZENIL

INJECTABLE; INJECTION  
 FLUMAZENIL

@ HIKMA  
 @

0.5MG/5ML (0.1MG/ML)  
 1MG/10ML (0.1MG/ML)

A076787 002 Oct 12, 2004 Mar DISC  
 A076787 001 Oct 12, 2004 Mar DISC

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL  
 FLUOCINOLONE ACETONIDE

>D> AT COSETTE 0.01% A089526 001 Jul 26, 1988 May CAHN  
 >D> @ 0.025% A089525 001 Jul 26, 1988 May CAHN  
 >D> AT 0.025% A210747 001 Nov 05, 2018 May CAHN  
 >A> AT COSETTE PHARMS NC 0.01% A089526 001 Jul 26, 1988 May CAHN  
 >A> @ 0.025% A089525 001 Jul 26, 1988 May CAHN  
 >A> AT 0.025% A210747 001 Nov 05, 2018 May CAHN  
 SYNALAR  
 AT +! EUROFARMA 0.01% N012787 004 Feb CAHN  
 AT +! 0.025% N012787 002 Feb CAHN  
 AT +! 0.025% N012787 005 Feb CAHN

SYNALAR-HP

@ EUROFARMA

0.2%

N016161 002 Feb CAHN

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

>D> AT COSETTE 0.025% A089524 001 Jul 26, 1988 May CAHN  
 >A> AT COSETTE PHARMS NC 0.025% A089524 001 Jul 26, 1988 May CAHN  
 SYNALAR  
 AT +! EUROFARMA 0.025% N013960 001 Feb CAHN  
 SOLUTION; TOPICAL  
 SYNALAR  
 AT +! EUROFARMA 0.01% N015296 001 Feb CAHN

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL  
 NEO-SYNALAR

! EUROFARMA

0.025%;EQ 3.5MG BASE/GM

A060700 001 Feb CAHN

FLUOCINONIDE

CREAM; TOPICAL  
 FLUOCINONIDE

>D> AB1 COSETTE 0.05% A073085 001 Feb 14, 1992 May CAHN  
 >A> AB1 COSETTE PHARMS NC 0.05% A073085 001 Feb 14, 1992 May CAHN  
 >A> @ ENCUBE 0.1% A211758 001 Apr 03, 2019 May CAHN  
 >D> @ PAI HOLDINGS PHARM 0.1% A211758 001 Apr 03, 2019 May CAHN  
 FLUOCINONIDE EMULSIFIED BASE  
 >D> AB2 COSETTE 0.05% A074204 001 Jun 13, 1995 May CAHN  
 >A> AB2 COSETTE PHARMS NC 0.05% A074204 001 Jun 13, 1995 May CAHN  
 SOLUTION; TOPICAL  
 FLUOCINONIDE  
 >D> @ SCIEGEN PHARMS 0.05% A207554 001 Mar 18, 2019 May CMFD  
 >A> AT 0.05% A207554 001 Mar 18, 2019 May CMFD

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS  
FLUORESCEIN SODIUM

AP	BPI LABS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A220046	001	Apr 30, 2026	Apr	NEWA
>D>	NEXUS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	May	DISC
>A>	@	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	May	DISC
>A>		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Apr	CHRS
>A>	AP ZYDUS LIFESCIENCES	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A218651	001	Jun 01, 2026	May	NEWA
>A>	!	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A218651	002	Jun 01, 2026	May	NEWA

FLUOROMETHOLONE

SUSPENSION/DROPS; OPHTHALMIC  
FLUOROMETHOLONE

>D>	AB DIFGEN PHARMS	0.1%	A218819	001	Feb 12, 2026	May	CAHN
	AB	0.1%	A218819	001	Feb 12, 2026	Jan	NEWA
>A>	AB SANDOZ	0.1%	A218819	001	Feb 12, 2026	May	CAHN

FLUOROURACIL

INJECTABLE; INJECTION  
FLUOROURACIL

>A>	@ INGENUS PHARMS LLC	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019	May	CAHN
>A>	@	1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019	May	CAHN
>A>	@	2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019	May	CAHN
>A>	@	5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	May	CAHN
>D>	@ NOVAST LABS	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019	May	CAHN
>D>	@	1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019	May	CAHN
>D>	@	2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019	May	CAHN
>D>	@	5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	May	CAHN

SOLUTION; INTRAVENOUS  
FAVLYXA

	+!	AVYXA HOLDINGS	250MG/10ML (25MG/ML)	N220201	001	Feb 20, 2026	Feb	NEWA
--	----	----------------	----------------------	---------	-----	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL  
FLUOXETINE HYDROCHLORIDE

>D>	AB AUROBINDO PHARMA	EQ 40MG BASE	A078619	003	Jan 31, 2008	May	CHRS
>A>	AB !	EQ 40MG BASE	A078619	003	Jan 31, 2008	May	CHRS
	AB1 SENORES PHARMS	EQ 10MG BASE	A075049	001	Aug 02, 2001	Feb	CAHN
	AB1	EQ 20MG BASE	A075049	002	Jan 29, 2002	Feb	CAHN
	AB	EQ 40MG BASE	A075049	003	Jan 29, 2002	Feb	CAHN
	@ STRIDES PHARMA INTL	EQ 10MG BASE	A076922	001	Dec 16, 2004	Jan	DISC
	@	EQ 20MG BASE	A076922	002	Dec 16, 2004	Jan	DISC
	@	EQ 40MG BASE	A076922	003	Dec 16, 2004	Jan	DISC
>D>	PROZAC						
>D>	AB1 + ELI LILLY AND CO	EQ 10MG BASE	N018936	006	Dec 23, 1992	May	DISC
>A>	@ +	EQ 10MG BASE	N018936	006	Dec 23, 1992	May	DISC
>D>	AB1 +	EQ 20MG BASE	N018936	001	Dec 29, 1987	May	DISC
>A>	@ +	EQ 20MG BASE	N018936	001	Dec 29, 1987	May	DISC
>D>	AB +!	EQ 40MG BASE	N018936	003	Jun 15, 1999	May	DISC
>A>	@ +	EQ 40MG BASE	N018936	003	Jun 15, 1999	May	DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE  
AA ! AUROBINDO PHARMA  
@ PHARM ASSOC

	!	AUROBINDO PHARMA	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Apr	CHRS
	@	PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	Apr	DISC

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE  
@ LUPIN

	@	LUPIN	EQ 60MG BASE	A211632	001	Feb 08, 2019	Mar	DISC
--	---	-------	--------------	---------	-----	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL  
FLUPHENAZINE HYDROCHLORIDE

	@	BRECKENRIDGE	1MG	A216891	001	Nov 15, 2022	Feb	DISC
	@		2.5MG	A216891	002	Nov 15, 2022	Feb	DISC
	@		5MG	A216891	003	Nov 15, 2022	Feb	DISC
	@		10MG	A216891	004	Nov 15, 2022	Feb	DISC
AB		ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Jan	CAHN
AB			2.5MG	A215141	002	Oct 20, 2021	Jan	CAHN

TABLET;ORAL

AB	FLUPHENAZINE HYDROCHLORIDE	5MG	A215141	003	Oct 20, 2021	Jan	CAHN
AB		10MG	A215141	004	Oct 20, 2021	Jan	CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

	FLURAZEPAM HYDROCHLORIDE						
@	HIKMA INTL PHARMS	15MG	A071108	002	Dec 08, 1986	Feb	CMS1

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

	BREO ELLIPTA						
+	GLAXO GRP LTD	0.05MG/INH;EQ 0.025MG BASE/INH	N204275	003	May 12, 2023	Jan	CHRS

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

AB	FLOVENT HFA						
+	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004	Feb	CFTG

AB	FLUTICASONE PROPIONATE						
	GLENMARK SPECLT	0.044MG/INH	A219602	001	Mar 03, 2026	Feb	NFTG

CREAM; TOPICAL

>D>	AB	FLUTICASONE PROPIONATE						
		COSETTE	0.05%	A077055	001	Jun 30, 2006	May	CAHN
>A>	AB	COSETTE PHARMS NC	0.05%	A077055	001	Jun 30, 2006	May	CAHN

OINTMENT; TOPICAL

>D>	AB	FLUTICASONE PROPIONATE						
		COSETTE	0.005%	A077168	001	Mar 03, 2006	May	CAHN
>A>	AB	COSETTE PHARMS NC	0.005%	A077168	001	Mar 03, 2006	May	CAHN

SPRAY, METERED; NASAL

>D>	AB	XHANCE							
		+	PARATEK PHARMS	0.093MG	N209022	001	Sep 18, 2017	May	CPOT
>A>	AB	+		0.093MG/SPRAY	N209022	001	Sep 18, 2017	May	CPOT

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

	AIRDUO RESPICLICK						
+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan	CHRS
+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan	CHRS

	FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE						
@	RESPIRENT PHARMS	0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Mar	DISC
AB		0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Jan	NEWA
@		0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Mar	DISC
AB		0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Jan	NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

AB	FLUVOXAMINE MALEATE						
	APPCO	100MG	A220328	001	Apr 30, 2026	Apr	NEWA
AB		150MG	A220328	002	Apr 30, 2026	Apr	NEWA

FOLIC ACID

SOLUTION; ORAL

	QUIOFIC						
+	CMP DEV LLC	0.2MG/ML	N216395	001	Jan 26, 2026	Jan	NEWA
+	SOLUBIOMIX	0.2MG/ML	N216395	001	Jan 26, 2026	Mar	CAHN

TABLET; ORAL

AA	FOLIC ACID							
	+	WATSON LABS	1MG	A080680	001		Feb	CHRS

FONDAPARINUX SODIUM

SOLUTION; SUBCUTANEOUS

AP	ARIXTRA						
+	MYLAN IRELAND LTD	2.5MG/0.5ML (2.5MG/0.5ML)	N021345	001	Dec 07, 2001	Mar	CPOT
AP	+	2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jan	CDFR
AP	+	5MG/0.4ML (5MG/0.4ML)	N021345	002	May 28, 2004	Mar	CPOT
AP	+	5MG/0.4ML	N021345	002	May 28, 2004	Jan	CDFR
AP	+	7.5MG/0.6ML (7.5MG/0.6ML)	N021345	003	May 28, 2004	Mar	CPOT
AP	+	7.5MG/0.6ML	N021345	003	May 28, 2004	Jan	CDFR
AP	+	10MG/0.8ML (10MG/0.8ML)	N021345	004	May 28, 2004	Mar	CPOT

SOLUTION;SUBCUTANEOUS  
ARIXTRA

AP	+	10MG/0.8ML	N021345	004	May 28, 2004	Jan	CDFR
	FONDAPARINUX SODIUM						
	@ BRIGHTGENE	2.5MG/0.5ML (2.5MG/0.5ML)	A218312	001	Dec 18, 2024	Mar	CPOT
	@	2.5MG/0.5ML	A218312	001	Dec 18, 2024	Jan	CDFR
AP	DR REDDYS LABS LTD	2.5MG/0.5ML (2.5MG/0.5ML)	A091316	001	Jul 11, 2011	Mar	CPOT
AP		2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jan	CDFR
AP		5MG/0.4ML (5MG/0.4ML)	A091316	002	Jul 11, 2011	Mar	CPOT
AP		5MG/0.4ML	A091316	002	Jul 11, 2011	Jan	CDFR
AP		7.5MG/0.6ML (7.5MG/0.6ML)	A091316	003	Jul 11, 2011	Mar	CPOT
AP		7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jan	CDFR
AP		10MG/0.8ML (10MG/0.8ML)	A091316	004	Jul 11, 2011	Mar	CPOT
AP		10MG/0.8ML	A091316	004	Jul 11, 2011	Jan	CDFR
AP	EUGIA PHARMA	2.5MG/0.5ML (2.5MG/0.5ML)	A206918	001	Dec 26, 2017	Mar	CPOT
AP		2.5MG/0.5ML	A206918	001	Dec 26, 2017	Jan	CDFR
AP		5MG/0.4ML (5MG/0.4ML)	A206918	002	Dec 26, 2017	Mar	CPOT
AP		5MG/0.4ML	A206918	002	Dec 26, 2017	Jan	CDFR
AP		7.5MG/0.6ML (7.5MG/0.6ML)	A206918	003	Dec 26, 2017	Mar	CPOT
AP		7.5MG/0.6ML	A206918	003	Dec 26, 2017	Jan	CDFR
AP		10MG/0.8ML (10MG/0.8ML)	A206918	004	Dec 26, 2017	Mar	CPOT
AP		10MG/0.8ML	A206918	004	Dec 26, 2017	Jan	CDFR
	@ HANGZHOU ZHONGMEI	2.5MG/0.5ML (2.5MG/0.5ML)	A216493	001	Aug 19, 2024	Mar	CPOT
	@	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Jan	CDFR
	@	5MG/0.4ML (5MG/0.4ML)	A216493	002	Aug 19, 2024	Mar	CPOT
	@	5MG/0.4ML	A216493	002	Aug 19, 2024	Jan	CDFR
	@	7.5MG/0.6ML (7.5MG/0.6ML)	A216493	003	Aug 19, 2024	Mar	CPOT
	@	7.5MG/0.6ML	A216493	003	Aug 19, 2024	Jan	CDFR
	@	10MG/0.8ML (10MG/0.8ML)	A216493	004	Aug 19, 2024	Mar	CPOT
	@	10MG/0.8ML	A216493	004	Aug 19, 2024	Jan	CDFR
AP	HENGRUI PHARMA	2.5MG/0.5ML (2.5MG/0.5ML)	A206812	001	May 15, 2018	Mar	CPOT
AP		2.5MG/0.5ML	A206812	001	May 15, 2018	Jan	CDFR
AP		5MG/0.4ML (5MG/0.4ML)	A206812	002	May 15, 2018	Mar	CPOT
AP		5MG/0.4ML	A206812	002	May 15, 2018	Jan	CDFR
AP		7.5MG/0.6ML (7.5MG/0.6ML)	A206812	003	May 15, 2018	Mar	CPOT
AP		7.5MG/0.6ML	A206812	003	May 15, 2018	Jan	CDFR
AP		10MG/0.8ML (10MG/0.8ML)	A206812	004	May 15, 2018	Mar	CPOT
AP		10MG/0.8ML	A206812	004	May 15, 2018	Jan	CDFR
AP	SCINOPHARM TAIWAN	2.5MG/0.5ML (2.5MG/0.5ML)	A208615	001	Nov 14, 2018	Mar	CPOT
AP		2.5MG/0.5ML	A208615	001	Nov 14, 2018	Jan	CDFR
AP		5MG/0.4ML (5MG/0.4ML)	A208615	002	Nov 14, 2018	Mar	CPOT
AP		5MG/0.4ML	A208615	002	Nov 14, 2018	Jan	CDFR
AP		7.5MG/0.6ML (7.5MG/0.6ML)	A208615	003	Nov 14, 2018	Mar	CPOT
AP		7.5MG/0.6ML	A208615	003	Nov 14, 2018	Jan	CDFR
AP		10MG/0.8ML (10MG/0.8ML)	A208615	004	Nov 14, 2018	Mar	CPOT
AP		10MG/0.8ML	A208615	004	Nov 14, 2018	Jan	CDFR

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE

>D>	AP	BAXTER HLTHCARE CORP	EQ 150MG BASE/VIAL	A211860	001	Sep 05, 2019	May	DISC
>A>	@		EQ 150MG BASE/VIAL	A211860	001	Sep 05, 2019	May	DISC
	@	CAPLIN	EQ 150MG BASE/VIAL	A203939	001	Dec 08, 2020	Jan	CAHN

FOSCARNET SODIUM

SOLUTION;INTRAVENOUS  
FOSCARNET SODIUM

>A>	AP	CAPLIN	6GM/250ML (24MG/ML)	A220068	001	May 13, 2026	May	NEWA
-----	----	--------	---------------------	---------	-----	--------------	-----	------

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL  
FOSFOMYCIN TROMETHAMINE

AA	AUCTA	EQ 3GM BASE/PACKET	A217772	001	Apr 09, 2026	Mar	NEWA
----	-------	--------------------	---------	-----	--------------	-----	------

FROVATRIPTAN SUCCINATE

TABLET;ORAL  
FROVA  
@ + ENDO OPERATIONS  
FROVATRIPTAN SUCCINATE

	@ +	ENDO OPERATIONS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Feb	DISC
AB	!	RENATA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Feb	CHRS

FULVESTRANT

SOLUTION; INTRAMUSCULAR  
CLIGAVYX

@	AVYXA HOLDINGS	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Apr	CTNA
@	EUGIA PHARMA	250MG/5ML (50MG/ML)	A215169	001	Jun 30, 2023	Mar	DISC

FUROSEMIDE

INJECTABLE; INJECTION  
FUROSEMIDE

AP	MICRO LABS	10MG/ML	A218188	001	Jan 08, 2026	Jan	NEWA
----	------------	---------	---------	-----	--------------	-----	------

FUTIBATINIB

TABLET; ORAL  
LYTGOBI

>D>	+	TAIHO ONCOLOGY	16MG	N214801	002	Jul 28, 2025	May	DISC
>A>	@ +		16MG	N214801	002	Jul 28, 2025	May	DISC

GABAPENTIN

CAPSULE; ORAL  
GABAPENTIN

AB	PRINSTON INC	100MG	A219814	001	Mar 06, 2026	Feb	NEWA	
AB		300MG	A219814	002	Mar 06, 2026	Feb	NEWA	
AB		400MG	A219814	003	Mar 06, 2026	Feb	NEWA	
>A>	AB	SENORES PHARMS	200MG	A219319	004	May 14, 2026	May	NEWA
		RELGAABI						
AB	SCIEGEN PHARMS	100MG	A204989	001	Feb 18, 2016	Mar	CTNA	
>D>		200MG	A204989	004	Mar 06, 2026	May	CFTG	
>A>	AB	200MG	A204989	004	Mar 06, 2026	May	CFTG	
		200MG	A204989	004	Mar 06, 2026	Mar	CTNA	
		200MG	A204989	004	Mar 06, 2026	Feb	NEWA	
AB		300MG	A204989	002	Feb 18, 2016	Mar	CTNA	
AB		400MG	A204989	003	Feb 18, 2016	Mar	CTNA	

TABLET; ORAL  
GABAPENTIN

>A>	AB2	EPIC PHARMA LLC	300MG	A216252	001	Feb 26, 2024	May	CAHN
>A>	AB2		600MG	A216252	002	Feb 26, 2024	May	CAHN
>D>	AB2	HUMANWELL	300MG	A216252	001	Feb 26, 2024	May	CAHN
>D>	AB2		600MG	A216252	002	Feb 26, 2024	May	CAHN

GADOBUTROL

SOLUTION; INTRAVENOUS  
GADOBUTROL

>A>	AP	ZENARA	1.20944GM/2ML (604.72MG/ML)	A219146	001	Jun 08, 2026	May	NEWA
>A>	AP		4.5354GM/7.5ML (604.72MG/ML)	A219146	002	Jun 08, 2026	May	NEWA
>A>	AP		6.0472GM/10ML (604.72MG/ML)	A219146	003	Jun 08, 2026	May	NEWA
>A>	AP		9.0708GM/15ML (604.72MG/ML)	A219146	004	Jun 08, 2026	May	NEWA
>A>	AP		18.1416GM/30ML (604.72MG/ML)	A219146	005	Jun 08, 2026	May	NEWA
>A>	AP		39.3068GM/65ML (604.72MG/ML)	A219146	006	Jun 08, 2026	May	NEWA

GALANTAMINE HYDROBROMIDE

TABLET; ORAL  
GALANTAMINE HYDROBROMIDE

AB	SENORES PHARMS	EQ 4MG BASE	A077593	001	Sep 11, 2008	Jan	CAHN
AB		EQ 8MG BASE	A077593	002	Sep 11, 2008	Jan	CAHN
AB		EQ 12MG BASE	A077593	003	Sep 11, 2008	Jan	CAHN

GALLIUM GA-68 GOZETOTIDE

SOLUTION; INTRAVENOUS  
GALLIUM GA 68 GOZETOTIDE

>A>	AP	RADIOMEDIX	0.5-5mCi/ML	A216410	001	Jun 08, 2026	May	NEWA
>D>	+	UNIV OF CA SAN FRAN	0.5-5mCi/mL	N212643	001	Dec 01, 2020	May	CFTG
>A>	AP	+	0.5-5mCi/mL	N212643	001	Dec 01, 2020	May	CFTG
>A>		GALLIUM GA-68 GOZETOTIDE						
>A>	AP	IONETIX	0.5-5mCi/mL	A219189	001	May 14, 2026	May	NFTG

GANAXOLONE

SUSPENSION;ORAL  
ZTALMY

+! IMMEDICA PHARMA 50MG/ML N215904 001 Jun 01, 2022 Mar CAHN

GANIRELIX ACETATE

INJECTABLE; INJECTION  
GANIRELIX ACETATE

@ TRIS PHARMA INC 250MCG/0.5ML A219454 001 Jun 27, 2025 Mar DISC

GEFITINIB

TABLET;ORAL  
GEFITINIB

@ APOTEX 250MG A209532 001 Sep 23, 2022 Jan DISC  
@ CIPLA 250MG A211826 001 May 16, 2025 Apr DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION  
GEMCITABINE HYDROCHLORIDE

>A> @ INGENUS PHARMS LLC 200MG/5.26ML (38MG/ML) A210383 001 Feb 14, 2019 May CAHN  
>A> @ 1GM/26.3ML (38MG/ML) A210383 002 Feb 14, 2019 May CAHN  
>A> @ 2GM/52.6ML (38MG/ML) A210383 003 Feb 14, 2019 May CAHN  
>D> @ NOVAST LABS 200MG/5.26ML (38MG/ML) A210383 001 Feb 14, 2019 May CAHN  
>D> @ 200MG/5.26ML (38MG/ML) A210383 001 Feb 14, 2019 Feb DISC  
>D> @ 1GM/26.3ML (38MG/ML) A210383 002 Feb 14, 2019 May CAHN  
>D> @ 1GM/26.3ML (38MG/ML) A210383 002 Feb 14, 2019 Feb DISC  
>D> @ 2GM/52.6ML (38MG/ML) A210383 003 Feb 14, 2019 May CAHN  
>D> @ 2GM/52.6ML (38MG/ML) A210383 003 Feb 14, 2019 Feb DISC

SOLUTION; INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

>D> +! ACCORD HLTHCARE 1GM/10ML (100MG/ML) N209604 002 Aug 03, 2017 May DISC  
>A> @ + 1GM/10ML (100MG/ML) N209604 002 Aug 03, 2017 May DISC  
>D> +! 1.5GM/15ML (100MG/ML) N209604 003 Aug 03, 2017 May DISC  
>A> @ + 1.5GM/15ML (100MG/ML) N209604 003 Aug 03, 2017 May DISC  
>D> +! 2GM/20ML (100MG/ML) N209604 004 Aug 03, 2017 May DISC  
>A> @ + 2GM/20ML (100MG/ML) N209604 004 Aug 03, 2017 May DISC  
>D> +! 200MG/2ML (100MG/ML) N209604 001 Aug 03, 2017 May DISC  
>A> @ + 200MG/2ML (100MG/ML) N209604 001 Aug 03, 2017 May DISC

GENTAMICIN SULFATE

CREAM; TOPICAL  
GENTAMICIN SULFATE

>D> AT COSETTE EQ 0.1% BASE A064056 001 Apr 29, 1994 May CAHN  
>A> AT COSETTE PHARMS NC EQ 0.1% BASE A064056 001 Apr 29, 1994 May CAHN

OINTMENT; TOPICAL

GENTAMICIN SULFATE

>D> AT COSETTE EQ 0.1% BASE A064054 001 Apr 29, 1994 May CAHN  
>A> AT COSETTE PHARMS NC EQ 0.1% BASE A064054 001 Apr 29, 1994 May CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

>D> AT BAUSCH AND LOMB EQ 0.3% BASE A064048 001 May 11, 1994 May CAHN  
>A> AT BAUSCH AND LOMB INC EQ 0.3% BASE A064048 001 May 11, 1994 May CAHN  
@ PADAGIS US EQ 0.3% BASE A065121 001 Jan 30, 2004 Mar DISC

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS  
GLATIRAMER ACETATE

AP HYBIO 20MG/ML A213382 001 Feb 11, 2026 Jan NEWA  
AP 40MG/ML A214022 001 Feb 11, 2026 Jan NEWA

GLECAPREVIR; PIBRENTASVIR

PELLETS; ORAL

MAVYRET

+! ABBVIE 50MG/PACKET; 20MG/PACKET N215110 001 Jun 10, 2021 Mar CPOT

GLIPIZIDE

TABLET; ORAL  
GLIPIZIDE

AB GRAVITI PHARMS 5MG A219159 001 Mar 04, 2026 Feb NEWA  
AB 10MG A219159 002 Mar 04, 2026 Feb NEWA  
! RUBICON RESEARCH 15MG A214874 004 Feb 04, 2026 Jan NFTG

GLUCAGONSOLUTION; INTRAVENOUS  
GVOKE VIALDX

>D>	+	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025	May DISC
>A>	@	+	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025	May DISC

GLYBURIDE; METFORMIN HYDROCHLORIDETABLET; ORAL  
GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB		IMPAX	1.25MG; 250MG	A076345	001	Feb 18, 2004	Mar CAHN
AB			2.5MG; 500MG	A076345	002	Feb 18, 2004	Mar CAHN
AB			5MG; 500MG	A076345	003	Feb 18, 2004	Mar CAHN

GLYCEROL PHENYLBUTYRATELIQUID; ORAL  
GLYCEROL PHENYLBUTYRATE

AA		AUROBINDO PHARMA	1.1GM/ML	A220313	001	Apr 15, 2026	Apr NEWA
AA		LUPIN	1.1GM/ML	A207694	001	Apr 30, 2026	Apr NEWA
AA		MSN	1.1GM/ML	A219540	001	Apr 15, 2026	Apr NEWA
AA		NAVINTA LLC	1.1GM/ML	A220568	001	Apr 23, 2026	Apr NEWA
AA		TEVA PHARMS INC	1.1GM/ML	A218738	001	Apr 15, 2026	Apr NEWA

GLYCOPYRROLATEINJECTABLE; INJECTION  
GLYCOPYRROLATE

AP		NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Apr CAHN
----	--	--------------------	----------	---------	-----	--------------	----------

SOLUTION; ORAL  
GLYCOPYRROLATE

>A>	AA		QUAGEN	A216910	001	May 18, 2026	May NEWA
-----	----	--	--------	---------	-----	--------------	----------

GLYCOPYRRONIUM TOSYLATECLOTH; TOPICAL  
GLYCOPYRRONIUM TOSYLATE

AB		@	PADAGIS US	EQ 2.4% BASE	A214448	001	Apr 03, 2026	Apr DISC
				EQ 2.4% BASE	A214448	001	Apr 03, 2026	Mar NFTG
			QBREXZA					
		+	JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018	Apr CTEC
AB		+		EQ 2.4% BASE	N210361	001	Jun 28, 2018	Mar CFTG

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATESOLUTION/DROPS; OPHTHALMIC  
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

>D>	AT	!	BAUSCH AND LOMB	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A064047	001	Jan 31, 1996	May CAHN
>A>	AT	!	BAUSCH AND LOMB INC	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A064047	001	Jan 31, 1996	May CAHN
			NEOSPORIN					
		@	MONARCH PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060582	001		Jan DISC

GRISEOFULVIN, MICROSIZESUSPENSION; ORAL  
GRISEOFULVIN

>D>	AB		COSETTE	125MG/5ML	A065438	001	Oct 08, 2010	May CAHN
>A>	AB		COSETTE PHARMS NC	125MG/5ML	A065438	001	Oct 08, 2010	May CAHN

GUANFACINE HYDROCHLORIDETABLET; ORAL  
GUANFACINE HYDROCHLORIDE

AB			ASCENT PHARMS INC	EQ 1MG BASE	A220675	001	Mar 24, 2026	Mar NEWA
AB				EQ 2MG BASE	A220675	002	Mar 24, 2026	Mar NEWA
AB			RUBICON RESEARCH	EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar CTEC
AB				EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar CTEC

HALOBETASOL PROPIONATEAEROSOL, FOAM; TOPICAL  
HALOBETASOL PROPIONATE

AB		!	PADAGIS ISRAEL	0.05%	A215266	001	Aug 11, 2023	Feb CTEC
		!		0.05%	A215266	001	Aug 11, 2023	Feb CHRS
			LEXETTE					
		@	+	MAYNE PHARMA	N210566	001	May 24, 2018	Feb DISC

CREAM;TOPICAL

HALOBETASOL PROPIONATE

>D>	AB	!	COSETTE	0.05%	A 078162	001	Apr 24, 2007	May	CAHN
>A>	AB	!	COSETTE PHARMS NC	0.05%	A 078162	001	Apr 24, 2007	May	CAHN

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

>D>	AB		COSETTE	0.05%	A 077109	001	Jun 14, 2005	May	CAHN
>A>	AB		COSETTE PHARMS NC	0.05%	A 077109	001	Jun 14, 2005	May	CAHN

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

	AB		AIPING PHARM INC	0.5MG	A 071130	004	Apr 08, 2026	Mar	NEWA
	AB			1MG	A 071130	005	Apr 08, 2026	Mar	NEWA
	AB			20MG	A 071130	006	Apr 08, 2026	Mar	NEWA
>A>	AB		ALEMBIC	1MG	A 214470	001	Jun 04, 2026	May	NEWA
>A>	AB			2MG	A 214470	002	Jun 04, 2026	May	NEWA
>A>	AB			5MG	A 214470	003	Jun 04, 2026	May	NEWA
>A>	AB			10MG	A 214470	004	Jun 04, 2026	May	NEWA
>A>	AB			20MG	A 214470	005	Jun 04, 2026	May	NEWA
		@	MYLAN	20MG	A 070278	003	Jul 16, 2009	Apr	DISC

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM PRESERVATIVE FREE

		+!	PFIZER	1,000 UNITS/ML	N 201370	004	Jul 21, 2011	Feb	CMFD
--	--	----	--------	----------------	----------	-----	--------------	-----	------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

		@	PADAGIS US	1.5MG/5ML;5MG/5ML	A 205731	001	Feb 15, 2017	Mar	DISC
--	--	---	------------	-------------------	----------	-----	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

		@	HERITAGE	10MG	A 086242	001	Feb 04, 2010	Mar	DISC
		@		25MG	A 086242	003		Mar	DISC
		@		50MG	A 086242	002		Mar	DISC
		@		100MG	A 086242	004	Feb 04, 2010	Mar	DISC
		@	STRIDES PHARMA INTL	10MG	A 087836	001	Oct 05, 1982	Jan	DISC
		@		25MG	A 086961	002		Jan	DISC
		@		50MG	A 086962	001		Jan	DISC
		@		100MG	A 088391	001	Sep 27, 1983	Jan	DISC

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

		@	STRIDES PHARMA INTL	25MG;25MG	A 088957	001	Oct 21, 1985	Jan	DISC
		@		50MG;50MG	A 088946	001	Oct 21, 1985	Jan	DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

	AB		INGENUS PHARMS LLC	37.5MG;20MG	A 215586	001	Apr 06, 2022	Feb	CAHN
--	----	--	--------------------	-------------	----------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

		@	CHARTWELL RX	12.5MG;150MG	A 201524	001	Feb 27, 2013	Apr	CAHN
		@		12.5MG;300MG	A 201524	002	Feb 27, 2013	Apr	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>A>	AB		HETERO LABS LTD V	12.5MG;50MG	A 219869	001	May 27, 2026	May	NEWA
>A>	AB			12.5MG;100MG	A 219869	002	May 27, 2026	May	NEWA
>A>	AB			25MG;100MG	A 219869	003	May 27, 2026	May	NEWA

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

@	STRIDES PHARMA INTL	15MG;250MG	A 070614	002	Feb 02, 1987	Jan CMS1
@		25MG;250MG	A 070614	003	Feb 02, 1987	Jan CMS1
@		30MG;500MG	A 070614	004	Feb 02, 1987	Jan CMS1

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC	25MG;100MG	A 202870	002	Nov 06, 2013	Feb CHRS
AB	! MYLAN	50MG;100MG	A 076792	003	Aug 20, 2004	Feb CHRS

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	MICRO LABS	12.5MG;20MG	A 206371	001	Apr 13, 2026	Apr NEWA
AB		12.5MG;40MG	A 206371	002	Apr 13, 2026	Apr NEWA
AB		25MG;40MG	A 206371	003	Apr 13, 2026	Apr NEWA
AB	SCIEGEN PHARMS	12.5MG;20MG	A 208465	001	Mar 31, 2026	Mar NEWA
AB		12.5MG;40MG	A 208465	002	Mar 31, 2026	Mar NEWA
AB		25MG;40MG	A 208465	003	Mar 31, 2026	Mar NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

>D>	AB	LUPIN LTD	12.5MG;80MG	A 078946	003	Mar 21, 2013	May DISC
>A>	@		12.5MG;80MG	A 078946	003	Mar 21, 2013	May DISC
>D>	AB		12.5MG;160MG	A 078946	004	Mar 21, 2013	May DISC
>A>	@		12.5MG;160MG	A 078946	004	Mar 21, 2013	May DISC
>D>	AB		12.5MG;320MG	A 078946	001	Mar 21, 2013	May DISC
>A>	@		12.5MG;320MG	A 078946	001	Mar 21, 2013	May DISC
>D>	AB		25MG;160MG	A 078946	005	Mar 21, 2013	May DISC
>A>	@		25MG;160MG	A 078946	005	Mar 21, 2013	May DISC
>D>	AB		25MG;320MG	A 078946	002	Mar 21, 2013	May DISC
>A>	@		25MG;320MG	A 078946	002	Mar 21, 2013	May DISC
	AB	SCIEGEN PHARMS	12.5MG;80MG	A 204687	001	Apr 23, 2026	Apr NEWA
	AB		12.5MG;160MG	A 204687	002	Apr 23, 2026	Apr NEWA
	AB		12.5MG;320MG	A 204687	003	Apr 23, 2026	Apr NEWA
	AB		25MG;160MG	A 204687	004	Apr 23, 2026	Apr NEWA
	AB		25MG;320MG	A 204687	005	Apr 23, 2026	Apr NEWA

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA ER

>A>	AB	+! KNOA PHARMA	20MG	N 206627	001	Nov 20, 2014	May CAHN
>A>	AB	+	30MG	N 206627	002	Nov 20, 2014	May CAHN
>A>	AB	+	40MG	N 206627	003	Nov 20, 2014	May CAHN
>A>	AB	+	60MG	N 206627	004	Nov 20, 2014	May CAHN
>A>	AB	+	80MG	N 206627	005	Nov 20, 2014	May CAHN
>A>	AB	+	100MG	N 206627	006	Nov 20, 2014	May CAHN
>A>	@	+	120MG	N 206627	007	Nov 20, 2014	May CAHN
>D>	AB	+! PURDUE PHARMA LP	20MG	N 206627	001	Nov 20, 2014	May CAHN
>D>	AB	+	30MG	N 206627	002	Nov 20, 2014	May CAHN
>D>	AB	+	40MG	N 206627	003	Nov 20, 2014	May CAHN
>D>	AB	+	60MG	N 206627	004	Nov 20, 2014	May CAHN
>D>	AB	+	80MG	N 206627	005	Nov 20, 2014	May CAHN
>D>	AB	+	100MG	N 206627	006	Nov 20, 2014	May CAHN
>D>	@	+	120MG	N 206627	007	Nov 20, 2014	May CAHN

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

REPRESXAIN

>D>	@	AMNEAL PHARMS NY	10MG;200MG	A 076642	004	Oct 19, 2007	May CMFD
>A>			10MG;200MG	A 076642	004	Oct 19, 2007	May CMFD

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE							
AB	APPCO	5MG	A220329	001	Feb 25, 2026	Feb	NEWA
AB		10MG	A220329	002	Feb 25, 2026	Feb	NEWA
AB		20MG	A220329	003	Feb 25, 2026	Feb	NEWA

HYDROCORTISONE BUTYRATE

OINTMENT;TOPICAL

HYDROCORTISONE BUTYRATE							
	! TARO	0.1%	A076842	001	Dec 27, 2004	Feb	CTEC
AB	! LOCROID	0.1%	A076842	001	Dec 27, 2004	Feb	CHRS
	@ + PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982	Feb	DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

HYDROCORTISONE SODIUM SUCCINATE							
AP	APOTEX	EQ 100MG BASE/VIAL	A219856	001	Feb 05, 2026	Jan	NEWA
AP	ZYDUS PHARMS	EQ 100MG BASE/VIAL	A217191	001	May 07, 2026	Apr	NEWA

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE							
>D>	AB COSETTE	0.2%	A213724	001	Feb 11, 2021	May	CAHN
>A>	AB COSETTE PHARMS NC	0.2%	A213724	001	Feb 11, 2021	May	CAHN
	@ PADAGIS ISRAEL	0.2%	A075666	001	May 24, 2000	Mar	DISC

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE							
>D>	AB COSETTE	0.2%	A211764	001	Mar 04, 2020	May	CAHN
>A>	AB COSETTE PHARMS NC	0.2%	A211764	001	Mar 04, 2020	May	CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE							
>D>	AT ! BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064053	001	Dec 29, 1995	May	CAHN
>A>	AT ! BAUSCH AND LOMB INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064053	001	Dec 29, 1995	May	CAHN

SUSPENSION/DROPS;OTIC

OTICAIR							
>D>	AT BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064065	001	Aug 28, 1996	May	CAHN
>A>	AT BAUSCH AND LOMB INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064065	001	Aug 28, 1996	May	CAHN

HYDROCORTISONE; UREA

CREAM;TOPICAL

ALPHADERM							
>D>	@ BIOGLAN	1%;10%	A086008	001		May	CRLD
>A>	@ +	1%;10%	A086008	001		May	CRLD

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID-HP							
AP	+! FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Apr	CMFD

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE							
AB	SENORES PHARMS	200MG	A212902	001	May 14, 2020	Jan	CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE							
>A>	AA SAPTALIS PHARMS	10MG/5ML	A220271	001	Jun 11, 2026	May	NEWA

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE							
	@ AMNEAL PHARM	10MG	A040808	001	Sep 24, 2008	Apr	DISC
	@	25MG	A040808	002	Sep 24, 2008	Apr	DISC
	@	50MG	A040808	003	Sep 24, 2008	Apr	DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS  
IBANDRONATE SODIUM

>D>	AP	CHEMI SPA	EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014	May DISC
>A>	@		EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014	May DISC

ICOSAPENT ETHYL

CAPSULE; ORAL  
ICOSAPENT ETHYL

AB		TORRENT	1GM	A218994	001	Dec 20, 2024	Apr CAHN
----	--	---------	-----	---------	-----	--------------	----------

ICOTROKINRA HYDROCHLORIDE

TABLET; ORAL  
ICOTYDE

	+	JANSSEN BIOTECH	EQ 200MG BASE	N220149	001	Mar 17, 2026	Mar NEWA
--	---	-----------------	---------------	---------	-----	--------------	----------

IDELALISIB

TABLET; ORAL  
IDELALISIB

AB		NATCO	100MG	A216921	001	Feb 17, 2026	Feb NFTG
AB			150MG	A216921	002	Feb 17, 2026	Feb NFTG
		ZYDELIG					
AB	+	GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014	Feb CFTG
AB	+		150MG	N205858	002	Jul 23, 2014	Feb CFTG

IMATINIB MESYLATE

TABLET; ORAL  
GLEEVEC

AB	+	NOVARTIS	EQ 100MG BASE	N021588	001	Apr 18, 2003	Mar CHRS
AB	+		EQ 400MG BASE	N021588	002	Apr 18, 2003	Mar CHRS
		IMATINIB MESYLATE					
	@	SUN PHARM	EQ 100MG BASE	A078340	001	Dec 03, 2015	Feb DISC
	@		EQ 400MG BASE	A078340	002	Dec 03, 2015	Feb DISC

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION  
INDIUM IN-111 PENTETREOTIDE KIT

	@	SUN PHARM INDS INC	3mCi/ML	A212785	001	Jul 01, 2024	Apr DISC
	+	OCTREOSCAN					
	+	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Apr CTEC

INDOCYANINE GREEN

INJECTABLE; INJECTION  
IC-GREEN

>D>	@	RENEW PHARMS	10MG/VIAL	N011525	003		May CMFD
>A>	!		10MG/VIAL	N011525	003		May CMFD

IOMEPROL

SOLUTION; INTRA-ARTERIAL  
IOMERVU

	+	BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Feb CMFD
	+		40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Feb CMFD
	+		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Feb CMFD
	+		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Feb CMFD

SOLUTION; INTRAVENOUS  
IOMERVU

	+	BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Feb CMFD
	+		40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Feb CMFD
	+		70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Feb CMFD
	+		80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Feb CMFD

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION  
ATROVENT HFA

AB	+	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004	Feb CFTG
AB		ARMSTRONG PHARMS	0.021MG/INH	A217953	001	Feb 23, 2026	Feb NFTG

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION  
IRINOTECAN HYDROCHLORIDE

>A>	AP	INGENUS PHARMS LLC	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	May CAHN
>A>	AP		100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	May CAHN
>D>	AP	NOVAST LABS	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	May CAHN
>D>	AP		100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	May CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION  
ISOPROTERENOL HYDROCHLORIDE

>A>	AP	ASPIRO	0.2MG/ML	A220299	001	May 18, 2026	May NEWA
-----	----	--------	----------	---------	-----	--------------	----------

ISOSORBIDE DINITRATE

TABLET; ORAL  
ISOSORBIDE DINITRATE

>D>	AB	RUBICON	5MG	A215723	001	Jul 08, 2022	May CAHN
>D>	AB		10MG	A215723	002	Jul 08, 2022	May CAHN
>D>	AB		20MG	A215723	003	Jul 08, 2022	May CAHN
>D>	AB		30MG	A215723	004	Jul 08, 2022	May CAHN
>D>	AB		40MG	A215723	005	Jul 08, 2022	May CAHN
>A>	AB	RUBICON RESEARCH	5MG	A215723	001	Jul 08, 2022	May CAHN
>A>	AB		10MG	A215723	002	Jul 08, 2022	May CAHN
>A>	AB		20MG	A215723	003	Jul 08, 2022	May CAHN
>A>	AB		30MG	A215723	004	Jul 08, 2022	May CAHN
>A>	AB		40MG	A215723	005	Jul 08, 2022	May CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL  
ISOSORBIDE MONONITRATE

AB		ANI PHARMS	10MG	A075147	002	Mar 27, 2026	Apr NEWA
AB			20MG	A075147	001	Nov 27, 1998	Mar CMFD

ISOSULFAN BLUE

SOLUTION; SUBCUTANEOUS  
ISOSULFAN BLUE

>D>	@	EUGIA PHARMA	50MG/5ML (10MG/ML)	A206831	001	Feb 02, 2016	May CMFD	
>A>	AP		50MG/5ML (10MG/ML)	A206831	001	Feb 02, 2016	May CMFD	
		!	MYLAN INSTITUTIONAL	10MG/ML (10MG/ML)	A090874	002	Jan 28, 2026	Jan NFTG
		!		30MG/3ML (10MG/ML)	A090874	003	Jan 28, 2026	Jan NFTG
>D>	@	SOMERSET THERAPS LLC	50MG/5ML (10MG/ML)	A210558	001	Jul 12, 2019	May CMFD	
>A>	AP		50MG/5ML (10MG/ML)	A210558	001	Jul 12, 2019	May CMFD	

ISOTRETINOIN

CAPSULE; ORAL  
ISOTRETINOIN

@	AMNEAL PHARMS NY	10MG	A216097	001	Oct 07, 2025	Mar DISC
@		20MG	A216097	002	Oct 07, 2025	Mar DISC
@		25MG	A216097	003	Oct 07, 2025	Mar DISC
@		30MG	A216097	004	Oct 07, 2025	Mar DISC
@		35MG	A216097	005	Oct 07, 2025	Mar DISC
@		40MG	A216097	006	Oct 07, 2025	Mar DISC

IVABRADINE

SOLUTION; ORAL  
CORLANOR

@ +	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Mar DISC
-----	-----------	------------------	---------	-----	--------------	----------

IVABRADINE HYDROCHLORIDE

TABLET; ORAL  
CORLANOR

@ +	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Jan DISC
@ +		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Jan DISC

TABLET;ORAL

IVABRADINE HYDROCHLORIDE  
 AB ! INGENUS PHARMS LLC EQ 7.5MG BASE A214051 002 Dec 30, 2021 Jan CHRS

IVERMECTIN

TABLET;ORAL

IVERMECTIN  
 AB AJANTA PHARMA LTD 3MG A218509 001 Apr 07, 2026 Mar NEWA  
 AB E5 PHARMA 3MG A216808 001 Mar 09, 2026 Feb NEWA  
 AB ZYDUS LIFESCIENCES 3MG A216863 001 Feb 26, 2026 Feb NEWA

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETAMINE HYDROCHLORIDE  
 @ CAPLIN EQ 10MG BASE/ML A217858 001 Aug 07, 2025 Apr DISC  
 >D> SOLUTION;INTRAMUSCULAR, INTRAVENOUS  
 >D> KETAMINE HYDROCHLORIDE  
 >D> ! BAXTER HLTHCARE CORP EQ 100MG BASE/10ML (EQ 10MG BASE/ML) A219684 001 Sep 17, 2025 May DISC  
 >A> @ EQ 100MG BASE/10ML (EQ 10MG BASE/ML) A219684 001 Sep 17, 2025 May DISC

KETOCONAZOLE

CREAM;TOPICAL

KETOCONAZOLE  
 @ PADAGIS US 2% A215185 001 Nov 17, 2021 Jan DISC

SHAMPOO;TOPICAL

KETOCONAZOLE  
 >D> AB COSETTE 2% A076942 001 Apr 11, 2005 May CAHN  
 >A> AB COSETTE PHARMS NC 2% A076942 001 Apr 11, 2005 May CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ACULAR LS  
 + ABBVIE 0.4% N021528 001 May 30, 2003 Apr CTEC  
 KETOROLAC TROMETHAMINE  
 @ APOTEX 0.4% A077308 001 Nov 05, 2009 Apr DISC

L-GLUTAMINE

FOR SOLUTION;ORAL

L-GLUTAMINE  
 >A> AA ANNORA PHARMA 5GM/PACKET A219722 001 May 26, 2026 May NEWA  
 >A> AA RENOVA PHARMS 5GM/PACKET A219750 001 May 14, 2026 May CAHN  
 >A> AA STIRA 5GM/PACKET A219750 001 May 14, 2026 May NEWA

LABETALOL HYDROCHLORIDE

TABLET;ORAL

LABETALOL HYDROCHLORIDE  
 AB APPCO 400MG A209603 004 Oct 18, 2024 Mar CTEC  
 AB HERITAGE PHARMA 400MG A074787 004 Mar 26, 2026 Mar NEWA

LACOSAMIDE

SOLUTION;INTRAVENOUS

LACOSAMIDE  
 AP ANTHEA PHARMA 200MG/20ML (10MG/ML) A220268 001 Jan 21, 2026 Jan NEWA  
 AP GLENMARK PHARMS 200MG/20ML (10MG/ML) A220268 001 Jan 21, 2026 Mar CAHN

SOLUTION;ORAL

LACOSAMIDE  
 @ APOTEX 10MG/ML A206355 001 Sep 26, 2022 Feb DISC  
 AA INDOCO 10MG/ML A220386 001 Jan 29, 2026 Jan NEWA  
 AA REGCON HOLDINGS 10MG/ML A220386 001 Jan 29, 2026 Jan CAHN  
 >A> AA STERANCO HLTHCARE 10MG/ML A220366 001 May 21, 2026 May NEWA

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE  
 @ LUPIN 150MG A205217 001 Dec 18, 2014 Jan DISC  
 @ 300MG A205217 002 Dec 18, 2014 Jan DISC

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@	LUPIN LTD	25MG	A078691	001	Jun 01, 2010	Apr	DISC
@		100MG	A078691	002	Jun 01, 2010	Apr	DISC
@		150MG	A078691	003	Jun 01, 2010	Apr	DISC
@		200MG	A078691	004	Jun 01, 2010	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

@	PH HEALTH	25MG	A201791	001	Jan 18, 2013	Apr	DISC
@		50MG	A201791	002	Jan 18, 2013	Apr	DISC
@		100MG	A201791	003	Jan 18, 2013	Apr	DISC
@		200MG	A201791	004	Jan 18, 2013	Apr	DISC
@		250MG	A201791	005	Jan 18, 2013	Apr	DISC
@		300MG	A201791	006	Jan 18, 2013	Apr	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

LAMOTRIGINE

AB	ALEMBIC	25MG	A217278	001	Feb 25, 2026	Feb	NEWA
AB		50MG	A217278	002	Feb 25, 2026	Feb	NEWA
AB		100MG	A217278	003	Feb 25, 2026	Feb	NEWA
AB		200MG	A217278	004	Feb 25, 2026	Feb	NEWA
AB	TORRENT	25MG	A217100	001	Jan 08, 2026	Jan	NEWA
AB		50MG	A217100	002	Jan 08, 2026	Jan	NEWA
AB		100MG	A217100	003	Jan 08, 2026	Jan	NEWA
AB		200MG	A217100	004	Jan 08, 2026	Jan	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

@	CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Feb	CAHN
---	----------	--------	---------	-----	--------------	-----	------

LENALIDOMIDE

CAPSULE; ORAL

LENALIDOMIDE

AB	ALVOGEN	2.5MG	A210480	005	Mar 06, 2023	Jan	CAHN
AB		5MG	A210480	001	Aug 31, 2022	Jan	CAHN
AB		10MG	A210480	002	Aug 31, 2022	Jan	CAHN
AB		15MG	A210480	003	Aug 31, 2022	Jan	CAHN
AB		20MG	A210480	006	Mar 06, 2023	Jan	CAHN
AB		25MG	A210480	004	Aug 31, 2022	Jan	CAHN
AB	CIPLA	5MG	A213165	001	Feb 02, 2026	Jan	NEWA
AB		10MG	A213165	002	Feb 02, 2026	Jan	NEWA
AB		15MG	A213165	003	Feb 02, 2026	Jan	NEWA
AB		20MG	A213165	004	Feb 02, 2026	Jan	NEWA
AB		25MG	A213165	005	Feb 02, 2026	Jan	NEWA
AB	@ TORRENT	2.5MG	A213405	005	Feb 10, 2026	Mar	DISC
AB		2.5MG	A213405	005	Feb 10, 2026	Jan	NEWA
AB	@	5MG	A213405	006	Feb 10, 2026	Mar	DISC
AB		5MG	A213405	006	Feb 10, 2026	Jan	NEWA
AB	@	15MG	A213405	004	Nov 04, 2025	Mar	DISC

LEUCOVORIN CALCIUM

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

LEUCOVORIN CALCIUM

@	INGENUS PHARMS LLC	EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018	Feb	CAHN
---	--------------------	--------------------------------------	---------	-----	--------------	-----	------

VYKOURA

+	AVYXA HOLDINGS	EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N220406	001	Feb 03, 2026	Feb	NEWA
+		EQ 350MG BASE/35ML (EQ 10MG BASE/ML)	N220406	002	Feb 03, 2026	Feb	NEWA
+		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	N220406	003	Feb 03, 2026	Feb	NEWA

TABLET; ORAL

LEUCOVORIN CALCIUM

>D>	AB	!	HIKMA	EQ 25MG BASE	A072736	001	Feb 22, 1993	May	CHRS
>A>	AB			EQ 25MG BASE	A072736	001	Feb 22, 1993	May	CHRS
	AB		INGENUS PHARMS LLC	EQ 5MG BASE	A211132	001	Jul 30, 2020	Apr	CAHN
	AB			EQ 10MG BASE	A211132	002	Jul 30, 2020	Apr	CAHN
	AB			EQ 15MG BASE	A211132	003	Jul 30, 2020	Apr	CAHN
>D>	AB			EQ 25MG BASE	A211132	004	Jul 30, 2020	May	CHRS
>A>	AB		!	EQ 25MG BASE	A211132	004	Jul 30, 2020	May	CHRS

		TABLET;ORAL								
		LEUCOVORIN CALCIUM								
AB		EQ 25MG BASE		A211132	004	Jul 30, 2020	Apr	CAHN		
		<u>LEUPROLIDE ACETATE</u>								
		SOLUTION;SUBCUTANEOUS								
		LEUPROLIDE ACETATE								
AP		SOMERSET THERAPS LLC	14MG/2.8ML (1MG/0.2ML)	A213829	001	Aug 13, 2021	Feb	CAHN		
		<u>LEUPROLIDE MESYLATE</u>								
		EMULSION;SUBCUTANEOUS								
		CAMCEVI ETM								
	+	!	ACCORD	EQ 21MG BASE		N219745	001	Aug 25, 2025	Jan	CAHN
		<u>LEVABUTEROL HYDROCHLORIDE</u>								
		SOLUTION;INHALATION								
		LEVABUTEROL HYDROCHLORIDE								
>A>	AN	NEPHRON	EQ 0.021% BASE	A215217	001	May 26, 2026	May	NEWA		
>A>	AN		EQ 0.042% BASE	A215217	002	May 26, 2026	May	NEWA		
		<u>LEVETIRACETAM</u>								
		INJECTABLE;INTRAVENOUS								
		LEVETIRACETAM								
>D>	AP	KNACK	500MG/5ML (100MG/ML)	A215465	001	Dec 02, 2025	May	DISC		
>A>		@	500MG/5ML (100MG/ML)	A215465	001	Dec 02, 2025	May	DISC		
		LEVETIRACETAM IN SODIUM CHLORIDE								
>A>	AP	MYLAN LABS LTD	500MG/100ML (5MG/ML)	A218364	001	May 08, 2026	May	NEWA		
>A>	AP		1GM/100ML (10MG/ML)	A218364	002	May 08, 2026	May	NEWA		
>A>	AP		1.5GM/100ML (15MG/ML)	A218364	003	May 08, 2026	May	NEWA		
		SOLUTION;ORAL								
		LEVETIRACETAM								
AA		ANDA REPOSITORY	100MG/ML	A218080	001	Nov 21, 2025	Mar	CAHN		
		TABLET;ORAL								
		LEVETIRACETAM								
AB		SENORES PHARMS	250MG	A076920	001	Jan 15, 2009	Jan	CAHN		
AB			500MG	A076920	002	Jan 15, 2009	Jan	CAHN		
AB			750MG	A076920	003	Jan 15, 2009	Jan	CAHN		
AB			1GM	A078904	001	Jan 15, 2009	Jan	CAHN		
		<u>LEVOBUNOLOL HYDROCHLORIDE</u>								
		SOLUTION/DROPS;OPHTHALMIC								
		LEVOBUNOLOL HYDROCHLORIDE								
>D>	AT	BAUSCH AND LOMB	0.5%	A074326	001	Mar 04, 1994	May	CAHN		
>A>	AT	BAUSCH AND LOMB INC	0.5%	A074326	001	Mar 04, 1994	May	CAHN		
		<u>LEVOFLOXACIN</u>								
		TABLET;ORAL								
		LEVOFLOXACIN								
>D>	AB	LUPIN	250MG	A078424	001	Jun 20, 2011	May	DISC		
>A>		@	250MG	A078424	001	Jun 20, 2011	May	DISC		
>D>	AB		500MG	A078424	002	Jun 20, 2011	May	DISC		
>A>		@	500MG	A078424	002	Jun 20, 2011	May	DISC		
>D>	AB		750MG	A078424	003	Jun 20, 2011	May	DISC		
>A>		@	750MG	A078424	003	Jun 20, 2011	May	DISC		
		<u>LEVOLEUCOVORIN CALCIUM</u>								
		SOLUTION;INTRAVENOUS								
		LEVOLEUCOVORIN CALCIUM								
		@	AMNEAL	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Mar	DISC	
>A>		@	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	May	CAHN	
>A>		@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	May	CAHN	
>D>		@	NOVAST LABS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	May	CAHN	
>D>		@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	May	CAHN	

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

## TABLET;ORAL

## EUTHYROX

@	EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr	DISC
@		0.05MG	N021292	002	May 31, 2002	Apr	DISC
@		0.075MG	N021292	003	May 31, 2002	Apr	DISC
@		0.088MG	N021292	004	May 31, 2002	Apr	DISC
@		0.1MG	N021292	005	May 31, 2002	Apr	DISC
@		0.112MG	N021292	006	May 31, 2002	Apr	DISC
@		0.125MG	N021292	007	May 31, 2002	Apr	DISC
@		0.137MG	N021292	008	May 31, 2002	Apr	DISC
@		0.15MG	N021292	009	May 31, 2002	Apr	DISC
@		0.175MG	N021292	010	May 31, 2002	Apr	DISC
@		0.2MG	N021292	011	May 31, 2002	Apr	DISC

## LEVOTHYROXINE SODIUM

>A>	AB2	ALEMBIC	0.025MG	A216370	001	May 20, 2026	May	NEWA
>A>	AB2		0.05MG	A216370	002	May 20, 2026	May	NEWA
>A>	AB2		0.075MG	A216370	003	May 20, 2026	May	NEWA
>A>	AB2		0.088MG	A216370	004	May 20, 2026	May	NEWA
>A>	AB2		0.1MG	A216370	005	May 20, 2026	May	NEWA
>A>	AB2		0.112MG	A216370	006	May 20, 2026	May	NEWA
>A>	AB2		0.125MG	A216370	007	May 20, 2026	May	NEWA
>A>	AB2		0.137MG	A216370	008	May 20, 2026	May	NEWA
>A>	AB2		0.15MG	A216370	009	May 20, 2026	May	NEWA
>A>	AB2		0.175MG	A216370	010	May 20, 2026	May	NEWA
>A>	AB2		0.2MG	A216370	011	May 20, 2026	May	NEWA
>A>	AB2		0.3MG	A216370	012	May 20, 2026	May	NEWA

LIDOCAINE

## OINTMENT;TOPICAL

## LIDOCAINE

>D>	BX	ALEMBIC	5%	A211469	001	Nov 23, 2018	May	CTEC
>A>	AT		5%	A211469	001	Nov 23, 2018	May	CTEC

## PATCH;TOPICAL

## LIDOCAINE

AB		USPHARMA	5%	A207059	001	Feb 09, 2026	Mar	CMFD
	@		5%	A207059	001	Feb 09, 2026	Feb	DISC
AB			5%	A207059	001	Feb 09, 2026	Jan	NEWA

LIDOCAINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## LIDOCAINE HYDROCHLORIDE

AP		ANTHEA PHARMA	2%	A219535	002	Feb 06, 2026	Jan	NEWA
AP		VIWIT PHARM	1%	A220071	001	Mar 19, 2026	Mar	NEWA
AP			2%	A220071	002	Mar 19, 2026	Mar	NEWA

## LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

>A>	@	CHARTWELL RX	2%	A090665	001	Sep 27, 2010	May	CAHN
>D>	@	EXTROVIS	2%	A090665	001	Sep 27, 2010	May	CAHN

## SOLUTION;ORAL

## LIDOCAINE HYDROCHLORIDE

AT		QUAGEN	2%	A218676	001	Mar 20, 2026	Mar	NEWA
----	--	--------	----	---------	-----	--------------	-----	------

LINAGLIPTIN

## TABLET;ORAL

## LINAGLIPTIN

>A>	AB	TEVA PHARMS USA	5MG	A208433	001	May 27, 2026	May	NEWA
-----	----	-----------------	-----	---------	-----	--------------	-----	------

LINERIXIBAT

## TABLET;ORAL

## LYNAVOY

>D>		+! GLAXOSMITHKLINE	40MG	N220295	001	Mar 17, 2026	May	CAHN
		+!	40MG	N220295	001	Mar 17, 2026	Mar	NEWA
>A>		+! INTERCEPT	40MG	N220295	001	Mar 17, 2026	May	CAHN

LIRAGLUTIDE

## SOLUTION;SUBCUTANEOUS

## LIRAGLUTIDE

AP1		BIOCON PHARMA	18MG/3ML (6MG/ML)	A215245	001	Mar 11, 2026	Feb	NEWA
AP2			18MG/3ML (6MG/ML)	A217063	001	Feb 24, 2026	Feb	NEWA
AP1		FRESENIUS KABI USA	18MG/3ML (6MG/ML)	A212552	001	Mar 30, 2026	Mar	NEWA

SOLUTION;SUBCUTANEOUS  
LIRAGLUTIDE

AP2	ORBICULAR	18MG/3ML (6MG/ML)	A217234	001	Feb 24, 2026	Feb	NEWA
AP1		18MG/3ML (6MG/ML)	A217590	001	Jan 14, 2026	Jan	NEWA

LITHIUM CITRATE

SYRUP;ORAL  
LITHIUM CITRATE

AA	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Mar	CMFD
----	--------------------	------------------------	---------	-----	--------------	-----	------

LOMITAPIDE MESYLATE

CAPSULE;ORAL  
JUXTAPID

	+ CHIESI	EQ 2MG BASE	N203858	007	Feb 25, 2026	Feb	NEWA
	+!	EQ 30MG BASE	N203858	004	Apr 23, 2015	Mar	CHRS

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL  
ALTOPREV

@	AZURITY	10MG	N021316	001	Jun 26, 2002	Mar	CAHN
@ +		20MG	N021316	002	Jun 26, 2002	Mar	CAHN
@ +		40MG	N021316	003	Jun 26, 2002	Mar	CAHN
@ +		60MG	N021316	004	Jun 26, 2002	Mar	CAHN

LUBIPROSTONE

CAPSULE;ORAL  
LUBIPROSTONE

AB	AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan	CMFD
AB		24MCG	A209450	002	Nov 30, 2021	Jan	CMFD

MACIMORELIN ACETATE

FOR SOLUTION;ORAL  
MACRILEN

@ +	AETERNA ZENTARIS	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	Jan	CAHN
-----	------------------	--------------------	---------	-----	--------------	-----	------

MACITENTAN

TABLET;ORAL  
MACITENTAN

>A>	AB	AMNEAL	10MG	A211000	001	Jun 08, 2026	May	NEWA
	AB	APOTEX	10MG	A211195	001	Jan 09, 2024	Mar	CMFD
>D>	@	MYLAN	10MG	A211161	001	Dec 03, 2025	May	CMFD
>A>	AB		10MG	A211161	001	Dec 03, 2025	May	CMFD
	AB	SEASONS BIOTECH	10MG	A211026	001	Dec 03, 2025	Apr	CMFD
>A>	AB	TEVA PHARMS USA INC	10MG	A211187	001	Jun 08, 2026	May	NEWA
	AB	TORRENT	10MG	A211107	001	Aug 05, 2024	Apr	CMFD
	AB	ZYDUS LIFESCIENCES	10MG	A211224	001	Apr 06, 2021	Apr	CMFD

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL  
MAFENIDE ACETATE

@	INGENUS PHARMS LLC	5%	A206716	001	Jul 31, 2017	Feb	CAHN
---	--------------------	----	---------	-----	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE;INJECTION  
MAGNESIUM SULFATE

!	BAXTER HLTHCARE CORP	3GM/100ML (30MG/ML)	A211966	004	Jan 08, 2026	Jan	NFTG
@	MYLAN LABS LTD	2GM/50ML (40MG/ML)	A209911	001	Sep 14, 2018	Mar	DISC

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

TABLET;ORAL

>A>		SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE						
>A>	AB	LUPIN	0.225GM;0.188GM;1.479GM	A216095	001	May 28, 2026	May	NFTG
		SUTAB						
>D>	+!	AZURITY	0.225GM;0.188GM;1.479GM	N213135	001	Nov 10, 2020	May	CFTG
>A>	AB	+!	0.225GM;0.188GM;1.479GM	N213135	001	Nov 10, 2020	May	CFTG

MARAVIROC

TABLET; ORAL

MARAVIROC

@ RHODES PHARMS 150MG A216143 001 Nov 04, 2025 Apr DISC  
 @ 300MG A216143 002 Nov 04, 2025 Apr DISC

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA SENORES PHARMS 12.5MG A087128 002 Feb CAHN  
 AA 25MG A087128 001 Feb CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

>A> @ INGENUS PHARMS LLC EQ 50MG BASE/VIAL A210947 001 Feb 18, 2020 May CAHN  
 >D> @ NOVAST LABS EQ 50MG BASE/VIAL A210947 001 Feb 18, 2020 May CAHN

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

AA MEDLEY PHARMS 2MG/ML A210319 001 Aug 31, 2020 Mar CAHN

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

AB ! DR REDDYS LABS LTD 10MG A090048 002 Apr 14, 2010 Mar CHRS  
 AB RENATA 5MG A209527 001 May 07, 2018 Feb CAHN  
 AB 10MG A209527 002 May 07, 2018 Feb CAHN  
 NAMENDA  
 @ + ABBVIE 5MG N021487 001 Oct 16, 2003 Mar DISC  
 @ + 10MG N021487 002 Oct 16, 2003 Mar DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

! FRESENIUS KABI USA 1% A089407 001 Dec 01, 1986 Jan CHRS  
 ! 2% A089410 001 Dec 01, 1986 Jan CHRS

POLOCAINE-MPF

! FRESENIUS KABI USA 1% A089406 001 Dec 01, 1986 Jan CHRS  
 ! 1.5% A089408 001 Dec 01, 1986 Jan CHRS  
 ! 2% A089409 001 Dec 01, 1986 Jan CHRS

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

MESALAMINE

AB DIFGEN PHARMS 250MG A219997 001 Mar 10, 2026 Feb NFTG  
 AB 500MG A219997 002 Mar 10, 2026 Feb NEWA

PENTASA

AB + TAKEDA PHARMS USA 250MG N020049 001 May 10, 1993 Feb CFTG

ENEMA; RECTAL

MESALAMINE

AB KLM LABS PVT 4GM/60ML A220016 001 Mar 31, 2026 Mar NEWA

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP EUGIA PHARMA 100MG/ML A220518 001 Jan 27, 2026 Jan NEWA

TABLET; ORAL

MESNA

AB INGENUS PHARMS LLC 400MG A218871 001 Jan 13, 2025 Feb CAHN

METAXALONE

TABLET; ORAL

METAXALONE

@ INGENUS PHARMS LLC 800MG A213836 001 Oct 21, 2020 Feb CAHN

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB	CHARTWELL	625MG	A 075972	005	Jan 24, 2002	Jan	CTEC
AB		750MG	A 075972	004	Jan 24, 2002	Jan	CTEC
AB	SCIEGEN PHARMS	625MG	A 203769	004	Feb 09, 2026	Jan	NEWA
AB		750MG	A 203769	005	Feb 09, 2026	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

	@ ALLIED	500MG	A 215629	001	Jun 20, 2023	Apr	CAHN
	@	1GM	A 215629	002	Jun 20, 2023	Apr	CAHN
	@ AMNEAL PHARMS NY	500MG	A 078596	001	Jan 03, 2008	Mar	DISC
	@	750MG	A 078596	002	Jan 03, 2008	Mar	DISC
	@ APOTEX	500MG	A 213356	001	Dec 13, 2021	Feb	DISC
	@	1GM	A 213356	002	Dec 13, 2021	Feb	DISC
AB1	PLATINUM	500MG	A 202306	001	Feb 23, 2017	Apr	CAHN
AB		750MG	A 202306	002	Feb 23, 2017	Apr	CAHN
	@ RK PHARMA	500MG	A 215629	001	Jun 20, 2023	Jan	DISC
	@	1GM	A 215629	002	Jun 20, 2023	Jan	DISC
	@ SENORES PHARMS	500MG	A 215629	001	Jun 20, 2023	Apr	CAHN
	@	1GM	A 215629	002	Jun 20, 2023	Apr	CAHN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB	APOTEX	500MG;EQ 50MG BASE	A 202426	001	Apr 30, 2026	Apr	NEWA
AB		1GM;EQ 50MG BASE	A 202426	002	Apr 30, 2026	Apr	NEWA

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

>D>	+ MSD SUB MERCK	500MG;EQ 50MG BASE	N 202270	001	Feb 02, 2012	May	CTEC
>A>	AB +	500MG;EQ 50MG BASE	N 202270	001	Feb 02, 2012	May	CTEC
>D>	+	1GM;EQ 50MG BASE	N 202270	002	Feb 02, 2012	May	CTEC
>A>	AB +	1GM;EQ 50MG BASE	N 202270	002	Feb 02, 2012	May	CTEC
>D>	+!	1GM;EQ 100MG BASE	N 202270	003	Feb 02, 2012	May	CTEC
>A>	AB +!	1GM;EQ 100MG BASE	N 202270	003	Feb 02, 2012	May	CTEC

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

>D>	@ PH HEALTH	500MG;EQ 50MG BASE	A 204144	001	Jun 04, 2025	May	CMFD
>A>	AB	500MG;EQ 50MG BASE	A 204144	001	Jun 04, 2025	May	CMFD
>D>	@	1GM;EQ 50MG BASE	A 204144	002	Jun 04, 2025	May	CMFD
>A>	AB	1GM;EQ 50MG BASE	A 204144	002	Jun 04, 2025	May	CMFD
>D>	@	1GM;EQ 100MG BASE	A 204144	003	Jun 04, 2025	May	CMFD
>A>	AB	1GM;EQ 100MG BASE	A 204144	003	Jun 04, 2025	May	CMFD

METHADONE HYDROCHLORIDE

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

AA	VISTAPHARM LLC	5MG/5ML	A 090707	001	Jun 30, 2010	Feb	CMFD
----	----------------	---------	----------	-----	--------------	-----	------

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB	AJANTA PHARMA LTD	25MG	A 217408	001	Feb 09, 2026	Jan	NEWA
AB		50MG	A 217408	002	Feb 09, 2026	Jan	NEWA
	@ POM PHARMA	25MG	A 040102	001	Aug 28, 1996	Apr	CAHN
	@	50MG	A 040102	002	Aug 28, 1996	Apr	CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

AB	INGENUS PHARMS LLC	1GM	A 210068	001	Nov 27, 2020	Feb	CAHN
----	--------------------	-----	----------	-----	--------------	-----	------

METHOCARBAMOL

SUSPENSION;ORAL

ATMEKSI

>D>	+! ROSEMONT PHARMS	750MG/5ML	N 219843	001	Jul 30, 2025	May	CAHN
>A>	+!	750MG/5ML	N 219843	001	Jul 30, 2025	May	CAHN

TABLET;ORAL

METHOCARBAMOL

AA	DBL PHARMS	500MG	A 203550	001	Feb 08, 2017	Mar	CAHN
AA		750MG	A 203550	002	Feb 08, 2017	Mar	CAHN
AA	HLTHCARE	500MG	A 203550	001	Feb 08, 2017	Feb	CAHN

TABLET; ORAL  
METHOCARBAMOL

AA 750MG A203550 002 Feb 08, 2017 Feb CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION  
METHOTREXATE SODIUM

AP ALEMBIC EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A220225 001 Apr 15, 2026 Apr NEWA

AP EQ 1GM BASE/40ML (EQ 25MG BASE/ML) A220225 002 Apr 15, 2026 Apr NEWA

AP HETERO LABS LTD VI EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A219865 001 Apr 30, 2026 Apr NEWA

AP ! HIKMA EQ 200MG BASE/8ML (EQ 25MG BASE/ML) A089342 001 Sep 16, 1986 Apr CTEC

METHOTREXATE SODIUM PRESERVATIVE FREE

@ CAPLIN ONE LABS EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A090039 001 Mar 31, 2009 Mar DISC

AP EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A090039 001 Mar 31, 2009 Jan CAHN

@ EQ 250MG BASE/10ML (EQ 25MG BASE/ML) A090039 002 Mar 31, 2009 Mar DISC

AP EQ 250MG BASE/10ML (EQ 25MG BASE/ML) A090039 002 Mar 31, 2009 Jan CAHN

@ EQ 1GM BASE/40ML (EQ 25MG BASE/ML) A090029 001 Mar 31, 2009 Mar DISC

AP EQ 1GM BASE/40ML (EQ 25MG BASE/ML) A090029 001 Mar 31, 2009 Jan CAHN

AP EUGIA PHARMA SPECLTS EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A201529 001 Mar 29, 2012 Apr CMFD

AP EQ 100MG BASE/4ML (EQ 25MG BASE/ML) A201529 002 Mar 29, 2012 Apr CMFD

AP EQ 200MG BASE/8ML (EQ 25MG BASE/ML) A201529 003 Mar 29, 2012 Apr CMFD

AP EQ 250MG BASE/10ML (EQ 25MG BASE/ML) A201529 004 Mar 29, 2012 Apr CMFD

TABLET; ORAL  
METHOTREXATE SODIUM

@ DAITO EQ 2.5MG BASE A213362 001 Aug 07, 2023 Mar DISC

METHYLDOPA

TABLET; ORAL  
METHYLDOPA

@ QUAGEN 125MG A070535 001 Jan 02, 1987 Apr CAHN

@ 250MG A070536 001 Jan 02, 1987 Apr CAHN

@ 500MG A070537 001 Jan 02, 1987 Apr CAHN

METHYLENE BLUE

SOLUTION; INTRAVENOUS  
METHYLENE BLUE

! ZYDUS LIFESCIENCES 5MG/ML (5MG/ML) A215636 003 Feb 02, 2026 Jan NFTG

! 100MG/10ML (10MG/ML) A215636 004 Mar 31, 2026 Mar NFTG

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL  
COTEMPLA XR-ODT

>D> + NEOS THERAPS INC 8.6MG N205489 001 Jun 19, 2017 May CTEC

>A> AB + 8.6MG N205489 001 Jun 19, 2017 May CTEC

>D> + 17.3MG N205489 002 Jun 19, 2017 May CTEC

>A> AB + 17.3MG N205489 002 Jun 19, 2017 May CTEC

>D> +! 25.9MG N205489 003 Jun 19, 2017 May CTEC

>A> AB +! 25.9MG N205489 003 Jun 19, 2017 May CTEC

METHYLPHENIDATE

>D> @ ACTAVIS ELIZABETH 8.6MG A210924 001 Jun 19, 2020 May CMFD

>A> AB 8.6MG A210924 001 Jun 19, 2020 May CMFD

>D> @ 17.3MG A210924 002 Jun 19, 2020 May CMFD

>A> AB 17.3MG A210924 002 Jun 19, 2020 May CMFD

>D> @ 25.9MG A210924 003 Jun 19, 2020 May CMFD

>A> AB 25.9MG A210924 003 Jun 19, 2020 May CMFD

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
ADHANSIA XR

>A>	@ +	KNOA PHARMA	25MG	N212038	001	Feb 27, 2019	May	CAHN
>A>	@ +		35MG	N212038	002	Feb 27, 2019	May	CAHN
>A>	@ +		45MG	N212038	003	Feb 27, 2019	May	CAHN
>A>	@ +		55MG	N212038	004	Feb 27, 2019	May	CAHN
>A>	@ +		70MG	N212038	005	Feb 27, 2019	May	CAHN
>A>	@ +		85MG	N212038	006	Feb 27, 2019	May	CAHN
>D>	@ +	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	May	CAHN
>D>	@ +		35MG	N212038	002	Feb 27, 2019	May	CAHN
>D>	@ +		45MG	N212038	003	Feb 27, 2019	May	CAHN
>D>	@ +		55MG	N212038	004	Feb 27, 2019	May	CAHN
>D>	@ +		70MG	N212038	005	Feb 27, 2019	May	CAHN
>D>	@ +		85MG	N212038	006	Feb 27, 2019	May	CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB1		DR REDDYS LABS SA	60MG	A078458	004	Jun 23, 2016	Feb	CHRS
AB1	!	GRANULES	60MG	A211796	005	May 23, 2019	Feb	CHRS

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	QUAGEN	2.5MG	A204954	001	Jan 26, 2017	Apr	CAHN
@		5MG	A204954	002	Jan 26, 2017	Apr	CAHN
@		10MG	A204954	003	Jan 26, 2017	Apr	CAHN

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

@	INGENUS PHARMS LLC	4MG	A210985	001	Jan 09, 2019	Feb	CAHN
---	--------------------	-----	---------	-----	--------------	-----	------

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	CAPLIN	40MG/ML	A220556	001	Jan 26, 2026	Jan	NEWA
AB		80MG/ML	A220556	002	Jan 26, 2026	Jan	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>D>	AA	!	GENUS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	May	CAHN
>A>	AA	!	PAI HOLDINGS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	May	CAHN

SPRAY, METERED;NASAL

GIMOTI

+!	QOL MEDCL	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020	Feb	CAHN
----	-----------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	STRIDES PHARMA INTL	EQ 10MG BASE	A070581	001	Oct 17, 1985	Jan	DISC
---	---------------------	--------------	---------	-----	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

>D>	AB		MYLAN PHARMS INC	EQ 100MG TARTRATE	A202033	003	Dec 15, 2011	May	DISC
>A>		@		EQ 100MG TARTRATE	A202033	003	Dec 15, 2011	May	DISC
		@		EQ 200MG TARTRATE	A202033	004	Dec 15, 2011	Mar	DISC
>A>	AB		ZHEJIANG JUTAI PHARM	EQ 25MG TARTRATE	A214110	004	May 15, 2026	May	NEWA

METRONIDAZOLE

CREAM;TOPICAL

METRONIDAZOLE

>D>	AB		COSETTE	0.75%	A077549	001	Dec 19, 2007	May	CAHN
>A>	AB		COSETTE PHARMS NC	0.75%	A077549	001	Dec 19, 2007	May	CAHN

GEL;TOPICAL

METRONIDAZOLE

>D>	AB	!	COSETTE	0.75%	A078178	001	Jan 19, 2011	May	CAHN
>D>	AB			1%	A216692	001	Jan 23, 2023	May	CAHN
>A>	AB	!	COSETTE PHARMS NC	0.75%	A078178	001	Jan 19, 2011	May	CAHN
>A>	AB			1%	A216692	001	Jan 23, 2023	May	CAHN
	AB		ZYDUS LIFESCIENCES	0.75%	A220095	001	Feb 13, 2026	Feb	NEWA

GEL;VAGINAL

METRONIDAZOLE

>D>	AB		COSETTE	0.75%	A216323	001	Jul 12, 2023	May	CAHN
>A>	AB		COSETTE PHARMS NC	0.75%	A216323	001	Jul 12, 2023	May	CAHN

GEL;VAGINAL

NUVESSA

>A>	+	!	ALEMBIC THERAP	1.3%	N205223	001	Mar 24, 2014	May	CAHN
>D>	+	!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	May	CAHN

INJECTABLE;INJECTION

METRO I.V. IN PLASTIC CONTAINER

	@	+	B BRAUN	500MG/100ML	N018900	001	Sep 29, 1983	Jan	DISC
			METRONIDAZOLE IN PLASTIC CONTAINER						
AP	!		INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Jan	CHRS

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

AB			INGENUS PHARMS LLC	150MG	A214352	001	Jan 25, 2021	Feb	CAHN
AB				200MG	A214352	002	Jan 25, 2021	Feb	CAHN
AB				250MG	A214352	003	Jan 25, 2021	Feb	CAHN
AB			MACLEODS PHARMS LTD	150MG	A219987	001	Mar 23, 2026	Mar	NEWA
AB				200MG	A219987	002	Mar 23, 2026	Mar	NEWA
AB				250MG	A219987	003	Mar 23, 2026	Mar	NEWA

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MICAFUNGIN SODIUM

AP			ASPIRO	EQ 50MG BASE/VIAL	A220296	001	Mar 17, 2026	Mar	NEWA
AP				EQ 100MG BASE/VIAL	A220296	002	Mar 17, 2026	Mar	NEWA
AP			HISUN PHARM HANGZHOU	EQ 50MG BASE/VIAL	A219712	001	Jan 21, 2026	Jan	NEWA
AP				EQ 100MG BASE/VIAL	A219712	002	Jan 21, 2026	Jan	NEWA
AP			YICHANG HUMANWELL	EQ 50MG BASE/VIAL	A219518	001	Feb 24, 2026	Feb	NEWA
AP				EQ 100MG BASE/VIAL	A219518	002	Feb 24, 2026	Feb	NEWA

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

	@		IMPAX PHARMS	2.5MG	A076449	001	May 27, 2004	Apr	DISC
	@			5MG	A076449	002	May 27, 2004	Apr	DISC
	@			10MG	A076449	003	Dec 16, 2005	Apr	DISC
AB			UNIQUE	2.5MG	A207613	001	Nov 02, 2018	Mar	CAHN
AB				5MG	A207613	002	Nov 02, 2018	Mar	CAHN
AB				10MG	A207613	003	Nov 02, 2018	Mar	CAHN

MIGLITOL

TABLET;ORAL

MIGLITOL

	!		ORIENT PHARMA	25MG	A203965	001	Feb 24, 2015	Mar	CAHN
				50MG	A203965	002	Feb 24, 2015	Mar	CAHN
				100MG	A203965	003	Feb 24, 2015	Mar	CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

AB			AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Jan	CMFD
AB				25MG	A205081	002	Apr 22, 2016	Jan	CMFD
AB				50MG	A205081	003	Apr 22, 2016	Jan	CMFD
AB				100MG	A205081	004	Apr 22, 2016	Jan	CMFD
AB			BRECKENRIDGE	12.5MG	A205071	001	Jan 27, 2016	Jan	CMFD
AB				25MG	A205071	002	Jan 27, 2016	Jan	CMFD
AB				50MG	A205071	003	Jan 27, 2016	Jan	CMFD
AB				100MG	A205071	004	Jan 27, 2016	Jan	CMFD
AB			HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Feb	CMFD
AB				25MG	A205147	002	Oct 03, 2024	Feb	CMFD
AB				50MG	A205147	003	Oct 03, 2024	Feb	CMFD
AB				100MG	A205147	004	Oct 03, 2024	Feb	CMFD
			SAVELLA						
AB	+		ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Jan	CTEC
AB	+			25MG	N022256	002	Jan 14, 2009	Jan	CTEC
AB	+	!		50MG	N022256	003	Jan 14, 2009	Jan	CTEC
AB	+			100MG	N022256	004	Jan 14, 2009	Jan	CTEC

MILRINONE LACTATE

INJECTABLE; INJECTION  
MILRINONE LACTATE

@	HIKMA	EQ 1MG BASE/ML	A 075530	001	May 28, 2002	Mar	DISC
---	-------	----------------	----------	-----	--------------	-----	------

MILSAPERIDONE

TABLET; ORAL  
BYSANTI

+	!	VANDA PHARMS INC	1MG	N 220358	001	Feb 20, 2026	Feb	NEWA
+			2MG	N 220358	002	Feb 20, 2026	Feb	NEWA
+			4MG	N 220358	003	Feb 20, 2026	Feb	NEWA
+			6MG	N 220358	004	Feb 20, 2026	Feb	NEWA
+			8MG	N 220358	005	Feb 20, 2026	Feb	NEWA
+			10MG	N 220358	006	Feb 20, 2026	Feb	NEWA
+			12MG	N 220358	007	Feb 20, 2026	Feb	NEWA

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
MINOCYCLINE HYDROCHLORIDE

AB		LUPIN	EQ 45MG BASE	A 091424	001	Nov 30, 2011	Apr	CAHN
AB			EQ 55MG BASE	A 091424	002	Nov 30, 2011	Apr	CAHN
AB			EQ 90MG BASE	A 091424	003	Nov 30, 2011	Apr	CAHN
AB			EQ 135MG BASE	A 091424	004	Nov 30, 2011	Apr	CAHN

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE; ORAL  
MIRABEGRON

AB		ALKEM LABS LTD	8MG/ML	A 219323	001	Jan 20, 2026	Jan	NFTG	
		MYRBETRIQ GRANULES							
AB	+	!	APGDI	8MG/ML	N 213801	001	Mar 25, 2021	Jan	CFTG
			TABLET, EXTENDED RELEASE; ORAL						
			MIRABEGRON						
AB		DEVA HOLDING AS	25MG	A 219941	001	May 01, 2026	Apr	NEWA	
AB			50MG	A 219941	002	May 01, 2026	Apr	NEWA	

MIRTAZAPINE

TABLET; ORAL  
MIRTAZAPINE

>A>	AB		MICRO LABS	7.5MG	A 220104	001	May 19, 2026	May	NEWA
>A>	AB			15MG	A 220104	002	May 19, 2026	May	NEWA
>A>	AB			30MG	A 220104	003	May 19, 2026	May	NEWA
>A>	AB			45MG	A 220104	004	May 19, 2026	May	NEWA
	AB		NOVITIUM PHARMA	7.5MG	A 219919	001	Feb 02, 2026	Jan	NEWA
	AB			15MG	A 219919	002	Feb 02, 2026	Jan	NEWA
	AB			30MG	A 219919	003	Feb 02, 2026	Jan	NEWA
	AB			45MG	A 219919	004	Feb 02, 2026	Jan	NEWA

MITAPIVAT SULFATE

TABLET; ORAL  
AQVESME

+	!	AGIOS PHARMS INC	EQ 100MG BASE	N 216196	004	Dec 23, 2025	Jan	NEWA
---	---	------------------	---------------	----------	-----	--------------	-----	------

MOMETASONE FUROATE

CREAM; TOPICAL  
MOMETASONE FUROATE

>D>	AB	!	COSETTE	0.1%	A 077447	001	May 22, 2006	May	CAHN	
>A>	AB	!	COSETTE PHARMS NC	0.1%	A 077447	001	May 22, 2006	May	CAHN	
			IMPLANT; IMPLANTATION							
			SINUVA							
		+	!	INTERSECT ENT INC	1.35MG	N 209310	001	Dec 08, 2017	Mar	CHRS
			OINTMENT; TOPICAL							
			MOMETASONE FUROATE							
>D>	AB		COSETTE	0.1%	A 077401	001	Jun 20, 2006	May	CAHN	
>A>	AB		COSETTE PHARMS NC	0.1%	A 077401	001	Jun 20, 2006	May	CAHN	
	AB		ENCUBE	0.1%	A 076481	001	Nov 14, 2003	Apr	CMFD	

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

>D>	AB	AJANTA PHARMA LTD	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	May	CHRS
>A>	AB	!	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	May	CHRS
		SINGULAIR						
>D>	AB	+! ORGANON	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002	May	DISC
>A>	AB	@ +	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002	May	DISC
		TABLET, CHEWABLE;ORAL						
		MONTELUKAST SODIUM						
		@ AMNEAL PHARMS	EQ 4MG BASE	A205107	001	Sep 04, 2020	Mar	DISC
		@	EQ 5MG BASE	A205107	002	Sep 04, 2020	Mar	DISC
	AB	SENORES PHARMS	EQ 4MG BASE	A201581	001	Aug 06, 2012	Jan	CAHN
	AB		EQ 5MG BASE	A201581	002	Aug 06, 2012	Jan	CAHN

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

@	PADAGIS US	100MG/5ML	A201574	001	Aug 06, 2012	Mar	DISC
@	TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

@	STRIDES PHARMA INTL	15MG	A075295	001	Oct 28, 1998	Jan	DISC
@		30MG	A075295	002	Oct 28, 1998	Jan	DISC
@		60MG	A075295	003	Oct 28, 1998	Jan	DISC
@		100MG	A075295	004	Sep 15, 2000	Jan	DISC
@		200MG	A075295	005	Sep 15, 2000	Jan	DISC

MS CONTIN

>A>	AB	+ KNOA PHARMA	15MG	N019516	003	Sep 12, 1989	May	CAHN
>A>	AB	+	30MG	N019516	001	May 29, 1987	May	CAHN
>A>	AB	+	60MG	N019516	002	Apr 08, 1988	May	CAHN
>A>	AB	+!	100MG	N019516	004	Jan 16, 1990	May	CAHN
>A>	AB	+	200MG	N019516	005	Nov 08, 1993	May	CAHN
>D>	AB	+ PURDUE PHARMA LP	15MG	N019516	003	Sep 12, 1989	May	CAHN
>D>	AB	+	30MG	N019516	001	May 29, 1987	May	CAHN
>D>	AB	+	60MG	N019516	002	Apr 08, 1988	May	CAHN
>D>	AB	+!	100MG	N019516	004	Jan 16, 1990	May	CAHN
>D>	AB	+	200MG	N019516	005	Nov 08, 1993	May	CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

@	FDC LTD	EQ 0.5% BASE	A219475	001	Aug 04, 2025	Feb	DISC
---	---------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	EQ 400MG BASE	A209143	001	Mar 02, 2026	Feb	NEWA
		@ TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Apr	DISC

MUPIROCIN

OINTMENT;TOPICAL

CENTANY

@	PADAGIS US	2%	N050788	001	Dec 04, 2002	Mar	DISC
---	------------	----	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

>D>	AB	MYLAN	250MG	A065520	001	May 04, 2009	May	DISC
>A>	AB	@	250MG	A065520	001	May 04, 2009	May	DISC

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

>A>	AB	CONCORD BIOTECH LTD	200MG/ML	A218566	001	Jun 01, 2026	May	NEWA
-----	----	---------------------	----------	---------	-----	--------------	-----	------

MYCOPHENOLATE SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLATE SODIUM

@	RK PHARMA	EQ 180MG BASE	A091248	002	Jan 08, 2014	Jan	DISC
@		EQ 360MG BASE	A091248	001	Jan 08, 2014	Jan	DISC
@	TWI PHARMS	EQ 180MG BASE	A214289	001	Nov 03, 2021	Mar	DISC
@		EQ 360MG BASE	A214289	002	Nov 03, 2021	Mar	DISC

NABUMETONE

TABLET;ORAL  
NABUMETONE

!	LGM PHARMA	1GM	A203166	003	Aug 30, 2019	Jan	CHRS
---	------------	-----	---------	-----	--------------	-----	------

NADOLOL

TABLET;ORAL  
NADOLOL

>A>	@	INGENUS PHARMS LLC	20MG	A210786	001	Jun 01, 2018	May	CAHN
>A>	@		40MG	A210786	002	Jun 01, 2018	May	CAHN
>A>	@		80MG	A210786	003	Jun 01, 2018	May	CAHN
>D>	@	NOVAST LABS	20MG	A210786	001	Jun 01, 2018	May	CAHN
>D>	@		40MG	A210786	002	Jun 01, 2018	May	CAHN
>D>	@		80MG	A210786	003	Jun 01, 2018	May	CAHN

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL  
NAFTIFINE HYDROCHLORIDE

@	AMNEAL	2%	A206960	001	Apr 10, 2017	Feb	DISC
---	--------	----	---------	-----	--------------	-----	------

GEL;TOPICAL  
NAFTIFINE HYDROCHLORIDE

@	AMNEAL	1%	A206165	001	Mar 20, 2019	Mar	DISC
---	--------	----	---------	-----	--------------	-----	------

+!	LEGACY PHARMA	1%	N019356	001	Jun 18, 1990	Mar	CTEC
----	---------------	----	---------	-----	--------------	-----	------

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
NALMEFENE HYDROCHLORIDE

>A>	AP	!	KNOA PHARMA	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May	CAHN
>D>	AP	!	PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May	CAHN

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS  
ZURNAI (AUTOINJECTOR)

>A>		+!	KNOA PHARMA	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	May	CAHN
>D>		+!	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	May	CAHN

NALOXONE HYDROCHLORIDE

SPRAY;NASAL  
REZENOPY

+!	SCIENTURE	10MG/SPRAY	N215487	001	Apr 19, 2024	Jan	CMFD
----	-----------	------------	---------	-----	--------------	-----	------

NAPROXEN

SUSPENSION;ORAL  
NAPROXEN

@	AUROBINDO PHARMA	25MG/ML	A216504	001	Oct 03, 2025	Mar	DISC
---	------------------	---------	---------	-----	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL  
NARATRIPTAN

@	PADAGIS US	EQ 1MG BASE	A091326	001	Jul 08, 2010	Mar	DISC
@		EQ 2.5MG BASE	A091326	002	Jul 08, 2010	Mar	DISC

NAVEPEGITIDE

POWDER;SUBCUTANEOUS  
YUVIWEL

+!	ASCENDIS	1.3MG/VIAL	N219164	001	Feb 27, 2026	Feb	NEWA
+!		2.8MG/VIAL	N219164	002	Feb 27, 2026	Feb	NEWA
+!		5.5MG/VIAL	N219164	003	Feb 27, 2026	Feb	NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL  
NEBIVOLOL HYDROCHLORIDE

@	TORRENT	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Mar	DISC
@		EQ 5MG BASE	A203966	002	Mar 02, 2018	Mar	DISC
@		EQ 10MG BASE	A203966	003	Mar 02, 2018	Mar	DISC
@		EQ 20MG BASE	A203966	004	Mar 02, 2018	Mar	DISC

NEOMYCIN SULFATE

TABLET; ORAL  
 NEOMYCIN SULFATE  
 AA SOLARIS PHARMA CORP 500MG A065220 001 Jul 28, 2006 Apr CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION  
 NEOMYCIN AND POLYMYXIN B SULFATE  
 @ WATSON LABS EQ 40MG BASE/ML;200,000 UNITS/ML A062664 001 Apr 08, 1986 Jan DISC  
 ! XGEN PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML A065106 001 Jan 31, 2006 Jan CTEC  
 AT ! EQ 40MG BASE/ML;200,000 UNITS/ML A065106 001 Jan 31, 2006 Jan CHRS  
 ! EQ 40MG BASE/ML;200,000 UNITS/ML A065108 001 Jan 31, 2006 Jan CTEC  
 AT ! EQ 40MG BASE/ML;200,000 UNITS/ML A065108 001 Jan 31, 2006 Jan CHRS  
 NEOSPORIN G.U. IRRIGANT  
 @ MONARCH PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML A060707 001 Jan DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS  
 NEOSTIGMINE METHYLSULFATE  
 @ HIKMA 3MG/3ML (1MG/ML) A216206 001 Jul 13, 2022 Mar DISC  
 AP NIVAGEN PHARMS INC 5MG/10ML (0.5MG/ML) A212627 001 Nov 03, 2022 Mar CAHN  
 AP 10MG/10ML (1MG/ML) A212627 002 Nov 03, 2022 Mar CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL  
 NICARDIPINE HYDROCHLORIDE  
 @ NAVINTA LLC 20MG A218638 001 Jun 25, 2025 Mar DISC  
 @ 30MG A218638 002 Jun 25, 2025 Mar DISC  
 AB SENORES PHARMS 20MG A215377 001 Jul 17, 2023 Jan CAHN  
 AB 30MG A215377 002 Jul 17, 2023 Jan CAHN  
 INJECTABLE; INJECTION  
 CARDENE  
 AP + CHIESI 25MG/10ML (2.5MG/ML) N019734 001 Jan 30, 1992 Jan CMFD  
 NICARDIPINE HYDROCHLORIDE  
 AP SOMERSET THERAPS LLC 25MG/10ML (2.5MG/ML) A090664 001 Nov 17, 2009 Jan CAHN

NIFEDIPINE

CAPSULE; ORAL  
 NIFEDIPINE  
 AB ! HERITAGE PHARMA 10MG A202644 001 Apr 25, 2013 Mar CHRS  
 PROCARDIA  
 @ + PFIZER 10MG N018482 001 Mar DISC  
 TABLET, EXTENDED RELEASE; ORAL  
 NIFEDIPINE  
 AB2 ! NOVAST LABS 90MG A210614 003 Mar 12, 2019 Apr CHRS  
 @ PHARMADAX 30MG A216019 001 Nov 18, 2022 Mar CAHN  
 @ 60MG A216019 002 Nov 18, 2022 Mar CAHN  
 PROCARDIA XL  
 @ + PFIZER 90MG N019684 003 Sep 06, 1989 Apr DISC

NILOTINIB

TABLET, ORALLY DISINTEGRATING; ORAL  
 CAVHANZA  
 >A>  
 >A> + FLEX PHARMA 60MG N217379 001 May 29, 2026 May NEWA  
 >A> +! 80MG N217379 002 May 29, 2026 May NEWA

NILUTAMIDE

TABLET; ORAL  
 NILANDRON  
 @ + ADVANZ PHARMA 150MG N020169 002 Apr 30, 1999 Apr DISC  
 NILUTAMIDE  
 ! ANI PHARMS 150MG A207631 001 Jul 15, 2016 Apr CTEC  
 AB ! 150MG A207631 001 Jul 15, 2016 Apr CHRS

NINTEDANIB ESYLATE

CAPSULE;ORAL

NINTEDANIB ESYLATE

AB	APOTEX	EQ 100MG BASE	A 219227	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A 219227	002	Apr 02, 2026	Mar	NFTG
AB	CIPLA	EQ 100MG BASE	A 212609	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A 212609	002	Apr 02, 2026	Mar	NFTG
AB	DEXCEL	EQ 100MG BASE	A 219819	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A 219819	002	Apr 02, 2026	Mar	NFTG
AB	DR REDDYS	EQ 100MG BASE	A 219283	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A 219283	002	Apr 02, 2026	Mar	NFTG
AB	SANDOZ	EQ 100MG BASE	A 216915	001	Apr 02, 2026	Mar	NFTG
AB		EQ 150MG BASE	A 216915	002	Apr 02, 2026	Mar	NFTG
	OFEV						
AB	+ BOEHRINGER INGELHEIM	EQ 100MG BASE	N 205832	001	Oct 15, 2014	Mar	CFTG
AB	+!	EQ 150MG BASE	N 205832	002	Oct 15, 2014	Mar	CFTG

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL

OGSIVEO

@ + SPRINGWORKS

EQ 50MG BASE

N 217677 001 Nov 27, 2023 Mar DISC

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

AB	AMTA	8.5MG	A 216606	001	Apr 10, 2023	Apr	CMFD
@	MYLAN	8.5MG	A 091001	001	Jan 26, 2011	Apr	DISC
@		17MG	A 091001	002	Jan 26, 2011	Apr	DISC
@		20MG	A 079051	001	Jul 25, 2008	Apr	DISC
@		25.5MG	A 091001	003	Jan 26, 2011	Apr	DISC
@		30MG	A 079051	002	Jul 25, 2008	Apr	DISC
@		34MG	A 091001	004	Jan 26, 2011	Feb	DISC
@		40MG	A 079051	003	Jul 25, 2008	Apr	DISC
	SULAR						
AB	+! AZURITY	8.5MG	N 020356	008	Jan 02, 2008	Apr	CTEC
	+!	8.5MG	N 020356	008	Jan 02, 2008	Apr	CTEC
AB	+!	8.5MG	N 020356	008	Jan 02, 2008	Feb	CAHN
@	+	10MG	N 020356	001	Feb 02, 1995	Feb	CAHN
AB	+!	17MG	N 020356	007	Jan 02, 2008	Feb	CAHN
AB	+!	17MG	N 020356	007	Jan 02, 2008	Feb	CAHN
AB	+!	17MG	N 020356	007	Jan 02, 2008	Feb	CAHN
AB	+!	17MG	N 020356	007	Jan 02, 2008	Feb	CAHN
@	+	20MG	N 020356	002	Feb 02, 1995	Feb	CAHN
@	+	25.5MG	N 020356	006	Jan 02, 2008	Feb	CAHN
@	+	30MG	N 020356	003	Feb 02, 1995	Feb	CAHN
+!		34MG	N 020356	005	Jan 02, 2008	Feb	CAHN
@	+	40MG	N 020356	004	Feb 02, 1995	Feb	CAHN
+!	COVIS	34MG	N 020356	005	Jan 02, 2008	Feb	CTEC

NITRIC OXIDE

GAS;INHALATION

NOXIVENT

@ VERO BIOTECH INC

100PPM

A 207141 001 Oct 02, 2018 Mar CAHN

AA 800PPM

A 207141 002 Oct 02, 2018 Mar CAHN

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

@ AMNEAL PHARMS

25MG/5ML

A 201679 001 May 11, 2011 Apr DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

@ POM PHARMA

25MG

A 074336 001 Jan 25, 1995 Apr CAHN

@

50MG

A 074336 002 Jan 25, 1995 Apr CAHN

@

100MG

A 074336 003 Jan 25, 1995 Apr CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB CREEKWOOD PHARMS 75MG;25MG A220269 001 Apr 07, 2026 Mar NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

+ USPHARMA 0.1MG/HR N020145 001 Apr 04, 1995 Jan CHRS  
 + 0.2MG/HR N020145 002 Apr 04, 1995 Jan CHRS  
 + 0.3MG/HR N020145 003 Apr 04, 1995 Jan CHRS  
 + 0.6MG/HR N020145 005 Apr 04, 1995 Jan CHRS  
 + 0.8MG/HR N020145 006 Apr 04, 1995 Jan CHRS

NITROGLYCERIN

AB2 MYLAN TECHNOLOGIES 0.1MG/HR A074559 004 Feb 06, 1998 Jan CHRS  
 AB2 0.2MG/HR A074559 003 Aug 30, 1996 Jan CHRS  
 AB2 0.6MG/HR A074559 001 Aug 30, 1996 Jan CHRS

OINTMENT;INTRA-ANAL

NITROGLYCERIN

>D> AB ! COSETTE 0.4% A216103 001 Feb 16, 2024 May CAHN  
 AB ! 0.4% A216103 001 Feb 16, 2024 Mar CHRS  
 >A> AB ! COSETTE PHARMS NC 0.4% A216103 001 Feb 16, 2024 May CAHN  
 RECTIV  
 @ + ABBVIE 0.4% N021359 001 Jun 21, 2011 Mar DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

>A> AP NEPHRON EQ 1MG BASE/ML A216272 001 Jun 11, 2026 May NEWA

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) N214313 004 Feb 06, 2026 Feb NEWA  
 +! EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) N214313 005 Feb 06, 2026 Feb NEWA  
 +! EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) N214313 006 Feb 06, 2026 Feb NEWA

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

AP +! BAXTER HLTHCARE CORP EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) N214313 003 Nov 21, 2023 Mar CFTG  
 AP SAGENT EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) A220483 001 Mar 26, 2026 Mar NFTG

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB INGENUS PHARMS LLC 5MG A206490 001 Nov 05, 2018 Feb CAHN

NUSINERSEN SODIUM

SOLUTION;INTRATHECAL

SPINRAZA

>A> +! BIOGEN EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) N209531 001 Dec 23, 2016 May CAHN  
 >A> +! EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML) N209531 002 Mar 27, 2026 May CAHN  
 >A> +! EQ 50MG BASE/5ML (EQ 10MG BASE/ML) N209531 003 Mar 27, 2026 May CAHN  
 >D> +! BIOGEN IDEC EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) N209531 001 Dec 23, 2016 May CAHN  
 >D> +! EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML) N209531 002 Mar 27, 2026 May CAHN  
 +! EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML) N209531 002 Mar 27, 2026 Apr NEWA  
 >D> +! EQ 50MG BASE/5ML (EQ 10MG BASE/ML) N209531 003 Mar 27, 2026 May CAHN  
 +! EQ 50MG BASE/5ML (EQ 10MG BASE/ML) N209531 003 Mar 27, 2026 Apr NEWA

NYSTATIN

CREAM; TOPICAL

NYSTATIN

>D>	AT	COSETTE	100,000 UNITS/GM	A 061966	001		May	CAHN
>A>	AT	COSETTE PHARMS NC	100,000 UNITS/GM	A 061966	001		May	CAHN
SUSPENSION; ORAL								
NILSTAT								
AA		+ CHARTWELL MOLECULES	100,000 UNITS/ML	N 050299	001		Mar	CMFD
NYSTATIN								
AA		SCIEGEN PHARMS	100,000 UNITS/ML	A 062832	001	Dec 27, 1991	Jan	CAHN
AA		STERANCO HLTHCARE	100,000 UNITS/ML	A 220367	001	Feb 05, 2026	Jan	NEWA

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT		MICRO LABS	0.3%	A 218557	001	Apr 08, 2026	Mar	NEWA
----	--	------------	------	----------	-----	--------------	-----	------

SOLUTION/DROPS; OTIC

OFLOXACIN

>D>	AT	! BAUSCH AND LOMB	0.3%	A 076128	001	Mar 17, 2008	May	CAHN
>A>	AT	! BAUSCH AND LOMB INC	0.3%	A 076128	001	Mar 17, 2008	May	CAHN

OLANZAPINE

POWDER; INTRAMUSCULAR

OLANZAPINE

AP		AM REGENT	10MG/VIAL	A 201741	001	Mar 20, 2012	Jan	CDFR
AP		ANTHEA PHARMA	10MG/VIAL	A 220323	001	Mar 05, 2026	Feb	NEWA
AP		ASPIRO	10MG/VIAL	A 217466	001	Mar 22, 2023	Jan	CDFR
AP		EUGIA PHARMA	10MG/VIAL	A 210968	001	Oct 22, 2020	Jan	CDFR
AP		OMNIVIUM PHARMS	10MG/VIAL	A 219048	001	Jan 23, 2026	Jan	NEWA
AP		QILU	10MG/VIAL	A 218116	001	May 16, 2025	Jan	CDFR
AP		SANDOZ INC	10MG/VIAL	A 201588	001	Oct 24, 2011	Jan	CDFR
AP		UBI	10MG/VIAL	A 211072	001	Jun 11, 2025	Jan	CDFR

ZYPREXA

AP		+! CHEPLAPHARM	10MG/VIAL	N 021253	001	Mar 29, 2004	Jan	CDFR
----	--	----------------	-----------	----------	-----	--------------	-----	------

TABLET; ORAL

OLANZAPINE

AB		SUNSHINE	2.5MG	A 206238	001	Nov 19, 2018	Feb	CMFD
AB			5MG	A 206238	002	Nov 19, 2018	Feb	CMFD
AB			7.5MG	A 206238	003	Nov 19, 2018	Feb	CMFD
AB			10MG	A 206238	004	Nov 19, 2018	Feb	CMFD
AB			15MG	A 206238	005	Nov 19, 2018	Feb	CMFD
AB			20MG	A 206238	006	Nov 19, 2018	Feb	CMFD
AB		TORRENT PHARMS LTD	2.5MG	A 091434	001	Apr 23, 2012	Jan	CMFD
AB			5MG	A 091434	002	Apr 23, 2012	Jan	CMFD
AB			7.5MG	A 091434	003	Apr 23, 2012	Jan	CMFD
AB			10MG	A 091434	004	Apr 23, 2012	Jan	CMFD
AB			15MG	A 091434	005	Apr 23, 2012	Jan	CMFD
AB			20MG	A 091434	006	Apr 23, 2012	Jan	CMFD

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

@		AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A 204940	001	Nov 27, 2015	Apr	DISC
---	--	---------------	--	----------	-----	--------------	-----	------

@		APOTEX	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A 090973	001	Sep 30, 2014	Apr	DISC
---	--	--------	--	----------	-----	--------------	-----	------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB		! GLENMARK PHARMS LTD	20MG	A 091672	002	Oct 31, 2014	Apr	CHRS
AB		!	40MG	A 091672	003	Oct 31, 2014	Apr	CHRS
AB		SANDOZ	20MG	A 075757	002	Jan 28, 2003	Apr	CHRS
AB			40MG	A 076515	001	Jan 21, 2009	Apr	CHRS

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL  
PRILOSEC

	+	AZURITY	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	Feb CAHN
	+	!	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	Feb CAHN

ONDANSETRON HYDROCHLORIDE

SOLUTION;ORAL  
ONDANSETRON HYDROCHLORIDE

AA		PHARM ASSOC	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	Feb CMFD
----	--	-------------	-----------------	---------	-----	--------------	----------

ORFORGLIPRON CALCIUM

TABLET;ORAL  
FOUNDAYO

	+	ELI LILLY AND CO	EQ 0.8MG BASE	N220934	001	Apr 01, 2026	Apr NEWA
	+		EQ 2.5MG BASE	N220934	002	Apr 01, 2026	Apr NEWA
	+		EQ 5.5MG BASE	N220934	003	Apr 01, 2026	Apr NEWA
	+		EQ 9MG BASE	N220934	004	Apr 01, 2026	Apr NEWA
	+		EQ 14.5MG BASE	N220934	005	Apr 01, 2026	Apr NEWA
	+	!	EQ 17.2MG BASE	N220934	006	Apr 01, 2026	Apr NEWA

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL  
OSELTAMIVIR PHOSPHATE

	@	CEDIPROF INC	EQ 30MG BASE	A217451	001	Dec 03, 2024	Apr DISC
	@		EQ 45MG BASE	A217451	002	Dec 03, 2024	Apr DISC
	@		EQ 75MG BASE	A217451	003	Dec 03, 2024	Apr DISC
	@	UPSHER SMITH LABS	EQ 30MG BASE	A213437	001	Jan 22, 2026	Apr DISC
AB			EQ 30MG BASE	A213437	001	Jan 22, 2026	Jan NEWA
	@		EQ 45MG BASE	A213437	002	Jan 22, 2026	Apr DISC
AB			EQ 45MG BASE	A213437	002	Jan 22, 2026	Jan NEWA
	@		EQ 75MG BASE	A213437	003	Jan 22, 2026	Apr DISC
AB			EQ 75MG BASE	A213437	003	Jan 22, 2026	Jan NEWA

FOR SUSPENSION;ORAL  
OSELTAMIVIR PHOSPHATE

>D>	AB	AMNEAL PHARMS NY	EQ 6MG BASE/ML	A210186	001	Feb 27, 2018	May DISC
>A>		@	EQ 6MG BASE/ML	A210186	001	Feb 27, 2018	May DISC

OXALIPLATIN

INJECTABLE;INTRAVENOUS  
OXALIPLATIN

	@	ACTAVIS	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Apr DISC
	@		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Apr DISC
	@	HENGRUI PHARMA	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Apr DISC
	@		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Apr DISC
>A>	@	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	May CAHN
>A>	@		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	May CAHN
>D>	@	NOVAST LABS	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	May CAHN
>D>	@		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	May CAHN
	@		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Apr DISC
AP		SHANDONG	50MG/10ML (5MG/ML)	A219765	001	Jan 15, 2026	Jan NEWA
AP			100MG/20ML (5MG/ML)	A219765	002	Jan 15, 2026	Jan NEWA
	@ +	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Apr DISC
	@ +		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Apr DISC

OXCARBAZEPINE

SUSPENSION;ORAL  
OXCARBAZEPINE

>A>	AB	MSN	300MG/5ML	A209020	001	May 29, 2026	May NEWA
	AB	STERANCO HLTHCARE	300MG/5ML	A220281	001	Mar 09, 2026	Feb NEWA

TABLET;ORAL  
OXCARBAZEPINE

AB		EPIC PHARMA LLC	150MG	A219556	001	Mar 02, 2026	Feb NEWA
AB			300MG	A219556	002	Mar 02, 2026	Feb NEWA
AB			600MG	A219556	003	Mar 02, 2026	Feb NEWA
AB		UMEDICA LABS PVT	150MG	A218341	001	Apr 29, 2026	Apr NEWA
AB			300MG	A218341	002	Apr 29, 2026	Apr NEWA
AB			600MG	A218341	003	Apr 29, 2026	Apr NEWA

OXICONAZOLE NITRATE

LOTION; TOPICAL  
OXISTAT

@ + ANI PHARMS EQ 1% BASE N020209 001 Sep 30, 1992 Apr DISC

OXYBUTYNIN CHLORIDE

TABLET; ORAL  
OXYBUTYNIN CHLORIDE

>D> @ AVET LIFESCIENCES 5MG A211682 001 May 10, 2019 May CMFD  
>A> AB 5MG A211682 001 May 10, 2019 May CMFD  
AB ! NOVITIUM PHARMA 5MG A209823 001 Oct 23, 2017 Jan CHRS  
AB ! RISING 2.5MG A209025 002 Feb 07, 2023 Feb CTEC  
AB STRIDES PHARMA INTL 2.5MG A075079 002 Mar 10, 2026 Feb NEWA  
AB 5MG A075079 001 Oct 31, 1997 Jan CHRS

TABLET, EXTENDED RELEASE; ORAL  
OXYBUTYNIN CHLORIDE

AB ACCORD HLTHCARE 15MG A207138 003 Feb 29, 2016 Jan CHRS  
AB ! ZYDUS PHARMS 15MG A202332 003 Jun 26, 2017 Jan CHRS

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
OXYCONTIN

>A> + KNOA PHARMA 10MG N022272 001 Apr 05, 2010 May CAHN  
>A> + 15MG N022272 002 Apr 05, 2010 May CAHN  
>A> + 20MG N022272 003 Apr 05, 2010 May CAHN  
>A> + 30MG N022272 004 Apr 05, 2010 May CAHN  
>A> +! 40MG N022272 005 Apr 05, 2010 May CAHN  
>A> + 60MG N022272 006 Apr 05, 2010 May CAHN  
>A> + 80MG N022272 007 Apr 05, 2010 May CAHN  
>D> + PURDUE PHARMA LP 10MG N022272 001 Apr 05, 2010 May CAHN  
>D> + 15MG N022272 002 Apr 05, 2010 May CAHN  
>D> + 20MG N022272 003 Apr 05, 2010 May CAHN  
>D> + 30MG N022272 004 Apr 05, 2010 May CAHN  
>D> +! 40MG N022272 005 Apr 05, 2010 May CAHN  
>D> + 60MG N022272 006 Apr 05, 2010 May CAHN  
>D> + 80MG N022272 007 Apr 05, 2010 May CAHN

OXYMETAZOLINE HYDROCHLORIDE

CREAM; TOPICAL  
OXYMETAZOLINE HYDROCHLORIDE

>D> @ SUN PHARMA CANADA 1% A213584 001 Oct 04, 2021 May CMFD  
>A> AB 1% A213584 001 Oct 04, 2021 May CMFD  
RHOFADÉ  
>D> +! MAYNE PHARMA 1% N208552 001 Jan 18, 2017 May CTEC  
>A> AB +! 1% N208552 001 Jan 18, 2017 May CTEC

OZENOXACIN

CREAM; TOPICAL  
XEPI

@ + LNHC 1% N208945 001 Dec 11, 2017 Jan CAHN

PACLITAXEL

INJECTABLE; INJECTION  
PACLITAXEL

@ NATCO PHARMA USA 6MG/ML A091540 001 Sep 29, 2011 Mar CAHN

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL  
PALIPERIDONE

AB AJANTA PHARMA LTD 3MG A218514 002 Jun 26, 2024 Mar CMFD  
AB 6MG A218514 003 Jun 26, 2024 Mar CMFD  
AB 9MG A218514 004 Jun 26, 2024 Mar CMFD  
AB @ APOTEX 3MG A203279 001 Jan 26, 2026 Apr DISC  
AB 3MG A203279 001 Jan 26, 2026 Jan NEWA  
AB @ 6MG A203279 002 Jan 26, 2026 Apr DISC  
AB 6MG A203279 002 Jan 26, 2026 Jan NEWA  
AB @ 9MG A203279 003 Jan 26, 2026 Apr DISC  
AB 9MG A203279 003 Jan 26, 2026 Jan NEWA  
>A> AB I3 PHARMS 1.5MG A205402 001 May 07, 2026 May NEWA  
>A> AB 3MG A205402 002 May 07, 2026 May NEWA  
>A> AB 6MG A205402 003 May 07, 2026 May NEWA

TABLET, EXTENDED RELEASE;ORAL  
PALIPERIDONE

>A>	AB		9MG	A205402	004	May 07, 2026	May	NEWA
	@	RK PHARMA	1.5MG	A203802	001	Sep 24, 2015	Jan	DISC
	@		3MG	A203802	002	Sep 24, 2015	Jan	DISC
	@		6MG	A203802	003	Sep 24, 2015	Jan	DISC
	@		9MG	A203802	004	Sep 24, 2015	Jan	DISC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA HAFYERA

+	!	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021	Jan	CHRS
+	!		1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021	Jan	CHRS

INVEGA SUSTENNA

+	!	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Mar	CHRS
+	!		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Mar	CHRS
+	!		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar	CHRS
+	!		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Mar	CHRS

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

>A>	@	INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	May	CAHN
>D>	@	NOVAST LABS	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	May	CAHN

PALOPEGTERIPARATIDE

SOLUTION;SUBCUTANEOUS

YORVIPATH

>D>	+	ASCENDIS PHARMA BONE	EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	N216490	002	Aug 09, 2024	May	CHRS
>A>	+	!	EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	N216490	002	Aug 09, 2024	May	CHRS
>D>	+		EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	N216490	003	Aug 09, 2024	May	CHRS
>A>	+	!	EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	N216490	003	Aug 09, 2024	May	CHRS

PANTOPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

PANTOPRAZOLE SODIUM

	@	PHARMOBEDIANT	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Jan	CAHN
AP	@	SHUANGCHENG	EQ 40MG BASE/VIAL	A219973	001	Apr 22, 2026	Apr	NEWA

PARICALCITOL

CAPSULE;ORAL

ZEMPLAR

@ + ABBVIE

			2MCG	N021606	002	May 26, 2005	Apr	DISC
--	--	--	------	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS

PARICALCITOL

	@	CAPLIN	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr	DISC
	@		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr	DISC
	@		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr	DISC
	@	EUGIA PHARMA	0.002MG/ML (0.002MG/ML)	A205982	001	Oct 09, 2018	Jan	DISC
	@		0.005MG/ML (0.005MG/ML)	A205982	002	Oct 09, 2018	Jan	DISC
	@		0.01MG/2ML (0.005MG/ML)	A205982	003	Oct 09, 2018	Jan	DISC

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAROXETINE HYDROCHLORIDE

AB		ANNORA PHARMA	EQ 10MG BASE/5ML	A219954	001	Mar 05, 2026	Feb	NEWA
AB	!	NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Feb	CTEC

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB		ALEMBIC	EQ 12.5MG BASE	A217280	003	Mar 26, 2026	Mar	NEWA
----	--	---------	----------------	---------	-----	--------------	-----	------

PENTAMIDINE ISETHIONATE

		FOR SOLUTION; INHALATION					
		PENTAMIDINE ISETHIONATE					
AN	PAI HOLDINGS	300MG/VIAL		A206667	001	Apr 24, 2019	Apr CAHN
		INJECTABLE; INJECTION					
		PENTAMIDINE ISETHIONATE					
AP	PAI HOLDINGS	300MG/VIAL		A206666	001	Sep 28, 2017	Apr CAHN
	@ PHARMOBEDIANT	300MG/VIAL		A206982	001	Mar 17, 2022	Apr DISC

PHENTERMINE HYDROCHLORIDE

		TABLET; ORAL					
		PHENTERMINE HYDROCHLORIDE					
	@ INGENUS PHARMS LLC	37.5MG		A091451	001	Sep 21, 2012	Feb CAHN

PHENYLEPHRINE HYDROCHLORIDE

		SOLUTION; INTRAVENOUS					
		PHENYLEPHRINE HYDROCHLORIDE					
AP1	BAXTER HLTHCARE CORP	10MG/ML (10MG/ML)		A217032	001	Apr 03, 2026	Mar NEWA
AP1		50MG/5ML (10MG/ML)		A217032	002	Apr 03, 2026	Mar NEWA
AP1		100MG/10ML (10MG/ML)		A217032	003	Apr 03, 2026	Mar NEWA
AP1	HAINAN POLY	10MG/ML (10MG/ML)		A218412	001	Mar 14, 2024	Jan CMFD
AP1		50MG/5ML (10MG/ML)		A218412	002	Mar 14, 2024	Jan CMFD
AP1		100MG/10ML (10MG/ML)		A218412	003	Mar 14, 2024	Jan CMFD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

		SYRUP; ORAL					
		PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE					
>D>	AA ! GENUS	5MG/5ML; 6.25MG/5ML		A040654	001	Dec 07, 2006	May CAHN
>A>	AA ! PAI HOLDINGS	5MG/5ML; 6.25MG/5ML		A040654	001	Dec 07, 2006	May CAHN

PHYTONADIONE

		INJECTABLE; INJECTION					
		PHYTONADIONE					
AB1	ALEMBIC	1MG/0.5ML		A216444	001	Sep 08, 2025	Mar CTEC
AB1	AMNEAL	1MG/0.5ML		A216601	001	Nov 04, 2025	Mar CTEC
>A>	AB1	10MG/ML		A217734	001	Jun 01, 2026	May NEWA
AB2	BAXTER HLTHCARE CORP	1MG/0.5ML		A216852	001	Feb 26, 2026	Mar CTEC
AB		1MG/0.5ML		A216852	001	Feb 26, 2026	Feb NEWA
AB2	! CIPLA	1MG/0.5ML		A214596	001	Apr 22, 2022	Mar CTEC
AB1		1MG/0.5ML		A214966	001	Jan 03, 2025	Mar CTEC
>A>	AB1 DR REDDYS	1MG/0.5ML		A215820	001	May 15, 2026	May NEWA
AB1	+! INTL MEDICATION	1MG/0.5ML		A083722	001		Mar CTEC
AB1	ORBICULAR	1MG/0.5ML		A216298	001	Mar 13, 2026	Mar CTEC
AB		1MG/0.5ML		A216298	001	Mar 13, 2026	Mar NEWA
AB1	SUNNY	10MG/ML		A215090	001	Jan 09, 2026	Jan NEWA
		TABLET; ORAL					
		PHYTONADIONE					
AB	SINOTHERAPEUTICS INC	5MG		A220454	001	Feb 26, 2026	Feb NEWA

PIFLUFOLASTAT F-18

		SOLUTION; INTRAVENOUS					
		PYLARIFY TRUVU					
	+! APHELION	1mCi/mL-120mCi/mL		N220089	001	Mar 06, 2026	Mar NEWA

PILOCARPINE HYDROCHLORIDE

		SOLUTION/DROPS; OPHTHALMIC					
		PILOCARPINE HYDROCHLORIDE					
	! AMNEAL	1.25%		A217733	001	Apr 28, 2025	Apr CTEC
AB	!	1.25%		A217733	001	Apr 28, 2025	Apr CHRS
>D>	AT FDC LTD	1%		A217052	001	Oct 02, 2025	May DISC
>A>	@	1%		A217052	001	Oct 02, 2025	May DISC
>D>	AT	2%		A217052	002	Oct 02, 2025	May DISC
>A>	@	2%		A217052	002	Oct 02, 2025	May DISC
>D>	AT	4%		A217052	003	Oct 02, 2025	May DISC
>A>	@	4%		A217052	003	Oct 02, 2025	May DISC
		VUITY					
	@ + ABBVIE	1.25%		N214028	001	Oct 28, 2021	Apr DISC
		TABLET; ORAL					
		PILOCARPINE HYDROCHLORIDE					
AB	AUROBINDO PHARMA USA	5MG		A212377	001	Aug 13, 2019	Jan CAHN
AB		7.5MG		A212377	002	Aug 13, 2019	Jan CAHN

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

@ PADAGIS US 5MG A076746 001 Nov 16, 2004 Mar DISC

PIMOZIDE

TABLET;ORAL

PIMOZIDE

AB NOVITIUM PHARMA 1MG A219897 001 Apr 13, 2026 Apr NEWA  
 AB 2MG A219897 002 Apr 13, 2026 Apr NEWA  
 AB PH HEALTH 1MG A204521 001 Sep 28, 2015 Apr CTEC  
 AB ! 2MG A204521 002 Sep 28, 2015 Apr CTEC

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

@ SANDOZ EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL A065363 001 Oct 21, 2010 Apr DISC  
 @ EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL A065363 002 Oct 21, 2010 Apr DISC  
 @ EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL A065363 003 Oct 21, 2010 Apr DISC

PIRFENIDONE

CAPSULE;ORAL

PIRFENIDONE

AB AUROBINDO PHARMA 267MG A212597 001 Apr 20, 2026 Apr NEWA

PIROXICAM

CAPSULE;ORAL

PIROXICAM

>D> AB UNICHEM 10MG A208340 001 Apr 13, 2017 May DISC  
 >A> @ 10MG A208340 001 Apr 13, 2017 May DISC  
 >D> AB 20MG A208340 002 Apr 13, 2017 May DISC  
 >A> @ 20MG A208340 002 Apr 13, 2017 May DISC

PIVMECILLINAM HYDROCHLORIDE

TABLET;ORAL

PIVYA

+! ALEMBIC THERAP EQ 185MG BASE N216483 001 Apr 24, 2024 Jan CAHN

>D> PLAZOMICIN SULFATE

>D> SOLUTION;INTRAVENOUS

>D> ZEMDRI

>D> +! CIPLA USA EQ 500MG BASE/10ML (EQ 50MG BASE/ML) N210303 001 Jun 25, 2018 May DISC  
 >A> @ + EQ 500MG BASE/10ML (EQ 50MG BASE/ML) N210303 001 Jun 25, 2018 May DISC

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

PLERIXAFOR

@ TEVA PHARMS USA INC 24MG/1.2ML (20MG/ML) A205197 001 Jul 24, 2023 Mar DISC

PODOFILOX

GEL;TOPICAL

CONDYLOX

@ + ALLERGAN 0.5% N020529 001 Mar 13, 1997 Jan DISC

PODOFILOX

! PADAGIS US 0.5% A211871 001 Nov 22, 2023 Jan CHRS

0.5% A211871 001 Nov 22, 2023 Jan CTEC

SOLUTION;TOPICAL

CONDYLOX

@ + TEVA BRANDED PHARM 0.5% N019795 001 Dec 13, 1990 Apr DISC

AT +! 0.5% N019795 001 Dec 13, 1990 Feb CAHN

PODOFILOX

! PADAGIS US 0.5% A075600 001 Jan 29, 2002 Apr CTEC

AT ! 0.5% A075600 001 Jan 29, 2002 Apr CHRS

POLIDOCANOL

SOLUTION;INTRAVENOUS  
VARITHENA

>A>	@ +	BOSTON SCITFC	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	May CAHN
>A>	+!		180MG/18ML (10MG/ML)	N205098	001	Nov 25, 2013	May CAHN
>D>	@ +	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	May CAHN
>D>	+!		180MG/18ML (10MG/ML)	N205098	001	Nov 25, 2013	May CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL  
TRILYTE

AA		AUROBINDO PHARMA USA	420GM/BOT;1.48GM/BOT;5.72GM/BO T;11.2GM/BOT	A076491	001	Feb 05, 2004	Apr CMFD
----	--	----------------------	--	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL  
COLYTE

@ +	QUAGEN	120GM/PACKET;1.49GM/PACKET;3.3 6GM/PACKET;2.92GM/PACKET;11.36 GM/PACKET	N018983	005	Oct 26, 1984	Apr CRLD
@ +		227.1GM/PACKET;2.82GM/PACKET;6 .36GM/PACKET;5.53GM/PACKET;21. 5GM/PACKET	N018983	004	Oct 26, 1984	Apr CRLD
@ +		227.1GM/BOT;2.82GM/BOT;6.36GM/ BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Apr CRLD
@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Apr CRLD
@ +		360GM/PACKET;4.47GM/PACKET;10. 08GM/PACKET;8.76GM/PACKET;34.0 8GM/PACKET	N018983	006	Oct 26, 1984	Apr CRLD
@ +	STRIDES PHARMA INTL	120GM/PACKET;1.49GM/PACKET;3.3 6GM/PACKET;2.92GM/PACKET;11.36 GM/PACKET	N018983	005	Oct 26, 1984	Apr CAHN
@ +		227.1GM/PACKET;2.82GM/PACKET;6 .36GM/PACKET;5.53GM/PACKET;21. 5GM/PACKET	N018983	004	Oct 26, 1984	Apr CAHN
@ +		227.1GM/BOT;2.82GM/BOT;6.36GM/ BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Apr CAHN
@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Apr CAHN
@ +		360GM/PACKET;4.47GM/PACKET;10. 08GM/PACKET;8.76GM/PACKET;34.0 8GM/PACKET	N018983	006	Oct 26, 1984	Apr CAHN
@ +	QUAGEN	240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr CRLD
@ +	STRIDES PHARMA INTL	240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr CAHN
@ +	QUAGEN	227.1GM/BOT;2.82GM/BOT;6.36GM/ BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Apr CRLD
@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Apr CRLD
@ +	STRIDES PHARMA INTL	227.1GM/BOT;2.82GM/BOT;6.36GM/ BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Apr CAHN
@ +		240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Apr CAHN
!	NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BO T;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr CHRS

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC  
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

>D>	AT	BAUSCH AND LOMB	10,000 UNITS/ML;EQ 1MG BASE/ML	A064120	001	Feb 14, 1997	May CAHN
>A>	AT	BAUSCH AND LOMB INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064120	001	Feb 14, 1997	May CAHN

POMALIDOMIDE

CAPSULE;ORAL  
POMALIDOMIDE

AB	APOTEX	1MG	A210164	001	Jun 11, 2024	Jan CMFD
AB		2MG	A210164	002	Jun 11, 2024	Jan CMFD
AB		3MG	A210164	003	Jun 11, 2024	Jan CMFD
AB		4MG	A210164	004	Jun 11, 2024	Jan CMFD
AB	BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Jan CMFD

CAPSULE;ORAL  
POMALIDOMIDE

AB		2MG	A210111	002	Oct 30, 2020	Jan	CMFD
AB		3MG	A210111	003	Oct 30, 2020	Jan	CMFD
AB		4MG	A210111	004	Oct 30, 2020	Jan	CMFD
AB	EUGIA PHARMA	1MG	A210249	001	Oct 30, 2020	Jan	CMFD
AB		2MG	A210249	002	Oct 30, 2020	Jan	CMFD
AB		3MG	A210249	003	Oct 30, 2020	Jan	CMFD
AB		4MG	A210249	004	Oct 30, 2020	Jan	CMFD
AB	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Jan	CMFD
AB		2MG	A210236	002	Sep 26, 2024	Jan	CMFD
AB		3MG	A210236	003	Sep 26, 2024	Jan	CMFD
AB		4MG	A210236	004	Sep 26, 2024	Jan	CMFD
AB	TEVA PHARMS USA	1MG	A209956	001	May 04, 2022	Jan	CMFD
AB		2MG	A209956	002	May 04, 2022	Jan	CMFD
AB		3MG	A209956	003	May 04, 2022	Jan	CMFD
AB		4MG	A209956	004	May 04, 2022	Jan	CMFD

POMALYST

AB	+ BRISTOL	1MG	N204026	001	Feb 08, 2013	Jan	CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Jan	CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Jan	CTEC
AB	+	4MG	N204026	004	Feb 08, 2013	Jan	CTEC

PONATINIB HYDROCHLORIDE

TABLET;ORAL  
ICLUSIG

	+! TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020	Jan	CHRS
	+	EQ 45MG BASE	N203469	002	Dec 14, 2012	Jan	CHRS

POSACONAZOLE

SOLUTION;INTRAVENOUS  
NOXAFIL

	@ + MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	Jan	DISC
AP	! GLAND	300MG/16.7ML (18MG/ML)	A217553	001	Dec 26, 2023	Jan	CHRS
AB	WELDING	100MG	A216326	001	Jun 20, 2023	Apr	CAHN

POTASSIUM ACETATE

INJECTABLE;INJECTION  
POTASSIUM ACETATE

	@ EXELA PHARMA	2MEQ/ML	A206203	001	Dec 29, 2015	Jan	DISC
--	----------------	---------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

	@ PADAGIS US	8MEQ	A200185	001	May 18, 2011	Mar	DISC
	@	10MEQ	A200185	002	May 18, 2011	Mar	DISC

FOR SOLUTION;ORAL  
POKONZA

	+ GENUS	15MEQ	N208019	004	Nov 12, 2025	Apr	NEWA
--	---------	-------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

	@ + BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989	Mar	DISC
--	---------------------	--------------	---------	-----	--------------	-----	------

SOLUTION;ORAL

POTASSIUM CHLORIDE

>D>	AA	APOTEX	20MEQ/15ML	A211067	001	Aug 08, 2018	May	DISC
>A>		@	20MEQ/15ML	A211067	001	Aug 08, 2018	May	DISC
>D>	AA		40MEQ/15ML	A211067	002	Aug 08, 2018	May	DISC
>A>		@	40MEQ/15ML	A211067	002	Aug 08, 2018	May	DISC

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

AP	CAPLIN	1.18GM/5ML (236MG/ML);1.12GM/5ML	A220373	001	Mar 12, 2026	Mar	NEWA
AP		3.54GM/15ML (236MG/ML);3.36GM/15ML	A220373	002	Mar 12, 2026	Mar	NEWA
AP		11.8GM/50ML (236MG/ML);11.2GM/50ML	A220373	003	Mar 12, 2026	Mar	NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

@	SENORES PHARMS	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan	CAHN
@		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan	CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	SENORES PHARMS	10MG	A077491	002	Oct 23, 2006	Feb	CAHN
AB		20MG	A077491	003	Oct 23, 2006	Feb	CAHN
AB		40MG	A077491	004	Oct 23, 2006	Feb	CAHN
AB		80MG	A077491	001	Feb 11, 2008	Feb	CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PEDIAPRED

AA	+! PAI HOLDINGS	EQ 5MG BASE/5ML	N019157	001	May 28, 1986	Apr	CAHN
----	-----------------	-----------------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

>D>	! BAUSCH AND LOMB	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994	May	CAHN
>A>	! BAUSCH AND LOMB INC	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994	May	CAHN

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB	FOURRTS LABS	25MG	A218529	001	Feb 24, 2026	Feb	NEWA
AB		50MG	A218529	002	Feb 24, 2026	Feb	NEWA
AB		75MG	A218529	003	Feb 24, 2026	Feb	NEWA
AB		100MG	A218529	004	Feb 24, 2026	Feb	NEWA
AB		150MG	A218529	005	Feb 24, 2026	Feb	NEWA
AB		200MG	A218529	006	Feb 24, 2026	Feb	NEWA
AB		225MG	A218529	007	Feb 24, 2026	Feb	NEWA
AB		300MG	A218529	008	Feb 24, 2026	Feb	NEWA
AB	RENATA	50MG	A210585	001	Dec 26, 2019	Feb	CAHN
AB		75MG	A210585	002	Dec 26, 2019	Feb	CAHN
AB		100MG	A210585	003	Dec 26, 2019	Feb	CAHN
AB		150MG	A210585	004	Dec 26, 2019	Feb	CAHN
AB		200MG	A210585	005	Dec 26, 2019	Feb	CAHN
AB		300MG	A210585	006	Dec 26, 2019	Feb	CAHN
AB	UNICHEM	25MG	A219593	001	Apr 30, 2026	Apr	NEWA
AB		50MG	A219593	002	Apr 30, 2026	Apr	NEWA
AB		75MG	A219593	003	Apr 30, 2026	Apr	NEWA
AB		100MG	A219593	004	Apr 30, 2026	Apr	NEWA
AB		150MG	A219593	005	Apr 30, 2026	Apr	NEWA
AB		200MG	A219593	006	Apr 30, 2026	Apr	NEWA
AB		225MG	A219593	007	Apr 30, 2026	Apr	NEWA
AB		300MG	A219593	008	Apr 30, 2026	Apr	NEWA

SOLUTION;ORAL

PREGABALIN

AA	PATRIN	20MG/ML	A212604	001	Feb 18, 2022	Mar	CAHN
----	--------	---------	---------	-----	--------------	-----	------

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE PHOSPHATE

AB	INGENUS PHARMS LLC	EQ 15MG BASE	A206043	001	Jun 23, 2016	Feb	CAHN
----	--------------------	--------------	---------	-----	--------------	-----	------

PRIMIDONE

TABLET;ORAL

PRIMIDONE

AB	CARNEGIE	50MG	A218366	001	Jan 23, 2024	Feb	CAHN
AB		250MG	A218366	002	Jan 23, 2024	Feb	CAHN

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP	! GLAND	100MG/ML	A218135	001	Jul 22, 2024	Jan	CHRS
AP	!	500MG/ML	A218135	002	Jul 22, 2024	Jan	CHRS
AP	HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Jan	CHRS
	@	500MG/ML	A089070	001	Feb 12, 1986	Jan	DISC

PROCHLORPERAZINE

SUPPOSITORY;RECTAL  
PROCHLORPERAZINE

>D>	AB	!	COSETTE	25MG	A 040058	001	Nov 24, 1993	May	CAHN
>A>	AB	!	COSETTE PHARMS NC	25MG	A 040058	001	Nov 24, 1993	May	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION  
PROCHLORPERAZINE EDISYLATE

@	AMNEAL	EQ 5MG BASE/ML	A 214192	001	Nov 28, 2022	Feb	DISC
---	--------	----------------	----------	-----	--------------	-----	------

PROGESTERONE

GEL;VAGINAL  
CRINONE

@ +	ABBVIE	4%	N 020701	001	Jul 31, 1997	Apr	DISC
-----	--------	----	----------	-----	--------------	-----	------

INSERT;VAGINAL  
PROGESTERONE

AB	GLENMARK PHARMS	100MG	A 216363	001	Apr 08, 2026	Apr	CAHN
AB	GLENMARK PHARMS LTD	100MG	A 216363	001	Apr 08, 2026	Mar	NEWA

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL  
PHENERGAN

>D>	@ +	NORVIUM BIOSCIENCE	12.5MG	N 010926	002		May	CAHN
>D>	@ +		25MG	N 010926	001		May	CAHN
>A>	@ +	PHARMOBEDIENT	12.5MG	N 010926	002		May	CAHN
>A>	@ +		25MG	N 010926	001		May	CAHN

PROMETHAZINE HYDROCHLORIDE

>D>	AB		COSETTE	12.5MG	A 040428	002	Mar 31, 2003	May	CAHN
>D>	AB	!		25MG	A 040428	001	Feb 05, 2002	May	CAHN
>A>	AB		COSETTE PHARMS NC	12.5MG	A 040428	002	Mar 31, 2003	May	CAHN
>A>	AB	!		25MG	A 040428	001	Feb 05, 2002	May	CAHN

PROMETHEGAN

>D>	!	COSETTE	50MG	A 087165	001	Aug 14, 1987	May	CAHN
>A>	!	COSETTE PHARMS NC	50MG	A 087165	001	Aug 14, 1987	May	CAHN

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

>D>	AA		COSETTE	6.25MG/5ML	A 091675	001	Jun 28, 2012	May	CAHN
>A>	AA		COSETTE PHARMS NC	6.25MG/5ML	A 091675	001	Jun 28, 2012	May	CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
PROPARACAINE HYDROCHLORIDE

>D>	AT	!	BAUSCH AND LOMB	0.5%	A 040074	001	Sep 29, 1995	May	CAHN
>A>	AT	!	BAUSCH AND LOMB INC	0.5%	A 040074	001	Sep 29, 1995	May	CAHN

PROPOFOL

INJECTABLE;INJECTION  
PROPOFOL

>A>	AB		EMERGE BIOSCIENCE	10MG/ML	A 217945	001	Dec 02, 2025	May	CAHN
>D>	AB		NANJING KING FRIEND	10MG/ML	A 217945	001	Dec 02, 2025	May	CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
PROPRANOLOL HYDROCHLORIDE

>A>	@	CHARTWELL RX	60MG	A 078022	001	Feb 15, 2007	May	CAHN
>A>	@		80MG	A 078022	002	Feb 15, 2007	May	CAHN
>A>	@		120MG	A 078022	003	Feb 15, 2007	May	CAHN
>A>	@		160MG	A 078022	004	Feb 15, 2007	May	CAHN
>D>	@	EXTROVIS	60MG	A 078022	001	Feb 15, 2007	May	CAHN
>D>	@		80MG	A 078022	002	Feb 15, 2007	May	CAHN
>D>	@		120MG	A 078022	003	Feb 15, 2007	May	CAHN
>D>	@		160MG	A 078022	004	Feb 15, 2007	May	CAHN
AB		IPCA LABS LTD	60MG	A 203103	001	May 01, 2026	Apr	NEWA
AB			80MG	A 203103	002	May 01, 2026	Apr	NEWA
AB			120MG	A 203103	003	May 01, 2026	Apr	NEWA
AB			160MG	A 203103	004	May 01, 2026	Apr	NEWA

INJECTABLE;INJECTION  
PROPRANOLOL HYDROCHLORIDE

@	ALLIED	1MG/ML	A 076400	001	Feb 26, 2003	Apr	CAHN
---	--------	--------	----------	-----	--------------	-----	------

SOLUTION;ORAL		HEMANGEOL							
	+!	ETON	4.28MG/ML	N205410	001	Mar 14, 2014	Mar	CAHN	
PROPRANOLOL HYDROCHLORIDE									
>D>	!	HIKMA	20MG/5ML	A070690	002	May 15, 1987	May	CTEC	
>A>	AA	!	20MG/5ML	A070690	002	May 15, 1987	May	CTEC	
		!	20MG/5ML	A070690	002	May 15, 1987	Feb	CMS1	
>A>	AA	PAI HOLDINGS	20MG/5ML	A219165	001	Jun 10, 2026	May	NEWA	
TABLET;ORAL		PROPRANOLOL HYDROCHLORIDE							
AB		MANKIND PHARMA	10MG	A216663	001	Jan 27, 2026	Jan	NEWA	
AB			20MG	A216663	002	Jan 27, 2026	Jan	NEWA	
AB			40MG	A216663	003	Jan 27, 2026	Jan	NEWA	
AB			60MG	A216663	004	Jan 27, 2026	Jan	NEWA	
AB			80MG	A216663	005	Jan 27, 2026	Jan	NEWA	
<u>PRUCALOPRIDE SUCCINATE</u>									
TABLET;ORAL		PRUCALOPRIDE SUCCINATE							
AB		AJANTA PHARMA LTD	EQ 1MG BASE	A219220	001	Jan 16, 2026	Jan	NEWA	
AB			EQ 2MG BASE	A219220	002	Jan 16, 2026	Jan	NEWA	
AB		TEVA PHARMS INC	EQ 1MG BASE	A219071	001	Feb 05, 2026	Jan	NEWA	
AB			EQ 2MG BASE	A219071	002	Feb 05, 2026	Jan	NEWA	
<u>PYRIDOSTIGMINE BROMIDE</u>									
TABLET, EXTENDED RELEASE;ORAL		PYRIDOSTIGMINE BROMIDE							
	@	IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Jan	DISC	
<u>QUETIAPINE FUMARATE</u>									
TABLET;ORAL		QUETIAPINE FUMARATE							
	@	SUN PHARM	EQ 25MG BASE	A201190	001	Mar 27, 2012	Apr	DISC	
	@		EQ 400MG BASE	A201190	006	Mar 27, 2012	Apr	DISC	
TABLET, EXTENDED RELEASE;ORAL		QUETIAPINE FUMARATE							
AB		PLATINUM	EQ 50MG BASE	A202939	001	May 09, 2017	Apr	CAHN	
AB			EQ 150MG BASE	A202939	002	May 09, 2017	Apr	CAHN	
AB			EQ 200MG BASE	A202939	003	May 09, 2017	Apr	CAHN	
AB			EQ 300MG BASE	A202939	004	May 09, 2017	Apr	CAHN	
AB			EQ 400MG BASE	A202939	005	May 09, 2017	Apr	CAHN	
<u>QUININE SULFATE</u>									
CAPSULE;ORAL		QUININE SULFATE							
>A>	AB	!	INGENUS PHARMS LLC	324MG	A204372	001	Jul 22, 2015	May	CAHN
>D>	AB	!	NOVAST LABS	324MG	A204372	001	Jul 22, 2015	May	CAHN
<u>RABEPRAZOLE SODIUM</u>									
TABLET, DELAYED RELEASE;ORAL		RABEPRAZOLE SODIUM							
AB		AUROBINDO PHARMA USA	20MG	A205761	001	Feb 17, 2017	Jan	CAHN	
<u>RAMELTEON</u>									
TABLET;ORAL		RAMELTEON							
AB		AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Feb	CTEC	
>A>	AB	HIBROW HLTHCARE	8MG	A215485	001	Jun 04, 2026	May	NEWA	
AB		XIROMED	8MG	A216209	001	Nov 25, 2022	Mar	CTEC	
<u>RAMIPRIL</u>									
CAPSULE;ORAL		RAMIPRIL							
AB		SENORES PHARMS	1.25MG	A078191	001	Jun 18, 2008	Jan	CAHN	
AB			2.5MG	A078191	002	Jun 18, 2008	Jan	CAHN	
AB			5MG	A078191	003	Jun 18, 2008	Jan	CAHN	
AB			10MG	A078191	004	Jun 18, 2008	Jan	CAHN	
SOLUTION;ORAL		VOSTALLY							
	@ +	ROSEMONT PHARMS	1MG/ML	N219757	001	Jul 23, 2025	Apr	DISC	
	+	!	1MG/ML	N219757	001	Jul 23, 2025	Feb	CAHN	

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

@	RISING	EQ 150MG BASE	A075564	001	Oct 27, 2000	Mar	CAHN
@		EQ 300MG BASE	A075564	002	Oct 27, 2000	Mar	CAHN

RANOLAZINE

GRANULE, EXTENDED RELEASE;ORAL

ASPRUZYO SPRINKLE

@ +	SPIL	500MG	N216018	001	Feb 28, 2022	Apr	CDFR
@ +		1GM	N216018	002	Feb 28, 2022	Apr	CDFR

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB	PIRAMAL	500MG	A213085	001	Jul 25, 2023	Feb	CMFD
AB		1GM	A213085	002	Jul 25, 2023	Feb	CMFD

REGADENOSON

SOLUTION;INTRAVENOUS

REGADENOSON

@	GE HEALTHCARE	0.4MG/5ML (0.08MG/ML)	A215955	001	Aug 05, 2024	Feb	DISC
---	---------------	-----------------------	---------	-----	--------------	-----	------

RELACORILANT

CAPSULE;ORAL

LIFYORLI (COPACKAGED)

+	CORCEPT THERAP	100MG;25MG	N220641	001	Mar 25, 2026	Mar	NEWA
---	----------------	------------	---------	-----	--------------	-----	------

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

@	PADAGIS US	0.5MG	A201189	001	Jul 17, 2013	Mar	DISC
@		1MG	A201189	002	Jan 22, 2014	Mar	DISC
@		2MG	A201189	003	Jan 22, 2014	Mar	DISC

RIBAVIRIN

FOR SOLUTION;INHALATION

RIBAVIRIN

@	NAVINTA LLC	6GM/VIAL	A207366	001	Oct 06, 2016	Mar	DISC
---	-------------	----------	---------	-----	--------------	-----	------

RIFABUTIN

CAPSULE;ORAL

RIFABUTIN

AB	I3 PHARMS	150MG	A212430	001	Mar 19, 2026	Mar	NEWA
----	-----------	-------	---------	-----	--------------	-----	------

RIFAXIMIN

TABLET;ORAL

RIFAXIMIN

AB	ACTAVIS LABS FL INC	550MG	A208959	001	Mar 19, 2026	Mar	NFTG	
AB	XIFAXAN							
AB	+	SALIX PHARMS	550MG	N021361	002	Mar 24, 2010	Mar	CFTG

RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

EDURANT

AB	+	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011	Jan	CFTG
AB		RILPIVIRINE HYDROCHLORIDE						
AB		SOMERSET THERAPS LLC	EQ 25MG BASE	A218798	001	Jan 29, 2026	Jan	NFTG

RILUZOLE

TABLET;ORAL

RILUTEK

@ +	AZURITY	50MG	N020599	001	Dec 12, 1995	Mar	CAHN
-----	---------	------	---------	-----	--------------	-----	------

RISPERIDONE

POWDER;INTRAMUSCULAR

RISPERDAL CONSTA

AB	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CHRS
AB	+		12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CDFR
AB	+		25MG/VIAL	N021346	001	Oct 29, 2003	Jan	CDFR
AB	+		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CHRS
AB	+		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CDFR

POWDER; INTRAMUSCULAR  
RISPERDAL CONSTA

AB	+	50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CHRS
AB	+	50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CDFR
RISPERIDONE							
AB	AMNEAL	12.5MG/VIAL	A218586	001	Sep 02, 2025	Jan	CDFR
AB		25MG/VIAL	A218586	002	Sep 02, 2025	Jan	CDFR
AB		37.5MG/VIAL	A218586	003	Sep 02, 2025	Jan	CDFR
AB		50MG/VIAL	A218586	004	Sep 02, 2025	Jan	CDFR
AB	NANOMI	25MG/VIAL	A211220	001	Sep 02, 2025	Jan	CDFR
AB		37.5MG/VIAL	A211220	002	Sep 02, 2025	Jan	CDFR
AB		50MG/VIAL	A211220	003	Sep 02, 2025	Jan	CDFR
AB	TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan	CDFR
AB		25MG/VIAL	A214068	002	Dec 05, 2023	Jan	CDFR
AB		37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan	CDFR
AB		50MG/VIAL	A214068	004	Dec 05, 2023	Jan	CDFR

TABLET; ORAL

RISPERIDONE

@	NATCO PHARMA USA	0.25MG	A076288	001	Sep 15, 2008	Mar	CAHN
@		0.5MG	A076288	002	Sep 15, 2008	Mar	CAHN
@		1MG	A076288	003	Sep 15, 2008	Mar	CAHN
@		2MG	A076288	004	Sep 15, 2008	Mar	CAHN
@		3MG	A076288	005	Sep 15, 2008	Mar	CAHN
@		4MG	A076288	006	Sep 15, 2008	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

@	NATCO PHARMA USA	0.25MG	A091537	006	Feb 12, 2013	Mar	CAHN
@		0.5MG	A091537	001	Mar 30, 2011	Mar	CAHN
@		1MG	A091537	002	Mar 30, 2011	Mar	CAHN
@		2MG	A091537	003	Mar 30, 2011	Mar	CAHN
@		3MG	A091537	004	Mar 30, 2011	Mar	CAHN
@		4MG	A091537	005	Mar 30, 2011	Mar	CAHN

RITONAVIR

TABLET; ORAL

NORVIR

AB	+	ABBVIE	100MG	N022417	001	Feb 10, 2010	Jan	CHRS
RITONAVIR								
	@	AMNEAL	100MG	A208890	001	Sep 17, 2018	Mar	DISC
AB	!	AUROBINDO PHARMA LTD	100MG	A206614	001	Sep 17, 2018	Jan	CHRS

RIVAROXABAN

FOR SUSPENSION; ORAL

RIVAROXABAN

AB	APOTEX	1MG/ML	A218427	001	Mar 02, 2026	Feb	NEWA	
TABLET; ORAL								
RIVAROXABAN								
	@	APOTEX	10MG	A208579	001	Nov 14, 2025	Apr	DISC
	@		15MG	A208579	002	Nov 14, 2025	Apr	DISC
	@		20MG	A208579	003	Nov 14, 2025	Apr	DISC
BX	BIOCON PHARMA	2.5MG	A218107	001	May 14, 2025	Feb	CTEC	
BX		10MG	A218107	002	May 14, 2025	Feb	CTEC	
BX		15MG	A218107	003	May 14, 2025	Feb	CTEC	
BX		20MG	A218107	004	May 14, 2025	Feb	CTEC	
AB	INVAGEN PHARMS	2.5MG	A218768	001	Feb 20, 2026	Feb	NEWA	

RIZATRIPTAN BENZOATE

FILM; ORAL

RIZAFILM

+	GENSCO	EQ 5MG BASE	N205394	002	Feb 26, 2026	Feb	NEWA
---	--------	-------------	---------	-----	--------------	-----	------

TABLET; ORAL

RIZATRIPTAN BENZOATE

@	PHARMOBEDIANT	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb	DISC
@		EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb	DISC

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	ASPIRO	50MG/5ML (10MG/ML)	A220124	001	Mar 04, 2026	Feb	NEWA
AP		100MG/10ML (10MG/ML)	A220124	002	Mar 04, 2026	Feb	NEWA
>D>	AP	KNACK	A213476	001	Jan 06, 2026	May	DISC
>A>	@	50MG/5ML (10MG/ML)	A213476	001	Jan 06, 2026	May	DISC

INJECTABLE; INJECTION  
ROCURONIUM BROMIDE

>D>	AP		100MG/10ML (10MG/ML)	A213476	002	Jan 06, 2026	May DISC
>A>	@		100MG/10ML (10MG/ML)	A213476	002	Jan 06, 2026	May DISC

ROFLUMILAST

TABLET; ORAL  
ROFLUMILAST

	@	PHARMOBEDIANT	500MCG	A208257	001	Jul 13, 2018	Feb DISC
AB		SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Feb CMFD
AB			500MCG	A208236	001	Oct 03, 2018	Feb CMFD

ROMIDEPSIN

SOLUTION; INTRAVENOUS

>A>		ROMIDEPSIN					
>A>	!	AMNEAL	27.5MG/5.5ML (5MG/ML)	A219099	001	Jun 02, 2026	May NFTG

ROSUVASTATIN CALCIUM

TABLET; ORAL  
ROSUVASTATIN CALCIUM

	@	ANVI	EQ 5MG BASE	A079161	001	Jul 19, 2016	Mar CAHN
	@		EQ 10MG BASE	A079161	002	Jul 19, 2016	Mar CAHN
	@		EQ 20MG BASE	A079161	003	Jul 19, 2016	Mar CAHN
	@		EQ 40MG BASE	A079161	004	Jul 19, 2016	Mar CAHN

RUXOLITINIB PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

>A>		JAKAFI XR					
>A>	+	INCYTE CORP	EQ 11MG BASE	N217180	001	May 01, 2026	May NEWA
>A>	+		EQ 22MG BASE	N217180	002	May 01, 2026	May NEWA
>A>	+		EQ 33MG BASE	N217180	003	May 01, 2026	May NEWA
>A>	+		EQ 44MG BASE	N217180	004	May 01, 2026	May NEWA
>A>	+	!	EQ 55MG BASE	N217180	005	May 01, 2026	May NEWA

SACUBITRIL; VALSARTAN

TABLET; ORAL  
SACUBITRIL AND VALSARTAN

AB		SOMERSET THERAPS LLC	24MG; 26MG	A219983	001	Jan 20, 2026	Jan NEWA
AB			49MG; 51MG	A219983	002	Jan 20, 2026	Jan NEWA
AB			97MG; 103MG	A219983	003	Jan 20, 2026	Jan NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL  
KUVAN

AB	+	BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Jan CHRS
		SAPROPTERIN DIHYDROCHLORIDE					
AB		MICRO LABS	100MG/PACKET	A219511	001	Jan 08, 2026	Jan NEWA
AB			500MG/PACKET	A219511	002	Jan 08, 2026	Jan NEWA

SELENIOS ACID

SOLUTION; INTRAVENOUS  
SELENIOS ACID

	@	CIPLA	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A218661	001	Jul 21, 2025	Jan DISC
	@		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218661	002	Jul 21, 2025	Jan DISC
AP		KINDOS	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219472	001	Feb 03, 2026	Jan NEWA
AP		STIRA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218536	001	Dec 31, 2025	Apr CAHN
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218536	002	Dec 31, 2025	Apr CAHN

SELEXIPAG

TABLET; ORAL  
SELEXIPAG

AB		RK PHARMA	0.2MG	A214055	001	Apr 16, 2026	Apr NEWA
AB			0.4MG	A214055	002	Apr 16, 2026	Apr NEWA
AB			0.6MG	A214055	003	Apr 16, 2026	Apr NEWA
AB			0.8MG	A214055	004	Apr 16, 2026	Apr NEWA
AB			1MG	A214055	005	Apr 16, 2026	Apr NEWA
AB			1.2MG	A214055	006	Apr 16, 2026	Apr NEWA
AB			1.4MG	A214055	007	Apr 16, 2026	Apr NEWA

TABLET;ORAL  
SELEXIPAG

AB		1.6MG	A214055	008	Apr 16, 2026	Apr	NEWA
	UPTRAVI						
AB	+ ACTELION	1MG	N207947	005	Dec 21, 2015	Apr	CTEC
AB	+	1.2MG	N207947	006	Dec 21, 2015	Apr	CTEC

SELUMETINIB SULFATE

GRANULE;ORAL  
KOSELUGO

>D>	+ ASTRAZENECA	EQ 5MG BASE	N219943	001	Sep 10, 2025	May	CHRS
>A>	+!	EQ 5MG BASE	N219943	001	Sep 10, 2025	May	CHRS
>D>	+!	EQ 7.5MG BASE	N219943	002	Sep 10, 2025	May	CHRS
>A>	+	EQ 7.5MG BASE	N219943	002	Sep 10, 2025	May	CHRS

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS  
OZEMPIC

>A>	+! NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N209637	005	May 05, 2026	May	NEWA
>A>	+!	0.5MG/0.5ML (0.5MG/0.5ML)	N209637	006	May 05, 2026	May	NEWA
>A>	+!	1MG/0.5ML (1MG/0.5ML)	N209637	007	May 05, 2026	May	NEWA

WEGOVY

>A>	+! NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N215256	007	May 05, 2026	May	NEWA
>A>	+!	0.5MG/0.5ML (0.5MG/0.5ML)	N215256	008	May 05, 2026	May	NEWA
>A>	+!	1MG/0.5ML (1MG/0.5ML)	N215256	009	May 05, 2026	May	NEWA
>A>	+!	1.7MG/0.75ML (1.7MG/0.75ML)	N215256	010	May 05, 2026	May	NEWA
>A>	+!	2.4MG/0.75ML (2.4MG/0.75ML)	N215256	011	May 05, 2026	May	NEWA

WEGOVY HD

	+! NOVO	7.2MG/0.75ML (7.2MG/0.75ML)	N215256	006	Mar 19, 2026	Mar	NEWA
--	---------	-----------------------------	---------	-----	--------------	-----	------

TABLET;ORAL  
OZEMPIC

	+! NOVO	1.5MG	N213051	004	Dec 09, 2024	Mar	CTNA
	+!	4MG	N213051	005	Dec 09, 2024	Mar	CTNA
	+!	9MG	N213051	006	Dec 09, 2024	Mar	CTNA

WEGOVY

	+! NOVO	1.5MG	N218316	001	Dec 22, 2025	Mar	CHRS
	+!	4MG	N218316	002	Dec 22, 2025	Mar	CHRS
	+!	9MG	N218316	003	Dec 22, 2025	Mar	CHRS

SERTRALINE HYDROCHLORIDE

CAPSULE;ORAL

SERTRALINE HYDROCHLORIDE

AB	AMNEAL	EQ 150MG BASE	A219655	001	Jan 28, 2026	Mar	CAHN
AB		EQ 200MG BASE	A219655	002	Jan 28, 2026	Mar	CAHN
AB	APPCO	EQ 150MG BASE	A218712	001	Jan 20, 2026	Jan	NEWA
AB		EQ 200MG BASE	A218712	002	Jan 20, 2026	Jan	NEWA
AB	NOVITIUM PHARMA	EQ 150MG BASE	A219714	001	Jan 20, 2026	Jan	NEWA
AB		EQ 200MG BASE	A219714	002	Jan 20, 2026	Jan	NEWA
AB	SKG PHARMA	EQ 150MG BASE	A219655	001	Jan 28, 2026	Jan	NEWA
AB		EQ 200MG BASE	A219655	002	Jan 28, 2026	Jan	NEWA
AB	UMEDICA	EQ 150MG BASE	A218342	001	Jan 20, 2026	Jan	NEWA
AB		EQ 200MG BASE	A218342	002	Jan 20, 2026	Jan	NEWA
AB	ZYDUS LIFESCIENCES	EQ 150MG BASE	A220275	001	Jan 29, 2026	Jan	NEWA
AB		EQ 200MG BASE	A220275	002	Jan 29, 2026	Jan	NEWA

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	Jan	CAHN
@		EQ 50MG BASE	A077713	002	Feb 06, 2007	Jan	CAHN
@		EQ 100MG BASE	A077713	003	Feb 06, 2007	Jan	CAHN

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

REVATIO

@	+ VIATRIS	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Mar	DISC
AB	! AUROBINDO PHARMA LTD	EQ 10MG BASE/ML	A214773	001	Dec 23, 2022	Mar	CHRS

TABLET;ORAL

SILDENAFIL CITRATE

@	TEVA PHARMS	EQ 20MG BASE	A078380	001	Jan 07, 2013	Apr	DISC
---	-------------	--------------	---------	-----	--------------	-----	------

SIPONIMOD

		TABLET; ORAL							
		MAYZENT							
		+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Mar	CTEC
AB		+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Feb	CTEC
		+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Mar	CTEC
AB		+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Feb	CTEC
		+		EQ 2MG BASE	N209884	002	Mar 26, 2019	Mar	CTEC
AB		+		EQ 2MG BASE	N209884	002	Mar 26, 2019	Feb	CTEC
		SIPONIMOD							
		@	AUROBINDO PHARMA LTD	EQ 0.25MG BASE	A218459	001	Mar 06, 2026	Mar	DISC
AB				EQ 0.25MG BASE	A218459	001	Mar 06, 2026	Feb	NEWA
		@		EQ 1MG BASE	A218459	002	Mar 06, 2026	Mar	DISC
AB				EQ 1MG BASE	A218459	002	Mar 06, 2026	Feb	NEWA
		@		EQ 2MG BASE	A218459	003	Mar 06, 2026	Mar	DISC
AB				EQ 2MG BASE	A218459	003	Mar 06, 2026	Feb	NEWA

SIROLIMUS

		POWDER; INTRAVENOUS							
		FYARRO							
		+	AADI	100MG/VIAL	N213312	001	Nov 22, 2021	Apr	CAHN

SITAGLIPTIN PHOSPHATE

		TABLET; ORAL							
		JANUVIA							
>D>	AB	+	MERCK SHARP DOHME	EQ 25MG BASE	N021995	001	Oct 16, 2006	May	CAHN
>D>	AB	+		EQ 50MG BASE	N021995	002	Oct 16, 2006	May	CAHN
>D>	AB	+		EQ 100MG BASE	N021995	003	Oct 16, 2006	May	CAHN
>A>	AB	+	MSD	EQ 25MG BASE	N021995	001	Oct 16, 2006	May	CAHN
>A>	AB	+		EQ 50MG BASE	N021995	002	Oct 16, 2006	May	CAHN
>A>	AB	+		EQ 100MG BASE	N021995	003	Oct 16, 2006	May	CAHN
		SITAGLIPTIN PHOSPHATE							
	AB		APOTEX	EQ 25MG BASE	A202425	001	Jan 20, 2026	Jan	NEWA
	AB			EQ 50MG BASE	A202425	002	Jan 20, 2026	Jan	NEWA
	AB			EQ 100MG BASE	A202425	003	Jan 20, 2026	Jan	NEWA
	AB		SANDOZ	EQ 25MG BASE	A202387	001	Jan 14, 2026	Jan	NEWA
	AB			EQ 50MG BASE	A202387	002	Jan 14, 2026	Jan	NEWA
	AB			EQ 100MG BASE	A202387	003	Jan 14, 2026	Jan	NEWA

SODIUM ACETATE

		SOLUTION; INTRAVENOUS							
		SODIUM ACETATE							
	AP		AMNEAL	40MEQ/20ML (2MEQ/ML)	A218469	003	Mar 02, 2026	Feb	NEWA
	AP		EXTROVIS	100MEQ/50ML (2MEQ/ML)	A220274	001	Apr 17, 2026	Apr	NEWA
	AP			200MEQ/100ML (2MEQ/ML)	A220274	002	Apr 17, 2026	Apr	NEWA

SODIUM BICARBONATE

		SOLUTION; INTRAVENOUS							
		SODIUM BICARBONATE							
	AP		AMNEAL	50MEQ/50ML (1MEQ/ML)	A217523	001	Jan 13, 2026	Jan	NEWA
	AP		ASPIRO	5MEQ/10ML (0.5MEQ/ML)	A220788	001	Apr 15, 2026	Apr	NEWA
	AP			10MEQ/10ML (1MEQ/ML)	A220788	002	Apr 15, 2026	Apr	NEWA
	AP			50MEQ/50ML (1MEQ/ML)	A220788	003	Apr 15, 2026	Apr	NEWA

SODIUM FLUORIDE F-18

		INJECTABLE; INTRAVENOUS							
		SODIUM FLUORIDE F-18							
		@	NUKEMED	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr	DISC

SODIUM PHENYL BUTYRATE

		POWDER; ORAL							
		BUPHENYL							
		@	HORIZON THERAP US	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Jan	DISC
		!	PH HEALTH	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jan	CHRS
		TABLET; ORAL							
		@	HORIZON THERAP US	500MG	N020572	001	May 13, 1996	Jan	DISC
		!	PH HEALTH	500MG	A220418	001	Feb 17, 2026	Feb	NEWA
AB			NAVINTA LLC	500MG	A220418	001	Feb 17, 2026	Feb	NEWA
AB		!	PH HEALTH	500MG	A204395	001	Apr 15, 2016	Jan	CHRS

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SOLUTION;INTRAVENOUS  
SODIUM PHOSPHATES

AP	CAPLIN	1.34GM/5ML;1.38GM/5ML (268MG/ML; 276MG/ML)	A 220683 001	Feb 23, 2026	Feb NEWA
AP		4.02GM/15ML;4.14GM/15ML (268MG/ML; 276MG/ML)	A 220683 002	Feb 23, 2026	Feb NEWA
AP		13.4GM/50ML;13.8GM/50ML (268MG/ML; 276MG/ML)	A 220683 003	Feb 23, 2026	Feb NEWA

SOLIFENACIN SUCCINATE

TABLET;ORAL  
SOLIFENACIN SUCCINATE

>D>	@	SUNSHINE	5MG	A 213346 001	Apr 13, 2020	May CMFD
>A>	AB		5MG	A 213346 001	Apr 13, 2020	May CMFD
>D>	@		10MG	A 213346 002	Apr 13, 2020	May CMFD
>A>	AB		10MG	A 213346 002	Apr 13, 2020	May CMFD

>A> SONROTOCLAX

>A> TABLET;ORAL  
>A> BEQALZI

>A>	+	BEONE MEDICINES USA	1MG	N 220711 001	May 13, 2026	May NEWA
>A>	+		5MG	N 220711 002	May 13, 2026	May NEWA
>A>	+		20MG	N 220711 003	May 13, 2026	May NEWA
>A>	+	!	80MG	N 220711 004	May 13, 2026	May NEWA

SUCCINYLMCHOLINE CHLORIDE

INJECTABLE;INJECTION  
SUCCINYLMCHOLINE CHLORIDE

AP		NIVAGEN PHARMS INC	20MG/ML	A 211625 001	May 19, 2020	Apr CAHN
AP	!	FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A 217884 001	Feb 11, 2025	Mar CHRS
	@ +	HIKMA	100MG/5ML (20MG/ML)	N 215143 001	Aug 20, 2021	Mar DISC

SUCRALFATE

SUSPENSION;ORAL  
SUCRALFATE

>D>	AB	COSETTE	1GM/10ML	A 217126 001	Nov 13, 2024	May CAHN
>A>	AB	COSETTE PHARMS NC	1GM/10ML	A 217126 001	Nov 13, 2024	May CAHN

SUFENTANIL CITRATE

INJECTABLE;INJECTION  
SUFENTANIL CITRATE

@	HIKMA	EQ 0.05MG BASE/ML	A 074413 001	Dec 15, 1995	Mar DISC
---	-------	-------------------	--------------	--------------	----------

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS  
SUGAMMADEX SODIUM

>D>	@	ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A 214290 001	Oct 04, 2023	May CMFD
>A>	AP		EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A 214290 001	Oct 04, 2023	May CMFD
>D>	@		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A 214290 002	Oct 04, 2023	May CMFD
>A>	AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A 214290 002	Oct 04, 2023	May CMFD

SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC  
SULFACETAMIDE SODIUM

@	PADAGIS US	10%	A 080029 001		Mar DISC
---	------------	-----	--------------	--	----------

SOLUTION/DROPS;OPHTHALMIC  
SULFACETAMIDE SODIUM

>D>	AT	!	BAUSCH AND LOMB	10%	A 040066 001	Dec 28, 1994	May CAHN
>A>	AT	!		10%	A 040066 001	Dec 28, 1994	May CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS  
SUMATRIPTAN SUCCINATE

AP	ONESOURCE SPECIALTY	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb	CMFD
----	---------------------	-------------------------------------	---------	-----	--------------	-----	------

TADALAFIL

TABLET;ORAL  
TADALAFIL

>A>	AB1	JUBILANT GENERICS	2.5MG	A210329	001	May 15, 2026	May	NEWA
>A>	AB1		5MG	A210329	002	May 15, 2026	May	NEWA
>A>	AB1		10MG	A210329	003	May 15, 2026	May	NEWA
>A>	AB1		20MG	A210329	004	May 15, 2026	May	NEWA
>A>	!	TORRENT	40MG	A212062	002	May 20, 2026	May	NFTG

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL  
VYNDAQEL

@ +	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	Jan	DISC
-----	---------------	------	---------	-----	--------------	-----	------

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL  
TAPENTADOL HYDROCHLORIDE  
NOVITIUM PHARMA

EQ 20MG BASE/ML	A219119	001	Jan 26, 2026	Jan	NFTG
-----------------	---------	-----	--------------	-----	------

TABLET;ORAL  
NUCYNTA

AB	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	Jan	CFTG
AB	+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Jan	CFTG
AB	+	!	EQ 100MG BASE	N022304	003	Nov 20, 2008	Jan	CFTG

TAPENTADOL HYDROCHLORIDE

>A>	AB	EPIC PHARMA LLC	EQ 50MG BASE	A214378	001	Jan 27, 2026	May	CAHN
>A>	AB		EQ 75MG BASE	A214378	002	Jan 27, 2026	May	CAHN
>A>	AB		EQ 100MG BASE	A214378	003	Jan 27, 2026	May	CAHN
>D>	AB	HIKMA	EQ 50MG BASE	A205057	001	Feb 10, 2026	May	DISC
>A>	@		EQ 50MG BASE	A205057	001	Feb 10, 2026	May	DISC
	AB		EQ 50MG BASE	A205057	001	Feb 10, 2026	Jan	NEWA
>D>	AB		EQ 75MG BASE	A205057	002	Feb 10, 2026	May	DISC
>A>	@		EQ 75MG BASE	A205057	002	Feb 10, 2026	May	DISC
	AB		EQ 75MG BASE	A205057	002	Feb 10, 2026	Jan	NEWA
>D>	AB		EQ 100MG BASE	A205057	003	Feb 10, 2026	May	DISC
>A>	@		EQ 100MG BASE	A205057	003	Feb 10, 2026	May	DISC
	AB		EQ 100MG BASE	A205057	003	Feb 10, 2026	Jan	NEWA
>D>	AB	HUMANWELL	EQ 50MG BASE	A214378	001	Jan 27, 2026	May	CAHN
	AB		EQ 50MG BASE	A214378	001	Jan 27, 2026	Jan	NFTG
>D>	AB		EQ 75MG BASE	A214378	002	Jan 27, 2026	May	CAHN
	AB		EQ 75MG BASE	A214378	002	Jan 27, 2026	Jan	NFTG
>D>	AB		EQ 100MG BASE	A214378	003	Jan 27, 2026	May	CAHN
	AB		EQ 100MG BASE	A214378	003	Jan 27, 2026	Jan	NFTG

TAVABOROLE

SOLUTION;TOPICAL  
TAVABOROLE

@	CIPLA	5%	A212224	001	Feb 09, 2021	Jan	DISC
@	LUPIN	5%	A212168	001	Feb 08, 2021	Feb	DISC
@	PADAGIS US	5%	A211848	001	Oct 13, 2020	Mar	DISC

TAZAROTENE

CREAM;TOPICAL  
TAZAROTENE

>D>	AB	COSETTE	0.05%	A208662	002	Mar 10, 2025	May	CAHN
>D>	AB		0.1%	A208662	001	Dec 22, 2017	May	CAHN
>A>	AB	COSETTE PHARMS NC	0.05%	A208662	002	Mar 10, 2025	May	CAHN
>A>	AB		0.1%	A208662	001	Dec 22, 2017	May	CAHN
	AB	SOLARIS PHARMA CORP	0.05%	A214560	001	Nov 24, 2025	Jan	CAHN

GEL;TOPICAL  
TAZAROTENE

>D>	AB	COSETTE	0.05%	A215433	001	Sep 13, 2022	May	CAHN
>D>	AB		0.1%	A214136	001	Sep 13, 2022	May	CAHN
>A>	AB	COSETTE PHARMS NC	0.05%	A215433	001	Sep 13, 2022	May	CAHN
>A>	AB		0.1%	A214136	001	Sep 13, 2022	May	CAHN

>D>	<u>TAZEMETOSTAT HYDROBROMIDE</u>						
>D>	TABLET; ORAL						
>D>	TAZVERIK						
>D>	+!	EPIZYME INC	EQ 200MG BASE	N211723	001	Jan 23, 2020	May DISC
>A>	@ +		EQ 200MG BASE	N211723	001	Jan 23, 2020	May DISC
	<u>TECHNETIUM TC-99M BICISATE KIT</u>						
	INJECTABLE; INJECTION						
	NEUROLITE						
	+!	SHINE	N/A	N020256	001	Nov 23, 1994	Feb CAHN
	<u>TECHNETIUM TC-99M SESTAMIBI KIT</u>						
	INJECTABLE; INJECTION						
	CARDIOLITE						
AP	+!	SHINE	N/A	N019785	001	Dec 21, 1990	Feb CAHN
	MIRALUMA						
	@	SHINE	N/A	N019785	003	May 23, 1997	Feb CAHN
	<u>TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR</u>						
	SOLUTION; INTRAVENOUS						
	TECHNELITE						
	+!	SHINE	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	Feb CAHN
	@		0.0083-2.7 CI/GENERATOR	N017771	001		Feb CAHN
	<u>TEMAZEPAM</u>						
	CAPSULE; ORAL						
	TEMAZEPAM						
AB		AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	Jan CMFD
AB			15MG	A203482	002	May 23, 2016	Jan CMFD
AB			22.5MG	A203482	003	May 23, 2016	Jan CMFD
AB			30MG	A203482	004	May 23, 2016	Jan CMFD
	<u>TERAZOSIN HYDROCHLORIDE</u>						
	CAPSULE; ORAL						
	TERAZOSIN HYDROCHLORIDE						
AB		SENORES PHARMS	EQ 1MG BASE	A074823	001	Mar 30, 1998	Feb CAHN
AB			EQ 2MG BASE	A074823	002	Mar 30, 1998	Feb CAHN
AB			EQ 5MG BASE	A074823	003	Mar 30, 1998	Feb CAHN
AB			EQ 10MG BASE	A074823	004	Mar 30, 1998	Feb CAHN
	<u>TERBINAFINE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	TERBINAFINE HYDROCHLORIDE						
>D>	@	CIPLA	EQ 250MG BASE	A077137	001	Jul 02, 2007	May CMFD
>A>	AB		EQ 250MG BASE	A077137	001	Jul 02, 2007	May CMFD
	<u>TERIFLUNOMIDE</u>						
	TABLET; ORAL						
	TERIFLUNOMIDE						
AB		CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Feb CMFD
AB			14MG	A218663	002	Apr 07, 2025	Feb CMFD
	<u>TESTOSTERONE CYPIONATE</u>						
	INJECTABLE; INJECTION						
	TESTOSTERONE CYPIONATE						
	@	CAPLIN ONE LABS	100MG/ML	A040615	001	Aug 10, 2006	Mar DISC
AO			100MG/ML	A040615	001	Aug 10, 2006	Jan CAHN
	@		200MG/ML	A040615	002	Aug 10, 2006	Mar DISC
AO			200MG/ML	A040615	002	Aug 10, 2006	Jan CAHN
	<u>THALIDOMIDE</u>						
	CAPSULE; ORAL						
	THALIDOMIDE						
AB		NATCO	50MG	A213267	002	Apr 24, 2026	Apr NFTG
AB			100MG	A213267	003	Apr 24, 2026	Apr NFTG
AB			200MG	A213267	004	Apr 24, 2026	Apr NFTG
	THALOMID						
AB	+	BRISTOL-MYERS	50MG	N020785	001	Jul 16, 1998	Apr CFTG
AB	+		100MG	N020785	002	Jan 17, 2003	Apr CFTG
AB	+!		200MG	N020785	003	Jan 17, 2003	Apr CFTG



SOLUTION;SUBCUTANEOUS

ZEPBOUND

+	!		20MG/2.4ML (8.33MG/ML)	N217806	014	Jan 07, 2026	Jan NEWA
+	!		30MG/2.4ML (12.5MG/ML)	N217806	015	Jan 07, 2026	Jan NEWA
+	!		40MG/2.4ML (16.7MG/ML)	N217806	016	Jan 07, 2026	Jan NEWA
+	!		50MG/2.4ML (20.8MG/ML)	N217806	017	Jan 07, 2026	Jan NEWA
+	!		60MG/2.4ML (25MG/ML)	N217806	018	Jan 07, 2026	Jan NEWA

ZEPBOUND KWIKPEN

+	!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N217806	019	Jan 20, 2026	Jan NEWA
+	!		20MG/2.4ML (8.33MG/ML)	N217806	020	Jan 20, 2026	Jan NEWA
+	!		30MG/2.4ML (12.5MG/ML)	N217806	021	Jan 20, 2026	Jan NEWA
+	!		40MG/2.4ML (16.7MG/ML)	N217806	022	Jan 20, 2026	Jan NEWA
+	!		50MG/2.4ML (20.8MG/ML)	N217806	023	Jan 20, 2026	Jan NEWA
+	!		60MG/2.4ML (25MG/ML)	N217806	024	Jan 20, 2026	Jan NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB		INGENUS PHARMS LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb CAHN
AB			EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb CAHN
AB			EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb CAHN
AB		SENORES PHARMS	EQ 4MG BASE	A213365	001	May 13, 2024	Jan CAHN
AB			EQ 6MG BASE	A213365	002	May 13, 2024	Jan CAHN
<u>ZANAFLEX</u>							
AB	+	LEGACY PHARMA USA	EQ 4MG BASE	N021447	002	Aug 29, 2002	Mar CHRS
AB	+		EQ 6MG BASE	N021447	003	Aug 29, 2002	Mar CHRS

TOBRAMYCIN

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

>D>	AT	BAUSCH AND LOMB	0.3%	A064052	001	Nov 29, 1993	May CAHN
>A>	AT	BAUSCH AND LOMB INC	0.3%	A064052	001	Nov 29, 1993	May CAHN

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP		EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Apr CMFD
----	--	--------------	--------------------	---------	-----	--------------	----------

TOFACITINIB CITRATE

SOLUTION;ORAL

TOFACITINIB CITRATE

>A>	AA	AUSON	EQ 1MG BASE/ML	A219370	001	Jun 09, 2026	May NEWA	
>D>		@ HIKMA	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	May CMFD	
>A>	AA		EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	May CMFD	
>A>	AA	MSN	EQ 1MG BASE/ML	A217298	001	Jun 03, 2026	May NEWA	
>A>	AA	SAPTALIS PHARMS	EQ 1MG BASE/ML	A218900	001	Jun 09, 2026	May NEWA	
>A>	AA	SUN PHARM INDS INC	EQ 1MG BASE/ML	A218407	001	Jun 03, 2026	May NEWA	
<u>XELJANZ</u>								
>D>		+	PFIZER	EQ 1MG BASE/ML	N213082	001	Sep 25, 2020	May CTEC
>A>	AA	+		EQ 1MG BASE/ML	N213082	001	Sep 25, 2020	May CTEC

TABLET;ORAL

TOFACITINIB CITRATE

	AB	AJANTA PHARMA LTD	EQ 10MG BASE	A212943	001	Jun 01, 2021	Apr CMFD
>A>	AB	APOTEX	EQ 5MG BASE	A218096	001	Jun 03, 2026	May NEWA
>A>	AB		EQ 10MG BASE	A218096	002	Jun 03, 2026	May NEWA
>A>	AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A215356	001	Jun 03, 2026	May NEWA
>A>	AB		EQ 10MG BASE	A215356	002	Jun 03, 2026	May NEWA
>A>	AB	BRECKENRIDGE	EQ 5MG BASE	A209633	001	Jun 03, 2026	May NEWA
>A>	AB		EQ 10MG BASE	A209633	002	Jun 03, 2026	May NEWA
>A>	AB	CONCORD BIOTECH LTD	EQ 5MG BASE	A218821	001	Jun 09, 2026	May NEWA
>A>	AB		EQ 10MG BASE	A218821	002	Jun 09, 2026	May NEWA
>A>	AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A219530	001	Jun 03, 2026	May NEWA
>A>	AB		EQ 10MG BASE	A219530	002	Jun 03, 2026	May NEWA
	AB	MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Apr CMFD
>A>	AB		EQ 10MG BASE	A209738	002	Jun 03, 2026	May NEWA
>A>	AB	MSN	EQ 5MG BASE	A217299	001	Jun 03, 2026	May NEWA
>A>	AB		EQ 10MG BASE	A217299	002	Jun 03, 2026	May NEWA
>A>	AB	SOMERSET THERAPS LLC	EQ 5MG BASE	A220137	001	Jun 03, 2026	May NEWA
>A>	AB		EQ 10MG BASE	A220137	002	Jun 03, 2026	May NEWA
>A>	AB	SPECGX LLC	EQ 5MG BASE	A219395	001	Jun 03, 2026	May NEWA
>A>	AB		EQ 10MG BASE	A219395	002	Jun 03, 2026	May NEWA
>A>	AB	YAOPHARMA CO LTD	EQ 5MG BASE	A215552	001	Jun 09, 2026	May NEWA
>A>	AB		EQ 10MG BASE	A215552	002	Jun 09, 2026	May NEWA

<u>TABLET;ORAL</u>							
<u>TOFACITINIB CITRATE</u>							
AB	ZYDUS PHARMS	EQ 5MG BASE	A209829	001	Mar 13, 2023	Apr	CMFD
>A>	AB	EQ 10MG BASE	A209829	002	Jun 05, 2026	May	NEWA
<u>XELJANZ</u>							
AB	+ PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Apr	CTEC
AB	+!	EQ 10MG BASE	N203214	002	May 30, 2018	Apr	CTEC
<u>TABLET, EXTENDED RELEASE;ORAL</u>							
<u>TOFACITINIB CITRATE</u>							
AB	AJANTA PHARMA LTD	EQ 11MG BASE	A219542	001	Aug 19, 2025	Apr	CMFD
	@	EQ 11MG BASE	A219542	001	Aug 19, 2025	Jan	DISC
>A>	AB	APOTEX	A220458	001	Jun 03, 2026	May	NEWA
AB	AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	Apr	CMFD
AB	DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024	Apr	CMFD
>A>	AB	ORIENT PHARMA	A219830	001	Jun 09, 2026	May	NEWA
AB	ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Apr	CMFD
AB		EQ 22MG BASE	A214264	002	Aug 19, 2021	Apr	CHRS
AB	!	EQ 22MG BASE	A214264	002	Aug 19, 2021	Apr	CMFD
<u>XELJANZ XR</u>							
AB	+! PFIZER	EQ 22MG BASE	N208246	002	Dec 12, 2019	Apr	CTEC
<u>TOLCAPONE</u>							
<u>TABLET;ORAL</u>							
<u>TASMAR</u>							
	+! BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar	CTEC
<u>TOLCAPONE</u>							
	@ INGENUS PHARMS LLC	100MG	A208937	001	Aug 07, 2018	Mar	DISC
AB		100MG	A208937	001	Aug 07, 2018	Feb	CAHN
<u>TOLTERODINE TARTRATE</u>							
<u>TABLET;ORAL</u>							
<u>TOLTERODINE TARTRATE</u>							
AB	UNIQUE	1MG	A204721	001	Jan 24, 2020	Mar	CAHN
AB		2MG	A204721	002	Jan 24, 2020	Mar	CAHN
<u>TOLVAPTAN</u>							
<u>TABLET;ORAL</u>							
<u>TOLVAPTAN</u>							
AB2	ALKEM LABS LTD	15MG	A220147	001	Apr 21, 2026	Apr	NEWA
AB2		30MG	A220147	002	Apr 21, 2026	Apr	NEWA
AB		45MG	A220147	003	Apr 21, 2026	Apr	NEWA
AB2		60MG	A220147	004	Apr 21, 2026	Apr	NEWA
AB		90MG	A220147	005	Apr 21, 2026	Apr	NEWA
<u>TOPIRAMATE</u>							
<u>CAPSULE;ORAL</u>							
<u>TOPIRAMATE</u>							
AB	SENORES PHARMS	15MG	A218642	001	Oct 10, 2024	Jan	CAHN
AB		25MG	A218642	002	Oct 10, 2024	Jan	CAHN
AB	STRIDES PHARMA	50MG	A078418	003	Feb 02, 2026	Jan	NEWA
<u>CAPSULE, EXTENDED RELEASE;ORAL</u>							
<u>TOPIRAMATE</u>							
AB1	ASCENT PHARMS INC	25MG	A217443	001	Jan 12, 2026	Jan	NEWA
AB1		50MG	A217443	002	Jan 12, 2026	Jan	NEWA
AB1		100MG	A217443	003	Jan 12, 2026	Jan	NEWA
AB1		200MG	A217443	004	Jan 12, 2026	Jan	NEWA
>A>	AB2	RICONPHARMA LLC	A220041	001	May 26, 2026	May	NEWA
>A>	AB2		A220041	002	May 26, 2026	May	NEWA
>A>	AB2		A220041	003	May 26, 2026	May	NEWA
>A>	AB2		A220041	004	May 26, 2026	May	NEWA
>A>	AB2		A220041	005	May 26, 2026	May	NEWA
<u>TABLET;ORAL</u>							
<u>TOPIRAMATE</u>							
	@ SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	Jan	CAHN
	@	50MG	A090353	002	Sep 01, 2010	Jan	CAHN
	@	100MG	A090353	003	Sep 01, 2010	Jan	CAHN
	@	200MG	A090353	004	Sep 01, 2010	Jan	CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION		TOPOTECAN HYDROCHLORIDE					
AP	INGENUS PHARMS LLC	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Feb	CAHN
SOLUTION; INTRAVENOUS		TOPOTECAN HYDROCHLORIDE					
	@ NATCO PHARMA USA	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	CAHN

TORSEMIDE

TABLET; ORAL		TORSEMIDE					
AB	MICRO LABS	5MG	A217239	001	May 01, 2026	Apr	NEWA
AB		10MG	A217239	002	May 01, 2026	Apr	NEWA
AB		20MG	A217239	003	May 01, 2026	Apr	NEWA

TRABECTEDIN

>A>	SOLUTION; INTRAVENOUS							
>A>	EVDI							
>A>	+!	APOTEX	1MG/20ML (0.05MG/ML)	N220837	001	May 01, 2026	May	NEWA

TRAMADOL HYDROCHLORIDE

SOLUTION; ORAL		QDOLO						
	@ +	ROSEMONT	5MG/ML	N214044	001	Sep 01, 2020	Mar	CAHN
TABLET; ORAL		TRAMADOL HYDROCHLORIDE						
>D>	AB	RUBICON	25MG	A208708	003	Nov 27, 2023	May	CAHN
	AB		25MG	A208708	003	Nov 27, 2023	Mar	CTEC
>A>	AB	RUBICON RESEARCH	25MG	A208708	003	Nov 27, 2023	May	CAHN
>D>	AB		50MG	A208708	001	Jun 28, 2019	May	CAHN
>A>	AB		50MG	A208708	001	Jun 28, 2019	May	CAHN
>D>			75MG	A208708	004	Apr 04, 2024	May	CAHN
>A>			75MG	A208708	004	Apr 04, 2024	May	CAHN
>D>	AB	!	100MG	A208708	002	Jun 28, 2019	May	CAHN
>A>	AB	!	100MG	A208708	002	Jun 28, 2019	May	CAHN
	AB	STRIDES PHARMA	25MG	A202075	002	Mar 23, 2026	Mar	NEWA

TRANDOLAPRIL

TABLET; ORAL		TRANDOLAPRIL						
	@	SENORES PHARMS	1MG	A078493	001	Aug 25, 2008	Jan	CAHN
	@		2MG	A078493	002	Aug 25, 2008	Jan	CAHN
	@		4MG	A078493	003	Aug 25, 2008	Jan	CAHN

TRANEXAMIC ACID

TABLET; ORAL		TRANEXAMIC ACID						
>D>	AB	BIONPHARMA	650MG	A219123	001	Aug 19, 2025	May	DISC
>A>		@	650MG	A219123	001	Aug 19, 2025	May	DISC
	AB	I 3 PHARMS	650MG	A219702	001	Jan 26, 2026	Jan	NEWA

TRETINOIN

CREAM; TOPICAL		TRETINOIN						
AB1		ENCUBE	0.05%	A217832	001	Mar 25, 2026	Mar	NEWA
AB			0.1%	A217833	001	Feb 10, 2026	Jan	NEWA
GEL; TOPICAL		RETIN-A-MICRO						
AB	+!	BAUSCH	0.06%	N020475	004	Oct 23, 2017	Apr	CFTG
TABLET; ORAL		TRETINOIN						
>A>	AB	AMNEAL	0.08%	A217497	001	May 14, 2026	May	NEWA
TABLET; ORAL		TRETINOIN MICROSPPHERE						
AB		ENCUBE	0.06%	A215609	002	Apr 15, 2026	Apr	NFTG

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL		TRIAMCINOLONE ACETONIDE						
>D>	AT	COSETTE	0.025%	A089797	001	May 31, 1991	May	CAHN
>D>	AT		0.1%	A089798	001	May 31, 1991	May	CAHN
>A>	AT	COSETTE PHARMS NC	0.025%	A089797	001	May 31, 1991	May	CAHN

CREAM; TOPICAL							
TRIAMCINOLONE ACETONIDE							
>A>	AT		0.1%	A089798	001	May 31, 1991	May CAHN
INJECTABLE; INJECTION							
KENALOG-10							
>D>	AB	+	APOTHECON	10MG/ML	N012041	001	May CHRS
>A>	AB	+		10MG/ML	N012041	001	May CHRS
	AB	+	!	10MG/ML	N012041	001	Jan CHRS
TRIAMCINOLONE ACETONIDE							
		@	CAPLIN	10MG/ML	A090166	001	May 27, 2009
>D>	AB		DR REDDYS	10MG/ML	A218773	001	Mar 12, 2025
>A>	AB		!	10MG/ML	A218773	001	Mar 12, 2025
LOTION; TOPICAL							
TRIAMCINOLONE ACETONIDE							
>D>	AT		COSETTE	0.1%	A089129	001	Aug 14, 1986
>A>	AT		COSETTE PHARMS NC	0.1%	A089129	001	Aug 14, 1986
>A>		@	ENCUBE	0.1%	A204606	001	Jul 07, 2016
>D>		@	PAI HOLDINGS PHARM	0.1%	A204606	001	Jul 07, 2016
OINTMENT; TOPICAL							
TRIAMCINOLONE ACETONIDE							
>D>	AT		COSETTE	0.025%	A089795	001	Dec 23, 1988
>D>	AT			0.1%	A089796	001	Dec 23, 1988
>A>	AT		COSETTE PHARMS NC	0.025%	A089795	001	Dec 23, 1988
>A>	AT			0.1%	A089796	001	Dec 23, 1988
>A>		@	ENCUBE	0.5%	A208590	001	Mar 03, 2017
>D>		@	PAI HOLDINGS PHARM	0.5%	A208590	001	Mar 03, 2017
PASTE; DENTAL							
TRIAMCINOLONE ACETONIDE							
>D>	AT		COSETTE	0.1%	A205592	001	Jan 12, 2017
>A>	AT		COSETTE PHARMS NC	0.1%	A205592	001	Jan 12, 2017
<u>TRIAZOLAM</u>							
TABLET; ORAL							
TRIAZOLAM							
		@	BRECKENRIDGE	0.125MG	A216890	001	Nov 08, 2022
		@		0.25MG	A216890	002	Nov 08, 2022
AB			INGENUS PHARMS LLC	0.125MG	A214219	001	Oct 20, 2020
AB				0.25MG	A214219	002	Oct 20, 2020
<u>TRIENTINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
TRIENTINE HYDROCHLORIDE							
>D>	AB	!	RISING	500MG	A212238	002	Sep 22, 2023
>A>		@	WATSON LABS TEVA	250MG	A207567	001	Feb 07, 2018
>A>		@		250MG	A207567	001	Feb 07, 2018
<u>TRIFLUOPERAZINE HYDROCHLORIDE</u>							
TABLET; ORAL							
TRIFLUOPERAZINE HYDROCHLORIDE							
		@	POM PHARMA	EQ 1MG BASE	A040153	001	Oct 25, 1996
		@		EQ 2MG BASE	A040153	002	Oct 25, 1996
		@		EQ 5MG BASE	A040153	003	Oct 25, 1996
		@		EQ 10MG BASE	A040153	004	Oct 25, 1996
<u>TROPICAMIDE</u>							
SOLUTION/DROPS; OPHTHALMIC							
TROPICAMIDE							
>D>	AT		BAUSCH AND LOMB	1%	A040064	001	Jul 27, 1994
>A>	AT			1%	A040064	001	Jul 27, 1994
<u>TROSPIMUM CHLORIDE</u>							
TABLET; ORAL							
TROSPIMUM CHLORIDE							
AB			ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022
<u>URSODIOL</u>							
CAPSULE; ORAL							
URSODIOL							
			STRIDES PHARMA	150MG	A210344	002	Jan 16, 2026

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	!	HETERO LABS LTD V	EQ 1GM BASE	A203047	002	Apr 08, 2015	Feb	CHRS
		VALTREX						
AB	+	GLAXOSMITHKLINE	EQ 1GM BASE	N020487	002	Jun 23, 1995	Feb	CHRS

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB		MICRO LABS	50MG/ML	A218838	001	Mar 19, 2026	Mar	NEWA
----	--	------------	---------	---------	-----	--------------	-----	------

VALSARTAN

SOLUTION;ORAL

VALSARTAN

>D>	AB		RUBICON	4MG/ML	A216460	001	Jun 05, 2025	May	CAHN
>A>	AB		RUBICON RESEARCH	4MG/ML	A216460	001	Jun 05, 2025	May	CAHN

TABLET;ORAL

VALSARTAN

	AB		LAURUS	40MG	A218897	001	Apr 21, 2026	Apr	NEWA
	AB			80MG	A218897	002	Apr 21, 2026	Apr	NEWA
	AB			160MG	A218897	003	Apr 21, 2026	Apr	NEWA
	AB			320MG	A218897	004	Apr 21, 2026	Apr	NEWA
>D>	AB		LUPIN	40MG	A201677	001	Jan 05, 2015	May	DISC
>A>		@		40MG	A201677	001	Jan 05, 2015	May	DISC
>D>	AB			80MG	A201677	002	Jan 05, 2015	May	DISC
>A>		@		80MG	A201677	002	Jan 05, 2015	May	DISC
>D>	AB			160MG	A201677	003	Jan 05, 2015	May	DISC
>A>		@		160MG	A201677	003	Jan 05, 2015	May	DISC
>D>	AB			320MG	A201677	004	Jan 05, 2015	May	DISC
>A>		@		320MG	A201677	004	Jan 05, 2015	May	DISC
		@	RENATA	40MG	A218169	001	Aug 05, 2024	Feb	CAHN
		@		80MG	A218169	002	Aug 05, 2024	Feb	CAHN
		@		160MG	A218169	003	Aug 05, 2024	Feb	CAHN
		@		320MG	A218169	004	Aug 05, 2024	Feb	CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

>D>	AB		LUPIN	EQ 125MG BASE	A090439	001	Jan 28, 2015	May	DISC
>A>		@		EQ 125MG BASE	A090439	001	Jan 28, 2015	May	DISC
>D>	AB			EQ 250MG BASE	A090439	002	Jan 28, 2015	May	DISC
>A>		@		EQ 250MG BASE	A090439	002	Jan 28, 2015	May	DISC
	AB		PAI HOLDINGS	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar	CMFD
	AB			EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar	CMFD

FOR SOLUTION;ORAL

FIRVANQ KIT

AA	+	!	AZURITY	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Apr	CTEC
AA	+	!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Apr	CTEC
			VANCOMYCIN HYDROCHLORIDE						
AA			ALKEM LABS LTD	EQ 25MG BASE/ML	A214913	001	Nov 14, 2022	Apr	CTEC
AA				EQ 50MG BASE/ML	A214913	002	Nov 14, 2022	Apr	CTEC

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP			EUROFARMA	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	CAHN
AP				EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	CAHN

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

	!		SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan	CHRS
				EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan	CTNA

VARENICLINE TARTRATE

TABLET;ORAL

VARENICLINE TARTRATE

>D>	AB		PHARMOBEDIENT	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May	DISC
>A>		@		EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May	DISC
	AB		PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jan	CMFD
	AB			EQ 1MG BASE	A217115	002	Jul 23, 2024	Jan	CMFD
	AB		UMEDICA	EQ 0.5MG BASE	A218985	001	Jan 09, 2026	Jan	NEWA
	AB			EQ 1MG BASE	A218985	002	Jan 09, 2026	Jan	NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

	@	EAGLE PHARMS	20UNITS/ML (20UNITS/ML)	A211538	001	Dec 15, 2021	Mar	DISC
AP		SANDOZ	20UNITS/ML (20UNITS/ML)	A212068	001	May 06, 2026	Apr	NEWA
AP			200UNITS/10ML (20UNITS/ML)	A212069	001	May 06, 2026	Apr	NFTG
		VASOPRESSIN IN DEXTROSE 5%						
>A>	AP	DR REDDYS	40UNITS/100ML (0.4UNITS/ML)	A213988	002	Jun 03, 2026	May	NEWA
		VASOSTRICT						
AP	+!	PH HEALTH	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Apr	CFTG

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

>D>	AP	EUGIA PHARMA	10MG/VIAL	A206670	001	Dec 20, 2018	May	CHRS	
>A>	AP	!	10MG/VIAL	A206670	001	Dec 20, 2018	May	CHRS	
>D>	AP		20MG/VIAL	A206670	002	Dec 20, 2018	May	CHRS	
>A>	AP	!	20MG/VIAL	A206670	002	Dec 20, 2018	May	CHRS	
>D>	AP	!	SUN PHARM	10MG/VIAL	A079001	001	Jun 17, 2009	May	CHRS
>A>	AP		10MG/VIAL	A079001	001	Jun 17, 2009	May	CHRS	
>D>	AP	!		20MG/VIAL	A079001	002	Jun 17, 2009	May	DISC
>A>		@		20MG/VIAL	A079001	002	Jun 17, 2009	May	DISC

VENETOCLAX

TABLET; ORAL

VENCLEXTA

>D>		+ ABBVIE	10MG	N208573	001	Apr 11, 2016	May	CFTG
>A>	AB	+	10MG	N208573	001	Apr 11, 2016	May	CFTG
>D>		+	50MG	N208573	002	Apr 11, 2016	May	CFTG
>A>	AB	+	50MG	N208573	002	Apr 11, 2016	May	CFTG
>D>		+!	100MG	N208573	003	Apr 11, 2016	May	CFTG
>A>	AB	+!	100MG	N208573	003	Apr 11, 2016	May	CFTG
>A>		VENETOCLAX						
>A>	AB	DR REDDYS	10MG	A214733	001	May 15, 2026	May	NFTG
>A>	AB		50MG	A214733	002	May 15, 2026	May	NFTG
>A>	AB		100MG	A214733	003	May 15, 2026	May	NFTG

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		PLATINUM	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Apr	CAHN
AB			EQ 75MG BASE	A201272	002	Nov 23, 2018	Apr	CAHN
AB			EQ 150MG BASE	A201272	003	Nov 23, 2018	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

	@	ADAPTIS	EQ 75MG BASE	A213927	001	Jan 21, 2021	Mar	DISC
	@	PHARMADAX	EQ 75MG BASE	A214423	001	Jan 04, 2022	Mar	CAHN
	@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Mar	CAHN

>A> VEPDEGESTRANT

TABLET; ORAL

VEPPANU

>A>		+ ARVINAS OPERATIONS	100MG	N219835	001	May 01, 2026	May	NEWA
>A>		+!	200MG	N219835	002	May 01, 2026	May	NEWA

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

	@	AMNEAL	5MG/2ML (2.5MG/ML)	A210994	001	Jul 13, 2018	Mar	DISC
	@		10MG/4ML (2.5MG/ML)	A210994	002	Jul 13, 2018	Mar	DISC

VIGABATRIN

FOR SOLUTION; ORAL

VIGABATRIN

	@	TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Jan	DISC
--	---	-----------------	--------------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION  
VINORELBINE TARTRATE

>A>	@	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A208997	001	Aug 05, 2019	May	CAHN
>D>	@	NOVAST LABS	EQ 10MG BASE/ML	A208997	001	Aug 05, 2019	May	CAHN

VORICONAZOLE

POWDER; INTRAVENOUS  
VORICONAZOLE

AP		ZHEJIANG NOVUS	200MG/VIAL	A220078	001	May 05, 2026	Apr	NEWA
----	--	----------------	------------	---------	-----	--------------	-----	------

XENON XE-133

GAS; INHALATION  
XENON XE 133

		SHINE	10mCi/VIAL	N017284	001		Feb	CAHN
			20mCi/VIAL	N017284	002		Feb	CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL  
PRIALT

	+	!	ESTEVE	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Apr	CAHN
	@			200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Apr	CAHN
	+	!		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Apr	CAHN
	+	!		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Apr	CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION  
ZINC CHLORIDE

AP		STIRA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr	CAHN
----	--	-------	----------------	---------	-----	--------------	-----	------

ZINC SULFATE

SOLUTION; INTRAVENOUS  
ZINC SULFATE

AP		STIRA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	Apr	CAHN
AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	Apr	CAHN
AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217624	003	Jun 10, 2025	Apr	CAHN

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS  
ZOLEDRONIC ACID

AP		GLAND	EQ 4MG BASE/100ML	A219984	001	Feb 05, 2026	Jan	NEWA
	@	HOSPIRA INC	EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Jan	DISC

ZOLPIDEM TARTRATE

CAPSULE; ORAL  
ZOLPIDEM TARTRATE

>D>		+	!	ALMATICA	7.5MG	N215721	001	May 09, 2023	May	CFTG
>A>	AB		+		7.5MG	N215721	001	May 09, 2023	May	CFTG
>A>	AB			UMEDICA LABS PVT	7.5MG	A220717	001	May 12, 2026	May	NFTG

TABLET; ORAL

ZOLPIDEM TARTRATE

		@		SENORES PHARMS	5MG	A077985	001	Apr 23, 2007	Jan	CAHN
		@			10MG	A077985	002	Apr 23, 2007	Jan	CAHN
>D>	AB			TEVA	5MG	A076410	001	Apr 23, 2007	May	DISC
>A>		@			5MG	A076410	001	Apr 23, 2007	May	DISC
>D>	AB				10MG	A076410	002	Apr 23, 2007	May	DISC
>A>		@			10MG	A076410	002	Apr 23, 2007	May	DISC

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB				BRECKENRIDGE	6.25MG	A213592	001	Jun 04, 2020	Jan	CMFD
AB					12.5MG	A213592	002	Jun 04, 2020	Jan	CMFD

ACETAMINOPHENSUPPOSITORY;RECTAL  
ACEPHEN

>D>	@	COSETTE	120MG	A 072218	001	Mar 27, 1992	May	CAHN
>D>	@		325MG	A 072344	001	Mar 27, 1992	May	CAHN
>D>	@		650MG	A 072237	001	Mar 27, 1992	May	CAHN
>A>	@	COSETTE PHARMS NC	120MG	A 072218	001	Mar 27, 1992	May	CAHN
>A>	@		325MG	A 072344	001	Mar 27, 1992	May	CAHN
>A>	@		650MG	A 072237	001	Mar 27, 1992	May	CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

>A>		DIFFERIN EPIDUO						
>A>	+	GALDERMA LABS LP	0.1%;2.5%	N220736	001	May 22, 2026	May	NEWA

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

AVAGARD

	+	SOLVENTUM	61%;1%	N021074	001	Jun 07, 2001	Apr	CAHN
--	---	-----------	--------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

	@	AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	Feb	DISC
--	---	--------	----------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	@	AMNEAL PHARMS NY	5MG	A 078780	001	Jan 21, 2010	Mar	DISC
	@		10MG	A 078780	004	Jan 21, 2010	Mar	DISC
		CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
	@	AMNEAL PHARMS NY	5MG	A 078780	003	Jan 21, 2010	Mar	DISC
	@		10MG	A 078780	002	Jan 21, 2010	Mar	DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

DYNA-HEX 2

	+	XTTRIUM	2%	N019422	001	Dec 17, 1985	Feb	CTNA
		DYNA-HEX 4						
		XTTRIUM	4%	N019125	001	Dec 24, 1984	Feb	CTNA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

SOLUPREP S

	+	SOLVENTUM	2%;70%	N208288	001	Aug 08, 2018	Apr	CAHN
--	---	-----------	--------	---------	-----	--------------	-----	------

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

>A>	!	ENCUBE	1%	A 074165	001	Jul 16, 1993	May	CAHN
>D>	!	P AND L	1%	A 074165	001	Jul 16, 1993	May	CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DEXTROMETHORPHAN POLISTIREX

		AUROBINDO PHARMA LTD	EQ 30MG HYDROBROMIDE/5ML	A218417	001	Apr 15, 2026	Apr	NEWA
--	--	----------------------	--------------------------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

	@	AMNEAL PHARMS CO	25MG;220MG	A 209726	001	Oct 23, 2018	Mar	DISC
--	---	------------------	------------	----------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	@	TEVA	30MG	A 076447	004	Apr 13, 2011	Mar	DISC
		TIME CAP LABS	30MG	A 079112	002	Feb 08, 2012	Mar	CAHN
		CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES						
	@	TEVA	30MG	A 076447	005	Apr 13, 2011	Mar	DISC

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	TIME CAP LABS	30MG	A079112	001	Feb 08, 2012	Mar	CAHN
	FEXOFENADINE HYDROCHLORIDE ALLERGY						
@	RISING	60MG	A077081	006	Jul 21, 2011	Mar	DISC
@		180MG	A077081	008	Jul 21, 2011	Mar	DISC
@	TEVA	60MG	A076447	006	Apr 13, 2011	Mar	DISC
@		180MG	A076447	008	Apr 13, 2011	Mar	DISC
	TIME CAP LABS	60MG	A079112	004	Feb 08, 2012	Mar	CAHN
		180MG	A079112	006	Feb 08, 2012	Mar	CAHN
	FEXOFENADINE HYDROCHLORIDE HIVES						
@	RISING	60MG	A077081	007	Jul 21, 2011	Mar	DISC
@		180MG	A077081	009	Jul 21, 2011	Mar	DISC
@	TEVA	60MG	A076447	007	Apr 13, 2011	Mar	DISC
	TIME CAP LABS	60MG	A079112	003	Feb 08, 2012	Mar	CAHN
		180MG	A079112	005	Feb 08, 2012	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	180MG;240MG	A215232	001	Apr 17, 2025	Feb	CMFD
--	----------------------	-------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

	GLENMARK PHARMS LTD	0.05MG/SPRAY	A218742	001	Mar 16, 2026	Mar	NEWA
	GLENMARK SPECLT	0.05MG/SPRAY	A218742	001	Mar 16, 2026	Apr	CAHN
>D>	RUBICON	0.05MG/SPRAY	A219060	001	Aug 15, 2025	May	CAHN
>A>	RUBICON RESEARCH	0.05MG/SPRAY	A219060	001	Aug 15, 2025	May	CAHN

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

	RUBICON RESEARCH	100MG/5ML	A220239	001	Mar 05, 2026	Feb	NEWA
--	------------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

IBUPROFEN

@	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Apr	DISC
@	AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987	Mar	DISC
>D>	PH HEALTH	200MG	A071229	001	Apr 01, 1987	May	DISC
>A>	@	200MG	A071229	001	Apr 01, 1987	May	DISC

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

DURAPREP

+	SOLVENTUM	EQ 0.7% IODINE; 74% (6ML)	N021586	001	Sep 29, 2006	Apr	CAHN
+		EQ 0.7% IODINE; 74% (26ML)	N021586	002	Sep 29, 2006	Apr	CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

@	APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006	Apr	DISC
---	------------	----------------	---------	-----	--------------	-----	------

LORATADINE

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

	INSTAPILL	5MG	A212795	001	Sep 18, 2020	Feb	CAHN
		10MG	A213294	001	Oct 30, 2020	Feb	CAHN

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

+	HISAMITSU PHARM CO	3%;10%	N022029	002	Nov 05, 2012	Mar	CHRS
---	--------------------	--------	---------	-----	--------------	-----	------

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE 7

>A>	ENCUBE	2%	A074164	001	Mar 29, 1996	May	CAHN
>D>	P AND L	2%	A074164	001	Mar 29, 1996	May	CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

>D>	COSETTE	2%,200MG	A074926	001	Apr 16, 1999	May	CAHN
>A>	COSETTE PHARMS NC	2%,200MG	A074926	001	Apr 16, 1999	May	CAHN

## SUPPOSITORY;VAGINAL

## MICONAZOLE NITRATE

>D>	COSETTE	100MG	A073507	001	Nov 19, 1993	May	CAHN
>A>	COSETTE PHARMS NC	100MG	A073507	001	Nov 19, 1993	May	CAHN

OLOPATADINE HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## OLOPATADINE HYDROCHLORIDE

@	FDC LTD	EQ 0.2% BASE	A217051	001	Jul 14, 2025	Feb	DISC
---	---------	--------------	---------	-----	--------------	-----	------

PERMETHRIN

## LOTION;TOPICAL

## PERMETHRIN

@	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001	Feb	DISC
---	------------------	----	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350

## FOR SOLUTION;ORAL

## POLYETHYLENE GLYCOL 3350

	ALLIED	17GM/SCOOPFUL	A090812	001	Oct 07, 2009	Apr	CAHN
--	--------	---------------	---------	-----	--------------	-----	------

RANITIDINE HYDROCHLORIDE

## TABLET;ORAL

## RANITIDINE HYDROCHLORIDE

@	RISING	EQ 75MG BASE	A075497	001	Jan 14, 2000	Mar	CAHN
---	--------	--------------	---------	-----	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2026**

NO MAY 2026 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2026 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11207311	Jul 28, 2037	U-2830		I-980	Dec 12, 2028
	11207311	Jul 28, 2037	U-4368			
	11673877	Mar 27, 2038	DS DP U-2830			
	11673877	Mar 27, 2038	DS DP U-4368			
	11986468	Jul 28, 2037	U-2830			
	11986468	Jul 28, 2037	U-4368			
	11986469	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-4368			
	11986470	Jul 28, 2037	U-4368			
	11992486	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-4368			
	12383543	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-4368			
	8071579	Aug 12, 2027	U-2830			
	8071579	Aug 12, 2027	U-4368			
	8143241	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-4368			
	8859562	Aug 04, 2031	U-2830			
	8859562	Aug 04, 2031	U-4368			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11207311	Jul 28, 2037	U-2830		I-980	Dec 12, 2028
	11207311	Jul 28, 2037	U-4368			
	11673877	Mar 27, 2038	DS DP U-2830			
	11673877	Mar 27, 2038	DS DP U-4368			
	11986468	Jul 28, 2037	U-2830			
	11986468	Jul 28, 2037	U-4368			
	11986469	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-4368			
	11986470	Jul 28, 2037	U-4368			
	11992486	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-4368			
	12383543	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-4368			
	8071579	Aug 12, 2027	U-2830			
	8071579	Aug 12, 2027	U-4368			
	8143241	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-4368			
	8859562	Aug 04, 2031	U-2830			
	8859562	Aug 04, 2031	U-4368			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	11166951	Aug 11, 2035	U-4426		D-200	Feb 19, 2029
	11166951	Aug 11, 2035	U-4427			
	11166951	Aug 11, 2035	U-4428			
	11166951	Aug 11, 2035	U-4429			
	11166951	Aug 11, 2035	U-4430			
	11166951	Aug 11, 2035	U-4431			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	11166951	Aug 11, 2035	U-4426		D-200	Feb 19, 2029
	11166951	Aug 11, 2035	U-4427			
	11166951	Aug 11, 2035	U-4428			
	11166951	Aug 11, 2035	U-4429			
	11166951	Aug 11, 2035	U-4430			
	11166951	Aug 11, 2035	U-4431			
<u>ACECLIDINE HYDROCHLORIDE - VIZZ</u>						
N 218585 001	12533347	Oct 08, 2039	U-3741			
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	12539290	Aug 16, 2039	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CABTREO</u>						
N 216632 001 >A>	12616710	Jul 31, 2040	DP			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 001	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 002	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 003	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 004	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001 >A>	12616708	May 15, 2035	U-2414			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 002 >A>	10117951	Mar 13, 2029	DP			
	10177951	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 003 >A>	10117951	Mar 13, 2029	DP			
	10177951	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
<u>AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK</u>						
N 215152 001	7977488	Apr 10, 2030	DS			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	11723898	Jan 14, 2041	U-4449			
	12303497	Jan 30, 2040	U-4448			
	12303497	Jan 30, 2040	U-4494			
	>A> 8445507	Feb 14, 2032	DS DP U-2237			
	>A> 8445507	Feb 14, 2032	DS DP U-2624			
	RE50642	Sep 23, 2033	U-4450			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	11723898	Jan 14, 2041	U-4449			
	12303497	Jan 30, 2040	U-4448			
	12303497	Jan 30, 2040	U-4494			
	>A> 8445507	Feb 14, 2032	DS DP U-2237			
	>A> 8445507	Feb 14, 2032	DS DP U-2624			
	RE50642	Sep 23, 2033	U-4450			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	12576034	Nov 30, 2033	DP U-1858			
	12576034	Nov 30, 2033	DP U-4290			
	12576034	Nov 30, 2033	DP U-4291			
	12576034*PED	May 30, 2034				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 002	12576034	Nov 30, 2033	DP U-1858			
	12576034	Nov 30, 2033	DP U-4290			
	12576034	Nov 30, 2033	DP U-4291			
	12576034*PED	May 30, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	12576034	Nov 30, 2033	DP U-1858			
	12576034	Nov 30, 2033	DP U-4290			
	12576034	Nov 30, 2033	DP U-4291			
	12576034*PED	May 30, 2034				
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 001 >A>	11707456	Nov 19, 2041	DS DP U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 002 >A>	11707456	Nov 19, 2041	DS DP U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 003 >A>	11707456	Nov 19, 2041	DS DP U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 004 >A>	11707456	Nov 19, 2041	DS DP U-4021			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001	12390442	Feb 16, 2044		U-4433		
<u>ARTICAINE HYDROCHLORIDE - CYKLX</u>						
N 218643 001	11096922	Mar 27, 2039	DP U-4423			
	11826347	Mar 27, 2039	DP U-4423			
	12403126	Mar 27, 2039	DP U-4422			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 001 >A>	12622897	Sep 27, 2042		U-4536		
	>A> 8754096	Sep 28, 2035	DS DP U-3534			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 002 >A>	12622897	Sep 27, 2042		U-4536		
	>A> 8754096	Sep 28, 2035	DS DP U-3534			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 003 >A>	8754096	Sep 28, 2035	DS DP U-3534			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001 >A>	12599553	Jun 07, 2037	DP			
<u>ATRASENTAN HYDROCHLORIDE - VANRAFIA</u>						
N 219208 001	12521369	Feb 23, 2041		U-3980		
	12582631	Mar 25, 2043		U-3980		
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2027	DS			
	9617546	Feb 14, 2027	DS	U-3673		
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	8906938	Jan 06, 2034	DS DP			
<u>AVATROMBOPAG MALEATE - DOPTLET</u>						
N 210238 001				>A> ODE-548		Jul 24, 2032
<u>AVATROMBOPAG MALEATE - DOPTLET SPRINKLE</u>						
N 219696 001				>A> ODE-548		Jul 24, 2032

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAFKI FAKZYNJA CO-PACK (COPACKAGED)</u>						
N 219616 001	12509450	Dec 29, 2042	DP		ODE-525	May 08, 2032
<u>AXITINIB - INLYTA</u>						
N 202324 001	12534530	Feb 03, 2035	U-4411			
	12534530	Feb 03, 2035	U-4412			
	12534530*PED	Aug 03, 2035				
<u>AXITINIB - INLYTA</u>						
N 202324 002	12534530	Feb 03, 2035	U-4411			
	12534530	Feb 03, 2035	U-4412			
	12534530*PED	Aug 03, 2035				
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 002	8987441	Oct 24, 2032	DS DP		>A> M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 003	8987441	Oct 24, 2032	DS DP		>A> M-187	Dec 19, 2027
<u>BAXDROSTAT - BAXFENDY</u>						
N 219878 001	>A> 9353081	Feb 04, 2033	DS DP		>A> NCE	May 15, 2031
<u>BAXDROSTAT - BAXFENDY</u>						
N 219878 002	>A> 9353081	Feb 04, 2033	DS DP		>A> NCE	May 15, 2031
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	12551491	Jul 23, 2045	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	12551491	Jul 23, 2045	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	12551491	Jul 23, 2045	U-713			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 001	>A> 10125102	Apr 07, 2035	DS		U-4535	
	>A> 10329260	Mar 09, 2035	DS			
	>A> 10662160	Nov 01, 2039	DS		U-4535	
	>A> 10689346	Mar 09, 2035			U-4535	
	>A> 11117867	Nov 01, 2039	DP		U-4535	
	>A> 11230530	Mar 09, 2035			U-4535	
	>A> 11618733	Nov 01, 2039			U-4535	
	>A> 11708333	Mar 09, 2035			U-4535	
	>A> 12116346	Mar 09, 2035	DS			
	>A> 12344585	Nov 01, 2039			U-4535	
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 002	>A> 10125102	Apr 07, 2035	DS		U-4535	
	>A> 10329260	Mar 09, 2035	DS			
	>A> 10662160	Nov 01, 2039	DS		U-4535	
	>A> 10689346	Mar 09, 2035			U-4535	
	>A> 11117867	Nov 01, 2039	DP		U-4535	
	>A> 11230530	Mar 09, 2035			U-4535	
	>A> 11618733	Nov 01, 2039			U-4535	
	>A> 11708333	Mar 09, 2035			U-4535	
	>A> 12116346	Mar 09, 2035	DS			
	>A> 12344585	Nov 01, 2039			U-4535	
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 003	>A> 10125102	Apr 07, 2035	DS		U-4535	
	>A> 10329260	Mar 09, 2035	DS			
	>A> 10662160	Nov 01, 2039	DS		U-4535	
	>A> 10689346	Mar 09, 2035			U-4535	
	>A> 11117867	Nov 01, 2039	DP		U-4535	
	>A> 11230530	Mar 09, 2035			U-4535	
	>A> 11618733	Nov 01, 2039			U-4535	
	>A> 11708333	Mar 09, 2035			U-4535	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 003	>A> 12116346	Mar 09, 2035	DS			
	>A> 12344585	Nov 01, 2039			U-4535	
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 004	>A> 10125102	Apr 07, 2035	DS		U-4535	
	>A> 10329260	Mar 09, 2035	DS			
	>A> 10662160	Nov 01, 2039	DS		U-4535	
	>A> 10689346	Mar 09, 2035			U-4535	
	>A> 11117867	Nov 01, 2039	DP		U-4535	
	>A> 11230530	Mar 09, 2035			U-4535	
	>A> 11618733	Nov 01, 2039			U-4535	
	>A> 11708333	Mar 09, 2035			U-4535	
	>A> 12116346	Mar 09, 2035	DS			
	>A> 12344585	Nov 01, 2039			U-4535	
	12545645	Nov 01, 2039	DS DP			
	12545645*PED	May 01, 2040				
	12545646	Nov 01, 2039	DS DP			
	12545646*PED	May 01, 2040				
	12545647	Nov 01, 2039	DS DP			
	12545647*PED	May 01, 2040				
	12552750	Nov 01, 2039	DS DP			
	12552750*PED	May 01, 2040				
	12590068	Nov 01, 2039	DS DP			
	12590068*PED	May 01, 2040				
	12590069	Nov 01, 2039	DS DP			
	12590069*PED	May 01, 2040				
<u>BEXAGLIFLOZIN - BREZVAVY</u>						
N 214373 001	12594243	Oct 05, 2041	DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	12594244	Nov 08, 2036	DP U-257		>A> ODE-540	Jul 30, 2032
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	12594244	Nov 08, 2036	DP U-257		>A> ODE-540	Jul 30, 2032
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2027	DS DP			
<u>BRIMONIDINE TARTRATE; CARBACHOL - YUVEZZI</u>						
N 220142 001	12268662	Nov 10, 2042	DP U-3741		NP	Jan 28, 2029
	12268662	Nov 10, 2042	DP U-4419			
	12268662	Nov 10, 2042	DP U-4420			
	8455494	May 24, 2030	U-3741			
	8455494	May 24, 2030	U-4419			
	8455494	May 24, 2030	U-4420			
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214460 001	>A> 9303051	Jul 30, 2034	DS DP U-3165			
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214461 001	>A> 9303051	Jul 30, 2034	DS DP U-3165			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE</u>						
N 216579 001	>A> 10716753	May 28, 2030	DP U-3203		>A> I-988	Apr 27, 2029
	>A> 10716753	May 28, 2030	DP U-4513			
	>A> 9415009	May 28, 2030	U-3203			
	>A> 9415009	May 28, 2030	U-4513			
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE</u>						
N 216579 002	>A> 10716753	May 28, 2030	DP U-4513		>A> NS	Apr 27, 2029
	>A> 9415009	May 28, 2030	U-4513			
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 002	>A> 10716753	May 28, 2030	DP U-4503		>A> NS	Apr 27, 2029
	>A> 11331442	Oct 05, 2038	DP			
	>A> 11833292	Oct 05, 2038	DP			
	>A> 8324266	May 28, 2030	U-4503			
	>A> 8703806	May 28, 2030	U-4503			
	>A> 8808713	May 28, 2030	DP U-4503			
	>A> 8815258	Mar 17, 2031	U-4503			
	>A> 9415009	May 28, 2030	U-4503			
	>A> 9463161	May 28, 2030	DP U-4503			
<u>BUMETANIDE - ENBUMYST</u>						
N 219500 001	12558330	May 14, 2045	DP U-4279			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	>A> 12622904	Nov 06, 2035	U-4528			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	>A> 12622904	Nov 06, 2035	U-4528			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	>A> 10058518	Nov 05, 2034	U-3419		>A> I-913	Apr 30, 2029
	>A> 10058518	Nov 05, 2034	U-4522			
	>A> 10064857	Nov 05, 2034	U-3419			
	>A> 10064857	Nov 05, 2034	U-4517			
	>A> 10092560	Nov 05, 2034	U-3419			
	>A> 10092560	Nov 05, 2034	U-4517			
	>A> 10092561	Nov 05, 2034	U-3419			
	>A> 10092561	Nov 05, 2034	U-4517			
	>A> 10596167	Nov 05, 2034	U-3419			
	>A> 10596167	Nov 05, 2034	U-4517			
	>A> 10780066	Nov 05, 2034	U-3419			
	>A> 10780066	Nov 05, 2034	U-4517			
	>A> 10786496	Nov 05, 2034	U-3419			
	>A> 10786496	Nov 05, 2034	U-4517			
	>A> 10806710	Nov 05, 2034	U-3419			
	>A> 10806710	Nov 05, 2034	U-4517			
	>A> 10881624	Nov 05, 2034	U-3419			
	>A> 10881624	Nov 05, 2034	U-4517			
	>A> 10966941	Nov 05, 2034	U-3419			
	>A> 10966941	Nov 05, 2034	U-4517			
	>A> 11007189	Nov 05, 2034	U-4516			
	>A> 11065248	Nov 05, 2034	U-3419			
	>A> 11065248	Nov 05, 2034	U-4517			
	>A> 11123344	Nov 05, 2034	U-3419			
	>A> 11123344	Nov 05, 2034	U-4517			
	>A> 11191739	Nov 05, 2034	DP U-3419			
	>A> 11191739	Nov 05, 2034	DP U-4516			
	>A> 11197839	Nov 05, 2034	DP U-3419			
	>A> 11197839	Nov 05, 2034	DP U-4516			
	>A> 11207281	Nov 05, 2034	U-3419			
	>A> 11207281	Nov 05, 2034	U-4537			
	>A> 11234946	Nov 05, 2034	U-3419			
	>A> 11234946	Nov 05, 2034	U-4526			
	>A> 11253492	Nov 05, 2034	U-3419			
	>A> 11253492	Nov 05, 2034	U-4526			
	>A> 11273133	Nov 05, 2034	U-3419			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	>A> 11273133	Nov 05, 2034	U-4526			
	>A> 11273134	Nov 05, 2034	U-3419			
	>A> 11273134	Nov 05, 2034	U-4517			
	>A> 11285118	Nov 05, 2034	U-3419			
	>A> 11285118	Nov 05, 2034	U-4526			
	>A> 11285146	Nov 05, 2034	U-3419			
	>A> 11285146	Nov 05, 2034	U-4517			
	>A> 11291638	Nov 05, 2034	U-3419			
	>A> 11291638	Nov 05, 2034	U-4517			
	>A> 11291665	Nov 05, 2034	U-3419			
	>A> 11291665	Nov 05, 2034	U-4517			
	>A> 11298352	Nov 05, 2034	U-3419			
	>A> 11298352	Nov 05, 2034	U-4517			
	>A> 11344544	Nov 05, 2034	U-3419			
	>A> 11344544	Nov 05, 2034	U-4517			
	>A> 11357744	Nov 05, 2034	U-3419			
	>A> 11357744	Nov 05, 2034	U-4517			
	>A> 11382874	Nov 05, 2034	U-3419			
	>A> 11382874	Nov 05, 2034	U-4517			
	>A> 11419867	Nov 05, 2034	U-3419			
	>A> 11419867	Nov 05, 2034	U-4517			
	>A> 11426370	Nov 05, 2034	U-3419			
	>A> 11426370	Nov 05, 2034	U-4526			
	>A> 11426401	Nov 05, 2034	U-3419			
	>A> 11426401	Nov 05, 2034	U-4517			
	>A> 11433067	Nov 05, 2034	DP U-3419			
	>A> 11433067	Nov 05, 2034	DP U-4516			
	>A> 11439636	Nov 05, 2034	U-3419			
	>A> 11439636	Nov 05, 2034	U-4517			
	>A> 11534414	Nov 05, 2034	DP U-3419			
	>A> 11534414	Nov 05, 2034	DP U-4516			
	>A> 11571417	Nov 05, 2034	U-3419			
	>A> 11571417	Nov 05, 2034	U-4526			
	>A> 11576909	Nov 05, 2034	U-3419			
	>A> 11576909	Nov 05, 2034	U-4526			
	>A> 11590124	Nov 05, 2034	U-3419			
	>A> 11590124	Nov 05, 2034	U-4526			
	>A> 12194005	Jan 23, 2043	U-4523			
	>A> 12194036	Apr 20, 2043	U-4521			
	>A> 12239642	Jan 20, 2043	U-4515			
	>A> 12263161	Jan 20, 2043	U-4515			
	>A> 12364674	Jan 23, 2043	U-4516			
	>A> 12370154	Feb 15, 2043	U-4518			
	>A> 12433884	Jun 05, 2040	U-4514			
	>A> 12472155	Feb 23, 2043	U-4519			
	>A> 12472156	Jun 05, 2040	U-4516			
	>A> 12472174	Jan 20, 2043	U-4515			
	>A> 12478622	Jan 20, 2043	U-4515			
	>A> 12564587	Jan 20, 2043	U-4515			
	>A> 12576078	Jun 05, 2040	U-4516			
	>A> 12599576	Feb 15, 2043	U-4518			
	>A> 8569328	Jul 18, 2032	DP U-3419			
	>A> 8569328	Jul 18, 2032	DP U-4516			
	>A> 9168234	Nov 05, 2034	U-3419			
	>A> 9168234	Nov 05, 2034	U-4517			
	>A> 9198905	Nov 05, 2034	U-3419			
	>A> 9198905	Nov 05, 2034	U-4520			
	>A> 9205083	Nov 05, 2034	U-3419			
	>A> 9205083	Nov 05, 2034	U-4520			
	>A> 9278095	Nov 05, 2034	U-3419			
	>A> 9278095	Nov 05, 2034	U-4517			
	>A> 9314462	Nov 05, 2034	U-3419			
	>A> 9314462	Nov 05, 2034	U-4517			
	>A> 9370513	Nov 05, 2034	U-3419			
	>A> 9370513	Nov 05, 2034	U-4520			
	>A> 9421176	Nov 05, 2034	U-3419			
	>A> 9421176	Nov 05, 2034	U-4517			
	>A> 9457023	Nov 05, 2034	U-3419			
	>A> 9457023	Nov 05, 2034	U-4517			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	>A> 9457025	Nov 05, 2034	U-3419			
	>A> 9457025	Nov 05, 2034	U-4517			
	>A> 9474731	Nov 05, 2034	U-3419			
	>A> 9474731	Nov 05, 2034	U-4520			
	>A> 9486450	Nov 05, 2034	U-3419			
	>A> 9486450	Nov 05, 2034	U-4517			
	>A> 9700528	Nov 05, 2034	U-3419			
	>A> 9700528	Nov 05, 2034	U-4517			
	>A> 9700553	Nov 05, 2034	U-3419			
	>A> 9700553	Nov 05, 2034	U-4517			
	>A> 9707191	Nov 05, 2034	U-3419			
	>A> 9707191	Nov 05, 2034	U-4522			
	>A> 9763932	Nov 05, 2034	U-3419			
	>A> 9763932	Nov 05, 2034	U-4517			
	>A> 9861595	Nov 05, 2034	U-3419			
	>A> 9861595	Nov 05, 2034	U-4517			
	>A> 9867819	Nov 05, 2034	U-3419			
	>A> 9867819	Nov 05, 2034	U-4517			
	>A> 9968568	Nov 05, 2034	U-3419			
	>A> 9968568	Nov 05, 2034	U-4517			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 002	>A> 10058518	Nov 05, 2034	U-4522		>A> I-913	Apr 30, 2029
	>A> 10080727	Nov 05, 2034	U-4520			
	>A> 10092560	Nov 05, 2034	U-4517			
	>A> 10105361	Nov 05, 2034	U-4522			
	>A> 10251879	Nov 05, 2034	U-4517			
	>A> 10780066	Nov 05, 2034	U-4517			
	>A> 11007189	Nov 05, 2034	U-4516			
	>A> 11207281	Nov 05, 2034	U-4537			
	>A> 11234946	Nov 05, 2034	U-4526			
	>A> 11253492	Nov 05, 2034	U-4526			
	>A> 11273133	Nov 05, 2034	U-4526			
	>A> 11273134	Nov 05, 2034	U-4517			
	>A> 11285118	Nov 05, 2034	U-4526			
	>A> 11285146	Nov 05, 2034	U-4517			
	>A> 11291638	Nov 05, 2034	U-4517			
	>A> 11291665	Nov 05, 2034	U-4517			
	>A> 11298352	Nov 05, 2034	U-4517			
	>A> 11344544	Nov 05, 2034	U-4517			
	>A> 11382874	Nov 05, 2034	U-4517			
	>A> 11419867	Nov 05, 2034	U-4517			
	>A> 11426370	Nov 05, 2034	U-4526			
	>A> 11571417	Nov 05, 2034	U-4526			
	>A> 11590124	Nov 05, 2034	U-4526			
	>A> 11617747	Nov 05, 2034	U-4526			
	>A> 12433884	Jun 05, 2040	U-4514			
	>A> 12472156	Jun 05, 2040	U-4516			
	>A> 12472174	Jan 20, 2043	U-4515			
	>A> 12576078	Jun 05, 2040	U-4516			
	>A> 8569328	Jul 18, 2032	DP U-4516			
	>A> 9168234	Nov 05, 2034	U-4517			
	>A> 9198905	Nov 05, 2034	U-4520			
	>A> 9205083	Nov 05, 2034	U-4520			
	>A> 9238032	Nov 05, 2034	U-4520			
	>A> 9314462	Nov 05, 2034	U-4517			
	>A> 9370513	Nov 05, 2034	U-4520			
	>A> 9375429	Nov 05, 2034	U-4517			
	>A> 9408815	Nov 05, 2034	U-4517			
	>A> 9421176	Nov 05, 2034	U-4517			
	>A> 9457023	Nov 05, 2034	U-4517			
	>A> 9457025	Nov 05, 2034	U-4517			
	>A> 9474731	Nov 05, 2034	U-4520			
	>A> 9486450	Nov 05, 2034	U-4517			
	>A> 9700528	Nov 05, 2034	U-4517			
	>A> 9700553	Nov 05, 2034	U-4517			
	>A> 9707191	Nov 05, 2034	U-4522			
	>A> 9763932	Nov 05, 2034	U-4517			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 002	>A> 9861595	Nov 05, 2034	U-4517			
	>A> 9867819	Nov 05, 2034	U-4517			
	>A> 9968568	Nov 05, 2034	U-4517			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030	U-2753			
	10583110*PED	Apr 27, 2031				
	10716777	Oct 27, 2030	U-2856			
	10716777*PED	Apr 27, 2031				
	12453712	Oct 27, 2030	U-4334			
	12453712*PED	Apr 27, 2031				
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	>A> 12636285	Oct 01, 2040	U-3348			
	>A> 12636286	Oct 01, 2040	U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	>A> 12636285	Oct 01, 2040	U-3348			
	>A> 12636286	Oct 01, 2040	U-3348			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001					>A> ODE-530	Mar 26, 2032
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002					>A> ODE-530	Mar 26, 2032
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003					>A> ODE-530	Mar 26, 2032
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	12582622	Feb 22, 2041	U-4044			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503			
	7737142*PED	Mar 17, 2030				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029		U-2543		
	RE49110	Jul 16, 2029		U-2544		
	RE49110	Jul 16, 2029		U-2545		
	RE49110	Jul 16, 2029		U-3503		
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029		U-2543		
	RE49302	Jul 16, 2029		U-2544		
	RE49302	Jul 16, 2029		U-2545		
	RE49302	Jul 16, 2029		U-3503		
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030			PED	Jun 18, 2029
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029		U-2543		
	RE49110	Jul 16, 2029		U-2544		
	RE49110	Jul 16, 2029		U-2545		
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029		U-2543		
	RE49302	Jul 16, 2029		U-2544		
	RE49302	Jul 16, 2029		U-2545		
	RE49302	Jul 16, 2029		U-3503		
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Sep 17, 2029	DS DP U-1750		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2543		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142*PED	Mar 17, 2030				
	7943621	Dec 16, 2028	DS DP			
	7943621*PED	Jun 16, 2029				
	RE49110	Jul 16, 2029		U-2543		
	RE49110	Jul 16, 2029		U-2544		
	RE49110	Jul 16, 2029		U-2545		
	RE49110*PED	Jan 16, 2030				
	RE49302	Jul 16, 2029		U-2543		
	RE49302	Jul 16, 2029		U-2544		
	RE49302	Jul 16, 2029		U-2545		
	RE49302	Jul 16, 2029		U-3503		
	RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 005	7737142	Sep 17, 2029	DS DP U-2543		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030				
	7943621	Dec 20, 2028	DS DP			
	7943621*PED	Jun 20, 2029				
	RE47350	Jul 16, 2029		U-2543		
	RE47350	Jul 16, 2029		U-2544		
	RE47350	Jul 16, 2029		U-2545		
	RE47350	Jul 16, 2029		U-3503		
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029		U-2543		
	RE49110	Jul 16, 2029		U-2544		
	RE49110	Jul 16, 2029		U-2545		
	RE49110	Jul 16, 2029		U-3503		
	RE49110*PED	Jan 16, 2030				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 006	7737142	Sep 17, 2029	DS DP U-2543		M-14	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2544		NPP	Dec 18, 2028
	7737142	Sep 17, 2029	DS DP U-2545		PED	Jun 18, 2029
	7737142	Sep 17, 2029	DS DP U-3503		PED	Jun 18, 2029
	7737142*PED	Mar 17, 2030				
	7943621	Dec 20, 2028	DS DP			
	7943621*PED	Jun 20, 2029				
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE47350*PED	Jan 16, 2030				
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49110*PED	Jan 16, 2030				
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	>A> 10028963	Sep 07, 2032	U-2565			
	>A> 10028963	Sep 07, 2032	U-2566			
	>A> 10028963*PED	Mar 07, 2033				
	>A> 10125149	Aug 14, 2035	DP			
	>A> 10125149*PED	Feb 14, 2036				
	>A> 10376496	Sep 09, 2034	U-2610			
	>A> 10376496	Sep 09, 2034	U-2611			
	>A> 10376496*PED	Mar 09, 2035				
	>A> 10420841	Mar 14, 2034	U-1672			
	>A> 10420841	Mar 14, 2034	U-2631			
	>A> 10420841	Mar 14, 2034	U-3360			
	>A> 10420841	Mar 14, 2034	U-3361			
	>A> 10420841*PED	Sep 14, 2034				
	>A> 10933053	Sep 09, 2034	U-3090			
	>A> 10933053	Sep 09, 2034	U-3091			
	>A> 10933053*PED	Mar 09, 2035				
	>A> 11278622	Mar 14, 2034	U-3335			
	>A> 11278622	Mar 14, 2034	U-3336			
	>A> 11278622*PED	Sep 14, 2034				
	>A> 7129232	May 15, 2028	DS DP U-1676			
	>A> 7129232	May 15, 2028	DS DP U-3360			
	>A> 7129232	May 15, 2028	DS DP U-3361			
	>A> 7129232	May 15, 2028	DS DP U-36			
	>A> 7129232*PED	Nov 15, 2028				
	>A> 8906898	May 28, 2034	DS DP			
	>A> 8906898*PED	Nov 28, 2034				
	>A> 8968753	Mar 14, 2034	U-1672			
	>A> 8968753	Mar 14, 2034	U-1673			
	>A> 8968753	Mar 14, 2034	U-3360			
	>A> 8968753	Mar 14, 2034	U-3361			
	>A> 8968753*PED	Sep 14, 2034				
	>A> 9320740	Mar 14, 2034	DP			
	>A> 9320740*PED	Sep 14, 2034				
	>A> 9724353	Sep 07, 2032	U-2565			
	>A> 9724353	Sep 07, 2032	U-2566			
	>A> 9724353*PED	Mar 07, 2033				
	>A> 9872906	Mar 14, 2034	DP			
	>A> 9872906*PED	Sep 14, 2034				
<u>CHENODIOL - CTEXTLI</u>						
N 219488 001					ODE-523	Feb 21, 2032
<u>CITALOPRAM HYDROBROMIDE - CITALOPRAM HYDROBROMIDE</u>						
A 219985 001					CGT	Sep 16, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	12576072	Jun 23, 2034	DP U-3261			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	12533408	Sep 10, 2041	U-4395			
	12539329	Sep 10, 2041	U-4399			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	11179465	Aug 31, 2030	DP U-1858			
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	12576032	Jul 28, 2041	U-2357			
<u>CLOTRIMAZOLE - CLOTIC</u>						
N 217628 001					>A> ODE-549	Sep 26, 2032
					>A> GAIN	Sep 26, 2037
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	12514819	Nov 22, 2036	U-2814			
<u>COPPER - MIUDELLA</u>						
N 218201 001	9180040	Mar 22, 2034	DP			
<u>COPPER HISTIDINATE - ZYCUBO</u>						
N 211241 001					NCE	Jan 12, 2031
					ODE-520	Jan 12, 2033
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 001	12582634	Jan 12, 2043	DS			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 002	12582634	Jan 12, 2043	DS			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 003	12582634	Jan 12, 2043	DS			
<u>CRINECERFONT - CRENESSITY</u>						
N 218820 001	12582634	Jan 12, 2043	DS			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028
	10028912	Oct 15, 2032	DP U-3150		PED	Sep 30, 2028
	10028912*PED	Apr 15, 2033				
	10166184	Oct 15, 2032	DP U-3149			
	10166184*PED	Apr 15, 2033				
	10835492	Oct 15, 2032	U-3150			
	10835492*PED	Apr 15, 2033				
	7850990	Jan 23, 2027	DP U-3147			
	7850990*PED	Jul 23, 2027				
	8022279	Sep 14, 2027	DP U-3147			
	8022279*PED	Mar 14, 2028				
	8092828	Apr 01, 2029	U-3147			
	8092828*PED	Oct 01, 2029				
	9271931	Jan 23, 2027	DP			
	9271931*PED	Jul 23, 2027				
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211156 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u>						
A 211156 002					PC	Oct 03, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211312 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211312 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211467 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211467 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211470 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211470 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211482 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211482 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211523 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211523 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211541 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211541 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211545 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211545 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211560 001					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN - DAPAGLIFLOZIN</u> A 211560 002					PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211479 001					>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211479 002					>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211479 003					>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u> A 211479 004					>A> PC	Oct 03, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u>						
A 211491	001				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u>						
A 211491	002				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u>						
A 211491	003				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u>						
A 211563	001				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u>						
A 211563	002				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u>						
A 211563	003				>A> PC	Oct 03, 2026
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE</u>						
A 211563	004				>A> PC	Oct 03, 2026
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415	001	>A> 12629337	Jan 09, 2043	DP		
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415	002	>A> 12629337	Jan 09, 2043	DP		
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099	001	12329742	Jun 17, 2042	DP		
		>A> 12611397	Jul 02, 2040	DP		
<u>DASATINIB - PHYRAGO</u>						
N 216099	001	12544376	Jan 22, 2041	U-3767		
		12544376	Jan 22, 2041	U-3768		
		12544376	Jan 22, 2041	U-3769		
		12544376	Jan 22, 2041	U-3770		
		12544376	Jan 22, 2041	U-3771		
		12544376	Jan 22, 2041	U-3772		
<u>DASATINIB - PHYRAGO</u>						
N 216099	002	12544376	Jan 22, 2041	U-3767		
		12544376	Jan 22, 2041	U-3768		
		12544376	Jan 22, 2041	U-3769		
		12544376	Jan 22, 2041	U-3770		
		12544376	Jan 22, 2041	U-3771		
		12544376	Jan 22, 2041	U-3772		
<u>DASATINIB - PHYRAGO</u>						
N 216099	003	12544376	Jan 22, 2041	U-3767		
		12544376	Jan 22, 2041	U-3768		
		12544376	Jan 22, 2041	U-3769		
		12544376	Jan 22, 2041	U-3770		
		12544376	Jan 22, 2041	U-3771		
		12544376	Jan 22, 2041	U-3772		
<u>DASATINIB - PHYRAGO</u>						
N 216099	004	12544376	Jan 22, 2041	U-3767		
		12544376	Jan 22, 2041	U-3768		
		12544376	Jan 22, 2041	U-3769		
		12544376	Jan 22, 2041	U-3770		
		12544376	Jan 22, 2041	U-3771		
		12544376	Jan 22, 2041	U-3772		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - PHYRAGO</u>						
N 216099 005	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 006	12544376	Jan 22, 2041	U-3767			
	12544376	Jan 22, 2041	U-3768			
	12544376	Jan 22, 2041	U-3769			
	12544376	Jan 22, 2041	U-3770			
	12544376	Jan 22, 2041	U-3771			
	12544376	Jan 22, 2041	U-3772			
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</u>						
N 214231 001 >A>	10442847	Mar 22, 2035	DS DP			
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</u>						
N 214231 002 >A>	10442847	Mar 22, 2035	DS DP			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	12529052	Jun 22, 2032	DP			
	12534722	Jun 22, 2032	DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	12514898	Feb 20, 2029	U-1978			
	12533387	Feb 20, 2029	U-4417			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	12514898	Feb 20, 2029	U-1978			
	12533387	Feb 20, 2029	U-4417			
<u>DEHYDRATED ALCOHOL - DEHYDRATED ALCOHOL</u>						
N 214988 001					ODE-521	Oct 23, 2032
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	12558349	Mar 14, 2034	U-3967			
<u>DESMOPRESSIN ACETATE - DESMODA</u>						
N 219873 001	12214010	Apr 03, 2044	DP			
	12343372	Apr 03, 2044	DP U-4432			
<u>DEUCRAVACITINIB - SOTYKTU</u>						
N 214958 001	12521390	Feb 11, 2043	DP U-3434		I-986	Mar 06, 2029
	12521390	Feb 11, 2043	DP U-4451			
	RE47929	Nov 07, 2033	DS DP U-3434			
	RE47929	Nov 07, 2033	DS DP U-4452			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 004	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 005	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 007	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	12589075	Jun 10, 2041	U-1995			
	12589075	Jun 10, 2041	U-3055			
	12599598	Jun 10, 2041	U-1995			
	12599598	Jun 10, 2041	U-3055			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	10081621	Mar 25, 2031	DP U-4087		ODE-526	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4468		>A> ODE-536	Mar 27, 2033
	10239867	Apr 09, 2027	DS DP U-4090			
	10239867	Apr 09, 2027	DS DP U-4464			
	11564916	Aug 13, 2029	U-4095			
	11564916	Aug 13, 2029	U-4466			
	11578062	Mar 25, 2031	DP U-4096			
	11578062	Mar 25, 2031	DP U-4465			
	11639347	Apr 09, 2027	DS DP U-4090			
	11639347	Apr 09, 2027	DS DP U-4464			
	11866450	Feb 14, 2039	U-4082			
	11866450	Feb 14, 2039	U-4463			
	11873300	Aug 13, 2040	DS DP U-4083			
	11873300	Aug 13, 2040	DS DP U-4462			
	8324242	Aug 05, 2027	U-4090			
	8324242	Aug 05, 2027	U-4464			
	8415387	Nov 12, 2027	U-4082			
	8415387	Nov 12, 2027	U-4463			
	8598181	May 01, 2027	U-4090			
	8598181	May 01, 2027	U-4463			
	9181192	May 17, 2032	DS DP U-4094			
	9181192	May 17, 2032	DS DP U-4472			
	9512079	May 17, 2032	DS DP U-4098			
	9512079	May 17, 2032	DS DP U-4471			
	9670163	Dec 28, 2026	DP U-4080			
	9670163	Dec 28, 2026	DP U-4470			
	9931334	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4469			
	9974781	Apr 09, 2027	DP U-4082			
	9974781	Apr 09, 2027	DP U-4463			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	10081621	Mar 25, 2031	DP U-4087		ODE-526	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4468		>A> ODE-536	Mar 27, 2033
	10239867	Apr 09, 2027	DS DP U-4090			
	10239867	Apr 09, 2027	DS DP U-4464			
	11564916	Aug 13, 2029	U-4095			
	11564916	Aug 13, 2029	U-4466			
	11578062	Mar 25, 2031	DP U-4096			
	11578062	Mar 25, 2031	DP U-4465			
	11639347	Apr 09, 2027	DS DP U-4090			
	11639347	Apr 09, 2027	DS DP U-4464			
	11866450	Feb 14, 2039	U-4082			
	11866450	Feb 14, 2039	U-4463			
	11873300	Aug 13, 2040	DS DP U-4083			
	11873300	Aug 13, 2040	DS DP U-4462			
	8324242	Aug 05, 2027	U-4090			
	8324242	Aug 05, 2027	U-4464			
	8415387	Nov 12, 2027	U-4082			
	8415387	Nov 12, 2027	U-4463			
	8598181	May 01, 2027	U-4090			
	8598181	May 01, 2027	U-4463			
	9181192	May 17, 2032	DS DP U-4094			
	9181192	May 17, 2032	DS DP U-4472			
	9512079	May 17, 2032	DS DP U-4098			
	9512079	May 17, 2032	DS DP U-4471			
	9670163	Dec 28, 2026	DP U-4080			
	9670163	Dec 28, 2026	DP U-4470			
	9931334	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4469			
	9974781	Apr 09, 2027	DP U-4082			
	9974781	Apr 09, 2027	DP U-4463			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	10081621	Mar 25, 2031	DP U-4087		ODE-526	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4468		>A> ODE-536	Mar 27, 2033
	10206877	Apr 14, 2035	DP U-4092			
	10206877	Apr 14, 2035	DP U-4467			
	10239867	Apr 09, 2027	DS DP U-4090			
	10239867	Apr 09, 2027	DS DP U-4464			
	11564916	Aug 13, 2029	U-4095			
	11564916	Aug 13, 2029	U-4466			
	11578062	Mar 25, 2031	DP U-4096			
	11578062	Mar 25, 2031	DP U-4465			
	11639347	Apr 09, 2027	DS DP U-4090			
	11639347	Apr 09, 2027	DS DP U-4464			
	11866450	Feb 14, 2039	U-4082			
	11866450	Feb 14, 2039	U-4463			
	11873300	Aug 13, 2040	DS DP U-4083			
	11873300	Aug 13, 2040	DS DP U-4462			
	11951212	Apr 14, 2035	DP U-4089			
	11951212	Apr 14, 2035	DP U-4461			
	12186306	Jan 10, 2043	U-4088			
	12186306	Jan 10, 2043	U-4460			
	8324242	Aug 05, 2027	U-4090			
	8324242	Aug 05, 2027	U-4464			
	8415387	Nov 12, 2027	U-4082			
	8415387	Nov 12, 2027	U-4463			
	8598181	May 01, 2027	U-4090			
	8598181	May 01, 2027	U-4463			
	9181192	May 17, 2032	DS DP U-4094			
	9181192	May 17, 2032	DS DP U-4472			
	9512079	May 17, 2032	DS DP U-4098			
	9512079	May 17, 2032	DS DP U-4471			
	9670163	Dec 28, 2026	DP U-4080			
	9670163	Dec 28, 2026	DP U-4470			
	9931334	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4469			
	9974781	Apr 09, 2027	DP U-4082			
	9974781	Apr 09, 2027	DP U-4463			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	10081621	Mar 25, 2031	DP U-4087		ODE-526	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4468		>A> ODE-536	Mar 27, 2033
	10206877	Apr 14, 2035	DP U-4092			
	10206877	Apr 14, 2035	DP U-4467			
	10239867	Apr 09, 2027	DS DP U-4090			
	10239867	Apr 09, 2027	DS DP U-4464			
	11564916	Aug 13, 2029	U-4095			
	11564916	Aug 13, 2029	U-4466			
	11578062	Mar 25, 2031	DP U-4096			
	11578062	Mar 25, 2031	DP U-4465			
	11639347	Apr 09, 2027	DS DP U-4090			
	11639347	Apr 09, 2027	DS DP U-4464			
	11866450	Feb 14, 2039	U-4082			
	11866450	Feb 14, 2039	U-4463			
	11873300	Aug 13, 2040	DS DP U-4083			
	11873300	Aug 13, 2040	DS DP U-4462			
	11951212	Apr 14, 2035	DP U-4089			
	11951212	Apr 14, 2035	DP U-4461			
	12186306	Jan 10, 2043	U-4088			
	12186306	Jan 10, 2043	U-4460			
	8324242	Aug 05, 2027	U-4090			
	8324242	Aug 05, 2027	U-4464			
	8415387	Nov 12, 2027	U-4082			
	8415387	Nov 12, 2027	U-4463			
	8598181	May 01, 2027	U-4090			
	8598181	May 01, 2027	U-4463			
	9181192	May 17, 2032	DS DP U-4094			
	9181192	May 17, 2032	DS DP U-4472			
	9512079	May 17, 2032	DS DP U-4098			
	9512079	May 17, 2032	DS DP U-4471			
	9670163	Dec 28, 2026	DP U-4080			
	9670163	Dec 28, 2026	DP U-4470			
	9931334	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4469			
	9974781	Apr 09, 2027	DP U-4082			
	9974781	Apr 09, 2027	DP U-4463			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 001 >A>	9079928	May 07, 2035	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 002 >A>	9079928	May 07, 2035	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 003 >A>	9079928	May 07, 2035	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM - MUCINEX 12HR COLD &amp; FEVER MULTI-SYMPTOM</u>						
N 217338 001	11278506	Oct 11, 2036	DP			
	12257218	Oct 11, 2036	DP			
	12370189	Oct 11, 2036	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	12521400	Mar 27, 2029	DP			
	12599611	Jun 10, 2042	U-4455			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	12521400	Mar 27, 2029	DP			
	12599611	Jun 10, 2042	U-4455			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	12521400	Mar 27, 2029	DP			
	12599611	Jun 10, 2042	U-4455			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZOXIDE CHOLINE - VYKAT XR</u> N 216665 001					>A> ODE-532	May 26, 2032
<u>DIAZOXIDE CHOLINE - VYKAT XR</u> N 216665 002					>A> ODE-532	May 26, 2032
<u>DIAZOXIDE CHOLINE - VYKAT XR</u> N 216665 003					>A> ODE-532	May 26, 2032
<u>DICLOFENAC EPOLAMINE - LICART</u> N 206976 001					NPP	Mar 27, 2029
<u>DIFAMILAST - ADOUEY</u> N 219474 001	10588893 RE46792	Dec 31, 2036 Mar 01, 2028	DS DP DS DP U-4445		NCE	Feb 12, 2031
<u>DIFELIKEFALIN ACETATE - KORSUVA</u> N 214916 001	>A> 7402564	Nov 12, 2032	DS DP U-3204			
<u>DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)</u> N 215400 001	>A> 11083712 >A> 11083712 >A> 11541043 >A> 12329749 >A> 12329749 >A> 12414941 12533351	Jun 30, 2039 Jun 30, 2039 Mar 20, 2039 May 27, 2039 May 27, 2039 Aug 24, 2039 Feb 26, 2039	DP U-2718 DP U-4508 DP DP U-2718 DP U-4508 DP DP			
<u>DIHYDROERGOTAMINE MESYLATE - ATZUMI</u> N 217901 001	12594273	Sep 24, 2033	DP			
<u>DONIDALORSEN SODIUM - DAWNZERA (AUTOINJECTOR)</u> N 219407 001					>A> ODE-550	Aug 21, 2032
<u>DORAVIRINE; ISLATRAVIR - IDVYNSO</u> N 216964 001	>A> 7339053 >A> 8486975	May 31, 2027 Aug 30, 2032	DS DS DP U-4527		NCE	Apr 20, 2031
<u>DORDAVIPRONE HYDROCHLORIDE - MODEYSO</u> N 219876 001					>A> ODE-547	Aug 06, 2032
<u>DUVELISIB - COPIKTRA</u> N 211155 001	8193182	Sep 24, 2032	DS			
<u>DUVELISIB - COPIKTRA</u> N 211155 002	8193182	Sep 24, 2032	DS			
<u>EDARAVONE - RADICAVA ORS</u> N 215446 001	12527769 12569469 12599586	Nov 12, 2041 Nov 12, 2041 Nov 01, 2039	U-4111 U-4111 DP			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u> N 215500 001	12582625	Feb 12, 2036	U-4444			
<u>ELAFIBRANOR - IQIRVO</u> N 218860 001	12589086	Mar 30, 2037	U-4473			
<u>ELAMIPRETIDE HYDROCHLORIDE - FORZINITY</u> N 215244 001	7576061	Jan 20, 2027	DS DP		>A> ODE-551	Sep 19, 2032

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		>A> ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-3157			
	10081621	Mar 25, 2031	DP U-4075			
	10081621	Mar 25, 2031	DP U-4480			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10239867	Apr 09, 2027	DS DP U-4475			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10758534	Oct 06, 2035	DS DP U-4475			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-4475			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11179367	Dec 08, 2037	DP U-4487			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11426407	Oct 06, 2035	DS DP U-4475			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11517564	Dec 08, 2037	DP U-4475			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11564916	Aug 13, 2029	U-4491			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4490			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	11639347	Apr 09, 2027	DS DP U-4475			
	12350262	Jul 17, 2038	U-4221			
	12350262	Jul 17, 2038	U-4475			
	12458635	Aug 13, 2029	DP U-4330			
	12458635	Aug 13, 2029	DP U-4486			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8324242	Aug 05, 2027	U-4475			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8415387	Nov 12, 2027	U-4475			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8598181	May 01, 2027	U-4475			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9670163	Dec 28, 2026	DP U-4477			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-4479			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	9974781	Apr 09, 2027	DP U-4475			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		>A> ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-4075			
	10081621	Mar 25, 2031	DP U-4480			
	10239867	Apr 09, 2027	DS DP U-3158			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10239867	Apr 09, 2027	DS DP U-4056			
	10239867	Apr 09, 2027	DS DP U-4475			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10758534	Oct 06, 2035	DS DP U-4475			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-4475			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11179367	Dec 08, 2037	DP U-4487			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11426407	Oct 06, 2035	DS DP U-4475			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11517564	Dec 08, 2037	DP U-4475			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11564916	Aug 13, 2029	U-4491			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4490			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	11639347	Apr 09, 2027	DS DP U-4475			
	12350262	Jul 17, 2038	U-4222			
	12350262	Jul 17, 2038	U-4475			
	12458635	Aug 13, 2029	DP U-4330			
	12458635	Aug 13, 2029	DP U-4486			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8324242	Aug 05, 2027	U-4475			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8415387	Nov 12, 2027	U-4475			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8598181	May 01, 2027	U-4475			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9670163	Dec 28, 2026	DP U-4477			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-4479			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	9974781	Apr 09, 2027	DP U-4475			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		>A> ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-4065			
	10081621	Mar 25, 2031	DP U-4481			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10239867	Apr 09, 2027	DS DP U-4476			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10272046	Feb 27, 2033	DP U-4482			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10758534	Oct 06, 2035	DS DP U-4476			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-4476			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11147770	Feb 27, 2033	DP U-4483			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11179367	Dec 08, 2037	DP U-4484			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11426407	Oct 06, 2035	DS DP U-4476			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11517564	Dec 08, 2037	DP U-4476			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11564916	Aug 13, 2029	U-4485			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4488			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11639347	Apr 09, 2027	DS DP U-4476			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	11752106	Feb 27, 2033	DP U-4489			
	12214083	Feb 27, 2033	DP U-4141			
	12214083	Feb 27, 2033	DP U-4492			
	12458635	Aug 13, 2029	DP U-4333			
	12458635	Aug 13, 2029	DP U-4493			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8324242	Aug 05, 2027	U-4476			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8415387	Nov 12, 2027	U-4476			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8598181	May 01, 2027	U-4476			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9670163	Dec 28, 2026	DP U-4478			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-4478			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
	9974781	Apr 09, 2027	DP U-4476			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	10081621	Mar 25, 2031	DP U-3600		>A> ODE-543	Mar 27, 2033
	10081621	Mar 25, 2031	DP U-4065			
	10081621	Mar 25, 2031	DP U-4481			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10239867	Apr 09, 2027	DS DP U-4476			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10272046	Feb 27, 2033	DP U-4482			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10758534	Oct 06, 2035	DS DP U-4476			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-4476			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11147770	Feb 27, 2033	DP U-4483			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11179367	Dec 08, 2037	DP U-4484			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	11426407	Oct 06, 2035	DS DP U-4476			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11517564	Dec 08, 2037	DP U-4476			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11564916	Aug 13, 2029	U-4485			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11578062	Mar 25, 2031	DP U-4488			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11639347	Apr 09, 2027	DS DP U-4476			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	11752106	Feb 27, 2033	DP U-4489			
	12214083	Feb 27, 2033	DP U-4141			
	12214083	Feb 27, 2033	DP U-4492			
	12350262	Jul 17, 2038	U-4220			
	12350262	Jul 17, 2038	U-4476			
	12458635	Aug 13, 2029	DP U-4333			
	12458635	Aug 13, 2029	DP U-4493			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8324242	Aug 05, 2027	U-4476			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8415387	Nov 12, 2027	U-4476			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8598181	May 01, 2027	U-4476			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9670163	Dec 28, 2026	DP U-4478			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-4478			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
	9974781	Apr 09, 2027	DP U-4476			
<u>ELINZANETANT - LYNKUET</u>						
N 219469 001	12533358	May 14, 2045	U-4402			
	>A> 7683056	Sep 15, 2027	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	12527810	Apr 22, 2033	U-4403			
	12527810*PED	Oct 22, 2033				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	>A> 12629338	Jun 29, 2036	DP			
	>A> 12648911	Jun 29, 2036	U-1259			
	>A> 12648911	Jun 29, 2036	U-1663			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335			
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10005761	Aug 27, 2030	U-3738			
	10005761	Aug 27, 2030	U-4051			
	10005761	Aug 27, 2030	U-4440			
	10258622	Nov 21, 2032	U-2802			
	10258622	Nov 21, 2032	U-4051			
	10258622	Nov 21, 2032	U-4439			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8541575	Feb 26, 2030	DS DP U-4051			
	8541575	Feb 26, 2030	DS DP U-4440			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9314464	Jul 04, 2031	U-4051			
	9314464	Jul 04, 2031	U-4440			
	9474754	Aug 05, 2033	U-2802			
	9474754	Aug 05, 2033	U-4051			
	9474754	Aug 05, 2033	U-4440			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	9850230	Aug 27, 2030	U-4051			
	9850230	Aug 27, 2030	U-4440			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 215425 001	12539283	Jan 17, 2045	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	8906887	Aug 27, 2032	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	8906887	Aug 27, 2032	DP			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003	8080580	Dec 19, 2031	DS DP U-2214			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	8080580	Dec 19, 2031	DS DP U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	8080580	Dec 19, 2031	DS DP U-2214			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	12551447	Nov 05, 2042	DP			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002					D-199	Jan 16, 2029
<u>ETRIPAMIL - CARDAMYST</u>						
N 218571 001	10010522	Jun 19, 2028	U-38			
	10010523	Jun 19, 2028	DS			
	10117848	Apr 13, 2036	DP U-4370			
	12257224	Jul 15, 2042	U-4370			
	9227918	Jun 19, 2028	DP			
	9463179	Jun 19, 2028	U-4370			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2027	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2027	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2027	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2027	DS DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 001	8436180	Aug 26, 2033	DS DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	8436180	Aug 26, 2033	DS DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 003	8436180	Aug 26, 2033	DS DP			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001					I-983	Dec 13, 2028
<u>FLURPIRIDAZ F-18 - FLYRCADO</u>						
N 215168 001	12527884	May 13, 2042	DP U-4406			
<u>FLUTICASONE PROPIONATE - FLUTICASONE PROPIONATE</u>						
A 219602 001					CGT	Sep 20, 2026
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	>A> 12616806	Feb 23, 2036	U-4524			
	>A> 12616806	Feb 23, 2036	U-4525			
<u>FOSFOMYCIN DISODIUM - CONTEPO</u>						
N 212271 001					NP GAIN	Oct 22, 2028 Oct 22, 2033

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	12064487	Jan 17, 2040	U-4424		NPP	Feb 20, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007					NPP	Feb 20, 2029
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	8318714	Nov 28, 2031	DP			
<u>GEMCITABINE HYDROCHLORIDE - INLEXZO</u>						
N 219683 001	12576253	Dec 17, 2030	DP			
<u>GEPOTIDACIN MESYLATE - BLUJEP</u>						
N 218230 001	12528809	Dec 13, 2042	DS DP U-4361			
	12528809	Dec 13, 2042	DS DP U-4408			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	>A> 12606519	May 03, 2040	DS DP			
	7329689	Jan 15, 2027	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	>A> 8148401	Nov 21, 2032	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	>A> 8148401	Nov 21, 2032	DS DP			
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001					NPP	Mar 17, 2028
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	12551448	Mar 03, 2036	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	12551448	Mar 03, 2036	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	12551448	Mar 03, 2036	DP			
<u>ICOTROKINRA HYDROCHLORIDE - ICOTYDE</u>						
N 220149 001	11845808	Jan 14, 2041	DS U-4447		NCE	Mar 17, 2031
	11939361	Nov 19, 2041	DP U-4447			
	12552836	Jul 12, 2039	DS DP			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	>A> 12606869	Sep 22, 2030	U-4504			
	>A> 12606869	Sep 22, 2030	U-4505			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	>A> 12606869	Sep 22, 2030	U-4504			
	>A> 12606869	Sep 22, 2030	U-4505			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	>A> 12606869	Sep 22, 2030	U-4504			
	>A> 12606869	Sep 22, 2030	U-4505			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	>A> 12606869	Sep 22, 2030	U-4504			
	>A> 12606869	Sep 22, 2030	U-4505			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	>A> 12606869	Sep 22, 2030	U-4504			
	>A> 12606869	Sep 22, 2030	U-4505			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	>A> 12606869	Sep 22, 2030	U-4504			
	>A> 12606869	Sep 22, 2030	U-4505			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	>A> 12606869	Sep 22, 2030	U-4504			
	>A> 12606869	Sep 22, 2030	U-4505			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	7494982	Dec 27, 2026	DS DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	7494982	Dec 27, 2026	DS DP			
<u>INCLISIRAN SODIUM - LEQVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-4249		I-985	Feb 12, 2029
	10125369	Aug 18, 2034	DS DP U-4413		NPP	Feb 12, 2029
	10125369	Aug 18, 2034	DS DP U-4414			
	10131907	Aug 24, 2028	DS DP U-4249			
	10131907	Aug 24, 2028	DS DP U-4413			
	10131907	Aug 24, 2028	DS DP U-4414			
	10851377	Aug 25, 2036	U-4249			
	10851377	Aug 25, 2036	U-4413			
	10851377	Aug 25, 2036	U-4414			
	8106022	Dec 12, 2029	DS DP U-4249			
	8106022	Dec 12, 2029	DS DP U-4413			
	8106022	Dec 12, 2029	DS DP U-4414			
	8222222	Dec 29, 2027	U-4249			
	8222222	Dec 29, 2027	U-4413			
	8222222	Dec 29, 2027	U-4414			
	8809292	May 10, 2027	DS DP U-4249			
	8809292	May 10, 2027	DS DP U-4413			
	8809292	May 10, 2027	DS DP U-4414			
	8828956	Dec 04, 2028	DS DP U-4249			
	8828956	Dec 04, 2028	DS DP U-4413			
	8828956	Dec 04, 2028	DS DP U-4414			
	9370582	Dec 04, 2028	DS DP U-4249			
	9370582	Dec 04, 2028	DS DP U-4413			
	9370582	Dec 04, 2028	DS DP U-4414			
<u>IOHEXOL - IOHEXOL</u>						
A 217737 001					CGT	Jul 26, 2026
<u>IPRATROPIUM BROMIDE - IPRATROPIUM BROMIDE</u>						
A 217953 001				>A> PC		Oct 13, 2026
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001					ODE-524	Mar 20, 2032

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LANDIOLOL HYDROCHLORIDE - RAPIBLYK</u>						
N 217202	001				NPP	Feb 13, 2029
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008	001	>A> 12599606	May 14, 2040	U-4512		
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008	002	>A> 12599606	May 14, 2040	U-4511		
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973	001	12594267	Jul 15, 2039	DP		
<u>LENACAPAVIR SODIUM - YEZTUGO</u>						
N 220018	001	12594267	Jul 15, 2039	DP		
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935	001	>A> 10799506	Apr 14, 2036	DP	>A> I-951	Sep 17, 2027
		>A> 10799506*PED	Oct 14, 2036		>A> PED	Mar 17, 2028
		>A> 12064434	Apr 14, 2036	DP		
		>A> 12064434*PED	Oct 14, 2036			
		>A> 12419894	Apr 14, 2036	DP		
		>A> 12419894*PED	Oct 14, 2036			
		>A> 12544380	Aug 07, 2034	U-3264		
		>A> 12544380	Aug 07, 2034	U-3998		
		>A> 12544380*PED	Feb 07, 2035			
		>A> 8324225	Jun 17, 2028	DS DP		
		>A> 8324225*PED	Dec 17, 2028			
		>A> 8415355	Mar 13, 2031	DS DP		
		>A> 8415355*PED	Sep 13, 2031			
		>A> 8685980	May 25, 2030	DS DP		
		>A> 8685980*PED	Nov 25, 2030			
		>A> 8962630	Dec 09, 2029	U-2505		
		>A> 8962630	Dec 09, 2029	U-3264		
		>A> 8962630	Dec 09, 2029	U-3998		
		>A> 8962630*PED	Jun 09, 2030			
		>A> 9193732	Nov 09, 2031	DS DP		
		>A> 9193732*PED	May 09, 2032			
		>A> 9416136	Aug 20, 2029	U-2505		
		>A> 9416136	Aug 20, 2029	U-3264		
		>A> 9416136	Aug 20, 2029	U-3998		
		>A> 9416136*PED	Feb 20, 2030			
		>A> 9868739	Nov 09, 2031	U-2505		
		>A> 9868739	Nov 09, 2031	U-3264		
		>A> 9868739	Nov 09, 2031	U-3998		
		>A> 9868739*PED	May 09, 2032			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406	001	12564592	Dec 23, 2044	DP		
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406	002	12564592	Dec 23, 2044	DP		
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406	003	12564592	Dec 23, 2044	DP		
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488	001	>A> 9572857	Aug 02, 2029	DP		
<u>LEUPROLIDE MESYLATE - CAMCEVI ETM</u>						
N 219745	001	>A> 10646572	Jan 16, 2027	DP		
		>A> 11717555	Jan 01, 2039	DP		
		>A> 12133878	Dec 18, 2037	DP		
		>A> 9572857	Aug 02, 2029	DP		
		>A> 9744207	Jan 16, 2027	DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 002	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 003	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 004	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 005	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 006	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 007	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 008	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 009	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 010	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 011	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 012	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 013	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 014	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 015	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 016	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 001	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 002	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 003	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 004	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 005	12564565	Sep 26, 2044	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 006	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 007	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 008	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 009	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 010	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 011	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 012	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 013	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 014	12564565	Sep 26, 2044	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 015	12564565	Sep 26, 2044	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u> N 021717 001	12558328	Jan 14, 2031	U-4421			
<u>LINACLOTIDE - LINZESS</u> N 202811 001					NPP PED	Nov 04, 2028 May 04, 2029
<u>LINERIXIBAT - LYNAVOY</u> N 220295 001	9040518	Sep 06, 2031	DS DP		NCE ODE-517	Mar 17, 2031 Mar 17, 2033
<u>LISDEXAMFETAMINE DIMESYLATE - ARYNTE</u> N 219847 001	12582620	Apr 16, 2040	DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u> N 203858 001	12472172	Jul 29, 2041	U-4438		>A> NPP	Feb 25, 2029
<u>LOMITAPIDE MESYLATE - JUXTAPID</u> N 203858 002	12472172	Jul 29, 2041	U-4438		>A> NPP	Feb 25, 2029
<u>LOMITAPIDE MESYLATE - JUXTAPID</u> N 203858 003	12472172	Jul 29, 2041	U-4438		>A> NPP	Feb 25, 2029
<u>LOMITAPIDE MESYLATE - JUXTAPID</u> N 203858 004	12472172	Jul 29, 2041	U-4438		>A> NPP	Feb 25, 2029
<u>LOMITAPIDE MESYLATE - JUXTAPID</u> N 203858 005					>A> NPP	Feb 25, 2029

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 007	12472172	Jul 29, 2041	U-4438		>A> NS	Feb 25, 2029
	7932268	Aug 19, 2027	U-1316			
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 001					CGT	May 19, 2026
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 002					CGT	May 19, 2026
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 003					CGT	May 19, 2026
<u>LOSARTAN POTASSIUM - ARBLI</u>						
N 218772 001	12605365	Oct 07, 2041	DP U-4159			
	12605365	Oct 07, 2041	DP U-4160			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	>A> 12589069	Jan 26, 2036	DP U-2764			
<u>LOTEPREDNOL ETABONATE; TOBRAMYCIN - LOTE PREDNOL ETABONATE AND TOBRAMYCIN</u>						
A 217597 001					CGT	Jul 14, 2026
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001					>A> M-319	Apr 24, 2029
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002					>A> M-319	Apr 24, 2029
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003					>A> M-319	Apr 24, 2029
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	10398791	Mar 23, 2036	DS DP			
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	>A> 8192719	Oct 12, 2027	U-2220			
	>A> 8192719*PED	Apr 12, 2028				
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001	12594298	Jun 14, 2044	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	12599602	Feb 12, 2040	U-3290			
	12599602	Feb 12, 2040	U-3974			
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	12527771	Oct 11, 2043	DS DP			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	>A> 10265399	Apr 11, 2036	U-4509			
	>A> 10265400	Apr 11, 2036	U-4509			
	>A> 10307484	Apr 11, 2036	U-4509			
	>A> 10369225	Apr 11, 2036	U-4356			
	>A> 10456471	Apr 11, 2036	U-4509			
	>A> 11266657	Apr 11, 2036	U-1719			
	>A> 11433078	Apr 11, 2036	U-1719			
	>A> 11433079	Apr 11, 2036	U-1719			
	>A> 11944683	Apr 11, 2036	U-1719			
	>A> 12005118	Jan 25, 2043	U-1719			
	12544383	Mar 10, 2045	U-1719			
	12551488	May 28, 2040	U-1719			
	12551489	May 28, 2040	U-1719			
	>A> 12611413	Dec 29, 2041	U-1719			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	>A> 12616752	May 18, 2038	U-4510			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	12533342	May 20, 2039	U-3421			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	12485111	May 14, 2043	DP U-4453			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-14	Oct 11, 2027
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-14	Oct 11, 2027
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-14	Oct 11, 2027
<u>METHOTREXATE - JYLAMVO</u>						
N 212479 001	>A> 12605385	Oct 25, 2035	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	12594268	May 23, 2041	U-2371			
	12599594	Jul 19, 2036	U-2371			
	12599595	Apr 28, 2028	U-2371			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 001	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	>A> 12606869	Sep 22, 2030	U-4506			
	>A> 12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 002	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	>A> 12606869	Sep 22, 2030	U-4506			
	>A> 12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 002	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 003	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	>A> 12606869	Sep 22, 2030	U-4506			
	>A> 12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 004	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	>A> 12606869	Sep 22, 2030	U-4506			
	>A> 12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 005	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	>A> 12606869	Sep 22, 2030	U-4506			
	>A> 12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 005	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 006	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	>A> 12606869	Sep 22, 2030	U-4506			
	>A> 12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MILSAPERIDONE - BYSANTI</u>						
N 220358 007	10563259	Jul 24, 2030	U-4436		NCE	Feb 20, 2031
	10563259	Jul 24, 2030	U-4437			
	10570453	Mar 28, 2028	U-4436			
	10570453	Mar 28, 2028	U-4437			
	12478619	May 31, 2044	U-4434			
	12478619	May 31, 2044	U-4435			
	>A> 12606869	Sep 22, 2030	U-4506			
	>A> 12606869	Sep 22, 2030	U-4507			
	8999638	Oct 28, 2030	U-4436			
	8999638	Oct 28, 2030	U-4437			
	9072742	Jan 16, 2031	U-4436			
	9072742	Jan 16, 2031	U-4437			
	9074254	Dec 28, 2031	U-4436			
	9074254	Dec 28, 2031	U-4437			
	9074255	Dec 17, 2030	U-4436			
	9074255	Dec 17, 2030	U-4437			
	9074256	Feb 10, 2031	U-4436			
	9074256	Feb 10, 2031	U-4437			
	9157121	Apr 05, 2030	U-4436			
	9157121	Apr 05, 2030	U-4437			
<u>MINOCYCLINE HYDROCHLORIDE - EMROSI</u>						
N 219015 001	12594252	Jan 07, 2039	U-4043			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	RE49582	Apr 11, 2035	DS DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	RE49582	Apr 11, 2035	DS DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	RE49582	Apr 11, 2035	DS DP			
<u>MITAPIVAT SULFATE - AOVESME</u>						
N 216196 004	10632114	May 03, 2032	U-4391		NCE	Feb 17, 2027
	11254652	Nov 21, 2038	DS DP		NP	Dec 23, 2028
	11878049	Jul 31, 2041	U-4390		ODE-522	Dec 23, 2032
	9193701	Oct 26, 2032	U-4393			
	9682080	May 03, 2032	U-4392			
	RE49582	Apr 11, 2035	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - AOVESME</u>						
N 216196 004	10632114	May 03, 2032		U-4391	NCE	Feb 17, 2027
	11254652	Nov 21, 2038	DS DP		NP	Dec 23, 2028
	11878049	Jul 31, 2041		U-4390	ODE-522	Dec 23, 2032
	9193701	Oct 26, 2032		U-4393		
	9682080	May 03, 2032		U-4392		
	RE49582	Apr 11, 2035	DS DP			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	12576089	Aug 21, 2039		U-4441		
	8486941	Jan 03, 2035	DS DP	U-1201		
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	12576089	Aug 21, 2039		U-4441		
	8486941	Jan 03, 2035	DS DP	U-1201		
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	12576089	Aug 21, 2039		U-4441		
	8486941	Jan 03, 2035	DS DP	U-1201		
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					ODE-528	Feb 07, 2032
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001	12514854	Feb 05, 2041		U-4397		
	>A> 12622903	Feb 05, 2041	DP			
<u>NAVEPEGRTIDE - YUWIWEL</u>						
N 219164 001	10835578	Jan 05, 2037	DS DP	U-4425	NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP	U-4425	ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP	U-4425		
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037		DP U-4425		
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037		U-4425		
	12156917	Jan 05, 2037		U-4425		
	12239689	Jan 05, 2037		U-4425		
	12377133	Nov 12, 2042		DP U-4425		
	8906847	Apr 30, 2031	DS DP	U-4425		
<u>NAVEPEGRTIDE - YUWIWEL</u>						
N 219164 002	10835578	Jan 05, 2037	DS DP	U-4425	NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP	U-4425	ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP	U-4425		
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037		DP U-4425		
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037		U-4425		
	12156917	Jan 05, 2037		U-4425		
	12239689	Jan 05, 2037		U-4425		
	12377133	Nov 12, 2042		DP U-4425		
	8906847	Apr 30, 2031	DS DP	U-4425		
<u>NAVEPEGRTIDE - YUWIWEL</u>						
N 219164 003	10835578	Jan 05, 2037	DS DP	U-4425	NCE	Feb 27, 2031
	11154593	Jan 05, 2037	DS DP	U-4425	ODE-516	Feb 27, 2033
	11224661	Jan 05, 2037	DS DP			
	11311604	Jan 05, 2037	DS DP	U-4425		
	11389510	Jan 05, 2037	DS DP			
	11389511	Jan 05, 2037		DP U-4425		
	11413351	Jan 05, 2037	DS DP			
	12083182	Jan 05, 2037		U-4425		
	12156917	Jan 05, 2037		U-4425		
	12239689	Jan 05, 2037		U-4425		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAVEPEGITIDE - YUWIWEL</u>						
N 219164 003	12377133	Nov 12, 2042	DP U-4425			
	8906847	Apr 30, 2031	DS DP U-4425			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 001					>A> ODE-531	Mar 27, 2032
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 002					>A> ODE-531	Mar 27, 2032
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 003					>A> ODE-531	Mar 27, 2032
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 001	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373		>A> ODE-546	Oct 07, 2032
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 002	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373		>A> ODE-546	Oct 07, 2032
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
<u>NILOTINIB TARTRATE - DANZITEN</u>						
N 219293 001 >A>	12629369	Feb 18, 2040	DP			
<u>NILOTINIB TARTRATE - DANZITEN</u>						
N 219293 002 >A>	12629369	Feb 18, 2040	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	12599587	Jul 08, 2042	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	12599587	Jul 08, 2042	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	12599587	Jul 08, 2042	DP			
<u>NITISINONE - HARLIKU</u>						
N 209449 004					>A> ODE-529	Jun 10, 2032
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 004	10888534	Apr 26, 2039	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 002	7838657	Jul 11, 2027	DS DP			
	8361977	Dec 23, 2030	DS DP			
	8980853	Nov 24, 2030			U-1941	
	9717750	Jun 17, 2030			U-1942	
	9717750	Jun 17, 2030			U-1943	
	9717750	Jun 17, 2030			U-2093	
	9717750	Jun 17, 2030			U-2094	
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 003	7838657	Jul 11, 2027	DS DP			
	8361977	Dec 23, 2030	DS DP			
	8980853	Nov 24, 2030			U-1941	
	9717750	Jun 17, 2030			U-1942	
	9717750	Jun 17, 2030			U-1943	
	9717750	Jun 17, 2030			U-2093	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 003	9717750	Jun 17, 2030	U-2094			
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 001					CGT	Aug 02, 2026
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 002					CGT	Jul 27, 2026
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 003					CGT	Jul 27, 2026
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
	>A> 9694018	Mar 18, 2034	U-3186			
	>A> 9694018	Mar 18, 2034	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
	>A> 9694018	Mar 18, 2034	U-3186			
	>A> 9694018	Mar 18, 2034	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
	>A> 9694018	Mar 18, 2034	U-3186			
	>A> 9694018	Mar 18, 2034	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	12545705	Nov 08, 2031	U-3186			
	12545705	Nov 08, 2031	U-3648			
	>A> 9694018	Mar 18, 2034	U-3186			
	>A> 9694018	Mar 18, 2034	U-3648			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	12509684	May 01, 2034	U-4050			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032 001	>A> 12599565	Jan 31, 2030	DP			
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 001	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 002	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 003	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 004	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 005	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORFORGLIPRON CALCIUM - FOUNDAYO</u>						
N 220934 006	RE50455	Sep 26, 2037	DS DP U-4474		NCE	Apr 01, 2031
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	12514899	Aug 29, 2029	U-4398			
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	12514899	Aug 29, 2029	U-4398			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	>A> 10709691	Oct 12, 2035	U-2770		>A> ODE-535	Apr 15, 2032
	>A> 10709691	Oct 12, 2035	U-4177			
	>A> 10709691	Oct 12, 2035	U-4529			
	>A> 8314097	May 20, 2033	DS DP			
	>A> 8609862	Jan 13, 2031	U-2770			
	>A> 8609862	Jan 13, 2031	U-4177			
	>A> 8609862	Jan 13, 2031	U-4529			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	>A> 10709691	Oct 12, 2035	U-2770		>A> ODE-535	Apr 15, 2032
	>A> 10709691	Oct 12, 2035	U-4177			
	>A> 10709691	Oct 12, 2035	U-4529			
	>A> 8314097	May 20, 2033	DS DP			
	>A> 8609862	Jan 13, 2031	U-2770			
	>A> 8609862	Jan 13, 2031	U-4177			
	>A> 8609862	Jan 13, 2031	U-4529			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 003					>A> ODE-535	Apr 15, 2032
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7771707	Oct 09, 2028	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	>A> 12605363	Dec 16, 2039	DP			
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001	>A> 9061057	Nov 29, 2035	DS DP U-3291			
<u>PALTUSOTINE HYDROCHLORIDE - PALSONIFY</u>						
N 219070 001					>A> ODE-537	Sep 25, 2032
<u>PALTUSOTINE HYDROCHLORIDE - PALSONIFY</u>						
N 219070 002					>A> ODE-537	Sep 25, 2032
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001					>A> ODE-533 >A> ODE-539	Jul 28, 2032 Jul 28, 2032
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	12528836	Oct 07, 2036	U-4394			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	12552792	Oct 03, 2040	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	12552792	Oct 03, 2040	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	12552792	Oct 03, 2040	DS DP			
<u>PERAMPANEL - PERAMPANEL</u>						
A 218152 001					>A> PC	Jun 14, 2026
<u>PHENOBARBITAL SODIUM - SEZABY</u>						
N 215910 001	>A> 12636254	Apr 07, 2042	DP U-3779			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	12201615	Oct 25, 2039	U-3804			
	12576066	Oct 25, 2039	U-3804			
	12576067	Oct 25, 2039	U-3804			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE</u>						
N 216830 001	12564561	Aug 08, 2044	DP			
<u>PIFLUFOLASTAT F-18 - PYLARIFY TRUVU</u>						
N 220089 001	10947197	Jun 09, 2037	DS DP U-3317		NCE	May 26, 2026
	11851407	Jun 09, 2037	DS DP U-3317			
	12070513	Jul 31, 2029	DS DP U-3317			
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3317			
	9861713	Jul 31, 2029	DS DP U-3317			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	7601740	Apr 29, 2030	DS DP		>A> M-14	Apr 27, 2029
	7601740*PED	Oct 29, 2030			>A> PED	Oct 27, 2029
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10517860	Mar 23, 2037	U-1974		>A> M-14	Apr 27, 2029
	10517860*PED	Sep 23, 2037			>A> PED	Oct 27, 2029
	10953000	Mar 23, 2037	U-1974			
	10953000*PED	Sep 23, 2037				
	7601740	Apr 29, 2030	DS DP			
	7601740*PED	Oct 29, 2030				
	7732615	Jun 03, 2028	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	7732615*PED	Dec 03, 2028				
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10449185	Aug 27, 2038	DP		>A> M-14	Apr 27, 2029
	10449185*PED	Feb 27, 2039			>A> PED	Oct 27, 2029
	10646480	Aug 27, 2038	DP			
	10646480*PED	Feb 27, 2039				
	10849891	Aug 27, 2038	DP U-1974			
	10849891*PED	Feb 27, 2039				
	11452721	Aug 27, 2038	DP			
	11452721*PED	Feb 27, 2039				
	7601740	Apr 29, 2030	DS DP			
	7601740*PED	Oct 29, 2030				
	7732615	Jun 03, 2028	DS DP			
	7732615*PED	Dec 03, 2028				
<u>PIMOZIDE - PIMOZIDE</u>						
A 219897 001					>A> CGT	Oct 18, 2026
<u>PIMOZIDE - PIMOZIDE</u>						
A 219897 002					>A> CGT	Oct 18, 2026
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					I-981 ODE-518	Dec 02, 2028 Dec 03, 2032
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002					I-981 ODE-518	Dec 02, 2028 Dec 03, 2032
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					ODE-519	Feb 13, 2033
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					ODE-519	Feb 13, 2033
<u>PLOZASIRAN SODIUM - REDEMPLO</u>						
N 219947 001					>A> ODE-541	Nov 18, 2032
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 001					>A> PC	Aug 29, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 002					>A> PC	Aug 29, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 003					>A> PC	Aug 29, 2026
<u>POMALIDOMIDE - POMALIDOMIDE</u>						
A 210111 004					>A> PC	Aug 29, 2026
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					NPP	Jan 27, 2029
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698		NPP	Jan 27, 2029
	9023790	Jul 04, 2031	DP U-3160			
	9023790	Jul 04, 2031	DP U-3171			
	9023790	Jul 04, 2031	DP U-4415			
	9023790	Jul 04, 2031	DP U-4416			
	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-4415			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9358297	Jun 24, 2031	DP U-4416			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					I-984	Jan 27, 2029
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
N 206814 001	12539314	Mar 07, 2039	DP			
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
N 206814 002	12539314	Mar 07, 2039	DP			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	12448366	Jul 07, 2042	DS			
	12539303	Apr 03, 2039	U-2828			
<u>PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH</u>						
N 213972 001	12544337	Dec 23, 2039	DP U-4026			
<u>RELACORILANT - LIFYORLI (COPACKAGED)</u>						
N 220641 001	10456392	May 24, 2033	U-4457		NCE	Mar 25, 2031
	11285145	May 26, 2041	U-4457			
	11285145	May 26, 2041	U-4458			
	11285145	May 26, 2041	U-4459			
	11464764	Apr 14, 2040	DP			
	11576907	May 24, 2033	DS DP U-4457			
	11576907	May 24, 2033	DS DP U-4458			
	11576907	May 24, 2033	DS DP U-4459			
	11925626	Dec 18, 2039	DP			
	12152028	Dec 22, 2041	DP U-4457			
	12152028	Dec 22, 2041	DP U-4458			
	12152028	Dec 22, 2041	DP U-4459			
	12514849	Dec 18, 2039	DP			
	12589094	May 26, 2041	U-4457			
	12589094	May 26, 2041	U-4458			
	12589094	May 26, 2041	U-4459			
	8859774	May 24, 2033	DS DP			
	9273047	May 24, 2033	U-4457			
	9273047	May 24, 2033	U-4458			
	9273047	May 24, 2033	U-4459			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001 >A>	12629370	Sep 29, 2037	U-3020			
<u>REMIBRUTINIB - RHAPSIDO</u>						
N 218436 001	12419889	Jan 19, 2043	U-4281			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001	12564590	Dec 18, 2042	DP U-4045			
	12564590	Dec 18, 2042	DP U-4327			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002	12564590	Dec 18, 2042	DP U-4045			
	12564590	Dec 18, 2042	DP U-4327			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003	12564590	Dec 18, 2042	DP U-4045			
	12564590	Dec 18, 2042	DP U-4327			
<u>REZAFUNGIN ACETATE - REZZAYO</u>						
N 217417 001	8722619	May 09, 2036	DS DP U-3566			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	>A> 10799506	Apr 14, 2036	DP		>A> I-950	Sep 17, 2027
	>A> 10799506*PED	Oct 14, 2036			>A> PED	Mar 17, 2028
	>A> 12064434	Apr 14, 2036	DP			
	>A> 12064434*PED	Oct 14, 2036				
	>A> 12419894	Apr 14, 2036	DP			
	>A> 12419894*PED	Oct 14, 2036				
	>A> 12544379	Aug 07, 2034	U-3975			
	>A> 12544379*PED	Feb 07, 2035				
	>A> 12544380	Aug 07, 2034	U-4404			
	>A> 12544380	Aug 07, 2034	U-4405			
	>A> 12544380*PED	Feb 07, 2035				
	>A> 8324225	Jun 17, 2028	DS DP			
	>A> 8324225*PED	Dec 17, 2028				
	>A> 8415355	Mar 13, 2031	DS DP			
	>A> 8415355*PED	Sep 13, 2031				
	>A> 8685980	May 25, 2030	DS DP			
	>A> 8685980*PED	Nov 25, 2030				
	>A> 8962630	Dec 09, 2029	U-1981			
	>A> 8962630	Dec 09, 2029	U-2355			
	>A> 8962630	Dec 09, 2029	U-2356			
	>A> 8962630	Dec 09, 2029	U-3265			
	>A> 8962630	Dec 09, 2029	U-3266			
	>A> 8962630	Dec 09, 2029	U-3975			
	>A> 8962630	Dec 09, 2029	U-3999			
	>A> 8962630*PED	Jun 09, 2030				
	>A> 9193732	Nov 09, 2031	DS DP			
	>A> 9193732*PED	May 09, 2032				
	>A> 9416136	Aug 20, 2029	U-1981			
	>A> 9416136	Aug 20, 2029	U-2355			
	>A> 9416136	Aug 20, 2029	U-2356			
	>A> 9416136	Aug 20, 2029	U-3265			
	>A> 9416136	Aug 20, 2029	U-3266			
	>A> 9416136	Aug 20, 2029	U-3975			
	>A> 9416136	Aug 20, 2029	U-3999			
	>A> 9416136*PED	Feb 20, 2030				
	>A> 9868739	Nov 09, 2031	U-1981			
	>A> 9868739	Nov 09, 2031	U-2355			
	>A> 9868739	Nov 09, 2031	U-2356			
	>A> 9868739	Nov 09, 2031	U-3265			
	>A> 9868739	Nov 09, 2031	U-3266			
	>A> 9868739	Nov 09, 2031	U-3975			
	>A> 9868739	Nov 09, 2031	U-3999			
	>A> 9868739*PED	May 09, 2032				
<u>RILZABRUTINIB - WAYRILZ</u>						
N 219685 001					>A> ODE-552	Aug 29, 2032
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001					I-982	Dec 17, 2028
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002					I-982	Dec 17, 2028
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003					I-982	Dec 17, 2028
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	12544381	May 20, 2031	DP			
	12564593	May 20, 2031	DP			
	12589096	Sep 04, 2040	U-3505			
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 001	>A> 10016429	Jun 12, 2028	U-3226			
	>A> 10016429	Jun 12, 2028	U-3230			
	>A> 10874616	Nov 14, 2033	DP			
	>A> 11213528	Jun 12, 2028	DP			
	>A> 11337927	Jan 17, 2034	U-3226			
	>A> 11337927	Jan 17, 2034	U-3227			
	>A> 11337927	Jan 17, 2034	U-3228			
	>A> 11337927	Jan 17, 2034	U-3230			
	>A> 11576864	Nov 14, 2033	U-3226			
	>A> 11576864	Nov 14, 2033	U-3227			
	>A> 11576864	Nov 14, 2033	U-3228			
	>A> 11576864	Nov 14, 2033	U-3230			
	>A> 11576865	Nov 14, 2033	DP U-3226			
	>A> 11576865	Nov 14, 2033	DP U-3227			
	>A> 11576865	Nov 14, 2033	DP U-3228			
	>A> 11576865	Nov 14, 2033	DP U-3230			
	>A> 11744832	Dec 12, 2026	U-3226			
	>A> 11744832	Dec 12, 2026	U-3230			
	>A> 11896717	Nov 14, 2033	DP U-3226			
	>A> 11896717	Nov 14, 2033	DP U-3227			
	>A> 11896717	Nov 14, 2033	DP U-3228			
	>A> 11896717	Nov 14, 2033	DP U-3230			
	>A> 7598257	Dec 24, 2027	DS DP U-3227			
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 8415362	Dec 24, 2027	DS DP			
	>A> 8530485	Dec 12, 2026	DP			
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9206187	Dec 12, 2026	U-3227			
	>A> 9206187	Dec 12, 2026	U-3228			
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 002	>A> 10016429	Jun 12, 2028	U-3226			
	>A> 10016429	Jun 12, 2028	U-3230			
	>A> 10874616	Nov 14, 2033	DP			
	>A> 11213528	Jun 12, 2028	DP			
	>A> 11337927	Jan 17, 2034	U-3226			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 002	>A> 11337927	Jan 17, 2034	U-3227			
	>A> 11337927	Jan 17, 2034	U-3228			
	>A> 11337927	Jan 17, 2034	U-3230			
	>A> 11576864	Nov 14, 2033	U-3226			
	>A> 11576864	Nov 14, 2033	U-3227			
	>A> 11576864	Nov 14, 2033	U-3228			
	>A> 11576864	Nov 14, 2033	U-3230			
	>A> 11576865	Nov 14, 2033	DP U-3226			
	>A> 11576865	Nov 14, 2033	DP U-3227			
	>A> 11576865	Nov 14, 2033	DP U-3228			
	>A> 11576865	Nov 14, 2033	DP U-3230			
	>A> 11744832	Dec 12, 2026	U-3226			
	>A> 11744832	Dec 12, 2026	U-3230			
	>A> 11896717	Nov 14, 2033	DP U-3226			
	>A> 11896717	Nov 14, 2033	DP U-3227			
	>A> 11896717	Nov 14, 2033	DP U-3228			
	>A> 11896717	Nov 14, 2033	DP U-3230			
	>A> 7598257	Dec 24, 2027	DS DP U-3227			
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 8415362	Dec 24, 2027	DS DP			
	>A> 8530485	Dec 12, 2026	DP			
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9206187	Dec 12, 2026	U-3227			
	>A> 9206187	Dec 12, 2026	U-3228			
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 003	>A> 10016429	Jun 12, 2028	U-3226			
	>A> 10016429	Jun 12, 2028	U-3230			
	>A> 10874616	Nov 14, 2033	DP			
	>A> 11213528	Jun 12, 2028	DP			
	>A> 11337927	Jan 17, 2034	U-3226			
	>A> 11337927	Jan 17, 2034	U-3227			
	>A> 11337927	Jan 17, 2034	U-3228			
	>A> 11337927	Jan 17, 2034	U-3230			
	>A> 11576864	Nov 14, 2033	U-3226			
	>A> 11576864	Nov 14, 2033	U-3227			
	>A> 11576864	Nov 14, 2033	U-3228			
	>A> 11576864	Nov 14, 2033	U-3230			
	>A> 11576865	Nov 14, 2033	DP U-3226			
	>A> 11576865	Nov 14, 2033	DP U-3227			
	>A> 11576865	Nov 14, 2033	DP U-3228			
	>A> 11576865	Nov 14, 2033	DP U-3230			
	>A> 11744832	Dec 12, 2026	U-3226			
	>A> 11744832	Dec 12, 2026	U-3230			
	>A> 11896717	Nov 14, 2033	DP U-3226			
	>A> 11896717	Nov 14, 2033	DP U-3227			
	>A> 11896717	Nov 14, 2033	DP U-3228			
	>A> 11896717	Nov 14, 2033	DP U-3230			
	>A> 7598257	Dec 24, 2027	DS DP U-3227			
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 8415362	Dec 24, 2027	DS DP			
	>A> 8530485	Dec 12, 2026	DP			
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 003	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9206187	Dec 12, 2026	U-3227			
	>A> 9206187	Dec 12, 2026	U-3228			
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 004	>A> 10016429	Jun 12, 2028	U-3226			
	>A> 10016429	Jun 12, 2028	U-3230			
	>A> 10874616	Nov 14, 2033	DP			
	>A> 11213528	Jun 12, 2028	DP			
	>A> 11337927	Jan 17, 2034	U-3226			
	>A> 11337927	Jan 17, 2034	U-3227			
	>A> 11337927	Jan 17, 2034	U-3228			
	>A> 11337927	Jan 17, 2034	U-3230			
	>A> 11576864	Nov 14, 2033	U-3226			
	>A> 11576864	Nov 14, 2033	U-3227			
	>A> 11576864	Nov 14, 2033	U-3228			
	>A> 11576864	Nov 14, 2033	U-3230			
	>A> 11576865	Nov 14, 2033	DP U-3226			
	>A> 11576865	Nov 14, 2033	DP U-3227			
	>A> 11576865	Nov 14, 2033	DP U-3228			
	>A> 11576865	Nov 14, 2033	DP U-3230			
	>A> 11744832	Dec 12, 2026	U-3226			
	>A> 11744832	Dec 12, 2026	U-3230			
	>A> 11896717	Nov 14, 2033	DP U-3226			
	>A> 11896717	Nov 14, 2033	DP U-3227			
	>A> 11896717	Nov 14, 2033	DP U-3228			
	>A> 11896717	Nov 14, 2033	DP U-3230			
	>A> 7598257	Dec 24, 2027	DS DP U-3227			
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 8415362	Dec 24, 2027	DS DP			
	>A> 8530485	Dec 12, 2026	DP			
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9206187	Dec 12, 2026	U-3227			
	>A> 9206187	Dec 12, 2026	U-3228			
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 005	>A> 10016429	Jun 12, 2028	U-3226			
	>A> 10016429	Jun 12, 2028	U-3230			
	>A> 10874616	Nov 14, 2033	DP			
	>A> 11213528	Jun 12, 2028	DP			
	>A> 11337927	Jan 17, 2034	U-3226			
	>A> 11337927	Jan 17, 2034	U-3227			
	>A> 11337927	Jan 17, 2034	U-3228			
	>A> 11337927	Jan 17, 2034	U-3230			
	>A> 11576864	Nov 14, 2033	U-3226			
	>A> 11576864	Nov 14, 2033	U-3227			
	>A> 11576864	Nov 14, 2033	U-3228			
	>A> 11576864	Nov 14, 2033	U-3230			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI XR</u>						
N 217180 005	>A> 11576865	Nov 14, 2033	DP U-3226			
	>A> 11576865	Nov 14, 2033	DP U-3227			
	>A> 11576865	Nov 14, 2033	DP U-3228			
	>A> 11576865	Nov 14, 2033	DP U-3230			
	>A> 11744832	Dec 12, 2026	U-3226			
	>A> 11744832	Dec 12, 2026	U-3230			
	>A> 11896717	Nov 14, 2033	DP U-3226			
	>A> 11896717	Nov 14, 2033	DP U-3227			
	>A> 11896717	Nov 14, 2033	DP U-3228			
	>A> 11896717	Nov 14, 2033	DP U-3230			
	>A> 7598257	Dec 24, 2027	DS DP U-3227			
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 8415362	Dec 24, 2027	DS DP			
	>A> 8530485	Dec 12, 2026	DP			
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9206187	Dec 12, 2026	U-3227			
	>A> 9206187	Dec 12, 2026	U-3228			
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
<u>SEBETRALSTAT - EKTERLY</u>						
N 219301 001					>A> ODE-534	Jul 03, 2032
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029			U-1798	
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030			U-1831	
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029			U-1798	
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030			U-1831	
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029			U-1798	
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030			U-1831	
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029			U-1798	
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030			U-1831	
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029			U-1798	
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030			U-1831	
	9284280*PED	Dec 25, 2030				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 214275 001	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	>A> 10519139	Aug 14, 2035	DS DP U-2584			
	>A> 10519139	Aug 14, 2035	DS DP U-3018			
	>A> 11746102	Aug 14, 2035	U-2584			
	>A> 11746102	Aug 14, 2035	U-3018			
	>A> 11753401	Aug 14, 2035	DP U-2584			
	>A> 11753401	Aug 14, 2035	DP U-3018			
	>A> 11787771	Jul 26, 2032	U-2584			
	>A> 11787771	Jul 26, 2032	U-2855			
	>A> 11787771	Jul 26, 2032	U-3018			
	>A> 12291508	Jul 26, 2032	U-2584			
	>A> 12291508	Jul 26, 2032	U-3018			
	>A> 9079865	Jul 26, 2032	U-2584			
	>A> 9079865	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	>A> 10519139	Aug 14, 2035	DS DP U-2584			
	>A> 10519139	Aug 14, 2035	DS DP U-3018			
	>A> 11746102	Aug 14, 2035	U-2584			
	>A> 11746102	Aug 14, 2035	U-3018			
	>A> 11753401	Aug 14, 2035	DP U-2584			
	>A> 11753401	Aug 14, 2035	DP U-3018			
	>A> 11787771	Jul 26, 2032	U-2584			
	>A> 11787771	Jul 26, 2032	U-3018			
	>A> 12291508	Jul 26, 2032	U-2584			
	>A> 12291508	Jul 26, 2032	U-3018			
	>A> 9079865	Jul 26, 2032	U-2584			
	>A> 9079865	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	>A> 10519139	Aug 14, 2035	DS DP U-2584			
	>A> 10519139	Aug 14, 2035	DS DP U-3018			
	>A> 11746102	Aug 14, 2035	U-2584			
	>A> 11746102	Aug 14, 2035	U-3018			
	>A> 11753401	Aug 14, 2035	DP U-2584			
	>A> 11753401	Aug 14, 2035	DP U-3018			
	>A> 11787771	Jul 26, 2032	U-2584			
	>A> 11787771	Jul 26, 2032	U-3018			
	>A> 12291508	Jul 26, 2032	U-2584			
	>A> 12291508	Jul 26, 2032	U-3018			
	>A> 9079865	Jul 26, 2032	U-2584			
	>A> 9079865	Jul 26, 2032	U-3018			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	>A> 10519139	Aug 14, 2035	DS DP U-2584			
	>A> 10519139	Aug 14, 2035	DS DP U-3018			
	>A> 11746102	Aug 14, 2035	U-2584			
	>A> 11746102	Aug 14, 2035	U-3018			
	>A> 11753401	Aug 14, 2035	DP U-2584			
	>A> 11753401	Aug 14, 2035	DP U-3018			
	>A> 11787771	Jul 26, 2032	U-2584			
	>A> 11787771	Jul 26, 2032	U-3018			
	>A> 12291508	Jul 26, 2032	U-2584			
	>A> 12291508	Jul 26, 2032	U-3018			
	>A> 9079865	Jul 26, 2032	U-2584			
	>A> 9079865	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 005	>A> 10519139	Aug 14, 2035	DS DP U-2584			
	>A> 10519139	Aug 14, 2035	DS DP U-3018			
	>A> 11746102	Aug 14, 2035	U-2584			
	>A> 11746102	Aug 14, 2035	U-3018			
	>A> 11753401	Aug 14, 2035	DP U-2584			
	>A> 11753401	Aug 14, 2035	DP U-3018			
	>A> 11787771	Jul 26, 2032	U-2584			
	>A> 11787771	Jul 26, 2032	U-3018			
	>A> 12291508	Jul 26, 2032	U-2584			
	>A> 12291508	Jul 26, 2032	U-3018			
	>A> 9079865	Jul 26, 2032	U-2584			
	>A> 9079865	Jul 26, 2032	U-3018			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001					>A> ODE-545	Nov 19, 2032
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002					>A> ODE-545	Nov 19, 2032
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 219943 001					>A> ODE*	Nov 19, 2032
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 219943 002					>A> ODE*	Nov 19, 2032
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	9457154	Sep 29, 2027	DP		Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	12569543	Apr 28, 2037	U-4446			
	9457154	Sep 29, 2027	DP		Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	12569543	Apr 28, 2037	U-4446			
	9457154	Sep 29, 2027	DP		Y	
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	12569543	Apr 28, 2037	U-4446			
	9457154	Sep 29, 2027	DP		Y	
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	>A> 11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
	12594326	Mar 15, 2033	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	>A> 11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
	12594326	Mar 15, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	>A> 11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
	12594326	Mar 15, 2033	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 004	>A> 11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 005	>A> 11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 213051 006	>A> 11033499	Jun 19, 2033	DP U-2628			
	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12551536	Oct 10, 2038	U-4418			
<u>SEMAGLUTIDE - WEGOVY HD</u>						
N 215256 006	10888605	Aug 24, 2038	DP U-4418		>A> NS	Mar 19, 2029
	11318191	Feb 17, 2041	DP U-4418			
	11752198	Aug 24, 2038	DP U-4418			
	12029779	Oct 10, 2038	U-4418			
	12214017	Aug 24, 2038	DP U-4418			
	12551536	Oct 10, 2038	U-4418			
	8129343	Dec 05, 2031	DS DP			
	9764003	Jun 21, 2033	U-4418			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 001	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	>A> 11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 002	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	>A> 11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 003	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	>A> 11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 004	10278923	May 02, 2034	U-4389		I-935	Mar 08, 2027
	>A> 11033499	Jun 19, 2033	DP U-4496		NP	Dec 22, 2028
	11382957	Dec 16, 2031	DP			
	11833248	Feb 01, 2039	DP U-4387			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 004	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			
<u>SEPIAPTERIN - SEPHIENCE</u>						
N 219666 001					>A> ODE-542	Jul 28, 2032
<u>SEPIAPTERIN - SEPHIENCE</u>						
N 219666 002					>A> ODE-542	Jul 28, 2032
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					I-987	Mar 19, 2029
<u>SEVABERTINIB - HYRNUO</u>						
N 219972 001	10428063	Oct 10, 2035	DS DP			
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 001	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 002	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 003	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 004	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	12533340	Apr 23, 2036	U-4407			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	12533340	Apr 23, 2036	U-4407			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	12533340	Apr 23, 2036	U-4407			
<u>SONROTOCLAX - BEOALZI</u>						
N 220711 001	>A> 11420968	Apr 29, 2039	DS DP			
<u>SONROTOCLAX - BEOALZI</u>						
N 220711 002	>A> 11420968	Apr 29, 2039	DS DP			
<u>SONROTOCLAX - BEOALZI</u>						
N 220711 003	>A> 11420968	Apr 29, 2039	DS DP			
<u>SONROTOCLAX - BEOALZI</u>						
N 220711 004	>A> 11420968	Apr 29, 2039	DS DP			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	12569183	Apr 05, 2039	U-4456			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 001	>A> 9662312	Mar 29, 2030	U-4495			
	>A> 9993461	Mar 29, 2030	U-3269			
	>A> 9993461	Mar 29, 2030	U-3993			
	>A> 9993461	Mar 29, 2030	U-4495			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SPARSENTAN - FILSPARI</u>						
N 216403 002	>A> 9662312	Mar 29, 2030	U-4495			
	>A> 9993461	Mar 29, 2030	U-3269			
	>A> 9993461	Mar 29, 2030	U-3993			
	>A> 9993461	Mar 29, 2030	U-4495			
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	>A> 12616689	Dec 02, 2035	U-2582			
<u>TALETRECTINIB ADIPATE - IBTROZI</u>						
N 219713 001					>A> ODE-544	Jun 11, 2032
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10195160	May 23, 2036	DP			
	12569453	Dec 18, 2039	U-4048			
<u>TECHNETIUM TC-99M LABELED CARBON - TECHNEGAS KIT</u>						
N 022335 001	7722856	Feb 24, 2031	U-4442			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	12539299	Nov 26, 2042	DP			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001					>A> NFP	Mar 27, 2027
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	>A> 12629483	Aug 07, 2035	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	>A> 12629483	Aug 07, 2035	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	>A> 12629483	Aug 07, 2035	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	12605391	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	12605391	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	12605391	Apr 12, 2039	U-1103			
<u>THIOTEPA - TEPADINA AND SODIUM CHLORIDE</u>						
N 208264 004	9931458	May 31, 2037	DP			
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 001	>A> 12622921	Aug 16, 2041	U-4530			
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 002	>A> 12622921	Aug 16, 2041	U-4530			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 001	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
>A>	12629404	Jun 14, 2039	DP U-4533			
>A>	12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 002	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
>A>	12629404	Jun 14, 2039	DP U-4533			
>A>	12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
>A>	12629404	Jun 14, 2039	DP U-4533			
>A>	12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 004	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
>A>	12629404	Jun 14, 2039	DP U-4533			
>A>	12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 005	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
>A>	12629404	Jun 14, 2039	DP U-4533			
>A>	12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
>A>	12629404	Jun 14, 2039	DP U-4533			
>A>	12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
>A>	12629404	Jun 14, 2039	DP U-4533			
>A>	12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	>A> 12629404	Jun 14, 2039	DP U-4533			
	>A> 12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	>A> 12629404	Jun 14, 2039	DP U-4533			
	>A> 12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	12343382	Jul 22, 2039	U-4229		NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	>A> 12629404	Jun 14, 2039	DP U-4533			
	>A> 12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
>A>	12629404	Jun 14, 2039	DP U-4533			
>A>	12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
>A>	12629404	Jun 14, 2039	DP U-4533			
>A>	12629404	Jun 14, 2039	DP U-4534			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 013	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 014	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 014	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 015	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 016	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 017	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 018	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 019	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 019	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 020	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 021	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 022	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 023	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	>A> 12616740	Jul 22, 2039	U-4500			
	>A> 12616740	Jul 22, 2039	U-4501			
	>A> 12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 024	12295987	Dec 30, 2041	U-4192		>A> NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 024	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
>A>	12616740	Jul 22, 2039	U-4500			
>A>	12616740	Jul 22, 2039	U-4501			
>A>	12616740	Jul 22, 2039	U-4502			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			
	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	12343382	Jul 22, 2039	U-4227			
	12343382	Jul 22, 2039	U-4228			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	12343382	Jul 22, 2039	U-4409			
	12343382	Jul 22, 2039	U-4410			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
>A>	12629404	Jun 14, 2039	DP U-4531			
>A>	12629404	Jun 14, 2039	DP U-4532			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 013	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 014	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 015	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 016	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
>A>	12616740	Jul 22, 2039	U-4497			
>A>	12616740	Jul 22, 2039	U-4498			
>A>	12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 017	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	>A> 12616740	Jul 22, 2039	U-4497			
	>A> 12616740	Jul 22, 2039	U-4498			
	>A> 12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 018	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	>A> 12616740	Jul 22, 2039	U-4497			
	>A> 12616740	Jul 22, 2039	U-4498			
	>A> 12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 019	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	>A> 12616740	Jul 22, 2039	U-4497			
	>A> 12616740	Jul 22, 2039	U-4498			
	>A> 12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 020	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	>A> 12616740	Jul 22, 2039	U-4497			
	>A> 12616740	Jul 22, 2039	U-4498			
	>A> 12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 021	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	>A> 12616740	Jul 22, 2039	U-4497			
	>A> 12616740	Jul 22, 2039	U-4498			
	>A> 12616740	Jul 22, 2039	U-4499			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 021	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 022	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	>A> 12616740	Jul 22, 2039	U-4497			
	>A> 12616740	Jul 22, 2039	U-4498			
	>A> 12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 023	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	>A> 12616740	Jul 22, 2039	U-4497			
	>A> 12616740	Jul 22, 2039	U-4498			
	>A> 12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 024	12343382	Jul 22, 2039	U-4227		>A> I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228		>A> M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4409		>A> NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4410			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	>A> 12616740	Jul 22, 2039	U-4497			
	>A> 12616740	Jul 22, 2039	U-4498			
	>A> 12616740	Jul 22, 2039	U-4499			
	9474780	Jan 05, 2036	DS DP			
<u>TRABECTEDIN - EVDI</u>						
N 220837 001	>A> 12303506	Feb 18, 2043	DP			
<u>TRADIPITANT - NEREUS</u>						
N 220152 001	10772880	Mar 04, 2036	U-4396			
	10821099	Mar 04, 2036	U-4396			
	11324735	Mar 04, 2036	U-4396			
	12318375	Aug 09, 2036	U-4396			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 001	7199162	Oct 12, 2026	U-4142			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 002	7199162	Oct 12, 2026	U-4142			
<u>TRihePTANOIN - DOJOLVI</u>						
N 213687 001	12551461	Nov 14, 2034	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12527798	Dec 05, 2037	U-3504			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE-425	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 002	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 003	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11370755*PED	Feb 03, 2041			ODE*	Mar 10, 2030
	11827600	Jul 12, 2042	DS DP U-3556		PED	Sep 10, 2028
	11827600*PED	Jan 12, 2043			PED	Sep 10, 2030
	12492167	Jul 12, 2042	DS DP U-3556			
	12492167*PED	Jan 12, 2043				
	9212204	Jan 27, 2032	U-3556			
	9212204*PED	Jul 27, 2032				
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 001	12558317	Oct 29, 2039	DP			
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 002	12558317	Oct 29, 2039	DP			
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 003	12558317	Oct 29, 2039	DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	8648087	Apr 17, 2034	DS DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	8648087	Apr 17, 2034	DS DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	12570664	Oct 17, 2036	U-4454		>A> ODE-538	Apr 28, 2032
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	12569474	Jun 04, 2034	U-3876			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	12569474	Jun 04, 2034	U-3876			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	12569474	Jun 04, 2034	U-3876			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	12576080	Oct 19, 2035	U-1900			
<u>VEPDEGESTRANT - VEPPANU</u>						
N 219835 001	>A> 10647698	Jan 30, 2038	DS DP		>A> NCE	May 01, 2031
	>A> 10899742	Dec 01, 2037	U-4278			
	>A> 11597720	Dec 01, 2037	DS DP U-4278			
<u>VEPDEGESTRANT - VEPPANU</u>						
N 219835 002	>A> 10647698	Jan 30, 2038	DS DP		>A> NCE	May 01, 2031
	>A> 10899742	Dec 01, 2037	U-4278			
	>A> 11597720	Dec 01, 2037	DS DP U-4278			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001					D-198	Jan 21, 2029
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002					D-198	Jan 21, 2029
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003					D-198	Jan 21, 2029
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12576054	Jun 08, 2043	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
	12582655	Dec 23, 2039	U-4145			
	>A> 12617775	Dec 06, 2044	DS DP			
	>A> 12643883	Dec 06, 2044	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
	12582655	Dec 23, 2039	U-4145			
	>A> 12617775	Dec 06, 2044	DS DP			
	>A> 12643883	Dec 06, 2044	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	12551483	Dec 06, 2044	DP			
	12582655	Dec 23, 2039	U-4145			
	>A> 12617775	Dec 06, 2044	DS DP			
	>A> 12643883	Dec 06, 2044	DS DP			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Oct 17, 2027	DS DP U-3056			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001	7977488	Apr 10, 2030	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 002	7977488	Apr 10, 2030	DS			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	12514906	Aug 01, 2036	DP U-3927			
	8198242	Jun 11, 2035	DS DP U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	12514906	Aug 01, 2036	DP U-3927			
	8198242	Jun 11, 2035	DS DP U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	12514906	Aug 01, 2036	DP U-3927			
	8198242	Jun 11, 2035	DS DP U-3927			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					ODE-527	Mar 20, 2032
<u>ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET</u>						
N 216386 001	8481546	Jun 26, 2034	DS DP U-3555			
<u>ZIFTOMENIB - KOMZIFTI</u>						
N 220305 001	12521396	Jul 16, 2044	DP			
<u>ZOLIFLODACIN - NUZOLVENCE</u>						
N 219491 001	8658641	Jun 20, 2030	DS			
	8889671	Jan 21, 2034	DS	U-4369		
	9040528	Oct 13, 2029		U-4369		
	9187495	Jan 21, 2034	DS	U-4369		
	9540394	Jan 21, 2034		U-4369		
	9839641	Jan 21, 2034		U-4369		

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 46<sup>TH</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)